Abstract Titles and Publications

All accepted abstracts are available in a Journal for ImmunoTherapy of Cancer (JITC) supplement published on Nov. 7, 2022. Click the following link to access the abstracts:

You can find all of our abstract titles, authors, and other information in the table below. Search the table by clicking the table header and entering your search query. Click the buttons to view by topic. Titles for late-breaking abstracts are available by clicking here. Once abstract titles are listed on the website, press releases can be issued with the titles and logistical information. Click here for more information on abstract embargo and release information. 



View Late-Breaking Abstracts >
1 Poster Presentation Capturing the spatial landscape of tumor and immune cell lineages in the microenvironment of human cancer tissues   Reggie Prioli, Ph.D.; Lisa Arvidson, B.S.; Sam Jensen, Ph.D.; Michael Smith, Ph.D.; Katie O. White, MBE; Richard A. Heil-Chapdelaine, Ph.D.; Melinda L. Angus-Hill, Ph.D. Biomarkers, Immune Monitoring and Novel Technologies B cell;MDSC;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
2 Poster Presentation Characterization of the tumor microenvironment in pancreatic ductal adenocarcinoma using multiplexed imaging Michael Smith, Ph.D., Katie White, Richard Heil-Chapdelaine, Melinda L. Angus-Hill, Ph.D. Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Metabolism;Solid tumors;T cell;Tumor microenvironment;Tumor stroma
3 Poster Presentation Adaptive immune receptor repertoire profiling for biomarker discovery Alex Chenchik, PhD; Mikhail Makhanov; Dongfang Hu; Tianbing Liu; Lester Kobzik, MD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Autoimmunity;B cell;Biomarkers;Immune monitoring;Inflammation;RNA;Solid tumors;T cell;Tumor antigens
4 Poster Presentation Potentiation of the immune checkpoint blockade response by tumor acidosis and hypoxia modulation is predictable using molecular imaging Renee Chin, MS; Xiaofei Liang, PhD; Tianzhe Li; Jorge de la Cerda; F. William Schuler; Mark D. Pagel, PhD Biomarkers, Immune Monitoring and Novel Technologies Checkpoint blockade;Immune monitoring;Metabolism;Tumor microenvironment
5 Poster Presentation Development of a Vaccine to Intercept Oral Cancer    Traci L. Hilton, PhD; Andrew J. Gunderson, PhD; Mark Schmidt; Christopher C. Paustian, PhD; Sam Bookhardt, BA; Glenna B. McDonnell, MS; Tarsem L. Moudgil, MS; Hong-Ming Hu, PhD; Bryan R. Bell, MD, DDS, FACS; Bernard A. Fox, PhD Biomarkers, Immune Monitoring and Novel Technologies Carcinogenesis;Neoantigens;Solid tumors;Tumor antigens;Vaccine
6 Poster Presentation Use of real-world (RW) data to assess the ability of circulating cell-free tumor DNA (ctDNA) molecular response to assess therapeutic outcomes in patients with non-small cell lung cancer (NSCLC) Caroline Weipert, MS; Leylah Drusbosky; Leslie A. Bucheit, MS CGC; Kyle Chang; Shaun Forbes; Sean Gordon Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Targeted therapy
7 Poster Presentation Anti-PD1 treatment response prediction and monitoring in non-small cell lung cancer patients using plasma cell-free DNA hydroxymethylation Gulfem D. Guler, PhD; Yuhong Ning; David Haan; Michael Kesling; Ceyda Coruh; Giuliana Mognol; Tierney Phillips; Kyle Hazen; Wayne Volkmuth; Samuel Levy Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Epigenetics
8 Poster Presentation Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody Noriko Iwamoto, PhD; Yoshinobu Koguchi, MD, PhD; Kotoko Yokoyama; Akinobu Hamada, PhD; Atsushi Yonezawa, PhD; Brian D. Piening, PhD; Eric Tran, PhD; Bernard A. Fox, PhD; William L. Redmond, Ph.D.; Takashi Shimada, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Immune monitoring
9 Poster Presentation A pan-cancer multi-omic immune single-cell atlas for cancer immunotherapy: focus on CD4+ T cells    Lydia Mok; Andrea Orlando; Julian Lehrer; Joshua M. Stuart; Nils-Petter Rudqvist, PhD; Benjamin G. Vincent, MD; Anne Monette, PhD; Yasin Senbabaoglu, PhD; Kellie N. Smith; Paul G. Thomas, PhD; Nicholas P. Tschernia, MD; Vesteinn Thorsson; Roberta Zappasodi, PhD; Vanessa D. Jonsson Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs)
10 Poster Presentation Automated detection of RNA, DNA, and Protein Targets in Tissues on the ONCORE ProX Julio S. Masabanda, PhD, MS; Jason Ramos, PhD, MS Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;RNA;Tumor microenvironment
11 Poster Presentation Tertiary lymphoid structures in melanomas harbor increased proportions of stem-like effector T-cells compared to tumor-infiltrating lymphocytes Ileana S. Mauldin, PhD; Priya Katyal; Nicole L. Edmonds; Craig L. Slingluff, Jr., MD Biomarkers, Immune Monitoring and Novel Technologies B cell;Biomarkers;Checkpoint blockade;Immune contexture;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
12 Poster Presentation Evaluating the contribution of extracellular matrix invasion for killing of tumor cells by natural killer cells Jyothi T. Mony, Ph.D; Yama Abassi, PhD; Brandon Lamarche, Ph.D Biomarkers, Immune Monitoring and Novel Technologies NK/NKT cell;Solid tumors;Tumor microenvironment
13 Poster Presentation Real-world Tissue-based circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay predicts outcome in lung cancer patients who had curative treatments  Youjin Oh, MD; Liam Il-Young Chung; Soowon Lee; Timothy Hong; Leesul Kim; Sung Mi Yoon; Joo Hee Park; Trie Arni Djunadi; Young Kwang Chae, MD, MPH, MBA Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Clinical study;Epidemiology
14 Poster Presentation Exploring real-world concordance of tumor mutation burden (TMB) from blood and tissue in patients with solid tumors  Youjin Oh, MD; Jewel Park; Liam Il-Young Chung; Soowon Lee; Timothy Hong; Young Kwang Chae, MD, MPH, MBA Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Clinical study;Epidemiology
15 Poster Presentation Integration of multiple immune-associated biomarkers facilitates classification of solid tumors by primary immune escape mode and prediction of patient outcomes R.J. Seager, PhD; Maria-Fernanda Senosain, PhD; Erik Van Roey; Shuang Gao; Mary K. Nesline; Jeffrey M. Conroy; Sarabjot Pabla, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Checkpoint blockade;Gene expression;Inflammation;RNA;Solid tumors;Tumor evasion;Tumor microenvironment
16 Poster Presentation Multi-dimensional analysis of CD19-CAR T cells at single cell resolution on the Berkeley Lights platform enable unique insights into relationships between cytotoxicity kinetics and cytokine secretion Joseph M. Valdez, Ph.D.; Guido Stadler, Ph.D.; Milton Quintanilla; Pei-Yu (Kate) Lin, Ph.D.; Aribet De Jesus, Ph.D.; Deric M. Griffin, Ph.D.; Sapna Tandon, M.D.; Yiyang Xu, Ph.D. Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;Antigen presenting cells;Biomarkers;CAR T cells;Carcinogenesis;Immune monitoring;Leukemia/Lymphoma;Solid tumors;T cell;Tumor antigens
17 Poster Presentation Isolation and expansion of circulating tumor-reactive lymphocytes for adoptive cell therapy    Shana Kelley; Zongjie Wang, Ph.D. Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;T cell;T cell lineages;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
18 Poster Presentation Identification and characterization of circular RNAs as novel putative biomarkers to predict the survival benefit among metastatic melanoma patients treated with anti-PD-1 monotherapy Jian-Guo Zhou, MD; Udo S. Gaipl; Hu Ma; Haitao Wang Biomarkers, Immune Monitoring and Novel Technologies Biomarkers
19 Poster Presentation Peripheral lymphocytes and lactate dehydrogenase correlate with improved response and survival in head and neck cancer treated with immune checkpoint inhibitors Cassie Pan, MD; Qian Vicky Wu; Jenna Voutsinas; Jeffrey J. Houlton; Brittany Barber; Zain Rizvi; Emily Marchiano; Neal Futran; George E. Laramore; Jay J. Liao; Upendra Parvathaneni; Renato G. Martins Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Granulocyte;Immune toxicity;Inflammation;Monocyte/Macrophage;Myeloid cells;Solid tumors
20 Poster Presentation Development of VISTA-centric tumor immunophenotyping as a novel approach for identification of potential biomarkers for anti-VISTA therapy Andrey Ugolkov, MD, PhD; Rosanna Hok; Reinhard von Roemeling, MD; Alexander Martin, MD; Robert Martell, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
21 Poster Presentation IL-6 as prognostic factor in adjuvant or metastatic skin cancer patients treated with immunotherapy - a real life study Domenico Mallardo, PhD; Maria Antonietta Isgrò; Vito Vanella, MD; Marilena Tuffanelli; Lucia Festino, MD; Maria Grazia Vitale, MD; Grazia D'Angelo; Francesca Sparano; Mario Mallardo; Eleonora Cioli; Benedetta Alfano; Claudia Trojaniello; Alfredo Budillon; Ester Simeone, MD; Corrado Caracò; Ernesta Cavalcanti; Paolo A. Ascierto, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Cytokine;Immune monitoring;Inflammation;Tumor evasion
22 Poster Presentation  Activity of the Tumor-intrinsic NLRP3 Inflammasome Pathway Predicts for Response to Checkpoint Inhibitor Immunotherapy in Melanoma Patients    Tarek Haykal, MD; Nagendra Yarla, PhD; Nicholas C. DeVito, MD; Georgia Beasley, MD, MHSc; April Salama, MD; Brent Hanks, MD, PhD; Balamayooran B.T. Theivanthiran, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Solid tumors
23 Poster Presentation Clues from the Matrix - peripheral collagen fragments originating from activity of lymphoid cells, myeloid cells, and fibroblasts may have biomarker potential for cancer immunotherapy Jeppe Thorlacius-Ussing; Nicholas N.W. Willumsen, PhD; Neel I. Nissen, PhD; Christina Jensen; Morten Karsdal, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune monitoring;Post-translational modifications;Solid tumors;Tumor microenvironment;Tumor stroma
24 Poster Presentation Proteomic analysis of breast cancer based on immune subtypes    Yeonjin Jeon, MD; Hee Jin Lee Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Chemotherapy;Immune suppression;Proteomics;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
25 Poster Presentation Potential predictive biomarkers for BXCL701 in Acute Myeloid Leukemia (AML) Veena R. Agarwal, Ph.D.; Shubhendu Trivedi, Ph.D.; Dimple Bhatia, Ph.D.; Zeenia Jagga, Ph.D.; Moses Donkor, Ph.D.; Vincent O'Neill, M.D. Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Gene expression;Leukemia/Lymphoma
26 Poster Presentation Tumor infiltrating CD8/CD103/TIM-3 expressing lymphocytes in Epithelial Ovarian Cancer co-express CXCL13 and associate with improved survival Vrouyr Bilemjian, MSc; Edwin Bremer Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Tumor infiltrating lymphocytes (TILs)
27 Poster Presentation Tumor agnostic CD8 Immune-phenotype related gene signature defines clinical outcome across early and late phase clinical trials Andreas Roller, PhD; Iakov I. Davydov, PhD; Martha Serrano-Serrano, PhD; Astrid Heller, PhD; Nicolas Staedler, PhD; Claudia Ferreira, PhD; Gabriele Dietmann; Irina Klaman; Konstanty Korski, MD; Petra Schwalie, PhD; Michael A. Cannarile, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Clinical trial;Gene expression;Immune contexture;Immune monitoring;Immunoscore;Systems biology;T cell;Tumor microenvironment
28 Poster Presentation Identification and Functional Validation of Neoantigens-Specific T-Cell Receptors in Lynch Syndrome    Fahriye Duzagac, PhD; Krishna Sinha, PhD; Ana M. Bolivar, MS; Nan Deng, PhD; Laura Reyes Uribe, MD; Alexandre Reuben, PhD; Eduardo Vilar-Sanchez, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Antigen presenting cells;Biomarkers;Immune monitoring;Neoantigens;T cell;Vaccine
29 Poster Presentation Lung-MAP Composite Signature for Immune Checkpoint Inhibitor (ICI) Efficacy in Advanced Squamous Cell Lung Cancer (SCC)    David R. Gandara, MD; Xing Hua, PhD; Khaled Tolba; David Fabrizio; Lee Albacker, Ph.D; Ryan Brennick, PhD; Meagan Montesion, Ph.D.; Geoff Oxnard; Stacey Adam; Fred Hirsch; Karen Kelly; Roy Herbst, MD, PhD; Michael LeBlanc; Mary Redman, Ph.D; Michael Wu; David Kozono, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immunoscore
30 Poster Presentation Single cell multiomic profiling of the antigen-specific immune response using antigen specific dCODE Dextramer (RiO) reagents and BD AbSeq Reagents on the BD Rhapsody™ Single-Cell Analysis System Kivin Jacobsen; Dilek Inekci, Ph.D; Liselotte Brix, Ph.D CSO Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;Antigen presenting cells;B cell;Biomarkers;Immune monitoring;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
31 Poster Presentation Cellular Composition of Malignant Pleural Effusions Show a Similar Landscape to that of their Primary Tumor Sites: A Pilot Study Caddie D. Laberiano-Fernández, MD; Qiong Gan, MD; Auriole Tamegnon, Technician; Sinchita Roy Chowdhuri, MD,PhD; Edwin Parra, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Immune monitoring;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
32 Poster Presentation Real-world prevalence of deficient mismatch repair across 5 solid tumor types in China Xiaohua Shi, PhD; Xiang-Hong Yang; Jing-Ping Yun; Xiang-Shan Fan; Ying-Yong Hou; Zhe Wang; Peng Li; Jie-Yu Chen; Juan Yu; Longyun Chen; Yan Wang; Rubentiran Ramar; Michael Wong; Zhiyong Liang Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Solid tumors
33 Poster Presentation Role of plasma T-cell-derived circulating DNA level in anti-PD(L)1 immunotherapy in advanced stage non-small cell lung cancer Nuthchaya Mejun; Nophol Leelayuwatanakul, MD; Pongsakorn Ouwongprayoon, MD; Chanida Vinayanuwattikun, MD, PhD; Nattiya Hirankarn, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Solid tumors;T cell
34 Poster Presentation Neutrophil-to-eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti-PD-1 therapy Vincent Pozorski; Yeonhee Park; Dahlia H. Tesfamichael; Yusuf R. Mohamoud; Vincent T. Ma, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immune monitoring;Immune toxicity
35 Poster Presentation Early pharmacodynamic changes measured by RNA sequencing in peripheral blood from patients in a phase 1 study with mitazalimab, a potent CD40 agonistic IgG1 monoclonal antibody     Malin Lindstedt, PhD; Peter Ellmark, PhD; Aastha Sobti, Doctoral Candidate, MClinDent Oral Surgery; Karin Enell Smith, PhD, MS; Yago Pico de Coaña, PhD; Sumeet V. Ambarkhane, MBBS, MD Biomarkers, Immune Monitoring and Novel Technologies Antibody;B cell;Dendritic cell;Gene expression;Myeloid cells;T cell
36 Poster Presentation Analysis of T-cell receptor sequences identifies signatures associated with neoantigen exposure in peripheral blood of Lynch Syndrome patients    Ana M. Bolivar, MS; Eduardo Vilar-Sanchez, MD, PhD; Krishna Sinha, PhD; Laura Reyes Uribe, MD; Nan Deng, PhD; Fahriye Duzagac, PhD; Alexandre Reuben, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Immune monitoring;Neoantigens;Solid tumors;T cell
37 Poster Presentation Signal amplification strategies for in situ detection of low-expressed markers in multiplex immunofluorescence Pino Bordignon, PhD; Paula Juricic, PhD; Victor de Gautard, M.Sc.; Alexandre Kehren, M.Sc.; Saska Brajkovic, PhD; Diego G. Dupouy, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Checkpoint blockade;Immune contexture;Proteomics;Solid tumors;T cell;Tumor microenvironment;Tumor stroma
38 Poster Presentation Fully automated spatial multi-omics analysis to map the tumor microenvironment with single-cell resolution Pino Bordignon, PhD; Alice Comberlato, PhD; Saska Brajkovic, PhD; Diego G. Dupouy, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Cytokine;Gene expression;Proteomics;RNA;Solid tumors;T cell;Tumor microenvironment;Tumor stroma
39 Poster Presentation Interrogating Elite Responder humoral responses to identify novel targets and therapeutic antibodies for the treatment of cancer Ramya Chandrasekaran, M.S. Ph.D.; Darbie Whitman, BS; Ray Fox; Tom Graddis; Kamal D. Puri, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;B cell;Biomarkers;Checkpoint blockade;Myeloid cells;Solid tumors
40 Poster Presentation NGS-based immunology panel: applications in preclinical immuno-oncology research Jia Xue, PhD; Xiaobo Chen, PhD; Xiaoyu An, PhD; Jingjing Wang, Ph.D; Henry Li, Ph.D; Sheng Guo, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Gene expression;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
41 Poster Presentation External reproducibility of PD-L1 IHC 22C3 pharmDx for cervical cancer at CPS >= 1 and CPS >= 10 Greg A. Cherryholmes, PhD; Alexander Posch, B.S.; Siena Tabuena-Frolli, B.A.; Jesse Vasquez, M.S.; Tiffany Evans, M.S.; Chris La Placa, M.S.; Kristopher Kersch, M.D.; Angeliki Apostolaki, Ph.D; Jonathan Juco, M.D., Ph.D.; Karina Kulangara, Ph.D Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Checkpoint blockade;Solid tumors;Targeted therapy
42 Poster Presentation Modulation of fibrosis and angiogenesis in post-ischaemic extracellular matrix    Paolo Contessotto, PhD; Doriana Orbanic; Mark Da Costa; Chunsheng Jin; Peter Owens; Niclas Karlsson; José Carlos Rodríguez-Cabello; Peter Dockery; Michelle Kilcoyne; Abhay Pandit Biomarkers, Immune Monitoring and Novel Technologies Angiogenesis;Inflammation;Post-translational modifications;Proteomics
43 Poster Presentation Tumor mutational burden corrected for human leukocyte antigen somatic defects predicts response to checkpoint blockade in advanced non-small cell lung cancer Yinjie Gao, MS; Ramit Bharanikumar, MS; Aly Khan; Michelle M. Stein Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Neoantigens;Tumor microenvironment
44 Poster Presentation Immune signatures of severe immune-related adverse events detected by mass cytometry immune profiling in blood in patients with advanced melanoma treated with immunotherapy Connor P. Healy, PhD; Magdalena Kovacsovics, MD; Natalia Sigal, PhD; Li-Chun Cheng, PhD; Shane Evans, PhD; John Marsiglio, MD; Berit Gibson; Yoko DeRose, PhD; Annaleah Larson; Carlos O. Medina, PhD; Jolien Sweere, PhD; Ramji Srinivasan; Matthew Spitzer, PhD; John Hyngstrom, MD; Siwen Hu-Lieskovan, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Autoimmunity;Bioinformatics;Biomarkers;Checkpoint blockade;Immune monitoring;Immune toxicity;Regulatory T cell (Treg cell);Solid tumors;Systems biology;T cell
45 Poster Presentation Prevalent binding motif in C57BL6 mice cured of B78 melanoma via immunotherapy    Anna Hoefges, MS; Nicholas G. Mathers; Sean J. Mcilwain, PhD; Richard S. Pinapati, PhD; Bradley Garcia, II, PhD; Jigar Patel, PhD; Amy K. Erbe, PhD; Irene M. Ong, PhD; Paul M. Sondel, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Neoantigens;Proteomics;Solid tumors;Tumor antigens
46 Poster Presentation Genetic Analysis of tumor cells derived from the stress of immune response for understanding of immunotherapy  Tomoyuki Ishiguro, MD; Daisuke Takayanagi; Toshiaki Tsurui; Risako Suzuki; Nana Iriguchi; Yuya Hirasawa, MD; Ryotaro Ohkuma, MD; Hirotsugu Ariizumi, MD. PhD; Yutaro Kubota; Kazuyuki Hamada, MD, PhD; Atsushi Horiike; Satoshi Wada, MD, PhD; Kiyoshi Yoshimura, PhD, MD; Kazuyoshi Takeda; Takuya Tsunoda, MD Biomarkers, Immune Monitoring and Novel Technologies Gene expression;Neoantigens;Tumor antigens;Tumor evasion
47 Poster Presentation Multispectral imaging to detect immune phenotypes associated with the tumor microenvironment in a multi-tissue study: A full automated 7-color mIF immuno-oncology workflow    Navi Mehra, PhD; Bhavika Patel, PhD; Stephanie Allen; Noah Ramirez; Najiba Mammadova, PhD; Agnes Haggerty, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Clinical study;Immune monitoring;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
48 Poster Presentation Whole-slide multispectral imaging reveals the immune subtypes of melanoma associated with the tumor microenvironment: An automated 7-color mIF assay Navi Mehra, PhD; Bhavika Patel, PhD; Stephanie Allen; Noah Ramirez; Najiba Mammadova, PhD; Agnes Haggerty, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Immune contexture;Immune monitoring;Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
49 Poster Presentation Immuno-Oncology Imaging Mass Cytometry Study of the Structural and Cellular Composition of the Tumor Microenvironment in Human Cancers  Thomas D. Pfister, PhD; Christina Loh, PhD; Sam Lim; Qanber Raza, PhD; Shaida Ouladan, PhD; Nick Zabinyakov Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immune monitoring;Myeloid cells;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
50 Oral Presentation Merkel cell polyomavirus-specific CD8 T cells in blood, but not in tumors, correlate with immunotherapy response in Merkel cell carcinoma Thomas Pulliam; Saumya H. Jani; Lichen Jing; Jiajia Zhang, MD, MPH; Rima Kulikauskas; Candice Church, Ph.D.; Charlie Garnett-Benson, PhD; Kelly G. Paulson, MD, PhD; Kellie N. Smith; Andrew M. Pardoll, MD, PhD; David M. Koelle, MD; Suzanne L. Topalian, MD; Paul T. Nghiem, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Checkpoint blockade;Clinical study;Clinical trial;Gene expression;Immune monitoring;Immunoscore;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
51 Poster Presentation A combination of antigen presentation and T-cell recognition features improves neoantigen immunogenicity predictions Neeraja Ravi, PhD; Hima Anbunathan; Rachel M. Pyke, PhD; Steven Dea, MS; Prateek Tandon; Richard O. Chen, MD; Sean M. Boyle, PhD, MS Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Neoantigens;T cell;Tumor antigens
52 Poster Presentation Digital pathology training effectiveness for the evaluation of PD-L1 expression in multiple tumor indications Jennifer D. Robinson, HT(ASCP)CM, BA; Edward A. Manna, CT(ASCP), BS; Charlotte M. Roach, BS; Ryan J. Marczak, BS; Arkendra De, PhD, BS; Joshua Littrell, BA; Micki Adams, BS Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor evasion
53 Poster Presentation Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab   Eric D. Routh, PhD; Benjamin G. Vincent, MD; Mark G. Woodcock, MD; Jonathan S. Serody, MD Biomarkers, Immune Monitoring and Novel Technologies Antibody;B cell;Bioinformatics;Checkpoint blockade;Immune monitoring;Neoantigens;Solid tumors;Tumor antigens
54 Poster Presentation Prognostic value of T cell immunoscore estimated from transcriptomic data in patients with advanced malignancies treated with immune checkpoint inhibitors Ahmad A. Tarhini, MD, PhD, MS; Payman Ghasemi Saghand, PhD; Aik Choon Tan, PhD; James Chen; Aakrosh Ratan; Martin McCarter, MD; John Carpton, PhD; Howard Colman, MD; Alexandra Ikeguchi, MD; Igor Puzanov, MD, MSCI, FACP; Susanne M. Arnold, MD; Michelle L. Churchman, PhD; Patrick Hwu; Jose Conejo-Garcia, MD, PhD; William (Bill) S. Dalton, PhD, MD; George J. Weiner, MD; Issam M. El Naqa, Ph.D. Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Gene expression;Immunoscore;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
55 Poster Presentation Identification of the O-glycan epitope targeted by an anti-human carcinoma monoclonal antibody (mAb) NEO-201    Massimo Fantini, PhD; Anjum Zaki; Sharon A. Mavroukakis; Christina M. Annunziata, MD, PhD; Kwong Y. Tsang, PhD; Philip M. Arlen, M.D. Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Immune monitoring;Neoantigens;Post-translational modifications;Targeted therapy;Tumor antigens;Tumor microenvironment
56 Poster Presentation High pretreatment DHEA level is associated with shorter overall survival in newly diagnosed metastatic non-small cell lung cancer patients receiving immune checkpoint inhibitors Yumeng Zhang, MD; Lancia Darville, PhD; Stephanie Hogue; Julie E. Hallanger Johnson; Youngchul Kim, PhD; Jhanelle E. Gray, MD; Lary A. Robinson, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immune suppression;Solid tumors
57 Oral Presentation CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy    Emily Cohen, BSc; Daphne W. Wang; Elizabeth L. Engle, MSc; Benjamin F. Green, BSc; Justina X. Caushi, PhD; Jiajia Zhang, MD, MPH; Joel C. Sunshine, MD, PhD; Sonali Uttam, MSc; Michael Fotheringham, BSc; Alexa Fiorante, BSc; Nicole Espinosa, BSc; Bhakti Pandey, BSc; Teodora Popa, MD; Aleksandra Ogurtsova; Sigfredo Soto-Diaz; Jose Loyola; Jeffrey S. Roskes, PhD; Margaret Eminizer, PhD; Dmitry Medvedev, MSc; Jamie E. Chaft, MD; Julie R. Brahmer, MD, MSc; Joshua E. Reuss, MD; Patrick Forde, MBBCh; Alexander S. Szalay, PhD; Andrew M. Pardoll, MD, PhD; Kellie N. Smith; Janis M. Taube, MD; Tricia R. Cottrell, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immune contexture;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
58 Poster Presentation Examining Elevated TMB and Clinical Benefit of 1L Immune Checkpoint Inhibitor in Advanced NSCLC David P. Carbone, MD, PhD; Jacob Sands, MD; Gerald Li; Alexa B. Schrock; Ryon P. Graf; Liangliang Zhang; Karthikeyan Murugesan; Jeffrey S. Ross; Khaled Tolba; Geoffrey R. Oxnard; Richard S. Huang, MD; David R. Spigel, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Chemotherapy;Solid tumors
59 Poster Presentation DetermaIO (IO score) is associated with efficacy of ICI monotherapy in advanced NSCLC patients: a retrospective BC Cancer study David L. Saltman, MD PhD; Nicole S. Croteau; Heather M. Lockyer; Rob S. Seitz, PhD; Frank B. McMahon; Jeremy Spille; Andrea Dickey; Jordan R. Jennings; Matthew G. Varga, PhD; Kimberly McGregor, MD; Tyler J. Nielsen, MS; David R. Hout, PhD; Brock L. Schweitzer, PhD; Douglas T. Ross, MD, PhD; David R. Gandara, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Clinical study;Gene expression;RNA;Solid tumors;Tumor microenvironment;Tumor stroma
60 Poster Presentation Enablement of single-cell spatial insight addressing T-cell and CAF involvement in pancreatic invasive ductal adenocarcinoma using AI-based deep learning image analysis    Andrew Quong, PhD; Smriti Kala, PhD; Nina Lane; Michelle MacPherson; Gourab Chatterjee; Devan Fleury; Kirsteen H. Maclean, Ph.D; Dan Winkowski, PhD; Fabian Schneider; Jeppe S. Thagaard; James R. Mansfield, MSc Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune contexture;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
61 Poster Presentation Combination of novel biomarkers of collagen fiber and immune architecture are associated with clinically relevant outcomes in gynecological cancers treated with immunotherapy Arpit Aggarwal, Pursuing PhD in Biomedical Engineering; Sepideh Azarianpour-Esfahani; Haojia Li; Pingfu Fu; Mojgan Mokhtari; Stefanie Avril; Haider Mahdi; Anant Madabhushi Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Chemotherapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
62 Poster Presentation Resistance to frameshift neoantigen-specific T cell surveillance in microsatellite unstable cancers Matthew Brown, MS, BA; Leandra Velazquez, BA; Mona Saleh, MD; Alexandros Polydorides, MD, PhD; Aimee Lucas, MD, MS; Cansu Cimen Bozkus, PhD; Robert Samstein, MD, PhD; Nina Bhardwaj, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immune suppression;Neoantigens;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
63 Poster Presentation EpiScan: A synthetic biology platform for targeted immunopeptidomics Peter M. Bruno, PhD; Richard Timms; Nouran S. Abdelfattah; Yumei Leng; Felipe Lelis; Duane R. Wesemann; Xu G. Yu; Stephen J. Elledge Biomarkers, Immune Monitoring and Novel Technologies Antigen presenting cells;Bioinformatics;Biomarkers;COVID and Immunotherapy;Neoantigens;Systems biology;T cell;Tumor antigens
64 Poster Presentation Spatial whole transcriptome profiling of the tumor microenvironment in archived and freshly-mounted FFPE tissues Jun Chiang, Dr, PhD; Augusto Tentori; Hardeep Singh; Anuj Patel; Han Lu; Alex Hermes Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Carcinogenesis;Gene expression;Immune monitoring;Tumor microenvironment
66 Poster Presentation Surface nanotopography and cell shape modulate tumor cell susceptibility to NK cell cytotoxicity Jeehun Park, PhD; Junsang Doh; Yongbum Cho Biomarkers, Immune Monitoring and Novel Technologies NK/NKT cell;Solid tumors;Tumor evasion;Tumor microenvironment
67 Poster Presentation Germline mutations in DNA damage response and repair genes are associated with increased clinical benefit from immune checkpoint inhibitors    Michael J. Dennis, MD; Sophia Bylsma; Lisa Madlensky, PhD; Sandip P. Patel, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Clinical study;Immune toxicity;Solid tumors
69 Poster Presentation A high content screening platform for testing immunotherapies in patient-derived organoids    Gera Goverse, Dr.; Saskia de Man; Tomas Veenendaal; Nataliia Beztsinna; Daniel Okkes; Ashgard Weterings; Kuan Yan; Leo Price Biomarkers, Immune Monitoring and Novel Technologies Immune monitoring;Immune suppression;Monocyte/Macrophage;Myeloid cells;Systems biology;T cell;Tumor microenvironment
70 Poster Presentation Whole genome CRISPR-Cas9 screens in a cancer cell line panel co-cultured with antigen-specific cytotoxic CD8 T cells are a powerful engine for immuno-oncology drug target discovery Serge Gueroussov; Chengyin Min; Alan Huang, PhD; Samuel Meier; Jessica Finkler; Lei Ji; Ashley Choi; Tenzing Khendu; Disha Subramanya; Shangtao Liu, BS; Binzhang Shen; Teng Teng; Xuewen Pan, PhD; Yi Yu, PhD Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;Systems biology;T cell
71 Poster Presentation High scoring precision demonstrated in multiple tumor indications stained with PD-L1 IHC 22C3 pharmDx used in conjunction with Combined Positive Score Julia Hand, B.S.; Francisco J. Ponce, BS; Stephanie Hund, B.S.; Lindsay Peltz, M.S.; Micki Adams, BS; Deanna Moquin, B.S.; Megan Kalpakoff, B.A.; Siena Tabuena-Frolli, B.A.; Jay Milo, M.A.S; Angeliki Apostolaki, Ph.D; Karina Kulangara, Ph.D Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Solid tumors;Targeted therapy
72 Poster Presentation Intravital multiphoton autofluorescence imaging is sensitive to changes in CD8 T cell and tumor cell metabolism during immunotherapy in a murine melanoma model Alexa R. Heaton, PhD; Anna Hoefges, MS; Peter R. Rehani, BS; Nathaniel J. Burkard; Arika S. Feils, BS; Dan V. Spiegelman, BS; Noah W. Tsarovsky, BS; Alina Hampton; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, Ph.D. Biomarkers, Immune Monitoring and Novel Technologies Antibody;Checkpoint blockade;Immune contexture;Metabolism;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
73 Poster Presentation Delta-radiomics predicts response and overall survival in advanced non-small cell lung cancer patients treated with durvalumab Mohammadhadi Khorrami, PhD; Vidya Sankar Viswanathan, M.B.B.S.; Amit Gupta, M.D.; Qin Li, PhD; Ashok Gupta; Ikbel Achour, PhD; Brian Fitzgerald; Vamsidhar Velcheti, MD FACP; Anant Madabhushi Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Solid tumors;Tumor microenvironment
74 Poster Presentation DeepTCRMatch: An effective way of computing T cells antigen specificity Seungtae Park, BA; Sungsik Kim, Ph.D.; Hee Joon Jeon; Na Ri Yoon; Bo Ryeong Lee; Sung-Min Kim, PhD; Woong-Yang Park, MD, PhD; Hyung Ju Hwang Biomarkers, Immune Monitoring and Novel Technologies Antibody;Bioinformatics;Biomarkers;Neoantigens;Proteomics;Systems biology;T cell;T cell lineages;Targeted therapy;Vaccine
75 Poster Presentation Methods to improve co-expression efficacy of genes modulating promoter and linker Suji Kim; Jong Moo Hong; Kwanghee Kim; Hee Jin Lee; Gyungyub Gong Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;Gene expression;T cell
76 Poster Presentation Discovery of blood pharmacodynamic biomarkers for ATR inhibitors Ya Kong; Lulu Jiang; Bin Jiang; Hui Yuwen; Jay Mei; Bo Shan; Bing Hou, Ph.D Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Chemokine;Cytokine;Gene expression;RNA;Targeted therapy
77 Poster Presentation An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity Scott Kopetz, PhD; Maria Pia Morelli; Julian R. Molina, MD, PhD; Diane M. Simeone, MD; J. Randolph Hecht, MD; Kedar Kirtane; Mitesh J. Borad, MD; Theodore H. Welling; Edward B. Garon; Armen Mardiros; Xueyin Wang; Eric W. Ng, MD; Tyler Danek; Shannon Gallagher; Ariane Lozac'hmeur; Karl Beutner; John S. Welch; David G. Maloney, MD, PhD; William Y. Go; Sandip P. Patel, MD Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;CAR T cells;Gene expression;Genetic polymorphism;Solid tumors;T cell;Tumor antigens;Tumor evasion
78 Poster Presentation Mapping the tissue composition with hyperplex immunofluorescence on delicate samples Joanna Kowal, PhD; Diego G. Dupouy, PhD; Jonathan Mignot, MSc; Benjamin Pelz, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Immune contexture;Solid tumors;Tumor microenvironment;Tumor stroma
79 Poster Presentation High-dimensional Spatial Phenotyping of Cutaneous Squamous Cell Carcinoma from Immune-competent and Immunocompromised Patients     Arutha Kulasinghe; Niyati Jhaveri; Dmytro Klymyshyn; Bassem Ben Cheikh; Rahul Ladwa; Howard Liu; Caroline Cooper; Gabrielle Belz; Sandro Porceddu; Oliver Braubach Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune contexture;Metabolism;Proteomics;Tumor microenvironment
80 Poster Presentation Tumor-specific alternative splicing generates immunogenic spatially-conserved HLA-binding neoantigens detected through integrative transcriptomic and proteomic analyses Darwin Kwok, MS; Takahide Nejo, MD, PhD; Chibo Hong, MD, PhD; Aidan Du; Maggie Colton; James Woo; Joseph Costello, PhD; Hideho Okada, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Antigen presenting cells;Bioinformatics;Epigenetics;Neoantigens;Proteomics;T cell;Targeted therapy;Tumor antigens;Vaccine
81 Poster Presentation T Cell stimulation Assay and Immunoassays comparison for Soluble Cytokines Profiling in Drug Discovery    Celine Lefranc; Nicole Meritet; Karine Berthelot; Odile Flamand; Jeremy Baudhuin; Jack Pollard, PhD; Luc Canard; Angelique Biancotto, ph.D Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Chemokine;Costimulation;Immune monitoring;T cell
82 Poster Presentation Differential expression and function of toll-like receptor 3 within tumor immune microenvironment of clear cell renal cell carcinoma Mingjia Li, MD; Patrick Stevens, MS; Maciej Pietrzak, PhD; Jinesh Gheeya, MD, PhD; Amir Mortazavi, MD; Ming Yin, MD; Steven Clinton, MD, PhD; Daniel Spakowicz, PhD; Anil Parwani, MD, PhD; Zihai Li, MD, PhD; Yuanquan Yang, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Solid tumors;TLR;Tumor microenvironment
83 Poster Presentation Immunotherapy eluting intratumoral nanoseed achieves local and systemic tumor control of pancreatic cancer    Hsuan-Chen Liu, PhD; Daniel Davila Gonzalez; Robin Vander Pol; Dixita I. Viswanath; Shani Saunders; Corrine Ying Xuan Chua, PhD; Alessandro Grattoni, PhD Biomarkers, Immune Monitoring and Novel Technologies Immune contexture;Immune monitoring;Immune toxicity;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
84 Poster Presentation Systemic levels of the soluble co-inhibitory and co-stimulatory immune checkpoint molecules in basal cell carcinoma    Nonkululeko Z. Malinga, MBChB; Bernardo L. Rapoport, MD, MMed; Siwele Shalete, MBChB; Helen Steel, PhD; Luyanda Kwofie; Pieter Meyer, PhD; Ronald Anderson, PhD; Mahlatse Kgokolo, PhD; Teresa T. Smit, MPharm Biomarkers, Immune Monitoring and Novel Technologies Coinhibition;Costimulation;Immune suppression;TLR;Tumor microenvironment;Tumor stroma
85 Poster Presentation Mapping the tumor microenvironment with sequential immunofluorescence, an automated image analysis pipeline, and spatial metrics Joanna Kowal, PhD; Diego G. Dupouy, PhD; Pedro Machado Almeida, PhD; James Mansfield; Benjamin Pelz, PhD; Fabian Schneider; David Mason, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Immune contexture;Immune monitoring;Monocyte/Macrophage;Solid tumors;T cell;Tumor microenvironment;Tumor stroma
86 Poster Presentation HPV16 E1 and E2 elicit a robust cytotoxic immune response in virally driven Oropharyngeal Squamous Cell Carcinoma Christine M. McInnis; Shilpa Bhatia; Brinda Vijaykumar; Qiaomu Tian; Yanbo Sun; Del Leistritz-Edwards; Charles Quinn; Sean Donnelly; Ravindra Uppaluri, MD PhD; Ann Marie Egloff; Daniel C. Pregibon; Lakshmi Srinivasan; Anthony Coyle, PhD; Glenn J. Hanna, MD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
87 Poster Presentation Deep phenotyping and spatial immune contexture through a combined multiplex immunofluorescence approach Harry Nunns, PhD; Arezoo Hanifi; Erinn A. Parnell; Nam Tran; Sara Pollan; Qingyan Au, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune contexture;Proteomics;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
88 Poster Presentation Genetic association between vitiligo genetic susceptibility and response to immune-checkpoint inhibitor therapy in advanced melanoma patients. Wouter Ouwerkerk, PhD; Saskia Chielie; Marcel W. Bekkenk; Remco van Doorn; Christian U. Blank; John B.A. Haanen; Karlijn de Joode; Ron HJ. Mathijssen; Astrid AM. van der Veldt; Ellen Kapiteijn; Karijn Suijkerbuijk; Kalijn Bol; Geke A.P. Hospers; Tomas Kirchhoff; Rosalie M. Luiten Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade
89 Poster Presentation Multiplexed Ion Beam Imaging (MIBI) uncovers adaptive immune responses associated with clinical outcomes in oral cavity squamous cell carcinoma treated with neoadjuvant PD-1 inhibitor Raghav Padmanabhan; Hannah M. Knochelmann, MD, PhD; Monirath Hav, MD, PhD; Mate L. Nagy, PhD; Peng Si, PhD; Sweta Bajaj, M.S.; Gregory B. Lesinski, Ph.D.; David Neskey, MD; Chrystal M. Paulos, PhD Biomarkers, Immune Monitoring and Novel Technologies Checkpoint blockade;Immune monitoring;Tumor microenvironment
90 Poster Presentation Circulating altruistic stem cells as a marker of immunosuppression in oral cancer     Lekhika Ms. Pathak, MSc.; Seema Bhuyan, MSc; Bidisha Pal, MS; Partha J. Saikia, MSc; Sukanya Gayan, MSc; Shirsajit Mitra, Btech; Tutumoni Baishya, MSc; Ramana V. Chilakamarti, PhD; Bikul Das, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Chemotherapy;Immune monitoring;Immune suppression;Inflammation;Stem cell/cancer-initiating cell;Tumor microenvironment;Tumor stroma
91 Poster Presentation Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors.    Federica Pecci, MD; Luca Cantini; Valeria Cognigni, MD; Fabiana Perrone, MD; Veronica Agostinelli, MD; Giulia Mazzaschi; Elda Favari; Michele Maffezzoli; Alessio Cortellini, MD, PhD; Francesca Rossi; Rebecca Chiariotti; Francesco Venanzi; Giulia Mentrasti; Giuseppe Lo Russo; Giulia Galli; Claudia Proto; Monica Ganzinelli; Francesca Tronconi; Francesca Morgese; Carla Campolucci; Marco Moretti; Arianna Vignini; Melissa Bersanelli, MD, PhD; Sebastiano Buti; Rossana Berardi Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Metabolism;Solid tumors
92 Poster Presentation Novel RNA-Seq Platform Enables Repurposing of Approved Drugs in Rare Cancers, Improving Outcomes Gitte Pedersen, MSc Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;RNA;Solid tumors;Tumor microenvironment;Vaccine
93 Poster Presentation PCR assay to identify Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element in CAR-T and TCR-T cells for fresh and formalin-fixed samples Shalini Pullarkat, Bachelor's of Science (In Progress); Jocelyn H. Wright; David W. Woolston; Erik L. Kimble; Bo M. Lee; Alexandre V. Hirayama; Aude G. Chapuis, PhD; Denise Buenrostro; Graeme Black; Marie Bleakley, MD; Brandon W. Seaton; Jennifer Specht; Cameron J. Turtle, MBBS, PhD; Cecilia C.S. Yeung, MD Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;Biomarkers;CAR T cells;Targeted therapy
94 Poster Presentation CyTOF and serum proteomics show distinct differences in immune responses between Mycosis Fungoides and Sezary Syndrome to mono- and combination anti-PD-1 immunotherapy Nirasha Ramchurren, PhD; Rachael Parks; Laura Islas; Steven P. Fling, PhD; Michael Khodadoust, MD PhD; Evan W. Newell, PhD; David R. Glass Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Immune monitoring;Proteomics;T cell;Tumor microenvironment
95 Poster Presentation Characterization of human breast cancer tissue with the Xenium In Situ platform reveals a novel marker for invasiveness Robert Y. Henley, PhD; Nicole Rapicavoli; Amanda Janesick; Robert Shelansky; Albert Kim; Janine Hensel; Francesca Meschi; Navid Farahani; Vijay Kumar; Xiaoyan Qian; Sarah Taylor, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Gene expression;RNA;Tumor microenvironment
96 Poster Presentation Metastatic breast cancer is associated with increased levels of soluble inhibitory immune checkpoint proteins and decreased levels of soluble stimulatory immune checkpoint proteins    Bernardo L. Rapoport, MD, MMed; Helen Steel, PhD; Carol Benn, MD; Liezl Heyman, BScHons(Med.Imun); Teresa T. Smit, MPharm; Ronald Anderson, PhD Biomarkers, Immune Monitoring and Novel Technologies Coinhibition;Costimulation;Solid tumors;TLR;Tumor microenvironment;Tumor stroma
97 Poster Presentation Effect of administration of neoadjuvant chemotherapy to newly diagnosed early breast cancer patients on the depressed plasma levels of soluble co-stimulatory and co-inhibitory immune checkpoint molecules    Bernardo L. Rapoport, MD, MMed; Helen Steel, PhD; Carol Benn, MD; Simon Nayler, MD; Teresa T. Smit, MPharm; Liezl Heyman, BScHons(Med.Imun); Annette Theron, PhD; Nomsa Hlatshwayo; Luyanda Kwofie; Pieter Meyer, PhD; Ronald Anderson, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Coinhibition;Costimulation;Immune monitoring;Solid tumors;Tumor microenvironment;Tumor stroma
98 Poster Presentation Imaging Mass Cytometry Identifies Immuno-Oncology-Based Pathophysiological Features of the Mouse Tumor Tissue Microenvironment    Thomas D. Pfister, PhD; Christina Loh, PhD; Michael Cohen, PhD; Sam Lim; Qanber Raza, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;Bioinformatics;Immune monitoring;Leukemia/Lymphoma;Metabolism;Myeloid cells;Proteomics;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
99 Poster Presentation Spatial Insights into Tumor Immune Evasion Illuminated with the CosMx™ Spatial Molecular Imager Platform Jason W. Reeves, PhD; Patrick Danaher; Shanshan He, MD, PhD; Sean Kim; Michael Patrick; Julian Preciado; Justin Jenkins; Rachel Liu; Sarah Murphy; Christine Kang, PhD; Byron Hartman; Vik Devgan, PhD; Youngmi Kim, PhD; Michael Rhodes, PhD; Joseph M. Beechem, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Gene expression;Immune contexture;Solid tumors;Systems biology;Tumor microenvironment;Tumor stroma
100 Poster Presentation Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy Guilhem Richard, PhD; Gary Steinberg; Nicole Ruggiero; William Martin, BA MD; Anne S. de Groot, MD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Immune tolerance;Neoantigens;Regulatory T cell (Treg cell);T cell;Tumor antigens;Tumor evasion
101 Poster Presentation DetermaIO (IO score) is associated with efficacy of ICI monotherapy in advanced NSCLC patients with ECOG 2 David L. Saltman, MD PhD; Rob S. Seitz; Tyler J. Nielsen, MS; Matthew G. Varga, PhD; Nicole S. Croteau; Heather M. Lockyer; David R. Hout, PhD; Brock L. Schweitzer, PhD; Douglas T. Ross, MD, PhD; Amit Jain, MD; Gregory Vidal, MD PhD; David R. Gandara, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Clinical study;Gene expression;RNA;Solid tumors;Tumor microenvironment;Tumor stroma
102 Poster Presentation Exploring the spatial heterogeneity of immune cells in nasopharyngeal tumours    Aastha Sobti, Doctoral Candidate, MClinDent Oral Surgery; Christina Sakellariou, PhD; Johan S. Nilsson, MD, PhD; David Askmyr, MD; Lennart Greiff, MD, PhD; Malin Lindstedt, PhD Biomarkers, Immune Monitoring and Novel Technologies Antigen presenting cells;Bioinformatics;Biomarkers;Dendritic cell;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
103 Poster Presentation Spatial protein analysis of the tumor microenvironment and biomarkers in Hodgkin's Lymphoma    Alexander M. Xu, PhD; Tomohiro Aoki; Aixiang Jiang; Alicia Gamboa; Anthony Colombo; Christian Stiedl; Akil A. Merchant, MD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Leukemia/Lymphoma;Systems biology;Tumor microenvironment
104 Poster Presentation Comprehensive Single-Cell Immune Profiling of Lymphoid and Peripheral Tissues of Aged Mice Using High-Parameter Flow Cytometry by CyTOF Technology. Wenxi Xu, Ph.D.; Stephen Li, Ph.D.; Alexandre Bouzekri; Thomas D. Pfister, PhD; Christina Loh, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;B cell;Dendritic cell;Immune contexture;Immune monitoring;Immunoscore;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;T cell
105 Poster Presentation Prevalence of Claudin18.2 and PD-L1 Expression in Chinese Gastric/Gastroesophageal Junction Adenocarcinoma   Linlin Mao, PhD; Wei Yi, PhD; Xu-Alan Lin, PhD; Ying Gu, PhD; Zhenzhong Xia, MD; Chuan Qi, MD; Michael Shi, MD; Steven Yu, PhD; Xueming Qian, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Solid tumors;Targeted therapy
106 Poster Presentation Development of RO assay for anti-PD-1 mAb and anti-PD-1×CD47 BsAb utilizing  hPD-1/hCD47 dual humanized mice, at preclinical setting to facilitate clinical validation Xiaoyu An, PhD; Mingfa Zang; Ke Hang, Ph.D; Xianfei He, Ph.D; Ruilin Sun; Jian Fei; Henry Li, Ph.D; Haijuan Yu Biomarkers, Immune Monitoring and Novel Technologies Antibody;Bispecifics;Solid tumors
107 Poster Presentation Tumor specific MHC-I expression determines the local immune microenvironment in breast cancer Xiaopeng Sun, BS; Brandie C. Taylor, MS; Paula I. Gonzalez Ericsson; Violeta Sanchez, MS; Justin M. Balko, PhD, PharmD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immune monitoring;NK/NKT cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
108 Poster Presentation Prediction of cancer immunotherapy response using ultrasound imaging of tumor stiffness and perfusion Chrysovalantis Voutouri, PhD; Triantafyllos Stylianopoulos; Fotios Mpekris; Myrofora Panagi; Christina Michael; John D. Martin Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Solid tumors;Tumor microenvironment
109 Oral Presentation Quantitative spatial assessment of the tumor-immune microenvironment in the metastatic melanoma lymph node    Rachel L. Maus, PhD; Raymond M. Moore; Alexey A. Leontovich, PhD; Zachary Fogarty; Ruifeng Guo, MD, PhD; Chathu Dona; Burak Tekin, MD; Jill Schimke; Betty Dicke; Benjamin Chen, MD,PhD; Svetomir N. Markovic, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Immune contexture;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
110 Poster Presentation Characterization of HPV-specific T-cells in Blood and Tissue in Ugandan Women Living with HIV with Cervical Low Grade Squamous Intraepithelial Lesions Amy S. Codd, PhD; Scott V. Adams; Cecilia C.S. Yeung, MD; Lauri D. Aicher; Corey Casper; Lisa M. Frenkel; Thomas S. Uldrick, MD; Evan W. Newell, PhD Biomarkers, Immune Monitoring and Novel Technologies Carcinogenesis;Immune monitoring;Neoantigens;T cell;Tumor antigens;Tumor microenvironment
111 Poster Presentation Integrating multidimensional mass cytometry and multiplex immunohistochemistry to infer spatial relationships between human glioblastoma infiltrating immune cells that correlate with patient outcome.    Todd Bartkowiak, Ph.D.; Asa A. Brockman; Sierra M. Lima; Madeline J. Hayes; Caroline E. Roe; Justine Sinnaeve; Akshitkumar M. Mistry, M.D.; Nalin Leelatian, M.D., Ph.D; Bret C. Mobley, M.D.; Lola B. Chambless, MD; Reid C. Thompson, MD; Kyle D. Weaver, M.D.; Rebecca A. Ihrie, Ph.D.; Jonathan M. Irish, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Immune contexture;Immune suppression;Monocyte/Macrophage;Myeloid cells;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
112 Poster Presentation Circulating and molecular markers of inflammation: impact on treatment response and survival among older patients with cancer treated with immune checkpoint inhibitors    Khalil Choucair, MD, MSc; Caroline A. Nebhan, MD, PhD; Alessio Cortellini, MD, PhD; Stijn Hentzen, MD; Yinghong Wang, MD, PhD; April Salama, MD; Andrew Elliott, PhD; Matthew J. Oberley, MD., PhD; Phillip Walker, PhD; Raza H. Bokhari; Raffaele Giusti; Marco Filetti; Paolo A. Ascierto, MD; Vito Vannella; Domenico Galetta; Annamaria Catino; Pamela Pizzutilo; Carlo Genova, MD, MD; Melissa Bersanelli, MD, PhD; Sebastiano Buti, MD; Azhaar Saeed; Wafik S. El-Deiry; Himisha Beltran, MD; Chadi Nabhan, MD; Douglas B. Johnson, M.D.; Claudia A.M. Fulgenzi; David J. Pinato, MD, MRes, PhD; Maluki Radford; Stephen V. Liu, MD; Chul Kim, MD; Rafeh Naqash; Anwaar Saeed, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Clinical study;Gene expression;Inflammation;Monocyte/Macrophage;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
113 Poster Presentation Uncovering the Dark Immunopeptidome of Head and Neck Squamous Cell Carcinoma (HNSCC): Relevance for Universal Cancer Vaccines, Immunological Monitoring and TIL therapy    Noriko Iwamoto, PhD; Takashi Shimada, PhD; Tarsem L. Moudgil, MS; Ryan Meng; Tanisha L. Christie; Alexa K. Dowell; Rom Leidner, MD; Bryan R. Bell, MD, DDS, FACS; William L. Redmond, Ph.D.; Eric Tran, PhD; Hong-Ming Hu, PhD; Traci L. Hilton, PhD; Brian D. Piening, PhD; Yoshinobu Koguchi, MD, PhD; Bernard A. Fox, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune monitoring;Neoantigens;Proteomics;Surfaceome;T cell;Tumor antigens;Vaccine
114 Poster Presentation Characterization of suppressive myeloid cells in solid tumors to refine disease selection in a Phase 1 study of the multi-Siglec inhibitor AL009 Julie Y. Huang, PhD; Sam C. Nalle, PhD; Helen Lam; Arnon Rosenthal, PhD; Daniel J. Maslyar, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Clinical trial;MDSC;Myeloid cells
115 Poster Presentation Spatial dissection of T cell clonotype identity, transcriptional profiles, and cell-cell interactions in the tumor microenvironment and tertiary lymphoid structures Bryan Iorgulescu; Sophia Liu; Shuqiang Li; Mehdi Borji; Irving Barrera-Lopez; Vignesh Shanmugam; Haoxiang Lyu; Julia Morriss; Zoe Garcia; Evan Murray; David Reardon, MD; Charles Yoon; David A. Braun; Ken J. Livak, PhD; Catherine J. Wu, MD; Fei Chen Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Gene expression;Monocyte/Macrophage;T cell lineages;Tumor microenvironment
116 Poster Presentation Deep High-plex Spatial Phenotyping of Glioblastoma multiforme Provides New Insights into the Immune Landscape and Tumor Heterogeneity    Dmytro Klymyshyn; Niyati Jhaveri; Yasmin Kassim; Bassem Ben Cheikh; Oliver Braubach; Keith L. Black; Tao Sun Biomarkers, Immune Monitoring and Novel Technologies Immune contexture;Proteomics;Solid tumors;Tumor microenvironment
117 Poster Presentation High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy response    Arutha Kulasinghe; Habib Sadeghirad; Ning Liu; James Monkman; Chin Wee Tan; Caroline Cooper; Sarah E. Church, PhD; Fabian Schneider; Jeppe Thaagard; James Mansfield; Kenneth J. O'Byrne, MD; Melissa Davis; Brett G.M. Hughes, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Proteomics;Solid tumors;Tumor microenvironment;Tumor stroma
118 Poster Presentation Delineation of spatial tissue signatures of immunotherapy response groups in non-small cell lung cancer (NSCLC)    Arutha Kulasinghe; James Monkman; Honesty Kim; Aaron Mayer, PhD; Ahmed Mehdi; Marie Cumberbatch; Milan Bhagat; Fabian Schneider; Jeppe Thaagard; James Mansfield; Rahul Ladwa; Scott N. Mueller; Mark Adams; Kenneth J. O'Byrne, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immune contexture;Solid tumors;Tumor microenvironment
119 Poster Presentation Sensitive prediction of immunotherapy response by integrating immune infiltration and neoantigen presentation score in late-stage melanoma Bailiang Li, MD; Charles W. Abbott, PhD; Lee D. McDaniel, Jr., MD, MSE; Rachel M. Pyke, PhD; Fabio Navarro, Ph.D.; Hima Anbunathan; Michael Synder; Sekwon Jang, MD; Sean M. Boyle, PhD, MS; Richard O. Chen, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Gene expression;Neoantigens;Tumor infiltrating lymphocytes (TILs)
120 Poster Presentation Decoding Immunotherapy Responses with High-dimensional and High-throughput Spatial Phenotyping of Non-small cell Lung Cancer (NSCLC) Ning Ma; Aditya Pratapa; James Monkman; Ken O'Byrne; Oliver Braubach; Arutha Kulasinghe Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune contexture;Proteomics;Solid tumors;Tumor microenvironment
121 Poster Presentation Tetraspanin molecule CD9 as a novel marker of tumor-reactive T cells    Yoshihiro Miyahara, MD, PhD; Makiko Yamane, MS; Tae Hayashi, MS; Yuji Toiyama, MD, PhD; Kazushi Hiranuka, PhD; Hiroyuki Kishi, PhD; Hiroshi Shiku, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;Gene expression;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
122 Poster Presentation The Next Generation of Immunotherapy Response Signatures Revealed by Biophysical Simulations Gregory Norris; John R. Pfeiffer; Joseph R. Peterson, PhD; Nicole Liadis; Matthew Biancalana; Dorys A. Lopez-Ramos, PhD; Anuja K. Antony, MD; Daniel J. Cook Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Solid tumors;Tumor evasion
123 Oral Presentation Landscape analysis of the neoepitope-specific T cell responses in patients with and without clinical benefit from immune checkpoint blockade therapy    Cristina Puig Saus; Barbara Sennino; Songming Peng; Zheng Pan, PhD; Benjamin Yuen; Bhamini Purandare; Kyle Jacoby; Olivier Dalmas; Duo An; Boi Quach; Clifford L. Wang; Huiming Xia; Sameeha Jilani; Diana Nguyen; Kevin Shao; Claire McHugh; John E. Greer; Phillip Peabody; Saparya Nayak; Jonaathan Hoover; Sara Said; Susan Foy, PhD; Andrew Conroy; Michael Yi; Christine Shieh; William Lu; Katharine A. Heeringa; Yan Ma; Shahab Chizari; Melissa Pilling; Marc Ting; Ramya Tunuguntla; Salemiz Sandoval; Robert Moot; Theresa Hunter; Sidi Zhao; Justin Saco; Ivan Perez-Garcilaso; Agustin Vega-Crespo; Ignacio Baselga; Gabriel Abril-Rodriguez, MS; Grace Cherry; Deborah J. Wong, M.D., Ph.D.; Jasreet Hundal; Bartosz Chmielowski, MD, PhD; Daniel E. Speiser, MD; Michael T. Bethune; Xiaoyan Bao; Alena Gros, PhD; Obi Griffith; Malachi Griffith, Ph.D.; James R. Heath, PhD; Alex Franzusoff; Stefanie J. Mandl, PhD; Antoni Ribas, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;Biomarkers;Checkpoint blockade;Neoantigens;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
124 Poster Presentation Identification of tumor antigens from multiple genomics sources using LENS (Landscape of Effective Neoantigens Software) Benjamin G. Vincent, MD; Steven Vensko; Kelly S. Olsen; Dante Bortone; Christof C. Smith, PhD; Shengjie Chai, PhD; Alexander Rubinsteyn Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Immune monitoring;Tumor antigens
125 Poster Presentation Characterization and label-free isolation of phenotypically defined Human immune cells using Ghost Cytometry, a novel AI powered flow cytometry technology Keisuke Wagatsuma; Hiroko Nomaru; Kazuki Teranishi; Satoru Akai; Yuri An; Kaoru Komoriya; Yoko Kawamura; Asako Tsubouchi; Andy Wu; Sadao Ota Biomarkers, Immune Monitoring and Novel Technologies Immune monitoring;T cell;Tumor microenvironment
126 Poster Presentation Prognostic gene signature reflecting CD8+ T cell enrichment in early-stage triple-negative breast cancer Chang M. Kim, PhD; Yun Suk Yu; Jin Young Park; Kyong Hwa Park Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Gene expression;RNA;T cell;Tumor microenvironment
127 Poster Presentation Spatial-specific gene signatures outperform bulk-mRNA signatures to define resistance to immunotherapy in melanoma patients.     Thazin N. Aung, PhD; Jonathan Warrell, PhD; Sandra Martinez-Morilla, PhD; Niki Gavrielatou, MD; Ioannis A. Vathiotis, MD; Nay N.N. Chan, PhD; Harriet Kluger, MD; David L. Rimm, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;RNA;Solid tumors;Systems biology;Tumor microenvironment;Tumor stroma
128 Poster Presentation Multiomic spatial interrogation of tumor-infiltrated immune cells using the RNAscope™ Co-detection assay with vivid dyes    Anushka Dikshit, PhD; Sayantani Basak; Emerald Doolittle, PhD Biomarkers, Immune Monitoring and Novel Technologies Chemokine;Cytokine;Immune contexture;Inflammation;RNA;T cell;Tumor infiltrating lymphocytes (TILs)
129 Poster Presentation Platform to conditionally induce lung tumors in genetically engineered mouse models using Cre mRNA containing nanoparticles Vidit Bhandarkar, BS; Elen Torres-Mejia; Namita Nabar; Tamara Dacoba; Paula T. Hammond; Stefani Spranger, PhD Biomarkers, Immune Monitoring and Novel Technologies Myeloid cells;RNA;Solid tumors
130 Poster Presentation Precise spatial multiplexing for immune cell profiling of the tumor microenvironment with ChipCytometry Thomas Campbell; Nancy Stanslowski; Jennifer Brooks Biomarkers, Immune Monitoring and Novel Technologies Immune monitoring;Proteomics;Tumor microenvironment
131 Poster Presentation Quantitative spatial profiling of the tumor microenvironment in NSCLC tissue microarray cores using a 6-plex multiplex imaging technology and AI-powered phenotyping analysis Nicole Couper; Bethany Remeniuk; Karen McClymont; Bei Hopkins, MS; Natalie Monteiro; Lorcan Sherry, PhD; Darren Locke Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune contexture;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
132 Poster Presentation Racial differences in TMB measures between paired tumor/normal and tumor-only sequencing across endometrial, bladder, and non-small cell lung cancers Francisco M. De La Vega, Ph.D.; Yannick Pouliot; Chad Reichard; Rotem Ben-Shachar; Brooke Rhead; Kenneth Carson; Matheww Cooney; Kristiyana Kaneva; Justin Guinney; Afshin Dowlati Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Solid tumors
133 Oral Presentation Spatially defined gene signatures uncover the association of extracellular matrix genes with immunotherapy resistance in head and neck squamous cell carcinoma    Niki Gavrielatou, MD; Jonathan Warrell, PhD; Thazin N. Aung, PhD; Ioannis A. Vathiotis, MD; Panagiota Economopoulou, MD, PhD; Barbara A. Burtness, MD; Amanda Psyrri, MD, PhD; David L. Rimm, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;Immune contexture;Immune suppression;Solid tumors;Tumor microenvironment;Tumor stroma
134 Poster Presentation B and Myeloid Cell Populations Dominate in the Metastasis Compared to Primary Tumors of Patients with Pancreatic Cancer Emily Greene, MS; Deon B. Doxie, PhD; Maria Diab; Bassel El-Rayes; Shishir K. Maithel, MD; Juan Sarmiento; Olatunji B. Alese, MD; Jayden Kim; Cameron J. Herting, PhD; Kavita M. Dhodapkar; Madhav V. Dhodapkar; Haydn Kissick, PhD; Chrystal M. Paulos, PhD; Gregory B. Lesinski, Ph.D. Biomarkers, Immune Monitoring and Novel Technologies B cell;Immune monitoring;Myeloid cells;Solid tumors;T cell;Tumor microenvironment
135 Poster Presentation Identification of super-exhausted T cells: a novel population predictive of response to immunotherapy    Alban Bessede, PhD; Florent Peyraud, MD; Jean Philippe Guegan, PhD; Christophe Rey, PhD; Sylvestre Le Moulec, MD, PhD; Fabrice Barlesi, MD, PhD; Sophie Cousin, MD, PhD; Guilhem Roubaud, MD; Mathilde Cabart, MD; Maxime Brunet, MD; Ezogelin Gruyters, PhD; Ariel Savina, PhD; Berengère Dadone-Montaudon, MD, PhD; Aurélien Marabelle, MD, PhD; Jean Charles Soria, MD, PhD; Yohann Loriot, MD, PhD; Jean-Yves Scoazec, MD, PhD; François Le Loarer, MD, PhD; Antoine Italiano, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Coinhibition;Immune contexture;Immunoscore;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
136 Poster Presentation A plasma proteomic based predictive biomarker for response to immunotherapy in NSCLC Michal Harel, PhD; Coren Lahav, MSc; Ido Wolf, MD. PhD; Ella Tepper, MD; Maya Gottfried, MD; Raya Leibowitz, MD. PhD; Mahmoud Abu-Amna, MD; Abed Agbarya, MD; Rivka Katzenelson, MD; Michal Lotem, MD. PhD; Mor Moskovitz, MD; Alona Zer, MD; Ina Koch, PhD; Niels Reinmuth, MD. PhD; Adam P. Dicker, MD, PhD; David R. Gandara, MD; David P. Carbone, MD, PhD; Petros Christopoulos, MD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Clinical study;Proteomics;Solid tumors;Systems biology
137 Poster Presentation FcγRIIa-specific DARPins as a novel tool toward specific gene delivery into HIV reservoir cells  Arezoo Jamali, PhD; Vanessa Riechert, MSc.; Samuel Theuerkauf, MSc.; Sascha Hein, Dr.; Philipp Adams, PhD; Elena Herreracarrillo, PhD; Ben Berkhout, Prof.PhD; Klaus Cichutek, PhD; Jessica Hartmann, PhD; Christian J. Buchholz, Prof, PhD Biomarkers, Immune Monitoring and Novel Technologies Targeted therapy
138 Poster Presentation Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy     Astrid Z. Johansen; Sif I. Novitski; Jessica X. Hjaltelin, Assistant Professor; Susann Theile; Mogens K. Boisen, MD, PhD; Søren Brunak, Professor, Head of Research; Daniel H. Madsen, Associate Professor; Dorte L. Nielsen, Professor; Inna M. Chen, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Inflammation;Radiotherapy;Solid tumors
139 Poster Presentation Identification of distinct tissue phenotypes in lung and colorectal cancers by Imaging Mass Cytometry is consistent across serial sections     Smriti Kala, PhD; Rasmus Lyngby, PhD; Rasmus Sorensen; Andrew Quong, PhD; Sam Lim; Clinton Hupple; Nina Lane; Jeppe S. Thagaard; Johan Dore-Hansen; James R. Mansfield, MSc; Fabian Schneider; Michelle MacPherson Biomarkers, Immune Monitoring and Novel Technologies Immune contexture;Immune monitoring;Myeloid cells;Proteomics;Solid tumors;Systems biology;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
140 Poster Presentation Assessment of differences in tumor mutational burden identified on liquid biopsy in 16,870 patients newly diagnosed with metastatic cancer Eugene Kwon; Daniel S. Childs; Bradley J. Stish; Stephen Boorjian; Matthew Tollefson; Cameron Britton; Ahmed Mahmoud; Ahmed Mohamed; Angela Thompson; Reagan Barnett; Leylah Drusbosky; Leslie A. Bucheit, MS CGC Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Solid tumors
141 Poster Presentation Indoleamine 2,3 dioxygenase expression predicts response to Immune Checkpoint Blockers in advanced Non-Small Cell Lung Cancer     Alban Bessede, PhD; Sylvestre Le Moulec, MD, PhD; Jean Philippe Guegan, PhD; Isabelle Soubeyran, MD, PhD; Florent Peyraud, MD; Christophe Rey, PhD; Antoine Italiano, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immune monitoring;Immune suppression;Immune tolerance;Metabolism;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
142 Poster Presentation Demonstrating the role of spatial contexture in determining response to immune check point inhibitors using a tumor histoculture platform    Satish Sankaran, PhD; Oliyarasi M; Rajashekar M.; Ritu Malhotra; Kowshik Jaganathan; Gowri Shankar K; Vasanth K.; Manjula B.V.; MS Ganesh; Amritha Prabha; Prakash BV; C. Jaya Prakash; Arjun Chakraborty; Syamkumar V.; Biswajit Das; Aditi Satish; Nandini P. Basak Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Cytokine;Immune contexture;Immune monitoring;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
143 Poster Presentation A comprehensive workflow for highplex imaging, tissue segmentation, and multiplex cellular phenotyping for tumor microenvironment analysis Fabian Schneider; Rasmus Lyngby, PhD; Rasmus Sorensen; Andrew Quong, PhD; Smriti Kala, PhD; Sam Lim; Clinton Hupple; Nina Lane; Michelle MacPherson; Jeppe S. Thagaard; Johan Dore-Hansen; James R. Mansfield, MSc Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune contexture;Immune monitoring;Monocyte/Macrophage;Solid tumors;Systems biology;T cell;T cell lineages;Tumor microenvironment;Tumor stroma
144 Poster Presentation CD3 humanized mouse models as validated tools to assess immune-related adverse events of T cell engagers    Perrine Martin-Jeantet; Gaelle Martin, PhD; Angela Pappalardo; Florence Renart-Depontieu; Patricia Isnard-Petit; Yacine Cherifi; Fabiane Sônego, PhD, MS; Kader Thiam Biomarkers, Immune Monitoring and Novel Technologies Antibody;Bispecifics;Cytokine;Immune toxicity;T cell;Targeted therapy
145 Poster Presentation Nadunolimab inhibits IL-1α/β-induced CXCR1/2 ligand expression and reduces serum levels of CXCL1 and CXCL5 in NSCLC and PDAC patients Camilla R. Millrud, PhD; Elin J. Gyllenbäck; Petter Skoog; Annika Sanfridson; David Liberg Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Chemokine;Chemotherapy;Clinical trial;Immune suppression;Myeloid cells;Solid tumors;Tumor microenvironment;Tumor stroma
146 Poster Presentation Transcriptome augmentation provides accurate and sensitive quantification of genes associated with the tumor microenvironment Fabio Navarro, Ph.D.; Pamela Milani, PhD; Koichi Hashikawa, Ph.D.; Shruti Bhide, M.S.; Upasana Dutta, M.S.; Dave Delano; Charles W. Abbott, PhD; Robin Li, MS; Zeid Rusan; John S. West, MBA; John Lyle; Sean M. Boyle, PhD, MS; Richard O. Chen, MD Biomarkers, Immune Monitoring and Novel Technologies B cell;Gene expression;Granulocyte;Immune contexture;T cell;Tumor infiltrating lymphocytes (TILs)
147 Poster Presentation Comprehensive in situ immune phenotyping with the CosMxTM high plex protein assay  Tien M. Phan-Everson, PhD; Jianji Chen, PhD; Zachary Lewis, PhD; Gary Geiss, PhD; Yan Liang, MD PhD; Emily Brown; Liuliu Pan, PhD; Stefan Phelan, MS; Charlie Glaser; Mithra Korukonda, PhD; Carl Brown, PhD; Dwayne Dunaway, PhD; Joseph Phan, PhD; Alyssa Rosenbloom, PhD; Brian Filanoski, PhD; Rhonda Meredith; Kan Chantranuvatana; Brian Birditt; Giang Ong, MS; Hye Son Yi; Erin Piazza, PhD; Jason W. Reeves, PhD; Subham Basu, PhD; Christine Kang, PhD; Vik Devgan, PhD; Edward Zhao, PhD; Michael Rhodes, PhD; Joseph M. Beechem, PhD Biomarkers, Immune Monitoring and Novel Technologies Antibody;B cell;Biomarkers;Monocyte/Macrophage;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
148 Oral Presentation TAP2 deficiency mediates adaptive immune evasion and immunotherapy resistance in human non-small cell lung cancer Kishu Ranjan, Ph.D.; Imad Ud Deen, MD; Miguel López de Rodas, MD; Nicole Gianino, MS; Soldano Ferrone, MD, PhD; Kurt A. Schalper, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Chemokine;Cytokine;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor microenvironment
149 Poster Presentation Complementary PhenoCode Signature Panels comprehensively map cell interactions and identify Spatial Phenotypic Signatures in the tumor microenvironment    Bethany Remeniuk; Bei Hopkins, MS; Natalie Monteiro; Darren Locke Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Immune contexture;Immune suppression;Inflammation;Myeloid cells;Solid tumors;T cell;Tumor microenvironment;Tumor stroma
150 Poster Presentation Circulatory plasma proteomic biomarkers predict response to immunotherapy in melanoma patients and reveal biological insights into the tumor microenvironment    Arnav Mehta; Marijana Rucevic; Emmett Sprecher; Nir Hacohen; Genevieve Boland, MD PhD; Milan Parikh; Jiajia Chen; Dennie T. Frederick; Elliot Woods; Lynn Bi; David Lieb; Lina Hultin-Rosenberg; Jamey Guess; Ryan J. Park; Alexis Schneider; William Michaud; Benchun Miao; Gyulnara Kasumova; Michelle S. Kim; Xue Bai; Russell W. Jenkins; Samuel J. Klempner; Anna LK. Gonye; Keren Yizhak; Moshe Sade-Feldman; David Liu; Ryan J. Sullivan; Keith T. Flaherty Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Cytokine;Immune monitoring;Immune suppression;Monocyte/Macrophage;Myeloid cells;Proteomics;Solid tumors;Tumor microenvironment
151 Poster Presentation Using Additional Morphology Markers in NanoString GeoMx Whole Transcriptome Atlas assay to assess NSCLC tumor subtype Jessica Runyon, MA; Christian Nievera, PhD; Vijay Baichwal, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Gene expression;RNA;Solid tumors;Tumor microenvironment
152 Poster Presentation The immune expression landscape of solid tumors with tertiary lymphoid structures Maria-Fernanda Senosain, PhD; R.J. J. Seager, Jr., Ph.D.; Erik Van Roey; Shuang Gao; Mary K. Nesline; Jeffrey Conroy, BS; Sarabjot Pabla, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
153 Poster Presentation Clinical implication of Exhaustive T-Cell Environment in Uveal Melanoma Patients  Mithalesh K. Singh, Dr., PhD; Seema Kashyap, MD; Nikhil Kumar, M.Sc; Jayanti Jha, M.Sc; Neiwete Lomi, MD; Lata Singh, Ph.D. Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Gene expression;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
154 Poster Presentation Generation of humanized mouse models for the preclinical evaluation of novel immune checkpoint inhibitors, immune cell engagers and cell therapies    Maria Stecklum, PhD; Annika Wulf-Goldenberg, PhD; Bernadette Brzezicha; Christian Rupp, PhD; Wolfgang Walther, PhD; Jens Hoffmann Biomarkers, Immune Monitoring and Novel Technologies Antibody;Bispecifics;Checkpoint blockade;Solid tumors;Tumor infiltrating lymphocytes (TILs)
155 Poster Presentation MHC class I antigen presentation is associated with an inflamed SCLC tumor microenvironment characterized by a higher density of cytotoxic T-cells in closer proximity to tumor cells    Markus Schick, PhD; Miljenka Vuko; Mingchao Xie, PhD; Monica Azqueta Gavaldon; Felix Segerer; Andreas Spitzmüller; Harald Hessel; Marco Testori; Johannes Zimmermann; Michael J. Surace, PhD; Mari Heininen-Brown; Jaime Rodriguez Canales; Shashank Saran; Helen K. Angell, PhD, BSc; Guenter Schmidt, PhD; Hadassah Sade, PhD; J. Carl Barrett, PhD; Giulia Fabbri Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune contexture;Immune monitoring;Solid tumors;Tumor microenvironment
156 Poster Presentation Establishment of an Immune Cell Phenotyping Multiplexed Immunofluorescence Assay and Digital Image Analysis Workflow to Investigate the Tumor Microenvironment in Solid Tumors Dirk Zielinski; Suso Platero Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune monitoring;Tumor microenvironment
157 Poster Presentation Interrogation of the Tumor Immune Microenvironment and ex vivo Profiling of PD-1 Blockade using the 3D-EXplore ex vivo Platform of Fresh Patient Tumor Tissue    Brittney Ruedlinger, PhD; Jasmin D'Andrea, MS; Jared C. Ehrhart, PhD; Soner Altiok, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Checkpoint blockade;Immune suppression;MDSC;Myeloid cells;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
158 Poster Presentation A novel, highly accurate liquid biopsy-based glycoproteomic predictor of checkpoint inhibitor treatment benefit in advanced non-small cell lung cancer.    Klaus Lindpaintner, MD, MPH; Apoorva Srinivasan, PhD; Alan Mitchell, PhD; Apurva Dixit, PhD; Gege Xu, PhD; Xin Cong, PhD; Daniel Serie, PhD Biomarkers, Immune Monitoring and Novel Technologies Checkpoint blockade;Post-translational modifications;Targeted therapy
159 Poster Presentation Xerna tumor microenvironment subtypes as a biomarker in lung cancer patients Mark Landers, B.S.; Patrick Eimerman, Ph.D; Steve Mastrian; Tracey White, Ph.D; Janine LoBello, D.O,. FCAP; Gargi Basu, Ph.D; Szabolcs Szelinger, PhD; Jessica Aldrich, Ph.D; Matthew Halbert; Jess Hoag; David Hall; Farjana Fattah, Ph.D; Daniel Pointing; Luka Ausec, Ph.D; Anze Gregorc; Seema Iyer; Mark Uhlik, Ph.D; Laura Benjamin, Ph.D; Rick Baehner, M.D. Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Gene expression;Immune suppression;RNA;Targeted therapy;Tumor microenvironment
160 Poster Presentation Novel, high-plex, and flexible biomarker panels for rapid development of spatial signatures to improve stratification of response to combination therapies Rachel Schaefer; Jacob Circelli; Oscar Perez; Linying Liu; Michael McLane, II; Yi Zheng, PhD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
161 Oral Presentation Single-cell spatial in situ transcriptomics unravels vulvar HSIL composition associated with complete response to therapeutic vaccination Ziena Abdulrahman, MD; Mariette I.E. van Poelgeest; Marij J.P. Welters; Sjoerd H. van der Burg Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Inflammation;Myeloid cells;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma;Vaccine
162 Poster Presentation Detecting T-cell reinvigoration and persistence using patient derived ex vivo three-dimensional spheroid models Katy A. Lassahn, MS; Ashley K. Elrod; Tessa M. DesRochers, PhD; Kathryn M. Appleton, PhD Biomarkers, Immune Monitoring and Novel Technologies Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Cytokine;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
163 Poster Presentation Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions Ziena Abdulrahman, MD; Natasja Hendriks; Arnold J. Kruse; Antonios Somarakis; Anna J.M. van de Sande; Heleen van Beekhuizen; Jurgen M.J. Piek; Noel F.C.C. de Miranda; Loes F.S. Kooreman; Brigitte F.M. Slangen; Sjoerd H. van der Burg; Peggy J. de Vos van Steenwijk; Edith M.G. van Esch Biomarkers, Immune Monitoring and Novel Technologies Antigen presenting cells;Bioinformatics;Biomarkers;Dendritic cell;Monocyte/Macrophage;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
164 Poster Presentation Evaluation of liquid biopsy-based plasma copy number burden, DNA methylation and Personalized minimal residual disease approach for monitoring molecular response to different drug regimens   in metastatic colorectal cancer patient    Zheng Feng, PhD, MD; Neil R. Smith, PhD; Giancarlo Bonora, PhD; Juergen Scheuenpflug; Pan Du Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Epigenetics;Solid tumors;Targeted therapy
165 Poster Presentation PAHR: the pan-cancer AHR signature pipeline Peter K. Schulz-Knappe, MD, PhD; Christiane A. Opitz; Saskia Trump; Ahmed Sadik Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Clinical trial;Gene expression;Immune monitoring;Immune suppression;Proteomics;Regulatory T cell (Treg cell);T cell;Tumor microenvironment
167 Poster Presentation Comprehensive profiling of cancer-associated fibroblasts in CD8+T cell-exclusive non-small cell lung cancer tumor microenvironments using the Nanostring GeoMX Digital Spatial Profiler Christina Cho, PhD; Gavitt Woodard, MD; Francesc Lopez-Giraldez, PhD; Ti Badri, MS, MS, MPH; Matthew D. Vesely, MD, PhD; Lieping Chen, MD, PhD, FAIO Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Gene expression;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
168 Poster Presentation Exploring features and parameters for neighborhood analysis in human cancer multiplexed immunofluorescence data Ian Dryg, PhD; Madison Turner; Ann-Elizabeth Le, MS; Anne E. Carlisle, PhD; Kathleen L. Pfaff, PhD; Jason L. Weirather, PhD; F. Stephen Hodi, Jr., MD; Scott J. Rodig, MD, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Biomarkers;Immune contexture;Proteomics;Solid tumors;Tumor microenvironment;Tumor stroma
169 Poster Presentation Immunotherapeutic Potential of the Humanized Anti-MUC16 Antibody AR9.6 against PDAC Christabelle Rajesh; Satish Sagar; Cory L. Brooks; Michael A. Hollingsworth; Prakash Radhakrishnan Biomarkers, Immune Monitoring and Novel Technologies Antibody;Biomarkers;Targeted therapy;Tumor antigens;Tumor microenvironment
171 Poster Presentation Tumor microenvironment immune cell landscape varies among molecular subtypes in gastric cancer.    Sanyog Dwivedi, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Immunoscore;MDSC;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
172 Poster Presentation Body mass index (BMI) and serum albumin level as a predictor of survival outcomes in advanced-stage melanoma patients treated with anti-PD1 therapy Yusuf R. Mohamoud; Yeonhee Park; Dahlia H. Tesfamichael; Vincent Pozorski; Vincent T. Ma, MD Biomarkers, Immune Monitoring and Novel Technologies Biomarkers;Checkpoint blockade;Clinical study
173 Poster Presentation Sensitivity and concordance of CD274 expression by RNA sequencing (RNA-seq) in comparison with three PD-L1 immunohistochemistry methods in head and neck squamous cell carcinoma (HNSCC) Mary K. Nesline; Sarabjot Pabla, Ph.D.; Jeffrey Conroy, BS; Paul DePietro, PhD; Shengle Zhang; Roger Klein; Achyut Bhagelu, PhD; Rebecca Previs; Prasanth Reddy; Shakti Ramkissoon; Eric Severson Biomarkers, Immune Monitoring and Novel Technologies Gene expression;RNA;Solid tumors
174 Poster Presentation Single cell FFPE and spatial transcriptomic profiling of an invasive ductal carcinoma enhances cellular and spatial insights Ryan Stott, PhD; Jawad Abousoud; Stephen Williams, PhD; Shamoni Maheshwari, PhD; Valeria Giangarra, PhD; Sarah Taylor, PhD; Andrew Kohlway, PhD Biomarkers, Immune Monitoring and Novel Technologies Bioinformatics;Gene expression;RNA;Solid tumors
175 Poster Presentation CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma    Paul D. Rennert, PhD; Lihe Su, PhD; Lan Wu, PhD; Roy R. Lobb, PhD; Christine Ambrose, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell
176 Poster Presentation Immune Activation by Antigen-specific T cells Elicited in Patients Receiving Standard Therapy for Pediatric Solid Tumors Jillian P. Smith, MD; Amy Hont, MD; Catherine Bollard, MD Cellular Therapies Adoptive immunotherapy;Pediatric tumors;Solid tumors;T cell
177 Poster Presentation Preclinical characterization of CYT-100 iPSC derived NK cells alone and in combination with CYT-303 NK cell engager for hepatocellular carcinoma (HCC). Liang Lin; Andrea Chambers; Marshall Chao Ma; Hao-Ming Chang; David Zou; Preeti Ashok; Elisabetta Burchi; Armin Rath; Stanley Frankel; Jean Kadouche; Daniel Tepper; Nejmi Dilmac; Antonio Arulanandam; Wei Li Cellular Therapies Adoptive immunotherapy;Bispecifics;NK/NKT cell
178 Poster Presentation Targeting ER-Mitochondrial dynamics to improve responses to immune checkpoint blockade Katherine L. Cook, PhD; Elizabeth R. Stirling, MS, PhD; Jessica D. Mackert, PhD; Mitra Kooshki, MS; Adam S. Wilson; Wei Zhang, PhD; Pierre L. Triozzi, MD; David R. Soto-Pantoja, PhD Cellular Therapies Checkpoint blockade;Immune suppression;Metabolism;Tumor evasion;Tumor microenvironment
179 Poster Presentation T-cells derived from malignant pleural effusions (MPE) are readily expandable, polyfunctional and cytotoxic to autologous tumor Vera S. Donnenberg, PHD; Albert D. Donnenberg, MD; James D. Luketich, MD; Shannon Puhalla, MD; Yasa S. Mutlu, MD; David Bartlett, MD Cellular Therapies Adoptive immunotherapy;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
180 Poster Presentation The in-vitro measure of T cell avidity between tumor-effector pairs, not affinity, predicts optimal anti-tumor response in vivo Justin M. Moser, PhD; Yotam Bar-Ephraim, PhD; Jens Eberlein, PhD; Keith Bailey, PhD; Song-My Hoang, PhD; Andrea Candelli, PhD; Will Singleterry, PhD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Bispecifics;Solid tumors;T cell
181 Poster Presentation High throughput screening strategies in the development of logic gated cell therapies Rona Harari-Steinfeld, PhD; Laura Lim; Angela C. Boroughs; Sofia Kyriazopoulou Panagiotopoulou; Cate Sue; Jamie Thomas; Jon Chen; Aaron Cooper; Ryan Fong; Mary Chua; Ed Yashin; Christine Shieh; Sophie Xu; Nicholas Haining Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell
182 Poster Presentation Discovery of TSC-203-A02: A PRAME-specific TCR-T cell therapy candidate for the treatment of solid tumors Mollie M. Jurewicz, PhD; Elizabeth M. Hall; Alexandra L. Luther; Kimberly M. Cirelli, PhD; Vivin Karthik; Kenneth L. Jahan; Tary Traore, PhD; Maytal Bowman; Victor Ospina; Sonal Jangalwe, PhD; Shubhangi Kamalia; Sadie Lee; Daniel C. Pollacksmith; Sida Liao, PhD; Amy Virbasius, PhD; Kristen Murray; Jillian L. Oliveira; Lisa Nip, PhD; Christina E. Lam; Livio Dukaj, PhD; Danielle Ramsdell; Jin He; Joel W. Sher, PhD; Ribhu Nayar, PhD; Qikai Xu, PhD; Yifan Wang, PhD; Antoine J. Boudot, PhD; Cagan Gurer, PhD; Gavin MacBeath, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy;Tumor antigens
183 Poster Presentation Cancer-mutation-specific T cells: novel immunotherapy approach for low mutational burden patients    Alfred E. Slanetz, Ph.D.; Walter Barry, Ph.D.; Benjamin Schwarz, M.D. Ph.D.; Farzonai Muzaffar; Ryan Campbell; Abenezer Abera Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Cytokine;Neoantigens;RNA;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor microenvironment
184 Poster Presentation Discovery, cloning and functional validation of a neoantigen specific patient derived TCR on the Berkeley Lights platform, with implications in personalized cancer immunotherapy Joseph M. Valdez, Ph.D.; Guido Stadler, Ph.D.; Pei-Yu (Kate) Lin, Ph.D.; Milton Quintanilla; Tyler Helmann; Xiuli Zhang, M.D.; S. Peter Goedegebuure, Ph.D.; Malachi Griffith, Ph.D.; William E. Gillanders, MD; William A. Hoos, MBA, MS; Yiyang Xu, Ph.D. Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Cytokine;Dendritic cell;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Vaccine
185 Poster Presentation Tuning the cell-cell distance via the non-signaling extracellular spacer domain of chimeric antigen receptors is critical for optimal activity Jason K. Yokoyama, BS; Lisa Song; Quinn Walker; Bijan A. Boldajipour, PhD; Howell Moffett; Brian Weitzner; Scott Boyken; Marc Lajoie Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell
186 Poster Presentation Tumor reactive, cytokine induced, engineered human natural killer cells demonstrate serial cytotoxicity against liquid and solid tumor cell targets Ting Lu; Christian Bustillos; Zhiyao Li; Jianying Zhang; Lei Zhang; Li Chen; Jianhua Yu; Michael A. Caligiuri, MD Cellular Therapies Adoptive immunotherapy;Cytokine;NK/NKT cell
187 Poster Presentation A live tumor fragment platform suitable for assessing response to T-cell therapies Christopher D. Zahm, PhD; Laura Hrycyniak; Ellen Wargowski; Dinesh Joshi; Team Adstamongkonkul; Greg Ochs; Gabriella Stueber; Debra Bloom; Ryan Fischer; Christina Scribano; Christin Johnson; Anura Shrestha; Nathan Marhefke; Ariah Law; Jonathan Oliner Cellular Therapies Biomarkers;CAR T cells;Clinical trial;Cytokine;Immune monitoring;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
188 Poster Presentation Arginine pre-conditioning enhances T-cell potency and metabolic fitness    Rashmi Pillai, PhD; Xiaoyu Zhang; Brandon Lamarche, Ph.D.; Yama Abassi, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Metabolism;T cell;Tumor microenvironment
189 Poster Presentation CRISPR-mediated metabolic reprograming of adoptively transferred T cells to potentiate antitumor response   Soraya Zorro Manrique, Ph.D.; Yunfei Wang, PHD; Ana L. Dominguez; Debra S. Armendariz; Patrick Hwu Cellular Therapies Adoptive immunotherapy;Immune suppression;Metabolism;Solid tumors;T cell;Tumor microenvironment
190 Poster Presentation Novel Cellular Immunotherapy with anti-mesothelin CAR-killer lymphocytes against advanced Cholangiocarcinoma Annamaria Massa, PhD; Annamaria Massa; Valeria Leuci; Federica Galvagno; Chiara Donini; Francesca Vita; Ramona Rotolo; Alessia Proment; Letizia Vitali; Elisabetta Fenocchio; Elisa Vigna; Giuliana Cavalloni; Massimo Aglietta; Dario Sangiolo Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell lineages;Tumor antigens
191 Poster Presentation Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Bladder Cancer to Enhance Efficacy of Adoptive Cell Therapy (ACT) Sarah Bazargan, PhD Candidate; Brittany Bunch, PhD; Jamie Blauvelt; Annick Landin; Johannes Ali; Dominique Abrahams; Amy Hall; Matthew Beatty, PhD; Michael Poch, MD; Shari Pilon-Thomas, PhD Cellular Therapies Adoptive immunotherapy;Chemotherapy;MDSC;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs)
192 Poster Presentation Characterization of antibodies against BTN2A1 for Vδ2+ γδ T cell-based tumor immunotherapy    Kok Fei Chan, PhD; Simone Ostrouska; Ranjeeta Prasad; Daria Kurtov; Andrew Hammet; Marc Rigau; Adam P. Uldrich; Andreas Behren Cellular Therapies Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
193 Poster Presentation CAR-T manufactured from frozen PBMC yield efficient function with delayed in vitro expansion Julieta Abraham-Miranda, Pharm, PhD; Meghan Menges; Reginald Atkins; Mike Mattie, PhD; Justyna Kanska; Joel Turner; Melanie J. Hidalgo-Vargas; Frederick L. Locke, MD Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;T cell
194 Poster Presentation Pre-clinical development of CT-1119, a mesothelin targeting chimeric antigen receptor macrophage (CAR-M), for solid tumor immunotherapy Nicholas R. Anderson, PhD; Michael Klichinsky, PharmD, PhD; Kerri Ciccaglione; Stefano Pierini; Brinda Shah; Alison Worth, MSc; Rashid Gabbasov, PhD; Brett Menchel, MBT; Daniel Blumenthal, PhD; Sabrina DeLong, PhD; Sascha Abramson, PhD; Thomas Condamine, PhD Cellular Therapies Antigen presenting cells;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy
195 Poster Presentation Characterization of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity Laura L. Arthur, PhD; Mary E. Mathyer, PhD; Celeste J. Dufour, B.S.; Bryan Cruz, B.S.; Melissa Berrien-Elliot, PhD; Mark Foster, PhD; Nitin Mahajan, PhD; Alun Carter, PhD; Matthew L. Cooper; Ryan Sullivan, PhD Cellular Therapies Adoptive immunotherapy;NK/NKT cell
196 Poster Presentation Expansion of tumor-infiltrating lymphocytes from colorectal cancer liver metastasis; characteristics and potential histologic marker of successful cell expansion Jina Baek, MD; Hyun Lee, MD; Gyungyub Gong; Chae-Lyul Lim; Hee Jin Lee Cellular Therapies Adoptive immunotherapy;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
197 Poster Presentation Preliminary safety and efficacy of autologous anti-MSLN T cell engager-loaded T cells (CAB-T) in patients with mesothelin-expressing advanced solid tumors    Xuanwen Bao; Lulu Liu; Jialin Gu; Mei Li; Zhou Tong; Hangyu Zhang; Yalin Li; Xinjiang Gong; Peng Wang; Andy Tsun; Guoqiang Hu; Chuan-Chu Chou, PhD; Zhiyuan Li; Weijia Fang Cellular Therapies Adoptive immunotherapy;Bispecifics;CAR T cells;Clinical study;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
198 Poster Presentation Innate-Enhanced Chimeric Adaptors (CAd): A Newly-Described Approach for Augmenting Potency of γδ T Cell Immunotherapy Marissa Herrman, PhD; Taylor Barca; Xue (Cher) Yang; Maryam Tabrizizad; Morgan Smith-Boeck; Louise Kiru; Jonathan T.S. Wong; Ramandeep Kaur; Smitha R.Y. Gundurao; Gauri Lamture, PhD; Aruna Azameera; Kevin P. Nishimoto, PhD; Arun Bhat; Blake T. Aftab, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell
199 Poster Presentation 3D Ex vivo Patient Tissue Platform for Immuno-Oncology Drug Testing  Sander Basten, PhD; Nataliia Beztsinna; Fanny Grillet; Kuan Yan; Niels Meesters; Donny van der Meer; Emma Spanjaard; Willemijn Vader; Leo Price Cellular Therapies Biomarkers;Checkpoint blockade;Chemokine;Chemotherapy;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
200 Poster Presentation A Unique CRISPR-Based Nuclease with a Non-NGG PAM Efficiently Targets Multiple Exclusive Genomic Sites for Immuno-Oncology Based Therapy Rachel Diamant, M.Sc; Lior Lior Izhar; Ira Gotliv; Yonit Ben David; Sigal Cohen; Maya Noff; Nir Shahar; Rafi Emmanuel; Bar Ben Baruch Cellular Therapies CAR T cells;NK/NKT cell;T cell;Targeted therapy;Tumor microenvironment
201 Poster Presentation Development of GUCY2C-TAC T cells for the treatment of colorectal cancer    Tania Benatar, PhD; Ling Wang, MD; Thanyashanthi Nitya-Nootan, BSc; Heather L. MacGregor, PhD; Suzanna L. Prosser, PhD; Philbert Ip, PhD; Prabha Lal, PhD; Stacey X. Xu, PhD; Laura M. Shaver; Sadhak Sengupta, PhD; Christopher W. Helsen, PhD; Andreas G. Bader, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens
202 Poster Presentation Single step knock-in of next generation inducible IL-12 armored CAR T constructs Alexander Benton, BA; Anze Smole, Ph.D.; Mathilde Poussin; Monika A. Eiva, BS; Daniel J. Powell, PhD Cellular Therapies CAR T cells;Cytokine;Immune toxicity;Solid tumors
203 Poster Presentation Preclinical Discovery and Characterization of Allogeneic anti-PSMA γδ CAR T Therapy for Prostate Cancer  Nitya S. Ramadoss, PhD; Aruna Azameera; Alexander G. Teague; Jonathan T.S. Wong; Atrish Bagchi; Tonya Capillo; Morgan Smith-Boeck; Michael Salum; Erika Meaddough; Elizabeth Speltz; Matthew Hoopes; Katherine Wang; Ramandeep Kaur; Smitha R.Y. Gundurao; Marissa Herrman, PhD; Yvan Chanthery; Blake T. Aftab, PhD; Kevin P. Nishimoto, PhD; Arun Bhat Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens
204 Poster Presentation Combining FT536, a pan-tumor targeting CAR NK cell therapy, with CD16 engagers provides a coordinated targeting strategy to overcome tumor heterogeneity     John Goulding, PhD; Bryan Hancock; Robert Blum; Wen-I Yeh, PhD; Chia-Wei Chang, PhD; Mochtar Pribadi, PhD; Yijia Pan, PhD; Hui-Yi Chu, PhD; Shohreh Sikaroodi, PhD; Thomas Dailey, BS; Miguel Meza; Lucas Ferrari de Andrade, PhD; Peter Szabo, MD, PhD; Sarah Cooley, MD, MS; Jeffrey Chou, MD, PhD; John D. Powderly, II, MD; Yu-Waye Chu, MD; Tom T. Lee, PhD; Ryan Bjordahl, PhD; Kai W. Wucherpfennig, MD, PhD; Bob Valamehr, PhD Cellular Therapies Adoptive immunotherapy;Antibody;NK/NKT cell;Solid tumors
205 Oral Presentation Specific AMPK agonism during CART in vitro expansion enhances oxidative metabolism and improves in vivo leukemia clearance    Erica Braverman, MD; Harrison Brown; Manda Ramsey; Craig Byersdorfer, MD, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;Metabolism
206 Poster Presentation Novel intermediate-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against human hepatocellular carcinoma Leidy D. Caraballo-Galva; Xiaotao Jiang; Mohamed S. Hussein; Huajun Zhang; Rui Mao; Pierce Brody; Yibing Peng; AIwu He; Mercy Kehinde-Ige; Ramses Sadek; Xiangguo Qiu; Huidong Shi; Yukai He Cellular Therapies Adoptive immunotherapy;Antibody;CAR T cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
207 Poster Presentation Claudin18.2-targeting CAB-T cells have superior safety over traditional CAR-T, while maintaining potent in vivo anti-tumor efficacy Jitian Chai; Weifeng Huang; Shaogang Peng; Zhenqing Zhang; Yao Yan; Chuan-Chu Chou, PhD; Andy Tsun; Zhiyuan Li Cellular Therapies Antibody;Bispecifics;Costimulation;Immune toxicity;Solid tumors;T cell lineages;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
208 Poster Presentation T-SIGn vector-mediated antigen 'spray painting' and tumor microenvironment (TME) reprogramming to enable CAR-T cell targeting of solid tumors Maria Stella Sasso; Rachel Bergin; Manuela Zonca; Eva Vainiute; Tae Hyun Jang; Zahra Oubihi; Meg Snowden; Alice Muntzer; Carla Cerqueira; Rochelle Lear; Katy West; Brian R. Champion, PhD Cellular Therapies Bispecifics;CAR T cells;Gene expression;Solid tumors;T cell;Tumor microenvironment
209 Poster Presentation Anti-ALPP CAR-T Cell Immunotherapy for Ovarian and Endometrial Cancer Si Li, PhD; Qi-Jing Li, PhD; Nicole Palmer; Johnny Guan; Zhenbo Su; Peter Alexander, PhD; Rui Chen, PhD; Lixia Zhao, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell;Tumor antigens
210 Poster Presentation Generation of hypoimmunogenic allogeneic CAR T cells by inactivation of transcriptional regulators of HLA Class I and II genes Hsinyuan Cheng, PhD; Michael Yi; Michael T. Bethune; Eric Gschweng; Melinda Au; Duy Nguyen; Kristen Zhang; Tanu Shenoy; Barbra J. Sasu, PhD; Thomas Van Blarcom; Cesar Sommer Cellular Therapies Adoptive immunotherapy;CAR T cells;Gene expression;Immune tolerance;Leukemia/Lymphoma;NK/NKT cell;T cell
211 Poster Presentation Chemical priming of natural killer cells for cancer immunotherapy   Seung Hee Choi; Eun-Su Ko; Joo Dong Park, MS; Kyung-Soon Park Cellular Therapies Chemokine;Cytokine;Granulocyte;Immune contexture;Immune toxicity;Metabolism;NK/NKT cell;Proteomics;Solid tumors;Tumor infiltrating lymphocytes (TILs)
212 Oral Presentation Adoptively transferred Th17 cells cooperate with host B cells to mediate robust immunity to tumors    Anna C. Cole, B.A.; Hannah M. Knochelmann, MD, PhD; Amalia M. Rivera-Reyes; Aubrey S. Smith, Ph.D.; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S.; Jeremy M. Boss, Ph.D.; Gregory B. Lesinski, Ph.D.; Chrystal M. Paulos, PhD Cellular Therapies Adoptive immunotherapy;B cell;Solid tumors;T cell
213 Poster Presentation Design, characterization and preclinical validation of a combinatorial CAR-based immunotherapy against colorectal cancer with HER2 amplification    Marco Cortese, PhD; Erica Torchiaro, Post-doc; Simonetta M. Leto, Post-doc; Consalvo Petti, Post-doc; Alice D'Andrea, MS; Federica Invrea, Post-doc; Sabrina Arena, Associate Professor; Enzo Medico, MD PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;NK/NKT cell;Solid tumors
214 Poster Presentation Investigating the Consequences of TIM-3 Expression on mTOR Activation and NK Cell Cytotoxicity against Glioblastoma    Tram Dao, BS; Sandro Matosevic, PhD Cellular Therapies Adoptive immunotherapy;Metabolism;NK/NKT cell;Tumor infiltrating lymphocytes (TILs)
215 Poster Presentation Targeting ovarian carcinoma with GDT002, a first-in-class γδTCR-based T cell therapy Esther Drent, PhD; Sabine Middendorp, PhD; Andrea Bisso, PhD; Sjoerd Baardman; Dagmar Verweij; Estefania Salcedo; Chris Coomans; Steven Braem; Sander van de Weg; Menno Meijer; Natalie Proost; Marieke van de Ven; Haakan Norell; Marleen van Loenen; Nia Emami; Sara Melief; Stefania Gobessi; Mark Throsby, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell
216 Poster Presentation Dual targeting of CAR-NK cells to PD-L1 and ErbB2 facilitates specific elimination of cancer cells of solid tumor origin and overcomes immune escape by antigen loss Jiri Eitler, PhD; Kristin Freudenberg; Paola Ortiz Montero; Wiebke Rackwitz; Winfried Wels, PhD; Torsten Tonn Cellular Therapies Checkpoint blockade;NK/NKT cell;Targeted therapy;Tumor evasion
217 Poster Presentation Multi-armored allogeneic MUC-1 CAR T-cells efficiently control triple negative breast cancer tumor growth Piril Erler, PhD; Tomasz Kurcon; Jordan Skinner; Chantel Dixon; Steven Grudman; Ben Mumford; Shipra Das, PhD; Alexander Boyne, PhD; Alexandre Juillerat; Roman Galetto, PhD; Julien Valton, PhD; Hana Cho; Laurent Poirot, PhD; Beatriz Aranda-Orgilles, PhD Cellular Therapies CAR T cells;Solid tumors;Tumor microenvironment
218 Oral Presentation Immunogenic landscape and therapeutic targeting of mutant NRAS 'public' neoantigens    Iñaki Etxeberria, PhD; Lauren B. Banks, MD PhD; Smita S. Chandran, PhD; Arianna Correa; Bryan C. Novak; Jessica M. Fleischman; Alexander Drilon, MD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD; Christopher A. Klebanoff, MD Cellular Therapies Adoptive immunotherapy;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
219 Poster Presentation The Functional Activity of Gavo-cel TRuC-T Cells is not Impaired by Soluble Mesothelin    Michael Lofgren, PhD; Robert Tighe, PhD; Robert Hofmeister, PhD; Jian Ding, PhD; Nate Bagge, BS; Alec Andrews, MS; Michelle Fleury, PhD; Courtney Anderson, PhD Cellular Therapies Clinical trial;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor microenvironment
220 Poster Presentation Luciferase reporter cancer cell lines facilitate CAR-T development John G. Foulke, MS; Luping Chen, BS; Brian Della Fera, BS; Hyeyoun Chang, PhD; Kevin Tyo, PhD; Zhizhan Gu, MD, PhD; Fang Tian, PhD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Immune monitoring;Leukemia/Lymphoma;Solid tumors;Targeted therapy;Tumor antigens
221 Poster Presentation SENTI-401, an Allogeneic Logic-Gated and Multi-Armed CAR-NK Cell Therapy for the Treatment of CEA-Expressing Solid Tumors with Enhanced Selectivity and Efficacy Alba Gonzalez Junca, PhD; Nicholas Frankel, PhD; Maelig Morvan, PhD; Assen Roguev, PhD; Michelle Hung, PhD; Russell Gordley, PhD; Miguel R. Palermo; Tyler Santomaso; Pearley Chinta; Aldo Sotelo, MS; Marcus Gainer, MS; Derrick Lee; Tony Hua, PhD; Andrew Banicki; Mengxi Tian; Niran Almudhfar; Atahualpa Contreras; Chen-Ting Lee, PhD; Timothy K. Lu, PhD Cellular Therapies Adoptive immunotherapy;Cytokine;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment
222 Poster Presentation Developing an Adoptive Cell Transfer Immunotherapy for Pediatric High-Grade Gliomas Stephen C. Frederico, M.S.; Chaim T. Sneiderman, B.S.; Ian F. Pollack, M.D.; Gary Kohanbash, Ph.D. Cellular Therapies Adoptive immunotherapy;Pediatric tumors;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
223 Poster Presentation anti-TnMuc1 CAR-T Cells that are Conditionally Armed with IL12 Eliminate Adenocarcinomas in Preclinical Models    Albert Gacerez, PhD; Eytan Herzig, PhD; Tiger G. Ren, MD,PhD; Nicole Grant; Jay Danao; Daniel Roche, PhD; Daeun Nam, PhD; Krista McNally; Ben Wang; Melissa Fardy, PhD; Gus Zeiner, PhD Cellular Therapies CAR T cells;Cytokine;Gene expression;Immune toxicity;Metabolism;Post-translational modifications;RNA;Solid tumors;T cell;Tumor microenvironment
224 Poster Presentation Generation of cell therapies for diverse applications using microfluidic Cell Squeeze manufacturing technology Jonathan Gilbert, PhD; Maisam Dadgar; Scott M. Loughhead, PhD; Ipsita Roymoulik; Devin Bridgen, PhD; Howard Bernstein, MD, PhD; Armon Sharei, PhD Cellular Therapies Antigen presenting cells;CAR T cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine
225 Poster Presentation Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) immune checkpoint as a modulator of T-cell effector function Miguel Gomez Fontela, PhD; Sebastian Snedal; Daniel Abate-Daga, PhD Cellular Therapies CAR T cells;Checkpoint blockade;Cytokine;Immune suppression;Solid tumors;Systems biology;T cell;Targeted therapy
227 Poster Presentation hunTR™: a hyperplex platform for the discovery of neoantigen-reactive T-cell receptors Guowei Gu, Ph.D Pharm.D; Julissa Simmons; Kristen Rimaila; Gaby Garland; Ugochi Ibekwe; Donghyun Joo; An Lu; Amanda Montoya; Pretty R. Mathew; Hao Zhao; Beatriz A. Santillan; Matthew R. Collinson-Pautz; Drew C. Deniger Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Bioinformatics;Gene expression;Neoantigens;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
228 Poster Presentation Multi-Arming and Regulator Dial gene circuits tackle key challenges in solid tumors Marcela Guzman Ayala, PhD; Michelle Hung, PhD; Deepika Kaveri, PhD; Rebecca Cottman, PhD; Elizabeth Leitner; Priscilla Wong; Ronni Ponek; Enping Hong, PhD; Manan Shah; Andrew Banicki; Lawrence Naitmazi; Kelly Lee, PhD; Wesley Gorman; Russell Gordley, PhD; Philip Lee, PhD; Timothy K. Lu, PhD Cellular Therapies Immune suppression;NK/NKT cell;Solid tumors;Targeted therapy
229 Poster Presentation A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer J. Randolph Hecht, MD; Mark L. Sandberg, PhD; Xueyin Wang; Aaron D. Martin, M.A.; Daniel Nampe; Grant Gabrelow; Chuck Z. Li; Michele Mcelvain; Wen-Hua Lee; Sanam Shafaattalab; Sara Martire; Fernando Fisher; Yuta Ando; Edwin Liu; David Ju; Jing-Ping Hsin; Alexandre Zampieri; Diane M. Simeone, MD; Scott Kopetz, PhD; Maria Pia Morelli; Mitesh J. Borad, MD; Theodore H. Welling; Sandip P. Patel, MD; Edward B. Garon; Kedar Kirtane; Frederick L. Locke, MD; John S. Welch; Eric W. Ng, MD; William Y. Go; Armen Mardiros; David G. Maloney, MD, PhD; Lu-Min Wong; Alexander Kamb, PhD; Han Xu, PhD; Julian R. Molina, MD, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Gene expression;Genetic polymorphism;Solid tumors;T cell;Tumor antigens;Tumor evasion
230 Poster Presentation TCR-like chimeric-antigen-receptor to recognize neoepitopes derived from driver mutations    Yafei Hou, phD; David Hou, BA Cellular Therapies CAR T cells;Neoantigens;Solid tumors;T cell
231 Poster Presentation Dysfunctional immune synapses restrain anti-DIPG activity of CAR T cells Jorge Ibanez, PhD; Haley Houke; Michaela Meehl; Jennifer Ocasio; Nikhil Hebbar; Paulina Velasquez; Suzanne Baker; Giedre Krenciute, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Immune suppression;Pediatric tumors;Solid tumors;T cell
232 Poster Presentation Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-RTM genetic reprogramming technology Helle Jensen; Rachel Fukuda; Megan Murt; Xiao Wang; Lora Zhao; Sheila Lou; Purnima Sundar; Christopher Navas; Andrew Jimena; Amanda Sims; Travis Beckett; Shobha Potluri; Rowena Martinez; David Chian; Candace Sims; Quinn Walker; Abira Bandyopadhyay; Breanna Pamintuan; Bijan Boldajipour; Chang-Chih Wu; Martin Wohlfahrt; Byoung Ryu; Viola C. Lam; Rachel C. Lynn; Hajime Hiraragi; Johannes Breuning; Ashley Hamilton; Fotini Kouri; Jack Euesden; Sara Brett; Blythe Sather Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Targeted therapy
233 Poster Presentation A real-world case of second chimeric antigen receptor t-cell therapy Jacinth Joseph, MD; Dennis Marjoncu, PharmD; Kori Holman, PharmD; Sara Leidy, PharmD Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma
234 Poster Presentation Bead-bound antibody-activation of T cells provides sub-optimal metabolic programming and tumour control compared to dendritic cell-activated T cells Meghan Kates, BSc; Gavin Yuen; Michael St. Paul, PhD; Alisha R. Elford; Pamela S. Ohashi, PhD; Sam Saibil, MD, PhD Cellular Therapies Adoptive immunotherapy;Dendritic cell;Metabolism;T cell
235 Poster Presentation CRISPR-mediated insertion of IL-12 into the PDCD1 locus improves the antitumor activity of TCR-T cells against solid tumors Segi Kim; Choi Park; Sunhwa Lee; Hyeongryeol Choi; Chan Hyuk Kim Cellular Therapies Adoptive immunotherapy;Cytokine;Solid tumors;T cell
236 Poster Presentation Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the successful expansion factors for developing adoptive cell therapy Mofazzal Hossain, MBBS; Jong Hyeok Kim; Hyun Lee, MD; Chae-Lyul Lim; Gyungyub Gong; Hee Jin Lee Cellular Therapies Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs)
237 Oral Presentation Neoantigen-specific expansion of tumor-infiltrating lymphocytes enables effective treatment of p53-mutant cancer in mice   Peter Kim, PhD; Noam Levin; Nolan Vale; Steven A. Rosenberg, MD, PhD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Neoantigens;Solid tumors;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
238 Poster Presentation Exogenous GOT2 in CAR-T cells improves metabolic function and preserves early memory T cell subsets John W. Hinds, PhD; Sujatha Muralidharan, PhD; Ann M. Ranger, PhD; Jennifer A. Coccia; Thomas P. Giordano, III; Emily G. Kuiper, PhD; Pratirodh Koirala, PhD Cellular Therapies CAR T cells;Metabolism;Solid tumors;T cell lineages;Tumor infiltrating lymphocytes (TILs)
239 Poster Presentation Engineering of potency-enhanced TCR-edited T cells for shared neoantigen-targeted cancer immunotherapy Lianne Kok; Sander R. Eshuis, MSc; Paula Kroon, PhD; Vanessa Tubb, PhD; Xiangjun Kong, PhD; Carsten Linnemann; Gavin M. Bendle; Jeroen W.J. van Heijst, PhD Cellular Therapies T cell
240 Poster Presentation Humanized CD30 chimeric antigen receptor T cells with a novel 4-1BB derived spacer have improved activity and safety against CD30-positive lymphomas​ Lindsay Kua, PhD; Chee Hoe Ng; Jin Wei Tan; Richard Ong; Cheah Chen Seh; Fiona Wong; Don Sim; Ivan David Horak; Lionel Low; Kar Wai Tan Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;T cell
241 Poster Presentation Development of a personalized neoantigen-specific TCR discovery platform Robbert M. Spaapen, PhD; Thomas Kuilman, PhD; Bo S. Schrikkema; Jules Gadiot; Raquel Gomez; Julia Walker; Laura Bies; Oscar Krijgsman; Yvonne B. Claassen; Milena Viyacheva; Demi Houg; Manuel Soarnil; Huiwen Ding; Bas Stringer; Gavin M. Bendle; Carsten Linnemann; Ton N. Schumacher, PhD Cellular Therapies Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
242 Poster Presentation Development of pooled screening platform for discovering the next generation Chimeric Antigen Receptors Taeyoon Kyung, PhD; Nicole Wong; Andreas Rolfs; Lucas Hartsough; Joshua Mace; Jai Raman; Adam Scheidegger; Adam Meyer; Siqi Zhao; Lauren Baugh; Keith Robison; Narendra Maheshri; Shawdee Eshghi Cellular Therapies CAR T cells;Costimulation;T cell
243 Poster Presentation NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo Viola C. Lam, PhD; Jessica Barragan; Christina Cheung, MS; Jia Lu, PhD; David Chian; Rowena Martinez; Candace Sims; Purnima Sundar; Hajime Hiraragi; Shobha Potluri; Rachel C. Lynn, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy
244 Oral Presentation AFNT-111, a safe and effective TCR-engineered T cell therapy targeting the oncogenic driver KRAS G12V mutation Hubert Lam, PhD; Xingyue He, PhD; Cheryl Black; Michele M. Hoffmann, PhD; Joshua Francis, PhD; James Parsons; Christian Roy; Jinsheng Liang; Hongjing Qu; Martin Campbell; Tomasz Sewastianik, PhD; Jessica Webb; Aude G. Chapuis, PhD; Thomas M. Schmitt, PhD; Philip D. Greenberg, MD; Damien Hallet; Markus P. Vallaster; Piotr Pierog; Gary Shapiro, PhD; Loic Vincent, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Clinical trial;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens
245 Poster Presentation Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia Monica Raimo, PhD; Nina Lamers-Kok; Didem O'Zkazanc; Daniëlle Steenmans; Greis Shahini; Amanda van Vliet; Denise Panella; Arianna Micciché; Youri van Waardenburg; Anna-Maria Georgoudaki; Jan Spanholtz; Adil D. Duru Cellular Therapies Adoptive immunotherapy;B cell;Bioinformatics;Gene expression;Leukemia/Lymphoma;NK/NKT cell;Tumor antigens
246 Poster Presentation Allogeneic 'off-the-shelf' γδ T cells modified with CD27-containing CAR for targeting CD70+ cancers Gauri Lamture, PhD; Alexander G. Teague; Morgan Smith-Boeck; Michael Salum; Ramandeep Kaur; Smitha R.Y. Gundurao; Pannaga Parthasarathy; Yvan Chanthery; Marissa Herrman, PhD; Blake T. Aftab, PhD; Arun Bhat; Kevin P. Nishimoto, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Tumor antigens
247 Poster Presentation Preclinical Discovery and Evaluation of Allogeneic 'Off-the-Shelf' γδ CAR T Cells Targeting B7-H6+ Tumors Gauri Lamture, PhD; Alexander G. Teague; Jonathan T.S. Wong; Morgan Smith-Boeck; Michael Salum; Erika Meaddough; Pannaga Parthasarathy; Atrish Bagchi; Matthew Hoopes; Elizabeth Speltz; Ramandeep Kaur; Smitha R.Y. Gundurao; Nitya S. Ramadoss, PhD; Marissa Herrman, PhD; Blake T. Aftab, PhD; Arun Bhat; Kevin P. Nishimoto, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens
248 Poster Presentation Intrathecal Delivery of Dendritic Cell Vaccine Eradicates Tumor Growth and Protects Against Leptomeningeal Disease Re-inoculation in Immunocompetent HER2+ and Triple Negative Breast Cancer LMD Xenograft Models Vincent Law, MS; Krithika N. Kodumudi, PhD; Colin Snyder, MS; Brian Czerniecki, MD, PhD; Peter Forsyth Cellular Therapies Adoptive immunotherapy;Dendritic cell;Targeted therapy
249 Poster Presentation Heterogeneity and changes of T-cell subset proportion during the expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer    Hyun Lee, MD; Gyungyub Gong; Chae-Lyul Lim; Hee Jin Lee Cellular Therapies Adoptive immunotherapy;Biomarkers;T cell;Tumor infiltrating lymphocytes (TILs)
250 Poster Presentation Chimeric antigen receptors containing CD30-derived costimulatory domain elicit augmented T cell effector functions and anti-tumor efficacy Hyun-Il Cho, Ph.D.; Chung-Hyo Kang; Sang-Eun Lee; In-Sil Song; Jung-Min Ha; Hyun-Jung Sohn; Tai-Gyu Kim Cellular Therapies Adoptive immunotherapy;CAR T cells;Costimulation;Solid tumors
251 Poster Presentation Application of Antibody-Cell Conjugation Technology in a Novel Off-the-shelf CD20-targeting Gamma Delta T Cell Therapy ACE1831 Hao-Kang Li, Ph.D; Tai-Sheng Wu; Yi-Chiu Kuo; Ching-Wen Hsiao; Hsiu-Ping Yang; Chia-Yun Lee; Pei-Ju Leng; Zih-Fei Cheng; Sen-Han Yang; Yang-Liang Lin; Shih-Chia Hsiao; Sai-Wen Tang Cellular Therapies Adoptive immunotherapy;Leukemia/Lymphoma;T cell
252 Poster Presentation Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-RTM technology, a programmable synthetic cell-signaling platform Aileen Li, PhD; Jessica Briones; Jia Lu, PhD; Candace Sims; Quinn Walker; Rowena Martinez; Stefan Siebert; Lora Zhao; Emily Fu-Sum; Sheila Lou; Andrew Jimena; Elizabeth Pedrosa; Purnima Sundar; Hajime Hiraragi; Shobha Potluri; Bijan Boldajipour; Omar Ali; Alexander Cheung Cellular Therapies CAR T cells;Costimulation;Solid tumors;T cell
253 Poster Presentation Fully human CD123 CAR T cells irradicate AML in pre-clinical models and exhibit a favorable safety profile    Genqing Liang, PhD; Peirong Hu; Ngoc Tran; Hasan Mahmud; Pradyot Dash; Dina Schneider, Ph.D Cellular Therapies CAR T cells;Leukemia/Lymphoma;T cell;Targeted therapy
254 Poster Presentation The CBL-B inhibitor, NX-0255, enhances human drug enhanced tumor infiltrating lymphocyte (DeTIL) expansion and T cell function in full-scale runs Xiaoyan Liang, PhD; Xianzhu Wu, PhD; Jeevitha Jeevan, MS; Samuel Butler; Pranav Murthy, MS; Arthur T. Sands, MD PhD; Michael T. Lotze, MD Cellular Therapies Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs)
255 Poster Presentation ExPRESSTM: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTILTM product     Sharon Lin; Leila J. Williams, MS; Mitali Ghose, MS; Hugh Gannon, PhD; Conor Calnan; Angelina Pizzo; Pei-Lun Kao; Mallory Brady; Katri Sofjan; Anne Dodson, PhD; Sol Shenker, PhD; Michael Schlabach, PhD; Fiona Sharp, PhD; Frank Stegmeier, PhD; Micah J. Benson, PhD; Karrie K. Wong, PhD Cellular Therapies Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
256 Poster Presentation In Vivo expansion of endogenous antigen-specific CD8+ T cells using artificial T-cell stimulating microparticles Natalie K. Livingston, BS; John W. Hickey, PhD; Hajin Sim; Hai-Quan Mao, PhD; Jonathan P. Schneck, MD, PhD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Neoantigens;Solid tumors;T cell;Tumor antigens
257 Poster Presentation An off-the-shelf personalized cellular approach to immunotherapy for the treatment of advanced solid tumors  Miguel Lopez-Lago; William Williams; Giuseppe del Priore; Sagarika Pachhal; Vikas Bhardwaj; Xiaoyi Zheng; Mingjin Chang; Charles Wiseman Cellular Therapies Antigen presenting cells;Solid tumors;T cell;Targeted therapy;Vaccine
258 Poster Presentation Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance in solid tumors    Yong Lu, Ph.D; Ningbo Zheng Cellular Therapies CAR T cells;T cell
259 Poster Presentation iPSC-derived NK cells engineered with a novel TGFβ signal redirector receptor exhibit enhanced performance against solid tumors    Eigen Peralta, PhD; Dan Lu; Hui-Yi Chu, PhD; Justin Rahman; Diana Galvan; Amit Mehta; Eric Sung; Jeffrey Chen; Masanao Tsuda; Elena Demeester; Earl Avramis; Alec Witty; Tom T. Lee, PhD; Bob Valamehr, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Costimulation;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
260 Poster Presentation Investigating cancer cell autonomous CAR T cell therapy resistance in DLBCL in vitro Fabiana Lueoend, PhD; Youngchul Song; Beverly Nguyen; Xiaoyan Li; Andreas Raue; Jennifer L. Brogdon; Glenn Dranoff; Matthew J. Niederst; Louise M. Treanor Cellular Therapies CAR T cells;Leukemia/Lymphoma;Tumor evasion
261 Poster Presentation Evidence for durable anti-tumor responses by TAC-T cells in preclinical models of solid tumors Heather L. MacGregor, PhD; Duane Moogk, PhD; Stacey X. Xu, PhD; Joanne A. Hammill, PhD; Philbert Ip, PhD; Ling Wang, MD; Swati Shetty; Kyle MacDonald; Laura M. Shaver; Sailaja Pirati; Prabha Lal, PhD; Christopher W. Helsen, PhD; Jonathan L. Bramson, PhD; Sadhak Sengupta, PhD; Andreas G. Bader, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens
262 Poster Presentation Multiple targeting of solid tumors with iPSC-derived gamma delta CAR T cells in combination with therapeutic antibodies Hillary J. Millar Quinn; Justin Bianchini; Liam Campion; Katherine Santostefano; Toshinobu Nishimura; Sydney Bucher; Buddha Gurung; Shelby Keating; Rebecca Genovese; Steven DeLuca; Bruno Bonanno; David Walker; Marilda Beqiri; Chris Dower; Kaitlin Idank; Tomas Aramburu; Michael Naso; Luis Borges; Mark Wallet, PhD Cellular Therapies Adoptive immunotherapy;Antibody;CAR T cells;Solid tumors;T cell;T cell lineages
263 Poster Presentation A2B694, an autologous logic-gated cell therapy targeting mesothelin Julian R. Molina, MD, PhD; Talar Tokatlian; Jason Wang; Shruti Sharma; Diane Manry; Martin S. Naradikian; Grace E. Asuelime; Breanna DiAndreth; Aaron Winters; Tisha San Miguel; Armen Mardiros; Sandip P. Patel, MD; Edward B. Garon; Diane M. Simeone, MD; Scott Kopetz, PhD; Maria Pia Morelli; Theodore H. Welling; Mitesh J. Borad, MD; Kedar Kirtane; Eric W. Ng, MD; John S. Welch; David G. Maloney, MD, PhD; William Y. Go; Alexander Kamb, PhD; Agi E. Hamburger, PhD; J. Randolph Hecht, MD Cellular Therapies Adoptive immunotherapy;CAR T cells;Gene expression;Genetic polymorphism;Solid tumors;T cell;Tumor antigens;Tumor evasion
264 Poster Presentation Allogeneic natural killer cells engineered to express HER2-directed CAR, interleukin-15 and TGFß dominant negative receptor effectively control HER2+ tumors      Finola Moore, PhD; Andres Alvarez; Alexia Barandiaran; Luke Barron; Eugene Choi; Krista Daniel; Charlotte Franco; Bashar Hamza; Jennifer Johnson; Annie Khamhoung; Marilyn Marques; Henry Moreno; Angela Nunez; Dominic Picarella; Jared Sewell; Alex Storer; Meghan Walsh, MS; Vipin Suri Cellular Therapies Adoptive immunotherapy;NK/NKT cell;Solid tumors;Targeted therapy;Tumor microenvironment
265 Poster Presentation Empowering iPSC-Derived iNK Cells with Multiple Gene Edits to Improve Persistence and Anti-Tumor Efficacy    Buddha Gurung, PhD; Annalise Jethon; Maisha Harris; Shelby Keating; Spencer Moros; Rebecca Genovese; Steven DeLuca; Arden Edgerton; Nicholas Alexander; Chiamin Bullaughey, PhD; Barry Morse, PhD; Liam Campion; Mark Mendonca; Kaitlin Idank; Hillary J. Millar Quinn; Diana Chin; Jill Carton, PhD; Michael F. Naso, PhD; Mark Wallet, PhD; Luis G. Borges, PhD Cellular Therapies Adoptive immunotherapy;NK/NKT cell
266 Poster Presentation STING activation improves T cell engaging immunotherapy of Acute Myeloid Leukemia    Daniel Nixdorf, M.Sc.; Andreas Linder, Dr. med.; Niklas Kuhl; TengTeng Xu, M.Sc.; Roman Kischel, PhD; Veit Bücklein, Dr. med.; Thomas Carell, Prof. Dr.; Veit Hornung, Prof. Dr.; Marion Subklewe, Prof. Dr. med. Cellular Therapies Bispecifics;Immune adjuvant;Leukemia/Lymphoma;T cell;Targeted therapy;Tumor microenvironment
267 Poster Presentation mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy    Irene Olivera, MSc; Elixabet Bolanos; Jose González-Gomariz; Sandra Hervas-Stubbs; Karina V. Mariño; Carlos Luri-Rey; Iñaki Etxeberria; Assunta Cirella; Josune Egea; Javier Glez-Vaz; Saray Garasa, BS; Maite Alvarez; Iñaki Eguren-Santamaria; Sonia Guedan; Miguel F. Sanmamed; Pedro Berraondo, PharmD; Gabriel A. Rabinovich, PhD; Alvaro Teijeira, PhD; Ignacio I.M. Melero, MD, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;Metabolism;RNA;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
268 Poster Presentation Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells Alessia Potenza, PhD; Chiara Bonini, MD; Chiara Balestrieri; Luca Albarello; Federica Pedica; Martina Spiga; Francesco Manfredi; Beatrice C. Cianciotti; Claudia De Lalla; Lorena Stasi; Elena Tassi; Silvia Bonfiglio; Giulia M. Scotti; Miriam Redegalli; Donatella Biancolini; Danilo Abbati; Fabio Simeoni; Dejan Lazarevic; Ugo Elmore; Guido Fiorentini; Giulia Di Lullo; Giulia Casorati; Paolo Dellabona; Claudio Doglioni; Giovanni Tonon; Riccardo Rosati; Luca Aldrighetti; Eliana Ruggiero, PhD Cellular Therapies Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
269 Poster Presentation Mitochondrial apoptosis mediates CAR T cell cytotoxicity    Alexandra L. Pourzia, MD, PhD; Michael L. Olson, PhD; Stefanie R. Bailey, PhD; Aditi Aryal, BS; Jeremy Ryan, MS; Marcela V. Maus, MD, PhD; Anthony Letai, PhD MD Cellular Therapies CAR T cells;Leukemia/Lymphoma;Solid tumors;T cell;Tumor evasion
270 Poster Presentation Developing placental CD34+-derived natural killer cells with high affinity and cleavage resistant CD16 (CYNK-101) in combination with Avelumab for enhanced therapy against PD-L1+ solid tumors Irene Raitman, PhD; Gavin Foley; Eric He; Hemlata Rana, MS; Niranjan Ghimire, PhD; Xuan Guo, PhD; Robert Hariri, MD PhD; Lin Kang, PhD Cellular Therapies Antibody;Checkpoint blockade;Solid tumors;Tumor antigens
271 Poster Presentation B cell primed CD8 T cells generate similar phenotype, function and anti-tumor responses to DC primed CD8 T cells. Ichwaku Rastogi, MS; Douglas G. McNeel, MD, PhD Cellular Therapies Antigen presenting cells;B cell;Dendritic cell;Vaccine
272 Poster Presentation Pre-clinical evaluation and first-in-dog clinical trials of intravenous infusion of PBMC-expanded adoptive NK cell therapy in dogs with cancer      Aryana M. Razmara, MS; Lauren E. Farley, BS; Rayna M. Harris, PhD; Sean J. Judge, MD, MS; Marshall Lammers, BS; Cordelia M. Dunai, MS; William J. Murphy; Robert M. Rebhun, DVM PhD; Michael S. Kent, DVM; Robert J. Canter, MD Cellular Therapies Adoptive immunotherapy;Bioinformatics;NK/NKT cell;Radiotherapy;Solid tumors
273 Poster Presentation GDA-501: Engineered NAM-NK cells with HER2-CAR expression demonstrate increased cytotoxicity against HER2-expressing solid tumors Julia Rifman Cellular Therapies NK/NKT cell;Solid tumors
274 Poster Presentation LCK Knockout CAR-T Cells as a Novel Allogeneic Platform Previtha Dawn Sakthi Vale, B.Sc; Ling Wu, Ph.D.; Vivian Jia Yi Tan, B.Sc; Benson Chua; Liangzhe Wu; Jia Chi Tan; Clara Kai Ting Koh; June Ong; Nicholas Gascoigne Cellular Therapies Adoptive immunotherapy;Autoimmunity;CAR T cells;Immune tolerance;Leukemia/Lymphoma;Pediatric tumors;T cell;Targeted therapy
275 Poster Presentation Manufacture of allogeneic, HLA-matched, TCR-edited T-cell therapy reactive against minor histocompatibility antigen 1 to treat Acute Myeloid Leukemia in combination with CD34 HSCT with the potential for high potency and durability Robert Keefe, PhD; Tim mayall; Egidio Cofano; Marlyn Anguelov; Constantinos Panousis; Paola Sette Cellular Therapies Adoptive immunotherapy;T cell
276 Poster Presentation Engineering of synthetic chemokine receptors into iPSC-derived CAR-T cells to increase homing and enhance trafficking into solid tumors    Soheila Shirinbak, PhD; Joy Grant; Angela Gentile; Bishwas Shrestha, PhD; Philip Chu; Amit Mehta; Yijia Pan, PhD; Bjoern Gaertner; Mochtar Pribadi, PhD; Joyee Yao; Matthew Denholtz; Alec Witty; Layton H. Smith, PhD; Tom T. Lee, PhD; Eigen Peralta, PhD; Martin Hosking, PhD; Bob Valamehr, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Chemokine;Chemotherapy;Immune suppression;Solid tumors;T cell;Tumor evasion;Tumor microenvironment
277 Poster Presentation Development of a robust manufacturing process for AB-1015, an integrated circuit T cell (ICT) product, using targeted, CRISPR integration of transgenes by electroporation (CITE) editing Alice Chang; Sophia Phillips; Max Lee; Elizabeth Huang; Navneet Anand; Hayden Ko; Stella Tran; Lindsay Rios; Rory Dai; Anton Nguyen; Anu Vasudevan; Rona Harari Steinfeld; Dina Polyak; Jessica Fuhriman; Hongruo Yun; Jun Feng; Haixia Wang; Ben Tran; Jenessa Smith; Tim Sirichoke Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;Targeted therapy;Tumor microenvironment
278 Poster Presentation Pharmacologically-controlled expression of membrane-bound IL-12 results in T-cell therapy with enhanced potency in preclinical solid tumor models Sean G. Smith, PhD; Benjamin Primack, MS; Theresa Ross; Patricia Timpug; Dexue Sun, MS; Dan Jun Li, MD; Scott Lajoie; Violet Young; Meghan Langley; Jeremy Tchaicha, PhD; Dhruv Sethi; Jan H. ter Meulen, MD, PhD; Michelle L. Ols, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
279 Poster Presentation Preclinical in vivo model development: Highlighting success and discussing xenograft advancements, a step closer to predicting patient outcomes     Thomas Dailey, BS; Angela Gentile; Lexe Linderhof; Layton H. Smith, PhD; Bob Valamehr, PhD Cellular Therapies CAR T cells;Solid tumors
280 Poster Presentation Rapid and simplified process for manufacturing multi-tumor-associated antigen specific T cells    Anastasiya Smith, PhD; Tara Shahim; Jeanette Crisostomo, M.D.; Eric A. Smith, PhD; Jennifer Pickering; Anna Wilga-Savitski; Tsvetelina Hoang, PhD; Juan Vera, M.D. Cellular Therapies Leukemia/Lymphoma;T cell
281 Poster Presentation The two sides of the coin: pro-inflammatory stimuli lead to upregulation of CD70 in AML, but also reduce NK-cell-based immunotherapy efficacy.    Monika Sponheimer; Gerulf Hänel; Lisa Rohrbacher; Nora Philipp; Daniel Nixdorf; Anetta Marcinek; Christian Wichmann, Dr. med.; Andreas Humpe, Prof. Dr. med.; Shyra J. Gardai; Daniel Diolaiti; Veit Leonhardt Bücklein, Dr. med.; Marion Subklewe, Prof. Dr. med. Cellular Therapies Antibody;Biomarkers;Costimulation;Cytokine;Immune suppression;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy;Tumor antigens;Tumor microenvironment
282 Poster Presentation Anti-folate receptor alpha (FRα) CoStimulatory Antigen Receptor (CoStAR) improves T-cell function across physiologically relevant ranges of FRα expression and T-cell receptor (TCR) affinities Martina Sykorova; Michelle Mojadidi; Leyuan Bao; Eric Gschweng; Milena Kalaitsidou; Gray Kueberuwa; Xingliang Zhou; Rubén Alvarez-Rodríguez; John S. Bridgeman Cellular Therapies Adoptive immunotherapy;Costimulation;Cytokine;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
283 Poster Presentation Genome-wide CRISPR screens of cytotoxic T cells identify a novel regulator that enhances T cell effector function    Vivian Jia Yi Tan, B.Sc; Ling Wu, Ph.D.; Clara Kai Ting Koh; Yen Leong Chua; Liangzhe Wu; June Xu Hui Ong; Nicholas Gascoigne Cellular Therapies Adoptive immunotherapy;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
284 Poster Presentation Epstein Barr Virus Specific T cells (EBVSTs) expressing B7-H3 targeting chimeric antigen receptors (CAR) exhibit good pre-clinical activity and safety against B7-H3 positive solid tumors    Kar Wai Tan, PhD; Kar Wai Tan; Lionel Low; Xin Yu Koh; Lindsay Kua, PhD; Jin Wei Tan; Siok Ping Yeo; Joanna Kristyn Lim; May Delos Santos; Fiona Wong; Chek Meng Poh; Ivan David Horak; Angeline Goh Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell
285 Poster Presentation Multiomic Analysis of TIL Suggests That CD4+ Polarization Represses TIL Expansion and CD8+ Activation and is Associated with Progression of Disease. Brian Thompson; David M. Woods, PhD; Ann M. Strange; Carol M. Amato, MS; Jonathan Hester-McCullough; Jeffrey S. Weber, MD, PhD; Amod A. Sarnaik, MD, FACS Cellular Therapies Adoptive immunotherapy;Biomarkers;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
286 Poster Presentation Systemic distribution of gamma-delta PSCA-CAR T cells in combination with zoledronate in a model of bone metastatic prostate cancer  Leticia Tordesillas, PhD; Junior Cianne; Jeremy S. Frieling, PhD; Xiomar E. Bustos, MS; Conor C. Lynch, PhD; Daniel Abate-Daga, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell
287 Poster Presentation Novel, boosted, fully human ROR1-targeting CAR T cells effectively eliminate hematologic and solid tumors, and resist tumor microenvironment    Tri M. Tran; Bal Krishna Chand Thakuri; Saule Nurmukhambetova; Brittany Steimle; Ngoc Tran; Darong Wu, MS; Peirong Hu, PhD; Pradyot Dash; Dina Schneider, PhD Cellular Therapies CAR T cells;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
288 Poster Presentation Targeting cold tumors using iPSC-derived CAR T Cells directed to the immune checkpoint molecule and tumor-associated antigen B7-H3 Jon Tuncel; Bahram Valamehr, PhD; Xu Yuan, PhD; Francisco Martinez, PhD; Nicholas Brookhouser; Philip Chu; Duygu Ozmadenci; Zachary Davis; Robert Blum; Bryan Hancock; Bjoern Gaertner; Nicholas Zorko; Shohreh Sikaroodi, PhD; Miguel Meza; Thomas Dailey, BS; Martin Felices; Frank Cichocki; Lauren Fong, PhD; Tom T. Lee, PhD; Raedun Clarke, PhD; John Goulding; Ryan Bjordahl, PhD; Jeffrey S. Miller, MD Cellular Therapies CAR T cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
289 Poster Presentation Clinical expansion and persistence of CAR T-cells: An essential biomarker in need of standardization David Turicek; Victoria Giordani; Naomi Taylor, M.D., Ph.D.; Nirali N. Shah, MD Cellular Therapies Biomarkers;CAR T cells;Immune monitoring
290 Poster Presentation A novel iPSC-derived CAR-invariant natural killer T (iNKT) cell therapy platform for hematologic malignancies and solid tumors    Akane Urakami, PhD; Tomokuni Shigeura; Makoto Kondo; Mari Isomi; Yuko Kokubu, PhD; Ken-Ichi Suzuki, PhD; Haruhiko Koseki, MD, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;NK/NKT cell;Targeted therapy;Tumor microenvironment
291 Poster Presentation CAR T cells as a surgical adjuvant for unresectable adenocarcinoma Ugur Uslu, MD; Tong Da; Charles-Antoine Assenmacher; John Scholler; Regina M. Young; Julia Tchou; Carl June Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;Surgery;T cell
292 Poster Presentation Discovery and development of t cell receptors for adoptive t cell therapy against solid tumors    Juliana Velez Lujan, PhD; Hannah Fields; Kan Xing Wu; Natalie Epstein; Florence Chioh; Nicholas Tan; Daniel Carbajo; Neeraja Kulkarni; Lorenz Gerber; Yovita Purwanti; Alessandra Nardin, DVM; Michael Fehlings; Katja Fink; Dan Macleod Cellular Therapies Adoptive immunotherapy;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens
293 Poster Presentation The effects of negative isolation and aggregate strainers on expanded gamma/delta T cells and their cancer cell cytotoxicity Georg von Massow, MSc, BSc; Kenth Gustafsson; Jack Firth; Steve Oh; Alan Lam Cellular Therapies T cell;T cell lineages
294 Poster Presentation Preclinical studies of TAC01-CLDN18.2, an autologous Claudin 18.2-directed TAC T cell therapy, in the treatment of gastric cancer Ling Wang, MD; Stacey X. Xu, PhD; Tania Benatar, PhD; Suzanna L. Prosser, PhD; Laura M. Shaver; Ritu R. Randhawa, MSc; Philbert Ip, PhD; Prabha Lal, PhD; Thanyashanthi Nitya-Nootan, BSc; Heather L. MacGregor, PhD; Sadhak Sengupta, PhD; Christopher W. Helsen, PhD; Andreas G. Bader, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;Targeted therapy;Tumor antigens
295 Poster Presentation Affinity Fine-Tuning Anti-CAIX CAR-T Cells Mitigate On-Target Off-Tumor Side Effects    Yufei Wang, PhD; Alicia Buck; Michael Lynch; Gabriella Kastrunes; Jae-Won Cho; Marion Grimaud; David A. Braun; Cecile Razimbaud; Matthew Chang, MS; Atef Fayed; Audrey Apollon; Ze-Hua Li; Luann Zerefa; Brandon Piel; Elena Ivanova; Dennis Bonal; Kristen L. Jones, LATg; Quang-De Nguyen; Zhu Zhu; Kevin Wei; Rebecca Jennings; Miriam Ficial; Maura Aliezah Sticco-Ivins; Sabina Signoretti, MD; Catherine J. Wu, MD; Toni K. Choueiri, MD; Jon Wee; Cloud P. Paweletz, Ph.D.; Martin Hemberg; Aedin Culhane; David A. Barbie, MD; Gordon J. Freeman, PhD; Wayne Marasco, MD, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors
296 Poster Presentation Targeting B-cell malignancies with anti-ROR1 CAR T-cell therapy Jinsheng Weng, MD, PhD; Owhofasa O. Agbedia; Jingjing Cao; Xiaoyun Cheng; Shao Qing Kuang; Fuliang Chu; Sridevi Patchv; Yongfu Tang; Divyam Bansal; Jingwei Liu; Neeraj Saini; Sattva S. Neelapu, MD Cellular Therapies Adoptive immunotherapy;Antibody;Biomarkers;CAR T cells;Leukemia/Lymphoma;Solid tumors;T cell;Targeted therapy
297 Poster Presentation Manufacture of KSQ-001, a CRISPR/Cas9-engineered TIL (eTIL) therapy, for the treatment of Head and Neck Squamous Cell Carcinoma     Karrie K. Wong, PhD; Leila J. Williams, MS; Nick Constant; Mitali Ghose, MS; Sharon Lin; Frank Thompson; Conor Calnan; Fiona Sharp, PhD; Sean Donnelly; Charles Quinn; Glenn J. Hanna, MD; Frank Stegmeier, PhD; Micah J. Benson, PhD Cellular Therapies Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs)
298 Poster Presentation Oncometabolites in the tumor microenvironment drive altered natural killer cell functional capacity    Xinyu Wu, MSc; Sandro Matosevic, PhD Cellular Therapies NK/NKT cell
299 Poster Presentation 3D in vitro Tumor microenvironment models for screening CAR-T cell therapy efficacy. Bin Xue, PhD; Sophie C. Vermond, MSc; Ulrike Herbrand, PhD; David Harris; Gemma Moiset; Kolin C. Hribar, PhD; Julia Schuler, DVM PhD Cellular Therapies CAR T cells;Immune toxicity;Solid tumors;Tumor microenvironment
300 Poster Presentation Tri-modal CAR+TCR+hnCD16+ iPSC-derived T cells co-targeting surface and intracellular/neoantigens demonstrate additive effect on overcoming tumor heterogeneity and cancer escape.  Bi-Huei Yang, PhD; Soheila Shirinbak, PhD; Wen-I Yeh, PhD; Alma Gutierrez; Mochtar Pribadi, PhD; Bjoern Gaertner; Hui-Yi Chu, PhD; David Gonzalez; Angela Liao, MSc; Tom T. Lee, PhD; Eigen Peralta, PhD; Ryan Bjordahl, PhD; Martin Hosking, PhD; Chia-Wei Chang, PhD; Bob Valamehr, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Leukemia/Lymphoma;Solid tumors;T cell;Targeted therapy
301 Poster Presentation Single-cell RNA study of transcriptional activities associated with anakinra prophylaxis and axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma Ning Yao, MS; Matthew J. Frigault; Marc Wehrli; Kathleen M.E. Gallagher; Charlotte Graham; Caron A. Jacobson, MD, MMSc; Rhine Shen; Simone Filosto, PhD; Justin Budka; Sao-Mai Nyugen-Mau; Jenny Nater; Mike Mattie, PhD; Gad Getz; Nicholas J. Haradhvala; Marcela V. Maus, MD, PhD Cellular Therapies Bioinformatics;CAR T cells;Chemokine;Clinical trial;Gene expression;Immune toxicity;Inflammation;Monocyte/Macrophage;Regulatory T cell (Treg cell);T cell
302 Poster Presentation Allogenic adoptive NK cells and irradiation join force to control triple negative breast cancer stem cells    Meesun Yoon, MD. PHD Cellular Therapies Adoptive immunotherapy;NK/NKT cell;Radiotherapy
303 Poster Presentation Targeting Ewing sarcoma with anti-IL1RAP chimeric antigen receptor modified natural killer cells    Wen Luo, PhD; Poul Sorensen, PhD; Mitchell S. Cairo; Hai Hoang; Yaya Chu, PhD; Janet Ayello, MS, MT(ASCP); Wei Li, PhD; Michael Lizardo, PhD; Renata Ribeiro; Melanie Rouleau; Dimiter S. Dimitrov, PhD; Dean A. Lee; Hai-Feng Zhang, PhD Cellular Therapies NK/NKT cell;Pediatric tumors;Solid tumors
304 Poster Presentation Off-the-shelf iPSC-derived CAR-T cells containing seven functional edits overcome antigen heterogeneity, improve trafficking, and withstand immunosuppression associated with failed tumor treatment Martin Hosking, PhD; Soheila Shirinbak, PhD; Bishwas Shrestha, PhD; Joy Grant; Kyla Omilusik, PhD; Hannah Keegan; Demetrio Cardenas; Angela Gentile; Shilpi Chandra, PhD; Lorraine Loter; Lexe Linderhof; Nicholas Brookhouser, PhD; Stephanie Kennedy; Francisco Martinez, PhD; Loraine Campanati; Chris Ecker, PhD; Xu Yuan, PhD; Karina Palomares, PhD; Yi-Shin Lai, PhD; Lauren Fong, PhD; Yijia Pan, PhD; Shohreh Sikaroodi, PhD; Mark Jelcic, PhD; Philip Chu; Amit Mehta, PhD; Layton H. Smith, PhD; Eigen Peralta, PhD; Tom T. Lee, PhD; Ramzey Abujarour, PhD; Raedun Clarke, PhD; Bob Valamehr, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Chemokine;Immune suppression;Solid tumors;T cell;Tumor evasion;Tumor microenvironment
305 Poster Presentation Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors    Anthony K. Park, PhD; Saul J. Priceman, PhD; Leslie M.O. Chong; Yuman Fong; Isabel Monroy; Colin Cook; Monil Shah, PharmD Cellular Therapies Adoptive immunotherapy;Bispecifics;CAR T cells;Solid tumors
306 Poster Presentation Evaluation of AB-101, an Allogeneic Cord Blood-derived Natural Killer (NK) Cell Therapy, as an ADCC Enhancer in Hematologic and Solid Tumors Paul Rogers, PhD; Bitna Yang; Hyojin Kim; Yusun Kim, PhD; Sunglim Cho, PhD; Bret Morin; Amanda Conerty; Lavakumar Karyampudi; Lisa Guerrettaz, PhD; Peter Flynn, PhD; Bokyung Min, PhD; Heather Raymon, PhD Cellular Therapies Adoptive immunotherapy;Antibody;Leukemia/Lymphoma;NK/NKT cell;Solid tumors
307 Poster Presentation IL12 genetically engineered myeloid cells effectively target the myeloid-enriched tumor and metastatic microenvironment in an immune-competent murine model of osteosarcoma    Kristin M. Wessel, MD; Miranda Clements, PhD; Wei Ju, PhD; Sabina Kaczanowska, PhD; Rosandra N. Kaplan, MD Cellular Therapies Adoptive immunotherapy;Myeloid cells;Pediatric tumors;Solid tumors;Tumor microenvironment
308 Poster Presentation Harnessing tumor localized IL-12 to enhance STEAP1 CAR T cell therapy for prostate cancer    Vipul Bhatia, PhD; Nikhil V. Kamat, MD; Tiffany E. Pariva; Li-Ting Wu; Annabelle Tsao; Koichi Sasaki; Lauren T. Wiest; Ailin Zhang; Dmytro Rudoy; Lawrence D. True; Radhika A. Patel; Martine P. Roudier; Roman Gulati; Michael C. Haffner; Peter S. Nelson; Saul J. Priceman, PhD; Jun Ishihara; John K. Lee Cellular Therapies Adoptive immunotherapy;CAR T cells;Immune adjuvant;Solid tumors;Surfaceome;T cell;Tumor antigens;Tumor microenvironment
309 Poster Presentation Determining the histocompatibility barriers between Universal CAR T (UCART) cells and NK cells Kimberly M. Apodaca, BS; Chong Xu, PhD; Kelsey Stanton; Beatriz M. Carreno, PhD; Gerald P. Linette, MD, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;NK/NKT cell;T cell
310 Poster Presentation Engineering optimal CAR T cells to overcome pancreatic tumors with secreted antagonistic peptides Heather K. Lin, BS; Ruby M. Freeman, BS; Alysa N. Evans, BS; Tenzin Passang Fnu, Bachelor of Arts; Tongrui Liu; Elyse Christensen; Raymond Fei; Tanisha Sinha; Sruthi Ravindranathan, PhD, MS; Lily Yang, MD PhD; Edmund K. Waller, MD/PHD; Sarwish Rafiq, PhD Cellular Therapies CAR T cells;Solid tumors;T cell;Tumor antigens;Tumor microenvironment
311 Poster Presentation PD-1 blockade protein coupled in 4th generation armored CAR-T cells enhances cytotoxicity effect with in vitro re-challenge system Zhifeng Zhao; Jinyan Ma; Tiantian Wang; Ka Fung Noi; Jie Xu; Qingyang Gu Cellular Therapies Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Solid tumors
312 Poster Presentation Identification of novel NSC lung cancer Dark Antigens™ with expression in multiple tumor types, as promising targets for immunotherapies Rachel J.M. Abbott, DPhil; Okba Alassadi; Matthew Davies; Magdalena Von Essen; Verónica Freire-Benéitez; Vicki Jefferson; Samit Kundu; Prathiba Kurupati; Ralf M. Leonhardt; Samuel Lukowski; Fabio Marino; Giulia Masi; Rayner ML. Queiroz; Hayden Selvadurai; Joana M. Senra; Emily X.C. Tye; Joseph Dukes Cellular Therapies Adoptive immunotherapy;Bioinformatics;Gene expression;Proteomics;RNA;Solid tumors;T cell;Targeted therapy;Tumor antigens;Vaccine
313 Poster Presentation EDIT-202, a multiplexed AsCas12a edited iPSC differentiated iNK, displays a mature phenotype, high KIR expression, and ADCC towards multiple solid tumor lines. Alex Allen, Ph.D.; Kaitlyn M. Izzo; Mrunali Jagdale; Scott Mordecai; Jared Getgano; Laura Blaha; Abhijit Dandapat; Mark S. Shearman; Kai-Hsin Chang, Ph.D. Cellular Therapies Adoptive immunotherapy;NK/NKT cell;Solid tumors
314 Poster Presentation Cell therapy development in oncology requires a collaboration between sponsors and cell therapy experienced CROs Jaikrishna Balkissoon, MD, FACS Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs)
315 Oral Presentation Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508     Michael Ball, PhD; Madison Kremp; Rehman Qureshi; Poonam Sonawane, Ph.D.; Maggie Schmierer; Josh VanDuzer; Michael Lynch; Adam Pfendt; Melissa Christiano; Ken Locke; Ramona Swaby; Daniel Cushing, PhD; Michael Klichinsky, PharmD, PhD; Thomas Condamine, PhD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Biomarkers;Monocyte/Macrophage;Myeloid cells;Solid tumors
316 Poster Presentation Next generation CAR-T incorporating an inhibitory CAR (iCAR) for increased safety in solid tumors David Bassan, PhD; Michael R. Weist; Leehee Weinberger; Jason Yi; Gregor Adams; Tanya Kim; Caitlin Schnair; Kristina Vucci; Sarit Tabak; Neta Chaim; Nir Bujanover; Yael Lopesco; Limor Levy-Kanfo; Orit Foord; Jim Johnston; Frank Calzone; Rick Kendell; Adi Sharbi-Yunger Cellular Therapies CAR T cells;Immune toxicity;Solid tumors
317 Poster Presentation ALK chimeric antigen receptor T cells cooperate with ALK inhibitors to target neuroblastoma cells with low target density    Elisa Bergaggio, Ph.D.; Wei-Tien Tai; Andrea Aroldi; Elisa Landoni; Manuel Nuesch; Ines Mota; Jasna Metovic; Leyuan Ma; Diego Alvarado, Ph.D.; Chiara Ambrogio; Claudia Voena; Rafael B. Blasco; Tongqing Li; Daryl Klein; Darrell J. Irvine, Ph.D.; Mauro Papotti; Barbara Savoldo; Gianpietro Dotti; Roberto Chiarle Cellular Therapies CAR T cells;Pediatric tumors;Solid tumors;Targeted therapy
318 Poster Presentation Pre-clinical development of a CAR Monocyte platform for cancer immunotherapy Linara Gabitova, PhD; Brett Menchel, MBT; Silvia Beghi, PhD; Larissa Ishikawa, PhD; Rehman Qureshi; Andrew Best, MA; Sabrina DeLong, PhD; Sascha Abramson, PhD; Thomas Condamine, PhD; Daniel Blumenthal, PhD; Michael Klichinsky, PharmD, PhD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Monocyte/Macrophage;Myeloid cells;Solid tumors
319 Poster Presentation Immunometabolic Modulation of Engineered iPSC-NK Cells for Immunotherapy of Solid Tumors    Shambhavi Borde, MS; Sandro Matosevic, PhD; Kyle Lupo, Ph.D. Cellular Therapies NK/NKT cell;Solid tumors;Stem cell/cancer-initiating cell
320 Poster Presentation Rapid identification of a TCR library targeting the HPV E6/E7 oncoproteins to enable multi-TCR T-cell therapies for patients with HPV16+ epithelial cancers    Magnolia Bostick; John E. Greer; Andrew Conroy; Mark Ting; Allison Xu; Kevin Shao; Claire McHugh; Rakesh Sudhakar; Connie Kong; Taylor Dowdell; Yvonne DaCosta; Shannon Sorn; Justin Win; Noha Elabed; Cheryl Kwan; Craig A. Fett; Evelyn Vilchez; Nimisha Gandhi; George Yam; Benjamin Yuen; Zheng Pan, PhD; Theresa Stueve; Papia Chakraborty; William Lu; Cliff Wang; Eric Stawiski; Stefanie J. Mandl, PhD; Eric Kunkel Cellular Therapies Adoptive immunotherapy;Bioinformatics;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
321 Poster Presentation Single mRNA constructs encoding multiple linked antigens allow for a multiantigen-specific CD8+ T cell response driven by SQZ eAPCs Ashley A. Brate, PhD; Michael F. Maloney, PhD; Carolyne K. Smith, PhD; Katarina Blagovic, PhD; Andrea A. Silva, BS; Amber Martin, ScM; Jodie Wong, MS; Scott M. Loughhead, PhD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Neoantigens;RNA;T cell;Tumor antigens;Vaccine
322 Poster Presentation MiNK-413: a Next generation armored allogenic BCMA CAR iNKT product    Eleni Chantzoura, PhD; Efrat Altman Sharoni; Reed Masakayan; Martyna Popis; Darrian Moskowitz; Paul Ibbett; Sapana Kadel; Moira Pinzan Rossi; Deborah Wright; Burcu Yigit, PhD; Olivier Le Tonqueze, PhD; Xavier Michelet, PhD; Marc A. Van Dijk, PhD Cellular Therapies CAR T cells;Chemokine;NK/NKT cell;Targeted therapy;Tumor microenvironment
323 Poster Presentation TALEN-based Gene Edited iPSC-derived NK (iNK) Cells Demonstrate Enhanced Antitumor Activity An-Ping Chen; Peng Gao; Preeti Ashok; Marshall Chao Ma; David Zou; Andrea Chambers; Liang Lin; Hao-Ming Chang; Antonio Arulanandam; Justin Eyquem; Elisabetta Burchi; Armin Rath; Stanley Frankel; Alex Boyne; Alexandre Juillerat; Philippe Duchateau; Daniel Teper; Nejmi Dilmac; Wei Li Cellular Therapies Adoptive immunotherapy;Leukemia/Lymphoma;NK/NKT cell;Stem cell/cancer-initiating cell;Targeted therapy
324 Oral Presentation Sensitizing poorly differentiated thyroid cancers to TSHR-CART cell therapy with MEK inhibitors John A. Copland, PhD; Kendall J. Schick; Justyna J. Gleba, PhD; Truc N. Huynh; James L. Miller; Erin E. MIller; Aylin Alasonyalilar Demirer, PhD; Erin Tapper; Reona Sakemura, MD, PhDs; Elizabeth L. Siegler, PhD, MS; Michelle J. Cox, PhD, MS; Carli M. Stewart; Ismail Can; Ekene J. Ogbodo, PhD; Claudia Manriquez Roman, MS; Bezerra D. Evandro, MD; Cui Gaofeng, PhD; Mer Georges, PhD; Olivier R. Gloria, PhD; Yushi Qui; Robert C. Smallridge, MD; Abba C. Zubair, MD, PhD; Han W. Tun, MD; Saad S. Kenderian, MB, ChB Cellular Therapies CAR T cells;Immune monitoring;Solid tumors;Targeted therapy
325 Poster Presentation TALEN-edited SMART CAR T-cells leverage solid tumor microenvironment for specific and effective immunotherapy     Shipra sd. Das, PhD; Sonal Dharani; Julien Valton, PhD; Philippe Duchateau; Laurent Poirot, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Carcinogenesis;Checkpoint blockade;Immune suppression;Immune toxicity;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor stroma
326 Poster Presentation Off-the-shelf iPSC-derived CAR-T cells targeting KLK2 demonstrate prolonged tumor control and survival in xenograft models of prostate cancer     Charles G. Drake, MD, PhD; Alex J. Garcia, PhD; Chia-Wei Chang, PhD; Bi-Huei Yang, PhD; Samad Ibitokou, PhD; Cameron Pride, BS; Spas Markov, PhD; Angela Liao, MSc; Mochtar Pribadi, PhD; Yijia Pan, PhD; Thomas Dailey, BS; Tom T. Lee, PhD; Szeman (Ruby) Chan, PhD; Michael Ports, PhD; Jode Goodridge, PhD; Ryan Bjordahl, PhD; Joseph Erhardt, PhD; Bahram Valamehr, PhD Cellular Therapies CAR T cells;Solid tumors
327 Poster Presentation Clonal expansion of CD22 CAR T-cells following lentiviral vector integration in the PWWP3A gene       Alka Dwivedi, Ph.D.; Ling Su; Justin M. Mirazee, B.S.; Mehdi Benzaoui, PHARM.D.; Christopher Chien, PhD; Nirali N. Shah, MD; Xiaolin Wu, PhD; Naomi Taylor, M.D., Ph.D. Cellular Therapies Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Cytokine;Gene expression;Pediatric tumors;T cell
328 Poster Presentation Promoting NK survival and function within the tumor microenvironment  Matthew Dysthe, B.S.; Ishwar Navin, MS; Corrine Baumgartner; Stephanie Fetzko, MD; Cliona Rooney, PhD; Robin Parihar, MD, PhD Cellular Therapies Adoptive immunotherapy;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Pediatric tumors;Tumor microenvironment
329 Poster Presentation Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment to universally reduce solid tumors Shannon L. Ferry; Rachel A. Brog; Courtney Shiebout; Cameron Messier; W J. Cook; Charles Sentman, PhD; H. R. Frost, PhD; Yina H. Huang, PhD Cellular Therapies CAR T cells;Cytokine;Immune suppression;Monocyte/Macrophage;Regulatory T cell (Treg cell);Solid tumors;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
330 Poster Presentation Redirecting glucose usage during in vitro expansion improves the in vivo persistence and function of adoptive T cell therapies for cancer    Andrew Frisch; Yiyang Wang; Yupeng Wang, BS; Konstantinos Lontos, MD, PhD; Greg M. Delgoffe, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Metabolism;T cell;Tumor microenvironment
331 Poster Presentation A novel small molecule inhibitor of CBL-B shows potent antitumor activity in combination with Pmel-1 adoptive cell transfer in an aggressive mouse melanoma model    Marilena Gallotta, PhD; Jose Gomez Romo; Serena Ranucci; Austin Tenn-McClellan; Frederick Cohen; Gwenn M. Hansen, PhD; Arthur T. Sands, MD PhD; Ryan Rountree, PhD; Cristiana Guiducci Cellular Therapies Adoptive immunotherapy;T cell;Tumor infiltrating lymphocytes (TILs)
332 Poster Presentation CRISPR/Cas9-based integration of a large and modular cassette into a safe harbor site to improve CAR T cell therapy efficacy and safety Brendan D. Galvin, PhD; Grace Zheng; Robby Moot; Michelle Nguyen; Michelle Tan; Rene Sit; Lionel Berthoin; David DeTomaso; Sofia Kyriazopoulou Panagiotopoulou; Shan Sabri; Jun Feng; Manching Ku; Anzhi Yao; Andrea Liu; Jennifer McDevitt; Matt Drever; Stephen Santoro, PhD; Aaron Cooper; Susie Jun; W Nicholas Haining; Tarjei Mikkelsen Cellular Therapies CAR T cells;Solid tumors;T cell;Targeted therapy
333 Poster Presentation Novel phytochemicals-based cell culture medium mitigates Natural Killer (NK) cellular exhaustion and enhances mature subpopulations, leading to higher anticancer cytotoxic activity Marc A. Gillig, PhD; Rafet N. Amoor, MS; Nicholas S. Ingala; Borom Chean; Rachit Ohri, Ph.D. Cellular Therapies Biomarkers;NK/NKT cell;Solid tumors;Tumor microenvironment
334 Poster Presentation Functional Validation of Single Domain Antibody-Derived CD33 Specific CAR-T Cells for the Treatment of Acute Myeloid Leukemia Brikena Gjeci, MS; Salar Khan; Julian Scherer, PhD; Tirtha Chakraborty Cellular Therapies CAR T cells;Leukemia/Lymphoma
335 Poster Presentation Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells Whitney Gladney, PhD; Adina Vultur, PhD; Michael T. Schweizer, MD; Joseph Fraietta, PhD; Andrew Rech, MD, PhD; Carl June; Matthew O'Rourke; Amy Roberts; Hinel Patel; Jamie Rosen; Pam Hufner; Yanping Luo, PhD; David Barrett, MD, PhD; Thomas J. Fountaine, MD; Karen Chagin, MD Cellular Therapies Biomarkers;CAR T cells;Cytokine
336 Poster Presentation A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-shelf Cancer Immunotherapy Davide Bernareggi; Caryn Gonsalves; Max Schabla; Alejandra Gárate-Carrillo; Mohammad El-Kalay; Dan S. Kaufman, CAMD, PhD; Robert Hollingsworth; Huang Zhu Cellular Therapies Adoptive immunotherapy;Leukemia/Lymphoma;NK/NKT cell;Solid tumors
337 Oral Presentation Development of potent iPSC-derived macrophages (iMACs) for off-the-shelf cancer immunotherapy - a new cell type in the EVOcells platform Kathrin Haake, Dr.; Michela Mirenda; Julien Bousquet; Philine Scheinpflug; Michael Esquerré; Audrey Holtzinger; Stefanie Pfaender; Michael Paillasse; Daniel Sommermeyer, Dr.; Oriane Bombarde, PhD; Loïc Ysebaert; Fabien Despas; Matthias Austen; Andreas Scheel; Markus Dangl; Monika Braun; Nadja Wagner, Dr. Cellular Therapies Adoptive immunotherapy;Monocyte/Macrophage;Solid tumors;Tumor microenvironment
338 Poster Presentation Analysis of chemokine expression profile of normal and tumor tissue for effective adoptive cell therapy Do Yeon Han, MS; Jung Han Seo; Cho Rong Hong; Hyeon Jin Lee; Gyung Yub Gong; Hee Jin Lee Cellular Therapies Adoptive immunotherapy;Chemokine;Tumor infiltrating lymphocytes (TILs)
339 Poster Presentation Quantitative assessment of CAR-T cell therapy targets using computational pathology     Nathalie Harder; Markus Schick, PhD; Pallavi Sontakke, PhD; Alma Andoni; Karma DaCosta; Ruppen Nalbandian; Philipp Wortmann; Ansh Kapil, Masters of Informatics; Gordon Moody; Maria Letizia Giardino Torchia; Martin Philip Lloyd; Nicholas Durham, PhD; Eric Tu Cellular Therapies Biomarkers;CAR T cells
340 Poster Presentation The Epi-RTM technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function Benjamin D. Harris, PhD; Yogin Patel, PhD; Ngoc-Han Ha; Lora Zhao; Sheila Lou; Stefan Siebert; Emily Fu-Sum; Rigel Kishton; Purnima Sundar; Suman Kumar Vodnala; Shobha Potluri Cellular Therapies Adoptive immunotherapy;Bioinformatics;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
341 Poster Presentation Novel immune reconstitution model highlights the importance of stealth strategies that potentiate effector cell function and promote functional persistence of next-generation adoptive cell therapies    Ken L. Hayama, PhD; Alan M. Williams, PhD; Yijia Pan, PhD; Brian Groff; Rina M. Mbofung, PhD; Lauren Fong, PhD; Nicholas Brookhouser, PhD; Ramzey Abujarour, PhD; Tom T. Lee, PhD; Peter Szabo, MD, PhD; Lilly Wong, PhD; Maksim Mamonkin, PhD; Karl-Johan Malmberg, MD, PhD; Ryan Bjordahl, PhD; Jode Goodridge, PhD; Bob Valamehr, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Chemotherapy;Immune tolerance;NK/NKT cell
342 Poster Presentation KRAS G12V T cell receptor-engineered T cells expressing the durability FAS-41BB switch receptor exhibit a potent, persistent, coordinated CD4/CD8 anti-tumor response in vitro and in vivo Xingyue He, PhD; Michelle M. Hoffmann, PhD; Jinsheng Liang; Hongjing Qu; Allison P. Drain, PhD; Hubert Lam, PhD; Shannon K. Oda, PhD; Thomas M. Schmitt, PhD; Aude G. Chapuis, PhD; Philip D. Greenberg, MD; Gary Shapiro, PhD; Loic Vincent, PhD Cellular Therapies Adoptive immunotherapy;Costimulation;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor microenvironment
343 Poster Presentation Identification of tumor-reactive T cells targeting melanoma Dark Antigens™ validates this novel class of targets for development of immunotherapies Rachel J.M. Abbott, DPhil; Tom Hofland; Thomas M. Hulen; Elizabeth (Els) M. Verdegaal, PhD; Michael D. Crowther; Joseph Dukes; Shawez Khan; Pita de Kok; Giulia Masi; Özcan Met, PhD; Aimilia Schina; Hayden Selvadurai; Marten Visser; Katarzyna Ward; Sjoerd H. van der Burg, Prof.Dr.; George Kassiotis, PhD; Inge M. Svane, MD, PhD Cellular Therapies Adoptive immunotherapy;Gene expression;RNA;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine
344 Poster Presentation Comparative assessment of product quality attributes associated with production of Chimeric Antigen Receptor T cells expressing scFv CD-19 and scFv IL-13Ra2 by two manufacturing platforms    Sujin Hwang, Ph.D.; Heba Degheidy; Mondona McCann; Steven R. Bauer; Raj K. Puri; Bharat H. Joshi Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell;Targeted therapy
345 Poster Presentation CRS assessment post Fast-Track - CAR T cells application in NSG-SGM3 mouse model    Arezoo Jamali, PhD; Naphang Ho, MSc.; Angela Braun, MSc.; Elham Adabi, MSc.; Frederic B. Thalheimer, PhD; Christian J. Buchholz, Prof, PhD Cellular Therapies CAR T cells;Cytokine;Monocyte/Macrophage;Myeloid cells;T cell
346 Poster Presentation Enhanced anti-tumor activity of HBsAg specific TCR-T (SCG101) in hepatitis B virus (HBV) related hepatocellular carcinoma (HCC) by preventing T cell exhaustion through PD-1/PD-L1 axis blockade      Pin Xie, Sr., PhD; Tao Jin; Yanzhou Huang; Lu Yang; Karin Wisskirchen; Ulrike Protzer; Ke Zhang Cellular Therapies Adoptive immunotherapy;Antibody;Checkpoint blockade;Solid tumors;T cell;Tumor microenvironment
347 Poster Presentation Development of Optimized CAR T Cells for Therapy of Glioblastoma Jonathan F. Khan, B.S; Winson Cai, B.S.; Yanhong Yang, Ph.D.; Lauren Dong, BS; Kelsey Hopland, B.S.; Kenny Kwok-Hei Yu, MBBS, Ph.D.; Ruby M. Freeman, B.S.; Terence J. Purdon, M.S.; Viviane Tabar, M.D.; Taha Merghoub, PhD; Jedd D. Wolchok, MD PhD; Renier J. Brentjens, MD, PhD Cellular Therapies CAR T cells;Checkpoint blockade;Solid tumors
348 Poster Presentation Defining T cell recognition of a highly conserved fusion neoantigen in fibrolamellar carcinoma Allison M. Kirk, MS; Jeremy C. Crawford, PhD; Ching-Heng Chou, PhD; Phuong Nguyen; Walid Awad, MD; E. Kaitlynn Allen, PhD; Xiaoyu Zhang, PhD; Anthony E. Zamora, PhD; Christopher DeRenzo, MD; Scott E. Strome, MD; Paul G. Thomas, PhD Cellular Therapies Adoptive immunotherapy;Neoantigens;Pediatric tumors;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
349 Poster Presentation Highly potent Tumor-targeting Optimally Primed Natural Killer cells produced under a feeder-cell free condition in a 50L-scale bioreactor with cytokine-fusion proteins elicits robust anti-tumor response in preclinical study Dongwoo Ko, Dr.; Jae Chan Park, Master Degree; Min-Kyong Hyon; Young Hyun Park; Gil-Jung Kim; Jong Beom Ku; Iseul Eom; Su Bin Lee; Jeong Mi Yun; Dan Bee Park; Do Yeon Kim; HyeHyeon Jang; Sora Lim; Do Soo Jang; Sung Yoo Cho; Chun Pyo Hong; Myung Ho Jang Cellular Therapies Adoptive immunotherapy;Chemokine;NK/NKT cell;Solid tumors
350 Poster Presentation Harnessing arginine metabolism to overcome hyperthermia-induced metabolic dysfunction of CAR T-cells Taisuke Kondo, Ph.D.; Justyn DuSold, B.S.; Sooraj R. Achar, B.S.; Serifat Adebola, B.S.; Pedro Gonzalez-Menendes, Ph.D.; Julie Perrault, M.S.; Bonnie Yates, NP, MS; Hannah Song, Ph.D.; Stephen Fox; Xia Xu; King Chan, Ph.D.; Abdalla Abdelmaksoud; Christopher Chien, PhD; Marie Pouzolles, Ph.D; Haiying Qin, MS; Steven L. Highfill, PhD; Thorkell Andresson, Ph.D.; Nirali N. Shah, MD; Valérie Dardalhon, Ph.D.; Grégoire Altan-Bonnet, Ph.D.; Naomi Taylor, M.D., Ph.D. Cellular Therapies Adoptive immunotherapy;CAR T cells;Metabolism;T cell
351 Poster Presentation Vitamin C treatment prevents CAR T cell exhaustion, maintains stem cell phenotype and enhances antitumor function Leonce Kouakanou, Ph.D.; Hanmin Wang, Ph.D.; Grace Sun; Tristan Chan; Jennifer Shepphird, Ph.D.; Darya Alizadeh, PhD; Christine E. Brown, PhD; Leo D. Wang, MD, Ph.D. Cellular Therapies Adoptive immunotherapy;CAR T cells;Epigenetics;Leukemia/Lymphoma
352 Poster Presentation STASH Select, a simple and robust method of purifying cells engineered with multiple vectors using a single selection marker Louai Labanieh, PhD; Kaithlen Zen B. Pacheco; Robbie G. Majzner, MD; Chris J. Fisher, MS; Elena Sotillo, PhD; Peng Xu, MD; Jennifer R. Cochran, PhD; Crystal Mackall, MD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell
353 Poster Presentation Artificial Immune Modulation adoptive cell therapies for virally driven malignancies David Langan, PhD; Keshanti D. Tidwell; Alison Farrell; Selome Z. Mitiku; Catrina A. Johnson; Pratima Kunwar, PhD; Ruipeng Wang, PhD; Sojung Kim; Mathias Oelke Cellular Therapies Leukemia/Lymphoma;Solid tumors;T cell;Targeted therapy
354 Poster Presentation Pulling the lever on all fronts: ICT01, a g9d2 T cell-activating monoclonal antibody, in combination with Venetoclax and 5-Azacytidine as a novel combination therapy for AML      Elisabeth Wieduwild, PhD; Anne-Charlotte Le Floch; Céline Garulli; Sarah Bourass; Caroline Imbert; Paul A. Frohna, MD, PhD, PharmD; Norbert Vey, MD, PhD; Daniel Olive, MD, PhD; Aude de Gassart, PhD;  Loui Madakamutil, PhD Cellular Therapies Antibody;Chemotherapy;Leukemia/Lymphoma;T cell
355 Poster Presentation TCR γδ+ TIL from patients with pancreatic cancer recognize autologous tumor cells restricted by CD1d Joana R. Lerias, DVM, PhD; Patrícia A. António; Jéssica O. Kamiki, MSc; Rodrigo Eduardo; Sara Cascais; Bernardo Marinheiro; Eric De Sousa; Carolina M. Gorgulho; Andreia Maia; Mireia Castillo-Martin; Markus Buechler; Carlos Carvalho, MD; Antonio Beltran; Sam Jeong; Ridong Chen; Markus J. Maeurer, MD, PhD, FRCP(London) Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
356 Poster Presentation Generation of GD2-CAR Neutrophils from hPSCs for Targeted Cancer Immunotherapy of Solid Tumors      Aditi Majumder, PhD; Ho Sun Jung, PhD; Jue Zhang; Kran Suknuntha; James Thomson; Igor Slukvin Cellular Therapies Adoptive immunotherapy;Granulocyte;Pediatric tumors;Solid tumors;Targeted therapy;Tumor antigens
357 Poster Presentation Phosphorylation of CD28-Y218 modulates IL-2 secretion and antitumor effect of CAR-T cells, in a preclinical model of pancreatic cancer   Elena Martinez Planes; Miguel G. Fontela; Cecilia Ramello; Daniel Abate-Daga, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;T cell
358 Poster Presentation Development of an allogenic FAP CAR iNKT product to target tumor stroma and modulate the Tumor Microenvironment Xavier Michelet, PhD; Martyna Popis; Shannon Boi; Magda Niedzielska; Reed Masakayan; Efrat Altman Sharoni; Paul Ibbett; Deborah Wright; Barbara Barbara Kalinowska; Justin Keith; Bishnu Joshi; Moira Pinzan Rossi; Rachel Smith; Burcu Yigit; Olivier Le Tonqueze, PhD; Eleni Chantzoura, PhD; Marc A. Van Dijk, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Immune suppression;NK/NKT cell;Tumor microenvironment;Tumor stroma
359 Poster Presentation Hyaluronic acid nanogel based cancer vaccine, in combination with adoptive T cell therapy totally suppresses ICI resistant-tumors    Hiroshi Shiku, MD, PhD; Fumiyasu Momose, PhD; Takashi Nakai, PhD; Kohei Yabuuchi, MS; Toru Katsumata, PhD; Tsuyoshi Shimoboji, PhD Cellular Therapies Adoptive immunotherapy;Neoantigens;T cell;TLR;Vaccine
360 Poster Presentation Novel immunotherapy for prostate cancer combining CAR T cells and myeloid cell STAT3 inhibition John P. Murad, PhD; Saul J. Priceman, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Immune suppression;RNA;Solid tumors;T cell;Targeted therapy;TLR;Tumor microenvironment
361 Poster Presentation Universal Expansion of CBL-B-inhibited Tumor Infiltrating Lymphocytes, DeTIL-0255, from Women with Ovarian Cancer: Process Validation  Pranav Murthy, MS; Nell Namitha Narasappa, MS; Xiaoyan Liang, PhD; Xianzhu Wu, PhD; Irene Luu, MS; Jeevitha Jeevan, MS; Sagar Sharma; Alison Ross; Caleb Lampenfeld; Sam Zahn; Thomas Musial, MS; Jennifer Bone, PhD; John Nakayama, MD; David Bartlett, MD; Jocelyn S. Chapman, MD; Greta Garrido, PhD; Nicholas P. Shinners, PhD; Arthur T. Sands, MD PhD; Michael Blackton, MBA; Ena Wang, MD MS; Michael T. Lotze, MD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Clinical trial;Dendritic cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
362 Poster Presentation Defining T cell exhaustion and memory correlates of GD2 CAR T cell expansion in pediatric patients with solid tumor malignancies Tara Murty, BS; Sneha Ramakrishna, MD; Sabina Kaczanowska, PhD; Cristina F. Contreras; Caroline Duault, PharmD, PhD; Priyanka Balasubrahmanyam; Warren Reynolds; Reema Baskar, PhD; Aashna Jhaveri; Yang Liu; Jennifer Altreuter, MD; Franziska Michor; Mina Pichavant; Bita Sahaf, PhD; Sean C. Bendall, PhD; Holden T. Maecker, PhD; Melinda Merchant; Crystal Mackall, MD; Rosandra N. Kaplan, MD Cellular Therapies Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Immune contexture;Immune monitoring;Pediatric tumors;Solid tumors;T cell
363 Poster Presentation Localized interleukin-2 cytokine factories eradicate mesothelioma tumors via activation of adaptive and innate immune cells    Samira Aghlara-Fotovat, BA; Amanda Nash, BS; Bertha Castillo; Andrea Hernandez; Aarthi Pugazenthi; Hyun-Sung Lee; Hee-Jin Jang; Annie Nguyen; Alexander Lu; Bryan Burt; Ravi Ghanta; Omid Veiseh, Ph.D Cellular Therapies Checkpoint blockade;Cytokine;Monocyte/Macrophage;T cell
364 Poster Presentation Antigen abundance and TCR avidity impact T cell-mediated tumor recognition in novel B16F10 ACT model    Jenna Newman, PhD; John Finnigan, MD; Andrew S. Ishizuka, DPhil; Geoffrey Lynn, PhD; Alexander Rubinsteyn; Timothy O'Donnell; Jeffrey Hammerbacher, BA; Nina Bhardwaj, MD, PhD Cellular Therapies Adoptive immunotherapy;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
365 Poster Presentation Comparison of viral vector transduction methods for tumor-infiltrating lymphocytes    Seung Eon OH; Won Seon Bang; Hee Jae Lee; Hee Jin Lee; Chae Lyul Lim Cellular Therapies Adoptive immunotherapy;Gene expression;Tumor infiltrating lymphocytes (TILs)
366 Poster Presentation Synthetic Receptor Enabled Differentiation (ShRED), a novel platform for manufacturing of iPSC-derived cytotoxic innate lymphocytes for 'off-the-shelf' cancer immunotherapies  Sam O'Hara, PhD; David Vereide, PhD; Teisha Rowland; Ashley Yingst; Dillon Jarrell; Ryan Koning; Cassidy Arnold; Susana Hernandez; Way Wu; Kristen L. Mittelsteadt, PhD; Chris Nicolai, PhD; Wai-Hang Leung, PhD; Laurie Beitz, MD; Shon Green, PhD; Byoung Ryu, PhD; Christopher Garbe; Ryan Crisman, PhD; Andrew Scharenberg, MD; Ryan Larson, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;NK/NKT cell;Solid tumors
367 Poster Presentation CRISPR/Cas9 gene-edited, allogeneic anti-CD83 CAR-T cells demonstrate potent activity in GvHD and AML tumor models Ismael Oumzil; Valerie Guerrero; Pooja Smruthi Keerthipati, MS; Jaqlyn Colangelo; Brendan Lawler; Victoria Singson; Aditya Khedkar; Shweta Singh, PhD; Jonathan Terrett, PhD; Daniel Hostetter, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells
368 Poster Presentation CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis CD19 T cells results in significant tumor killing    Isabel Monroy, BS; Anthony K. Park, PhD; Colin Cook; Guangyan Xiong; Vivien Chan; Cheng Liu; Saul J. Priceman, PhD; Monil Shah; Nimali Withana; Leslie M.O. Chong; Yuman Fong, BS, MD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors
369 Poster Presentation Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with immunosuppressive microenvironments Carmela Passaro, PhD; Balazs Koscso, PhD; Sean G. Smith, PhD; Violet Young; Theresa Ross; Benjamin Primack, MS; Natasha Ly; Patricia Timpug; Shabnam Davoodi, PhD; Rachel A. Burga, PhD; Gauri Kulkarni; Scott Lajoie; Meghan Langley; Nirzari Shah; Dexue Sun, MS; Dan Jun Li, MD; Raina Duan; Arman Aksoy, PhD; Mithun Khattar, PhD; Jeremy H. Tchaicha, PhD; Dhruv Sethi; Jan H. ter Meulen, MD, PhD; Michelle L. Ols, PhD Cellular Therapies Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
370 Poster Presentation The Epi-RTM technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity Yogin Patel, PhD; Benjamin D. Harris, PhD; Melissa Bedard, PhD; Joanna Kritikou; Meritxell Galindo Casas; Carson Harms; Melissa DeFrancesco; Purnima Sundar; Nicholas P. Restifo, MD; Gary Lee, Ph.D.; Shobha Potluri, PhD; Suman Kumar Vodnala Cellular Therapies Adoptive immunotherapy;Epigenetics;Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
371 Poster Presentation Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy Stefano Pierini, PhD; Rashid Gabbasov, PhD; Cecilia Nunes, PhD; Alison Worth, MSc; Yumi Ohtani, PhD; Michael Ball, PhD; Rehman Quereshi, PhD; Olga Shestova; Saar Gill, MD; Serody S. Jonathan, MD; Sascha Abramson, PhD; Thomas Condamine, PhD; Michael Klichinsky, PharmD, PhD Cellular Therapies Adoptive immunotherapy;Checkpoint blockade;Monocyte/Macrophage;Solid tumors
372 Poster Presentation agenT-797, a native allogeneic 'off-the-shelf' invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment       Sapana Pokharel, PhD; John Chamberland; Yu Qin; Darrian Moskowitz; Reed Masakayan; Xavier Michelet, PhD; Dhan Chand, PhD; Burcu Yigit; Marc A. Van Dijk, PhD Cellular Therapies Dendritic cell;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor antigens;Tumor microenvironment
373 Poster Presentation Combination vaccine, adoptive NK cell transfer and checkpoint blockade reduce murine neuroblastoma progression after bone marrow transplant Aicha Quamine, MS; Nicholas R. Mohrdieck; Chloe A. King; Anastasia Griggs; Paul D. Bates; Sean P. Rinella; Katharine E. Tippins; Tyce J. Kearl, MD, PhD; Bryce D. Johnson, PhD; Christian Capitini, MD Cellular Therapies Adoptive immunotherapy;Antibody;Checkpoint blockade;NK/NKT cell;Pediatric tumors;Solid tumors;Vaccine
374 Oral Presentation Discovery of a public HPV16-E6 directed T cell response that is associated with overall and progression free survival Klaudia A. Szymonowicz; Bo Jiang; Laurene S. Cheung; Weihong Xiao, MD; Alexa J. Halliday; Emily Bontekoe; Keiko Akagi, PhD; Gregory A. Lizee; Kellie N. Smith; Maura L. Gillison, MD, PhD; Nils-Petter Rudqvist, PhD Cellular Therapies Adoptive immunotherapy;Bioinformatics;Biomarkers;Immune monitoring;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
375 Poster Presentation In vivo generation of universal CAR T cells that mediate durable anti-tumor immunity through combinatorial targeting with bispecific small molecule adapters Kristen L. Mittelsteadt, PhD; Isabel Leung, PhD; Kelsey Lynch, PhD; Haiyan Chu, MD-PhD; Chang-Chih Wu, PhD; Seungjin Shin, PhD; Ryan Larson, PhD; Andrew Scharenberg, MD; Byoung Ryu, PhD; Laurie Beitz, MD Cellular Therapies CAR T cells;Solid tumors;Targeted therapy;Tumor antigens;Tumor microenvironment;Tumor stroma
376 Poster Presentation Macrophages engineered to express synthetic cytokine switch receptors act as living microenvironment converters Chris Sloas, PhD; Yuhao Huangfu, MS, MD; Thomas Condamine, PhD; Michael Klichinsky, PharmD, PhD; Yumi Ohtani, PhD Cellular Therapies Adoptive immunotherapy;Cytokine;Immune suppression;Inflammation;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment
377 Poster Presentation Adoptive cell therapy with Cytokine-Induced Killer cells retargeted with immunotools against HER-2 positive breast cancer. Roberta Sommaggio, PhD; Elisa Cappuzzello; Annavera Ventura; Sara Perpinello; Anna Dalla Pieta; Emilia Vigolo; Giulia D'Accardio; Pierangela Palmerini; Antonio Rosato Cellular Therapies Adoptive immunotherapy;Antibody;Bispecifics;Solid tumors;Targeted therapy
378 Poster Presentation Chimeric Engulfment Receptor (CER) T Cells with a TLR2 Domain Synergize with an EGFR Inhibitor to Target NSCLC Cells In Vitro and Demonstrate APC-like Function Sunil Thomas, PhD; Harini Kethar; Linh P. Nguyen, PhD; Brandon Cieniewicz, PhD; Alex Arballo; Priya Baichoo; Damoun Torabi; Ankit Bhatta, MS; Daniel Corey, MD Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;T cell lineages;TLR;Tumor antigens
379 Poster Presentation Engineering of gamma/delta T cells derived from cord blood for chimeric antigen receptor-T cell therapies Chelsia Qiuxia Wang, PhD; Alice Cheung; Andy Hee-Meng Tan Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell;T cell lineages;Tumor antigens;Tumor microenvironment
380 Poster Presentation Development and characterization of a CAR T cell potency assay with 3D cancer spheroid models Omari Weems; Denise Sullivan; Austin Passaro; Stacie Chvatal; Daniel Millard, PhD Cellular Therapies CAR T cells;Solid tumors;Tumor microenvironment
381 Poster Presentation Large-scale expansion and engineering of human NK cells sourced from peripheral blood versus umbilical cord blood Michael I. Whang, PhD; Ming-Hong Xie, MD; Kate Jamboretz, MS; Chang N. Kim, BS; Sombeet Sahu, MS; Hadia Lemar; Nafees Rahman, PhD; Ivan H. Chan, PhD; Erik M. Whiteley, PhD; Ralph Brandenberger, PhD; Sasha Lazetic, BA; James B. Trager, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;NK/NKT cell;Targeted therapy
382 Poster Presentation A novel peripheral blood mononuclear cell humanized mouse model for preclinical efficacy and toxicity evaluation of chimeric antigen receptor T-cell immunotherapy    Jiwon Yang, PhD; Won Lee; Heather Gustafson; Blair Amrstrong; Katelym Burleigh; Mingshan Cheng; James G. Keck Cellular Therapies Adoptive immunotherapy;CAR T cells;Cytokine;Immune toxicity;T cell
383 Poster Presentation Targeting IgE-producing Blood Cancers Using EMPD-specific Chimeric Antigen Receptor T Cells    Shenyu Zhang, MS; Zhengyu Ma; Brittany F. Fay Cellular Therapies B cell;CAR T cells;T cell;Targeted therapy
384 Poster Presentation Systematic, Antigen-agnostic Discovery of Tumor-Reactive TCRs Powered by Repertoire-Scale TCR Gene Synthesis and The Use of Banked Allogeneic Cancer Cell Lines    Xi Chen; Yue Zhao, PhD; Ely Porter, PhD; Danielle R. Cook, PhD; Jiekun Xuan; Xiao-Wu Huang; Bin Li; Jingwei Zhang; Lili Ren; Teng Wei; Ning Li Cellular Therapies Adoptive immunotherapy;Neoantigens;Systems biology;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
385 Poster Presentation Engineering a TGF-β switch receptor enhances CAR-T cell function in a suppressive TGF-β-enriched tumor microenvironment Joe Jiang Zhu, PhD; Criselle DSouza, PhD; Vicky Qin; Niko Thio; Michael H. Kershaw, PhD; Joe A. Trapani, MD; Phillip K. Darcy, PhD; Paul J. Neeson, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Costimulation;Immune suppression;Solid tumors;Tumor microenvironment
386 Poster Presentation Efficient ex-vivo expansion of adaptive NKG2C+/CD57+ NK cells from CMV-positive donors using dendritic cells derived from the acute myeloid cell line DCOne. Haoxiao Zuo, PhD; Remco Bos; Alex Karlsson-Parra, MD, PhD; Satwinder Kaur Singh, PhD Cellular Therapies Adoptive immunotherapy;Dendritic cell;Immune adjuvant;NK/NKT cell
387 Poster Presentation Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal cancer (CRC)  Matthew Beatty, PhD; MacLean Hall, BS; Holly Branthoover; Mary Rau; Jake Nikota, PhD; James Bender, PhD; Jake Ceccarelli, PhD; Timothy J. Langer; Jamie Teer, PhD; Jason Fleming, MD; Shari Pilon-Thomas, PhD Cellular Therapies Adoptive immunotherapy;Neoantigens;Tumor infiltrating lymphocytes (TILs)
388 Poster Presentation Targeted ovarian cancer immunotherapy through engineering of follicle stimulating hormone receptor (FSHR) antibody to engage T cells    Devivasha Bordoloi, PhD; Pratik S. Bhojnagarwala, MS; Alfredo Perales-Puchalt, PhD; Abhijeet J. Kulkarni, MS; Xizhou Zhu; Kevin Liaw, PhD; Ryan P. O’Connell; Daniel H. Park; Daniel Kulp, PhD; Rugang Zhang, PhD; David B. Weiner, PhD Cellular Therapies Antibody;Bispecifics;Targeted therapy;Tumor antigens;Tumor microenvironment;Vaccine
389 Poster Presentation Multiplexed TCR-T cell therapy targeting MAGEA1 and PRAME enhances the activity of adoptive T cell therapy in pre-clinical models    Cagan Gurer, PhD; Gavin MacBeath, PhD; Mollie Jurewicz, PhD; Nancy Nabilsi, PhD; Antoine J. Boudot, PhD; Jenny Tadros; Tary Traore, PhD; Maytal Bowman; Elizabeth M. Hall; Yifan Wang, PhD; Qikai Xu, PhD; Victor Ospina Cellular Therapies Solid tumors;T cell;Targeted therapy;Tumor antigens
390 Poster Presentation Digital spatial profiling and antigen-dependent phenotypic analysis of IL15-engineered tumor-infiltrating lymphocytes (cytoTIL15 therapy) in an allogeneic melanoma PDX model Rachel A. Burga, PhD; Zheng Ao, PhD; Arman Aksoy, PhD; Scott Lajoie; Kyle Pedro, PhD; Jack Tremblay; Gauri Kulkarni; Alonso Villasmil Ocando; Benjamin Primack, MS; Meghan Langley; Theresa Ross; Jeremy H. Tchaicha, PhD; Michelle L. Ols, PhD; Jan H. ter Meulen, MD, PhD; Mithun Khattar, PhD Cellular Therapies Adoptive immunotherapy;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
391 Poster Presentation Development of a GMP-Compatible, Virus-Free CRISPR CAR T Cell Manufacturing Process Dan Cappabianca, BS; Madison Bugel; Sarah Caroline Gomes de Lima; Ross Schwartz; Krishanu Saha; Christian Capitini, MD Cellular Therapies CAR T cells;Clinical trial;Cytokine;Pediatric tumors;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
392 Poster Presentation Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies    Jae Woong Chang, Ph.D.; Joshua Kreuger; Joseph Skeate; Erin Stelljes; Walker Lahr; Nicholas Slipek; Emily Pomeroy; Meghan Walsh; Jennifer Johnson; Charlotte Franco; Simarjot Pabla; Jared Sewell; Eugene Choi; Vipin Suri; Beau Webber; Branden Moriarity Cellular Therapies NK/NKT cell;Solid tumors
393 Poster Presentation ATAK receptors, a new class of chimeric antigen receptor that harness innate immunity in myeloid cells to target cancer Neha Diwanji; Edward Cochran; Michael Gorgievski; Thomas Prod'Homme; Yuxiao Wang, Ph.D.; Bruce McCreedy; Daniel Getts Cellular Therapies Adoptive immunotherapy;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;TLR;Tumor antigens;Tumor microenvironment
394 Poster Presentation Using co-stimulatory CARs in natural killer cells to safely target soft-tissue sarcomas and their inhibitory microenvironments    Stephanie Fetzko, MD; Ishwar Navin, MS; Matthew Dysthe, B.S.; Tim Sauer, MD; Cliona Rooney, PhD; Robin Parihar, MD, PhD Cellular Therapies MDSC;NK/NKT cell;Pediatric tumors;Solid tumors;Tumor microenvironment
395 Poster Presentation Engineering non-activated CAR T cells with enhanced potency against advanced cancers    Saba Ghassemi, PhD; Joseph S. Durgin, MD; Frederic D. Bushman, PhD; Saar I. Gill, MD, PhD; Roddy S. O'Connor, PhD; Michael C. Milone Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors;T cell
396 Poster Presentation Investigating the role of the endogenous CD28 co-stimulatory receptor in achieving optimal CAR-T cell therapeutic efficacy    Mackenzie M. Honikel; Kelvin P. Lee, MD; Scott H. Olejniczak, PhD Cellular Therapies CAR T cells;Costimulation
397 Poster Presentation Deep myeloid cell profiling provides new insights into modulators of CAR T cell expansion in patients with solid tumor malignancies Sabina Kaczanowska, PhD; Sneha Ramakrishna, MD; Tara Murty, BS; Cristina F. Contreras; Ahmad Alimadadi, PhD; Norma Gutierrez; Aashna Jhaveri; Yang Liu; Jennifer Altreuter, MD; Franziska Michor; Caroline Duault, PharmD, PhD; Priyanka Balasubrahmanyam; Warren Reynolds; Reema Baskar, PhD; Mina Pichavant; Bita Sahaf, PhD; Sean C. Bendall, PhD; Holden T. Maecker, PhD; Melinda Merchant, MD, PhD; Crystal Mackall, MD; Catherine C. Hedrick, PhD; Rosandra N. Kaplan, MD Cellular Therapies CAR T cells;Clinical study;Immune contexture;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Pediatric tumors;Solid tumors;T cell
398 Poster Presentation Expansion of therapeutic NK cell line under hypoxic and hyperbaric culture conditions enhances anti-tumor potency  James Lim, PhD; Ann Lu, PhD; Yunmin Li, PhD; Yelena Bronevetsky, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Immune suppression;Metabolism;NK/NKT cell;Tumor microenvironment
399 Poster Presentation Developing a new targeted therapy for pediatric rhabdomyosarcoma: αvβ3 and HER2 as promising targets for bispecific CAR T-cell therapy Amanda M. Lulu, PhD; Joseph J. Caruso, BS; Dustin A. Cobb, PhD; Daniel W. Lee, III, MD Cellular Therapies Bispecifics;CAR T cells;Pediatric tumors;Solid tumors;Tumor evasion
400 Poster Presentation PDGFRα-specific CAR T cell therapy of pediatric high-grade glioma Sara A. Mazrimas, BA; Kathryn Eckholdt, BS; Paul Hauser, PhD; Wafik Zaky, MD; Amer Najjar, Ph.D. Cellular Therapies CAR T cells;Pediatric tumors
401 Poster Presentation Hinge length: A novel method of predicting cytotoxicity of CAR constructs against antigen-low leukemia Justin M. Mirazee, B.S.; Dongya Jia, Ph.D; Xiang Chen, Ph.D; Sooraj R. Achar, B.S.; Chris D. Chien, Ph.D; Marie Pouzolles, Ph.D; Kniya D. DeDe, B.S.; Philippe Youkharibache, Ph.D; Kylie J. Walters, Ph.D; Grégoire Altan-Bonnet, Ph.D; Naomi Taylor, M.D., Ph.D. Cellular Therapies CAR T cells
402 Poster Presentation T cell killing is facilitated by multiple cytotoxic pathways Melisa J. Montalvo, BS; Irfan N. Bandey, PhD; Ali Rezvan; Kwan-Ling Wu; Arash Saeedi; Yongshuai Li; Rohan Kulkarni; Xingyue An, BS; Navin Varadarajan, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Immune toxicity;Leukemia/Lymphoma;Solid tumors;T cell;Targeted therapy;Tumor evasion
403 Poster Presentation Rapid and Multiplexed Identification of Novel TCRs for TCR-T Cell Therapy  Tamson V. Moore, Ph.D.; Bindu Hegde, Ph.D.; John Leonard, PhD; Nathan Katz; Akshay Sharathchandra; Bryan J. Xie, Ph.D.; Joanna Dreux; May Khadilkar; Marvin H. Gee, PhD; Leah V. Sibener, PhD Cellular Therapies Adoptive immunotherapy;Immune toxicity;T cell;Tumor antigens
404 Poster Presentation Enrichment of neoantigen reactive TIL in a CRC patient sample by FACS: The TIDAL-01 process    Jake Nikota, PhD; Larissa Pikor, PhD; Anna Fritzsche; Zachary Jilesen; Sara Fallahi; Barbara Sennino; David Stojdl Cellular Therapies Adoptive immunotherapy;Antigen presenting cells;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
405 Poster Presentation A non-canonical role for CCL2 in T cell migration: improving dual-interferon-treated autologous monocytes as a therapy for ovarian cancer.    Franklin Ning; Thomas Meyer, PhD; Brittney Harrington, PhD; Christina M. Annunziata, MD, PhD Cellular Therapies Chemokine;Clinical trial;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment
406 Poster Presentation An unbiased survey of tumor reactivity and transcriptional landscape of 1,000 clones of PD-1hi T-cells from peripheral blood during ICB treatment reveals breath and dynamics of anti-tumor immunity      Danielle R. Cook, PhD; Immaculada Creus; Andrea Garcia-Garijo; Pierre Levy; Seon Kinrot; Rodrigo Toledo; Elena Garralda, MD, MSc; Ely Porter, PhD; Xi Chen; Alena Gros, PhD Cellular Therapies Adoptive immunotherapy;Checkpoint blockade;Gene expression;Solid tumors;Systems biology;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
407 Poster Presentation Mitochondrial transcription is required for the enhanced anti-tumor activity of adoptively transferred stem-like memory T cells Guillermo O. Rangel RIvera, B.S.; Connor J. Dwyer, PhD; Hannah M. Knochelmann, MD, PhD; Aubrey S. Smith, BS; Anna C. Cole, B.A.; Megan M. Wyatt, MS; Chrystal M. Paulos, PhD; Jessica E. Thaxton, PhD, MS; Shikhar Mehrotra, PhD; Haydn Kissick, PhD; Mark P. Rubinstein, PhD; Gregory B. Lesinski, Ph.D. Cellular Therapies Adoptive immunotherapy;Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
408 Oral Presentation Neutralizing oxidative damage at telomeres prevents T cell dysfunction and improves adoptive cell therapy    Dayana B. Rivadeneira, PhD; Sanjana Thosar; Konstantinos Lontos, MD, PhD; Jessica A. Jana, BSE; Marcel Bruchez; Patricia L. Opresko; Greg M. Delgoffe, PhD Cellular Therapies Metabolism;T cell;Tumor microenvironment
409 Poster Presentation Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYLTM PH-762 Colin J. Thalhofer, PhD; Simon P. Fricker, PhD; Ryan D. Montler, MBA; Elaine A. Ballinger, PhD; Nick P. Morris, PhD; Jake Moses, BS; Dingxue Yan; Tarsem L. Moudgil, MS; Bernard A. Fox, PhD; Nelson Sanjuan, BS; Eric Tran, PhD; James Cardia, PhD; Andrew D. Weinberg, PhD Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
410 Poster Presentation Priming of SynNotch CAR T cells via CNS-specific antigen allows spatial and temporal regulation of CAR expression, effective homing and persistence of T cells in the CNS, resulting in the complete eradication of aggresive glioblastoma Payal B. Watchmaker, PhD; Milos Simic, PhD; David Diebold; Psalm Pineo-Cavanaugh; Jason Duecker; Wei Yu; Wendell Lim, PhD; Hideho Okada, MD, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Solid tumors
411 Poster Presentation The multi-omics analyses of 'off-the-shelf' CD19-CAR-T cells identifies the subpopulation complexity and the deep characterization of the anti-tumor properties Asma Al Sulaiti, MSC; Mohammed El-Anbari, PhD; Shana Jacob, PhD; Toufiq Mohamed, BSc; Saroja Kotegar Balayya, MSC; Suruchi Mohan, MD; Damilola Olagunju, BSC; Chiara Cugno, MD; Sara Deola, MD; Jean-Charles J. Grivel, PhD; Damien Chaussabel, PhD; Chiara Bonini, MD; Monica Casucci, PhD; Cristina Maccalli, PhD Cellular Therapies Adoptive immunotherapy;CAR T cells;Gene expression;Leukemia/Lymphoma;RNA;Systems biology;T cell;T cell lineages
412 Poster Presentation Synthetic PD-1 co-stimulatory molecule preserves a cytolytic CAR T cell immune synapse while reducing tonic signaling Rebecca M. Brock, PhD; Jessica Morris; Ahmed Z. Gad, BPharm, MSc; Daniel Landi, MD; Shoba A. Navai, MD; Zeid Y. Nawas; Sujith K. Joseph, PhD; Nabil Ahmed, MD, MPH; Alexandre F. Carisey, PhD; Meenakshi Hegde, MD Cellular Therapies CAR T cells;Checkpoint blockade;Costimulation;Solid tumors
413 Poster Presentation Genetic deletion of TIGIT enhances CAR-NK cell function in the solid tumor microenvironment Ishwar Navin, MS; Matthew Dysthe, B.S.; Corrine Baumgartner, BS; Robin Parihar, MD, PhD Cellular Therapies Adoptive immunotherapy;Immune suppression;NK/NKT cell;Pediatric tumors;Solid tumors;Tumor microenvironment
414 Poster Presentation Target Ephrin A3 on Cancer cells and tumor microenvironment in brain cancer Ekene J. Ogbodo, PhD; Reona L. Sakamura, MD PhD; Michael W. Ruff, MD; Claudia M. Roman; Truc Huynh Huynh; James H. Girsch; Olivia L. Sirpilla; Kun Yun; Carli M. Stewart; Ismail Can Can; Mohamad M. Adada; Lionel K. Fonkoua; Mehrdad Hefazi; Elizabeth L. Siegler; Saad S. Kenderian, MB, ChB Cellular Therapies CAR T cells;Immune suppression;Monocyte/Macrophage;Solid tumors;T cell;Tumor antigens;Tumor microenvironment
415 Poster Presentation PD-1 Immune Checkpoint Blockade Enhances Eradication of Disseminated Ovarian Cancer    Rita E. Serda, PhD Cellular Therapies Checkpoint blockade;TLR;Vaccine
417 Poster Presentation Rapid discovery of personalized TCRs through a single-cell transcriptomic signature that predicts tumor reactivity     Ely Porter, PhD; Yue Zhao, PhD; Danielle R. Cook, PhD; Seon Kinrot; Shuang Mao; Yanzhen Ye; Jiayu Ou; Dandan Hu; Xi Chen Cellular Therapies Adoptive immunotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
418 Poster Presentation 6-gingerol Suppresses Angiogenesis and Promotes T-cell cytotoxicity in Mice Model of Colorectal Cancer.    Babajide O. Ajayi, PhD; Anuoluwapo A. Adeshina, MD Checkpoint Blockade Therapy Angiogenesis;Bioinformatics;Carcinogenesis;Checkpoint blockade;Immune monitoring;Inflammation;T cell;T cell lineages;Tumor evasion;Tumor microenvironment
419 Poster Presentation Combined anti-VEGF, anti-CTLA4 and anti-PDL1 treatment induces strong immune responses in patients with cholangiocarcinoma: results from a clinical trial/in depth correlative studies and mouse studies.    Reda Benmebarek; Tim F. Greten, MD; Cecilia Monge; Benjamin Ruf, M.D.; Yuta Myojin, MD, PhD; Cihan Oguz; Justin Lack; William Telford; Changqing Xie Checkpoint Blockade Therapy Immune contexture;Immune monitoring;Immune toxicity;T cell;Tumor microenvironment
420 Poster Presentation Doxycycline regulatable β-catenin demonstrates inducible immune evasion in a melanoma GEM model. Alexandra Cabanov, BS; Thomas F. Gajewski, MD, PhD; Stefani Spranger, PhD; Elen Torres-Mejia Checkpoint Blockade Therapy Checkpoint blockade;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
422 Poster Presentation KZR-540 is a novel oral small molecule inhibitor of Sec61 cotranslational translocation that potently and selectively blocks PD-1 expression Cristina Delgado-Martin, PhD; Neel K. Anand; Janet L. Anderl; Chengguo Dong; Andrea Fan, PhD; Ying Fang; Christopher J. Kirk, PhD; Tony Muchamuel; Yu Qian; Jinhai Wang; Jennifer A. Whang, PhD; Patricia Zuno-Mitchell Checkpoint Blockade Therapy Checkpoint blockade;T cell
423 Poster Presentation Treatment of Relapsed and Refractory Lymphomas with Nivolumab in a Limited Recourse Country     Lusine Harutyunyan, Dr, MD; Anahit Ter-Grigoryan; Hayk Grigoryan; Marina Kazaryan; Miranush Saaryan; Nerses Ghahramanyan; Artem Oganesyan, MD; Levon Evoyan; Marina Melik-Andreasyan; Anahit Aynajyan; Karapet Hakobyan; Astghik Voskanyan; Karen Meliksetyan; Yervand Hakobyan Checkpoint Blockade Therapy Checkpoint blockade;Chemotherapy;Leukemia/Lymphoma;Radiotherapy;Targeted therapy
424 Poster Presentation An allosteric, orally administered CBL-B inhibitor remodels the tumor microenvironment and enhances immune-mediated tumor growth inhibition Yilin Qi, Ph.D; Jun Kuai, PhD; Yingzhi Bi; Huadong Sun; Samira Jaeger; David Greco; Ken Carson; Timothy Reilly; Geraldine Harriman; Fang Wang Checkpoint Blockade Therapy Checkpoint blockade;Costimulation;T cell;Tumor microenvironment
425 Poster Presentation KVA12.1: an anti-VISTA monoclonal antibody with strong single agent anti-tumor activity and no evidence of cytokine mediated toxicity.    Thierry Guillaudeux, PhD; Kurt H. Lustig; Emily Frazier; Neda Kabi; Chen Katz; David Peckham; Mei Xu; Shawn Iadonato, PhD Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Clinical trial;Cytokine;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment
426 Poster Presentation ES005, a high affinity anti-LAG3 monoclonal antibody, inhibits the interactions between LAG3 and multiple ligands and enhances anti-tumor activity of T cells in preclinical models Xiaofeng Niu, PhD; Chunnian Wang, PhD; Jinfeng Zhao; Yefeng Lu; Yingchao Liu; Rui Gao, PhD; Zhihao Wu, PhD; Yangsheng Qiu, PhD; Zheng Song, PhD; Hongtao Lu, PhD Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Immune suppression;Solid tumors;T cell
427 Poster Presentation Approval Timings and Review Speed of Immune Checkpoint Inhibitors (ICIs) in Cancer Therapy between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) from 2010-2022    Numair M. Rizwan, MD; Ali Raza Khaki, MD MS; Aakash Desai, MBBS MPH; Jeremy L. Warner, MD MS; Jonathan Krell, PhD; Mark Lythgoe, MBBS, MRPharmS Checkpoint Blockade Therapy Checkpoint blockade;Solid tumors
428 Poster Presentation Diffusing alpha-emitters Radiation Therapy Promotes a Pro-immunogenic Tumor Microenvironment and Synergizes with PD-1 Blockade        Sara Roumani, PhD; Yossi Nishri; Amit Shai; Margalit Efrati; Itzhak Kelson; Yona Keisari; Vered Domankevich; Robert Den Checkpoint Blockade Therapy Checkpoint blockade;Gene expression;Myeloid cells;Radiotherapy;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
429 Poster Presentation Human tumor response to a standard monotherapy checkpoint inhibitor in a humanized HSC-NCG mouse model engrafting adult healthy donor-mobilized human CD34+ hematopoietic stem cells Jenny Rowe, PhD; Christoph S. Eberle, PhD; Ann Fiore; Robert Mihalek; Brianna Schoen; Stephen Festin, PhD Checkpoint Blockade Therapy Checkpoint blockade;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
430 Poster Presentation Real-world outcomes of patients with resected stage IIIA melanoma treated with adjuvant nivolumab in a US Community Setting    Wolfram Samlowski, MD; Phillip K. Chan, PhD; Anna C. Pavlick, MD, MBA; Justin C. Moser, MD; Nicholas Robert, MD; Tayla M. Poreta, PharmD, MPH; Andriy Moshyk, MSc, MD; Leon Sakkal, PharmD; Jennell Palaia, PharmD, MS; Nicole M. Niehoff, PhD; Jonathan Rajkumar, MPH; Asim Amin, MD, PhD Checkpoint Blockade Therapy Checkpoint blockade;Immune adjuvant;Solid tumors
431 Poster Presentation Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy. Megan Smith-Uffen, MD; John Park; Andrew Parsonson; Anuradha Vasista Checkpoint Blockade Therapy Checkpoint blockade;Targeted therapy
432 Poster Presentation Evaluation of novel anti-TIGIT antibody M6223 as a single agent and in combination with avelumab on human natural killer (NK) cell cytotoxicity Anton Titov; Nancy Sun; Christie Kelton; Mirek Jurzak; Hong Ma; Chunxiao Xu Checkpoint Blockade Therapy Antibody;Checkpoint blockade;NK/NKT cell;Targeted therapy;Tumor antigens
433 Poster Presentation Prevalence of PD-L1 expression among patients with recurrent and metastatic head and neck squamous cell carcinoma in Taiwan Chia-Jui Yen; Ming-Yu Lien; Rebecca Cheng; Yu-Wen Su, MD; Han-Nan Lin; Michael Thomas Wong; Song Ling Poon; Chih-Yen Chien; Ruey-Long Hong Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Clinical study;Epidemiology;Solid tumors
434 Poster Presentation Targeting the expression of Neuropilin-1 by locked nucleic acid modified antisense oligonucleotides results in potent anti-tumor activity in vivo Richard Klar, PhD; Clara Seger; Nicole Kirchhammer; André Maaske; Julia Festag; Laura Fernandez Rodriguez; Mélanie Buchi; Monika Schell; Stefanie Raith; Sven Michel; Alfred Zippelius, MD; Frank Jaschinski, PhD Checkpoint Blockade Therapy Checkpoint blockade;Gene expression;Immune suppression;Tumor microenvironment
435 Poster Presentation Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer Namrata S. Patil, Ph.D.; Barzin Y. Nabet, PhD; Sören Müller; Hartmut Koeppen; Wei Zou; Jennifer Giltnane; Jason H. Cheng; Chikara Takahashi; Avantika S. Chitre; Linda Rangell; Sangeeta Jayakar; William E. O’Gorman; Marcus Ballinger; Romain Banchereau; David S. Shames Checkpoint Blockade Therapy B cell;Checkpoint blockade;Chemotherapy;T cell
437 Oral Presentation Safety and Efficacy of Immune Checkpoint Inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium Talal El Zarif, MD; Amin Nassar, MD; Elio Adib, MD; Bailey Fitzgerald, MD; Jiaming Huang, MS; Tarek H. Mouhieddine; Taylor Nonato, BS; Rana R. McKay, MD; Mingjia Li, MD; Arjun Mittra, MD; Dwight H. Owen, MD, MSc; Michael Lorentsen, MD; Christopher Dittus, DO; Nazli Dizman, MD; Brinda Emu, MD; Adewunmi Falohun, DO; Noha Abdel-Wahab, MD, PhD; Anand Bankapur, MD; Alexandra Reed, BA; Ryan Dobbs, MD; Chul Kim, MD; Aakriti Arora, MD; Neil J. Shah, MBBS; Edward El-Am, MD; Elie Kozaily, MD; Wassim Abdallah, MD; Ahmad Al-Hader, MD; Batool Abu Ghazal, MD; Anwaar Saeed, MD; Claire Drolen, MD; Melissa G. Lechner, MD, PhD; Javier B. Espinar, MD; Caroline A. Nebhan, MD, PhD; Douglas B. Johnson, M.D.; Tarek Haykal, MD; Michael A. Morse, MD; Alessio Cortellini, MD, PhD; David J. Pinato, MD, MRes, PhD; Alessia Dalla Pria, MD; Mark Bower, MD; Evan T. Hall, MD, MPhil; Veli Bakalov, MD; Nathan Bahary, MD, PhD; Aarthi Rajkumar, MD; Ankit Mangla, MD; Vishal Shah, PharmD, MBA; Parminder Singh, MD; Frank Aboubakar Nana, MD; Nerea Lopetegui Lia, MD; Danai Dima, MD; Pauline Funchain, MD; Rabia Saleem, MD; Rachel Woodford, MD; Georgina V. Long  AO, BSc PhD MBBS FRACP FAHMS; Alexander M. Menzies, MD; Carlo Genova, MD, MD; Giulia Barletta, MD, MD; Sonam Puri, MD; Vaia Florou, MD; Dame Idossa, MD; Paola Queirolo, MD; Giuseppe Lamberti, MD; Alfredo Addeo, MD; Melissa Bersanelli, MD, PhD; Dory Freeman, BSc; Wanling Xie, MS; Ramya Ramaswami, MD, MPH; Thomas U. Marron, MD, PhD; Toni K. Choueiri, MD; Kathryn Lurain, MD, MPH; Lindsey R. Baden, MD; Guru P. Sonpavde, MD; Abdul Rafeh Naqash, MD Checkpoint Blockade Therapy Checkpoint blockade;Clinical study;Immune suppression;Immune toxicity
438 Poster Presentation Interrogation of immune toxicity in patients with thymic epithelial tumors (TETs) Meredith J. McAdams, MD; Shannon Swift, RN, BSN; Madison Ballman, BA; Abigail Wong-Rolle, BSc; Renee N. Donahue, PhD; Claudia M. Palena, PhD; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD; Arun Rajan, MD; Chen Zhao, MD Checkpoint Blockade Therapy Antibody;Autoimmunity;Biomarkers;Checkpoint blockade;Cytokine;Gene expression;Immune toxicity;Solid tumors
439 Poster Presentation Healthcare resource utilization in patients with pre-existing autoimmune diseases who received immune checkpoint inhibitors in the Marketscan database Jennell Palaia, PharmD, MS; Anna C. Pavlick, MD, MBA; Radhika Pisupati, PharmD; Benjamin C. Fu, PhD, MPH; Keith Wittstock, PharmD, MBA; Ying Zhang, MD, MsPH Checkpoint Blockade Therapy Autoimmunity;Checkpoint blockade
440 Poster Presentation Outcomes in patients with pre-existing autoimmune diseases who received immune checkpoint inhibitors: a real-world study Anna C. Pavlick, MD, MBA; Jennell Palaia, PharmD, MS; Radhika Pisupati, PharmD; Benjamin C. Fu, PhD, MPH; Keith Wittstock, PharmD, MBA; Ying Zhang, MD, MsPH Checkpoint Blockade Therapy Autoimmunity;Checkpoint blockade
441 Oral Presentation Checkpoint inhibitor-associated inflammatory arthritis is comprised of multiple clinical endotypes characterized by distinct transcriptional programs    Gary D. Reynolds, MBBS PhD; Mazen Nasrallah, MD; Neal P. Smith; Molly Thomas, MD PhD; Leyre Zubiri, MD; Alice Tirard; John McGuire; Kasidet Manakongtreecheep; Jessica Tantivit; Steven Blum, MD; Daniel A. Zlotoff, MD, PhD; Elaina PuiYee Chan; Dejan Juric, MD; Ryan J. Sullivan, MD; Genevieve M. Boland, MD, PhD; Andrew Luster; Sara Schoenfeld; Minna Kohler; Kerry L. Reynolds, MD; Chloe Villani, PhD Checkpoint Blockade Therapy Autoimmunity;Checkpoint blockade;Immune toxicity;Inflammation;T cell
442 Poster Presentation Pre-Treatment Interstitial Abnormalities is a Risk Factor for Immune Checkpoint Inhibitor Pneumonitis in Patients with Lung Cancer Alexander Wong, MD; Maria Riley, BS; Songzhu Zhao, MS; Jessica Zimmer, BS, BA; Matthew Viveiros, BS; Jing Gennie Wang, MD; Vince Esguerra, MD; Mingjia Li, MD; Gabrielle Lopez, BS; Gregory Otterson, MD; Kari Kendra, MD; Carolyn Presley, MD; Lai Wei, PhD; Dwight H. Owen, MD, MSc; Kevin Ho, MD Checkpoint Blockade Therapy Checkpoint blockade;Epidemiology;Immune toxicity;Inflammation;Radiotherapy
444 Poster Presentation TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11 Leanne G. Ahronian, PhD; Xinyuan Wu; Minjie Zhang; Chengyin Min; Alice W. Tsai; Jacques Ermolieff; Patrick McCarren; Margaret Wyman; Ye Wang; Alborz Bejnood; Kenjie Amemiya; Brian McMillan; Nikitha Das; Brian Doyon; Andre Mignault; Colin Liang; Vassil Elitzin; Yi Yu, PhD; Samuel Meier; Ashley Choi; John P. Maxwell; Alan Huang, PhD Checkpoint Blockade Therapy Checkpoint blockade;Epigenetics;MDSC;Regulatory T cell (Treg cell);T cell;Targeted therapy
445 Poster Presentation Treatment patterns and immunotherapy rechallenge in advanced or metastatic upper gastrointestinal cancer in a US real-world setting Jaffer A. Ajani, MD; Marley Boyd; Jenifer Wogen; Ilia Ferrusi; Peyman Nakhaei; Lakshmi Menon-Singh; Ailis Fagan Checkpoint Blockade Therapy Checkpoint blockade;Chemotherapy;Clinical study;Immune suppression;Solid tumors;T cell;Tumor microenvironment
446 Poster Presentation HR+ breast cancer: Defining innate and acquired resistance to immune checkpoint inhibitors  Aitziber Buqué Martinez, PhD; Norma Bloy, PhD; Michal Hensler, PhD; Giulia Petroni, PhD; Ai Sato, MSc; Takahiro Yamazaki, PhD; Bhavneet Bhinder, MS; Jitka Fucikova; Olivier Elemento, PhD; Silvia C. Formenti, MD; Lorenzo Galluzzi, PhD Checkpoint Blockade Therapy Carcinogenesis;Immune adjuvant;Immune suppression;Immune tolerance;Tumor microenvironment
447 Poster Presentation Dual targeting of PD-1 and CTLA-4 synergizes with focal radiation to durably increase survival against glioblastoma    Mara De Martino, PhD; Camille Daviaud; Claire I. Vanpouille-Box, PhD Checkpoint Blockade Therapy Checkpoint blockade;Immune suppression;Radiotherapy;Solid tumors;T cell;Tumor microenvironment
448 Poster Presentation Driver mutation analysis as a selective marker for immunotherapy in patients with pheochromocytoma and paraganglioma Katerina Hadrava Vanova, PhD; Ondrej Uher, PhD; Leah Meuter; Suman Ghosal, PhD; Jiri Neuzil, PhD; Karel Pacak, MD, PhD Checkpoint Blockade Therapy Checkpoint blockade;Gene expression;Genetic polymorphism;Immune monitoring;Solid tumors;Targeted therapy;Tumor microenvironment
449 Poster Presentation Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors Brett Hall, Ph.D.; Anna Travesa, Ph.D.; Amy Yamamura; Amy Axel; Sarah Kolitz, PhD; Jason Funt, Ph.D.; Kevin Fowler, Ph.D.; Matthew Nord, Ph.D.; Praveen Nair, Ph.D.; Scott Barrett, M.D.; Peter J. King, Ph.D.; Benjamin J. Zeskind, PhD, MBA Checkpoint Blockade Therapy Checkpoint blockade;Targeted therapy
450 Poster Presentation Increased activity of the ATX/LPA axis diminishes CD8+ T cell cytotoxicity via LPAR5 signaling, driving immune checkpoint blockade resistance in non-small cell lung cancer    Jessica M. Konen, PhD; B. Leticia Rodriguez; Haoyi Wu; Jared J. Fradette; Lixia Diao; Jing Wang, PhD; Don L. Gibbons, MD, PhD Checkpoint Blockade Therapy Checkpoint blockade;Immune suppression;Solid tumors;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs)
451 Poster Presentation Serum albumin predicts outcome in patients with extensive stage small-cell lung cancer (ES-SCLC) receiving first-line combination of PD-(L)1 inhibitors and platinum-etoposide chemotherapy. Giuseppe Lamberti, MD; Biagio Ricciuti, MD; Victor R. Vaz; Joao Victor M. Alessi, MD; Federica Pecci, MD; Alessandro Di Federico, MD; Mark Awad, MD, PhD Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Chemotherapy;Solid tumors
452 Poster Presentation Efficacy and safety of camrelizumab combination therapy in patients with recurrent or metastatic cervical and endometrial carcinoma:a retrospective study    Hong Liu, MD; Shuhuai Niu; Zhaohui Fang; Xi Chen; Siyang Liu; Ge Jin; Yunfeng Guo; Qianying Zhang Checkpoint Blockade Therapy Checkpoint blockade;Chemotherapy;Clinical study;Radiotherapy
453 Poster Presentation Pharmacologic tumor PDL1 depletion as a translational approach to inhibit tumor-intrinsic PDL1 signals and create novel treatment vulnerabilities Clare E. Murray, B.S.; Haiyan H.B. Bai, PhD; Anand V. Kornepati, PhD; Carlos O. Ontiveros, BS; Yilun Deng, PhD; Alvaro S. Padron; Eva M. Galvan; Myrna G. Garcia, BS; Tyler J. Curiel, MD Checkpoint Blockade Therapy Checkpoint blockade;Chemotherapy;Solid tumors;Targeted therapy;Tumor microenvironment
454 Poster Presentation Real-world treatment patterns among patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC) in a community oncology setting Eric Nadler, MD MPP; Christopher M. Black, PhD; Karthik Ramakrishnan; Wan-Yu Tseng; Chuck Wentworth; John Murphy; Nicole Fulcher; Liya Wang; Melannie Alexander; Gregory Patton Checkpoint Blockade Therapy Chemotherapy;Radiotherapy;Solid tumors;Targeted therapy
455 Poster Presentation Fostrox (MIV-818) in combination with anti-PD-1 shows increased efficacy in nonclinical tumor models in vivo Fredrik G. Oberg, PhD; Sujata Bhoi, PhD; Malene Jensen, PhD; Tom Morris, MD; Karin Tunblad, PhD; Hans Wallberg, PhD Checkpoint Blockade Therapy Checkpoint blockade;Chemotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs)
456 Poster Presentation Patterns and Outcomes of Palliative Radiation Therapy with Immunotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma     Logan Roof, MD; Anirudh Yalamanchali, MD; David Buchberger, MD; Shauna Campbell, DO; Shlomo Koyfman, MD; Neil M. Woody, MD; Natalie Silver, MD, MS, FACS; Jessica L. Geiger, MD; Emrullah Yilmaz, MD, PhD Checkpoint Blockade Therapy Checkpoint blockade;Costimulation;Radiotherapy
457 Poster Presentation Efficacy of Pembrolizumab as cross-line treatment in advanced non-small cell lung cancer: a multi-center non-interventional study from China    Kexin Ruan; Jing Zheng; Jianying Zhou; Yuping Li; Xiaodong Lv; Xiaoyu Wu; Liren Ding; Jianya Zhou, MD Checkpoint Blockade Therapy Angiogenesis;Checkpoint blockade;Chemotherapy;Clinical study
458 Poster Presentation Characterization of HZ-G206: A potent and oral small molecule PD-L1 inhibitor Yizhe Wu, PhD; Xingguo Liu, PhD; Xinxin Jin; Jinglai Huang; Xinglu Zhou Checkpoint Blockade Therapy Checkpoint blockade;Solid tumors
459 Poster Presentation Gene therapy with p19Arf and interferon-beta sensitizes cells to PD-1 checkpoint blockade and enhances antitumor immune responses in resistant mouse models Ana Domingues, BS; Nayara Tessarollo; Bryan Strauss Checkpoint Blockade Therapy Checkpoint blockade;Gene expression;Solid tumors
460 Poster Presentation Discovery of Potent Cbl-b inhibitors Demonstrating Enhanced Immune Cell Activity and Tumor Growth Inhibition in Murine Syngeneic Models Silvana Leit, PhD; David Ciccone, PhD Checkpoint Blockade Therapy B cell;Checkpoint blockade;Cytokine;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell
461 Poster Presentation Generation of AZD7789, a novel PD-1 and TIM-3 targeting bispecific antibody, which binds to a differentiated epitope of TIM-3    Eleanor Clancy-Thompson, PhD; Trinity L. Perry; Stacy Pryts; Ashvin Jaiswal, PhD; Vaheh Oganesyan; Nydia van Dyk; Chunning Yang; Andrew Garcia; Wenhan Yu; James R. Moynihan, MS; Caroline Miller; Kathy A. Mulgrew; Mark Cobbold, MD, PhD; Yariv Mazor; Scott A. Hammond, PhD; Kristen N. Pollizzi, PhD Checkpoint Blockade Therapy Antibody;Bispecifics;Checkpoint blockade;Dendritic cell;Genetic polymorphism;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
462 Poster Presentation PD-L1/PD-L2 dual-specific cytotoxic antibodies augment survival and mediate tumor regression across immune 'hot' and 'cold' murine cancers    Coline A. Couillault, PhD; Anupallavi Srinivasamani, MS; Shweta M. Hedge; Qinying Liu; Guillaume Trusz; Ashvin Jaiswal, PhD; Dongxing Zha; Michael A. Curran, PhD Checkpoint Blockade Therapy Antibody;Bispecifics;Checkpoint blockade;MDSC;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
463 Poster Presentation Investigating the T cell-intrinsic regulatory role of VISTA in anti-tumor immunity      Cassandra K. Gilmour, BS; Yikun Wang; Sachin Patnaik, BA; Sarah Stone; Li Wang, PhD Checkpoint Blockade Therapy Checkpoint blockade;Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
464 Poster Presentation Anti-CTLA-4 therapy depletes Tregs and expands ICOS+ T-cells in neuroblastoma tumors with induced DNA mismatch repair deficiency    Megan Hong, BMSc; Rene Figueredo, MSc; Saman Maleki, PhD Checkpoint Blockade Therapy Checkpoint blockade;Costimulation;Neoantigens;Pediatric tumors;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
465 Poster Presentation Synergistic approach to overcome the solid tumor microenvironment of mesothelioma with natural killer cell-focused immunotherapy Philippa (Pippa) R. Kennedy, PhD; Quinlan M. Kile; Blake A. Jacobson, PhD; Brianna Ettestad; Sarah E. Miller; Jeffrey S. Miller, MD; Manish R. Patel, DO; Martin Felices Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Costimulation;Cytokine;Immune suppression;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment
466 Poster Presentation Combination therapy with anti-VSIG4 and anti-PD-L1 suppress growth of tumor via conditioning of tumor microenvironment.    Byoung S. Kwon, PhD; Hye Jeong KIM; Joong Won Lee Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Monocyte/Macrophage;Tumor microenvironment
467 Poster Presentation YH38560, a novel bispecific fusion protein targeting 5T4 and CD47 in a tumor-selective manner for the treatment of solid cancers Narae Lee, MS; Eunjeong Jeong; Jung-Hoon Pyun; Minji Choi; Young Bong Park; Yoon ha Hwang; Eunjung Lee; Junhwan Kim; Se-Woong Oh Checkpoint Blockade Therapy Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment
468 Poster Presentation Application of Organoid-based Discovery Platform for Innovative Screening, Evaluation, and Identification (ODISEI) in Immunotherapy Bo Eun Lee, MS; Sarang Kim; Yuri Shin; Hee-Ra Lee; Suyoung Jo; Dong Wook Han; Jongman Yoo Checkpoint Blockade Therapy B cell;Bispecifics;Checkpoint blockade;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
469 Poster Presentation Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT    Karin Lee, PhD; Deepali Malhotra, PhD; Stacy Pryts; Eleanor Clancy-Thompson, PhD; Bilal Omar, PhD; Brian Naiman; Michael Overstreet, PhD; Devon K. Taylor; Chunning Yang; Kathy A. Mulgrew; Zhan Xiao; Yue Wang, PhD; Gordon Moody; Mark Cobbold, MD, PhD; Yariv Mazor; Scott A. Hammond, PhD; Kristen N. Pollizzi, PhD Checkpoint Blockade Therapy Antibody;Bispecifics;Checkpoint blockade;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
470 Poster Presentation Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors Chloe Delepine, MEng, MS; Daniel L. Levey, PhD; Shanmugarajan Krishnan, PhD; Kwang-Soo Kim, PhD; Adam Sonabend; Margaret Wilkens; Antoine Tanne, PhD; Pilar Garcia-Brocano; Claire H. Galand, PhD; Haiyong Han, PhD; Christopher MacDermaid; Jacky Chow, PhD, MS; Sylvia Vincent; Shalu Karkwal; Yan Sun; Racehl Smith; Xavier Michelet, PhD; Kah Teong; Katherine Rosenthal, RN, MSN, OCN, CCRP; David Savitsky, PhD; Cailin Joyce, PhD; Steven J. O'Day, MD; Joseph E. Grossman, MD; Jaymin M. Patel, MD; Dhan Chand, PhD Checkpoint Blockade Therapy Antibody;Antigen presenting cells;Checkpoint blockade;Clinical study;Costimulation;Dendritic cell;Gene expression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
471 Poster Presentation Transient inhibition of cyclin-dependent kinase 4/6 with trilaciclib enhances inhibitory receptor immunotherapy to improve antitumor efficacy Kun-Hui Lu; Catherine Dietrich; Sarah Ahn; Subing Cao; John S. Yi, PhD; Shom Goel Checkpoint Blockade Therapy Checkpoint blockade;Solid tumors;T cell;Tumor microenvironment
472 Poster Presentation Knockdown of VISTA protein using antisense oligonucleotides promotes superior anti-tumor immunity compared to antibody blockade      Brittany A. Morrow, BS; Michael A. Curran, PhD; Priyamvada Jayaprakash, PhD; Alexey Revenko; Patrick Younan Checkpoint Blockade Therapy Checkpoint blockade;Granulocyte;Immune suppression;Immune toxicity;MDSC;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
473 Poster Presentation PD-1 blockade administered before or at the time of T cell activation enhances anti-tumor immunity Jena E. Moseman, BSE; Douglas G. McNeel, MD, PhD Checkpoint Blockade Therapy Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine
474 Poster Presentation First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity     Akram Obeidat, PhD; Anas Atieh; Alon Vitenshtein; Guy Cinamon, PhD; Keren Paz, PhD; Tihana Roviš; Paola Brilc; Lea Hirsl; Ofer Mandelboim; Stipan Jonjic; Pini Tsukerman, PhD Checkpoint Blockade Therapy Antibody;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
475 Poster Presentation Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade Namrata S. Patil, Ph.D.; Raymond Meng, PhD; Robert Johnston; Patrick S. Chang; Shyam Srivats; Yoonha Choi; Xiangnan Guan; Barzin Y. Nabet, PhD; Lisa McGinnis; Eugene Chiang; Thinh Pham; Alexis Dunkle; Bill O’Gorman; Ira Mellman, PhD; Ruozhen Hu; John Silva; Joy Han; Amelia Au-Yeung; Chikara Takahashi; Nandini Molden; Pallavi Daggumati; Wendy Connolly; Melissa L. Johnson, MD; Delvys Rodriguez Abreu; Byoung Chul Cho, MD, PhD; Antoine Italiano, MD, PhD; Ignacio Gil Bazo; Enriqueta Felip; Sanjeev Mariathasan, PhD; Carlos Bais; David S. Shames, PhD Checkpoint Blockade Therapy Checkpoint blockade;Myeloid cells;Regulatory T cell (Treg cell);T cell
476 Poster Presentation LAIR-1 inhibition enhances anti-PD-1 efficacy    Yoshiko Takeuchi, MD PhD; Corazon D. Arthur; Heather N. Kohlmiller; James M. White; Betty Lee; Bin Fan; Jiawei Huang; James Sissons; Jonathan Sitrin; Lee Rivera; Robert D. Schreiber, PhD Checkpoint Blockade Therapy Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Neoantigens;Solid tumors
477 Poster Presentation HBM1047, a novel fully human anti-CD200R1 antagonist antibody with potent anti-tumor efficacy in preclinical model Yuhua Wang, Ph.D; Qiumei Du; Hongjie Pan; Geetika Bajpai; Tao Liu; Jason Noon; Yao Lu; Jinqiu He; Yan Li; Qingfang Chen; Yongqiang Wang; Xingxing Jia; Fei Chen; Youhong Wang; Yiping Rong; Yun He; Joe Zhao; Musheng Bao Checkpoint Blockade Therapy Antibody;Antigen presenting cells;Checkpoint blockade;Coinhibition;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
478 Poster Presentation Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI) Tony Z. Zhuang, MD; Subir Goyal, MBBS, PhD, MSc; Jacqueline T. Brown, MD; Bradley C. Carthon, MD, PhD; Omer Kucuk, MD; Greta R. McClintock, MSN, FNP, DC; Lauren Yantorni, ARNP; Mehmet A. Bilen, MD; Viraj A. Master, MD, PhD; Bassel Nazha, MD, MPH Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Clinical study;Epidemiology;Gene expression;Immune adjuvant;Inflammation;Solid tumors;Targeted therapy;Tumor microenvironment
479 Poster Presentation Expression of Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) on CD4+/CD8+ T cells may associate with pathological characteristics of different types of cancer Dia Roy, PhD; Hieu M. Ta, PhD; Cassandra K. Gilmour, BS; Timothy A. Chan, MD, PhD; Keman Zhang, PhD; Li Wang, PhD; Sarah Stone Checkpoint Blockade Therapy Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
480 Poster Presentation Impact of infections in patients with advanced or metastatic non-small cell lung cancer (NSCLC) receiving pembrolizumab-based therapies Ethan A. Burns, MD; Jiaqiong Xu, PhD; Ryan B. Kieser, MD; Shivan Shah, MD; Ibrahim N. Muhsen, MD; Godsfavour Umoru, PharmD; Charisma Mylavarapu, MD; Yuqi Zhang, MD; Aubrey Crenshaw, DO; Kai Sun, MD; Abdullah Esmail; Carlo Guerrero, MD; Zimu Gong, MD, PhD; Kelly Gee, DO; Kirk Heyne, MD; Monisha Singh, MD; Jun Zhang, MD; Eric Bernicker; Maen Abdelrahim, MD, PhD, Pharm B Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Chemotherapy;COVID and Immunotherapy;Immune toxicity
481 Poster Presentation An affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade Xavier Chauchet, PhD; Sebastien Calloud; Margaux Legrand; Laura Cons; Laurence Chatel; Adeline Lesnier; Nicolas Bosson; Pauline Lloveras; Pauline Malinge; Ulla Ravn; Valery Moine; Bruno Daubeuf; Yves Poitevin; Giovanni Magistrelli; Susana Salgado-Pires, PhD; Dmitry Shchelokov, PhD; Oleg Demin, Jr., PhD; Limin Shang, PhD; Krzysztof Masternak, PhD; Walter Ferlin, PhD Checkpoint Blockade Therapy Bispecifics;Checkpoint blockade;Solid tumors
482 Oral Presentation ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking 'don't-eat-me' signal Peng Chen; Min Deng; Yun Liu; Jiamei Luo; Rong Guo; Jay Mei; Bo Shan; Bing Hou, Ph.D Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Monocyte/Macrophage;Tumor microenvironment
483 Poster Presentation Preclinical evaluation of JTX-1484, an anti-LILRB4 antagonist antibody, for re-programming of immunosuppressive myeloid cells Heather Condurso; Amy Mueller; Jessica Jimenez; Lauren Badalucco; Kelly Aldridge; Pauline Sarraf; Michelle Priess; Vikki Spaulding; Sarah Jaffe; Prashanna Balaji Venkatasubramanian; Alexa Diiorio; Geneva Young; Kameron Mori; Karl Wetterhorn; Jeffrey Smith; Morgan Thompson; Jean-Christophe Pignon; Changyun Hu; Brandon Chin; Briana Murphy; Matthew Southard; Katalin Kis-Toth; Monica Gostissa, PhD; Dmitri Wiederschain; Andre P. da Cunha Checkpoint Blockade Therapy Antibody;Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;Myeloid cells;Solid tumors;Tumor microenvironment;Tumor stroma
484 Poster Presentation Blockade of the myeloid CLEC-1 checkpoint enhances antitumor responses and tumor antigen cross-presentation Vanessa Gauttier, PhD; Marion Drouin; Isabelle Girault, MD; Irène Baccelli; Sabrina Pengam; Emmanuelle Wilhelm; Javier Saenz; Julien Taurelle; Emmanuel Merieau; Bérangère Evrard; Caroline Mary; Géraldine Teppaz; Ariane Desselle; Virginie Thépénier; Nicolas Poirier; Elise Chiffoleau Checkpoint Blockade Therapy Antigen presenting cells;Checkpoint blockade;Dendritic cell;Monocyte/Macrophage
485 Poster Presentation Functional characterization of the inhibitory activity and identification of novel T-cell receptors for the tumor-associated macrophage receptor VSIG4 Tim Eitas, PhD; Edward H. van der Horst, PhD; Faith Finley, BS; Thomas Thisted, PhD; Kanam Malhotra, MS; Arnab Mukherjee, PhD; Zuzana Biesova, PhD; Anokhi Cifuentes, MS; Sandra Marder, PhD; Paul Helbling, PhD; Robert H. Pierce, Jr., MD Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Coinhibition;Immune suppression;Monocyte/Macrophage;Myeloid cells;Surfaceome;T cell;Targeted therapy;Tumor microenvironment
486 Poster Presentation Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy.    Silvia Guglietta, PhD; Lukas M. Weber, PhD; Bruno Fosso, PhD; Marinella Marzano; Gary Hardiman; Monica M.M. Olcina, PhD; Mark D. Robinson, PhD; Carsten Krieg, PhD Checkpoint Blockade Therapy Checkpoint blockade;Inflammation;Microbiome;Solid tumors
487 Poster Presentation The Role of VSIG4 as an Immuno-Regulatory protein in cancer    William Huang, BS; Michele Doucet; Rupashree Sen; Andrew M. Pardoll, MD, PhD; Sudipto Ganguly, PhD Checkpoint Blockade Therapy Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment
488 Poster Presentation GNUV201, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer immunotherapy    Haemi Kim; Kyoung-Jin Kim; Myeong Jin Yoon; Jenny Choih, PhD; Eun Ji Cho; Hak-Jun Jung, PhD; Kwanghyun Lee, PhD; Jayoung Kim; Chae Gyu Park; Sungho Han, PhD; Donggoo Bae; Heungrok Park Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Cytokine;Solid tumors;T cell;Tumor microenvironment
489 Poster Presentation NPX267, a first-in-class monoclonal antibody targeting KIR3DL3, blocks HHLA2-mediated immunosuppression and potentiates T and NK cell-mediated antitumor immunity    McKenna Lamb; Yao Wei; Xiaoxin Ren; Rachel O'Connor; Austin Dulak, PhD; Matthew Rausch, PhD; Jamie Strand, PhD; Bijan Etemad-Gilbertson, PhD; Riale Gilligan; Scott Chappel, PhD; Tomonari Shigemura; David McDermott, MD; Gordon J. Freeman, PhD; XingXing Zang, PhD Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Coinhibition;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs)
490 Poster Presentation Galectin-9 drives TIM-3+ natural killer cell dysfunction in head and neck squamous cell carcinoma Lazar Vujanovic, PhD; Housaiyin Li; Juncheng Wang; Aditi Kulkarni; Jennifer L. Anderson, M.D., Ph.D.; Lidia M. Arantes; Hridesh Banerjee, PhD; Lawrence P. Kane, PHD; Xin Zhang; Tullia Bruno, PhD; Riyue Bao, PhD; Robert L. Ferris, MD, PhD Checkpoint Blockade Therapy Checkpoint blockade;Gene expression;Immune suppression;NK/NKT cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
491 Poster Presentation Preclinical pharmacology modeling of HX009, a clinical stage first-in-class PD-1xCD47 BsAb, for anti-lymphoma applications    Xiaoyu An, PhD; Henry Li, Ph.D; Hang Ke; Lingxin Xiong, Ph.D; Faming Zhang, Ph.D; Mingfa Zang; Xiaolong Tu, Ph.D; Jingjing Wang, Ph.D; Demi Liu; Cen Chen; Cunxiang Ju; Xianfei He, Ph.D; Lei Zhang, Ph.D Checkpoint Blockade Therapy Antibody;Bispecifics;T cell
492 Poster Presentation SIRPα blockade results in tumor intrinsic and immune microenviroment effects resulting in the inhibition of breast-to-brain metastatsis Jessica D. Mackert, PhD; Elizabeth R. Stirling, MS, PhD; Steven M. Bronson, DVM; Adam S. Wilson; Mitra Kooshki, MS; Dawen Zhao, MD PhD; Pierre L. Triozzi, MD; Glenn Lesser, MD; David R. Soto-Pantoja, PhD Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Monocyte/Macrophage;Tumor evasion;Tumor microenvironment
493 Poster Presentation PH-804, an INTASYL self-delivering RNAi compound that targets TIGIT enhances NK cell cytotoxicity to tumor cells    Melissa Maxwell; Dingxue Yan; Brianna Rivest; Andrew Boone; Shenghua Zhou, MD, PhD; Benjamin Cuiffo, PhD; James Cardia, PhD; Simon P. Fricker, PhD Checkpoint Blockade Therapy Adoptive immunotherapy;Checkpoint blockade;Gene expression;NK/NKT cell;RNA
494 Poster Presentation CO-1: A Novel Potent Dual Function Anti-CD47 Antibody for Cancer Therapy    Sittana Matar, Industrial PhD candidate; Seham Skah, PhD; Rolf D. Pettersen, PhD; Kjetil Hestdal, MD, PhD; Nina Richartz, PhD Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Immune suppression;Leukemia/Lymphoma;Monocyte/Macrophage;Solid tumors;Tumor evasion
495 Poster Presentation BYON4228, a pan-allelic SIRPα blocking antibody with a favorable pre-clinical safety profile, enhances anti-tumor immunity in vitro and in vivo   Mary van Helden; Roel Arends; Seline Zwarthoff; Monique van der Vleuten; Marc Paradé; Karin de Laat-Arts; Hugo Olsman; Ellen Mattaar; Dirk Glaudemans; Daniëlle van Wijk; Lilian Driessen-Engels; Inge Reinieren-Beeren; Paul Boersema; Eva Hanckmann; Gerard Rouwendal; Ruud Ubink; Miranda van der Lee; Gijs Verheijden; Wim Dokter; Timo van den Berg Checkpoint Blockade Therapy Checkpoint blockade;Myeloid cells
496 Poster Presentation HCB101: A safe and effective ligand trap therapeutic targeting the CD47-SIRPa signaling pathway for cancer treatment    Jiin-Tarng Wang; Chi-Ling Tseng; Han-Feng Teng; Pan-Hsien Kuo; Yun-Chih Cheng; Yi-Jing Chen; Yi-Hsuan Lu; Tsai-Kuei Shen; Hong-Fan Wang; Pei-Lun Tsai; Yu-Chen Wu; Chien-Hsin Ho; Wei-Tse Sun; Yen-Cheng Li; Yi-Hsuan Lee; Zong Sean Juo, PhD Checkpoint Blockade Therapy Checkpoint blockade;Monocyte/Macrophage;Solid tumors;Targeted therapy
497 Poster Presentation Evaluation of the TIGIT+ immune subset depletion effect of the anti-TIGIT antibody M6223    Chunxiao Xu; Sireesha Yalavarthi; Clotilde Bourin; Jacques Moisan; Andree Blaukat; Laura Helming Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
498 Poster Presentation Preclinical characterization of OR502, an anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression    Meghan E. Zuck, PhD; Myriam N. Bouchlaka, PhD; Huyen Dinh; Kevin Green; Meilyn Sylvestre; Francisco Zapata; Ramya Chandrasekaran, M.S. Ph.D.; Gajendra S. Naika; Lauren Loh; Ray Fox; Darbie Whitman; Tom Graddis; Kamal D. Puri, PhD; Peter Probst, PhD Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors
499 Poster Presentation The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model Kathleen Sullivan, PhD; Linda Ertl; Zhenhua Miao; Pingchen Fan; Yibin Zeng; Carolyn Dunlap; Karen Ebsworth; Suprit Gupta; Shijie Chris Li; Ton Dang; Shichang Miao; Israel Charo Checkpoint Blockade Therapy Checkpoint blockade;Solid tumors;Tumor microenvironment
500 Poster Presentation INV322, a TME selective CD25 x CTLA4 bispecific antibody approach for depletion of tumor restricted Tregs    Anna C. Ritter, Ph.D.; Nicholas M. Marshal, PhD; Dileep K. Pulukkunat, PhD; Nikhil Pereira; Alexander L. Rakhmilevich, MD, PhD; Joseph Gawdzik, PhD; Jessica M. Wiwczar, PhD; Jason D. Russell, PhD; Laura J. McCormick; Catherine R. Aversa, PhD; Paul M. Sondel, MD, PhD; Hilario J. Ramos, PhD; Bonnie J. Hammer, PhD; Daniel S. Pereira, PhD Checkpoint Blockade Therapy Bispecifics;Checkpoint blockade;Regulatory T cell (Treg cell);T cell;Tumor microenvironment
501 Poster Presentation Anti-PDL2 uses IL17-driven interferon-gamma to treat aged but not young cutaneous melanoma-bearing mice, and treats other tumors in an age- and TME-dependent manner    Myrna G. Garcia, BS; Yilun Deng, PhD; Clare E. Murray, B.S.; Carlos O. Ontiveros, BS; Alvaro S. Padron; Sladjana Skopelja-Gardner; Kah Teong Soh; Dhan Chand, PhD; Tyler J. Curiel, MD Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Costimulation;Solid tumors;Tumor microenvironment
502 Poster Presentation Transplant Oncology: Utilization of Immunotherapy in the Peri-transplant Setting Maen Abdelrahim, MD, PhD, Pharm B; Abdullah Esmail; Ala Abudayyeh, MD; Ashish Saharia, MD; R. Mark Ghobrial, MD Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Immune monitoring;Immune suppression;Targeted therapy
503 Poster Presentation Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma Alexander B. Afeyan, BA; Giacomo Oliveira, PhD; Ann Marie Egloff; Zexiang Zeng, PhD; Rebecca Chernock; Liye Zhou, Ph.D.; Cameron Messier; Patrick Lizotte, PhD; Jacquelyn O. Wolff; Kathleen L. Pfaff, PhD; Kari Stromhaug; Robert Haddad, MD; Glenn J. Hanna, MD; Jonathan Schoenfeld, MD MPH; Laura A. Goguen, MD; Donald J. Annino, MD, DMD; Vickie Y. Jo, MD; Peter Oppelt, MD; Patrik Pipkorn, MD; Ryan Jackson, MD; Sidharth V. Puram; Randal C. Paniello, MD, PhD; Jason T. Rich, MD; Jason Webb; Jose Zevallos; Mena Mansour, MD; Jingxin Fu; Gavin P. Dunn, MD, PhD; Scott J. Rodig, MD, PhD; Jessica Ley; Luc G.T. Morris, MD; Lara A. Dunn, MD; Cloud P. Paweletz, Ph.D.; Dorina Kallogjeri, MD, MPH; Jay F. Piccirillo, MD; Douglas R. Adkins; Catherine J. Wu, MD; Ravindra Uppaluri, MD PhD Checkpoint Blockade Therapy Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
504 Oral Presentation PVRIG, a novel T cell checkpoint, is preferentially expressed in TLS on stem-like memory T cells, potentially inhibiting their expansion    Zoya Alteber, PhD; Roy Granit; Gady Cojocaru; Amit Novik; Niv Sabath; Assaf Wool; Yossef Kliger; Yu Liang; Natalia Petrenko; Jiang He; Pierre Ferre; Yaron Turpaz; Zurit Levin; Eran Ophir, PhD Checkpoint Blockade Therapy Antigen presenting cells;Checkpoint blockade;Dendritic cell;Gene expression;Immune contexture;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
505 Oral Presentation High-dimensional analyses of intratumoral myeloid cells highlights presence of distinct myeloid cell phenotypes in immune checkpoint-sensitive and resistant tumors    Swetha Anandhan, M.Sc.; Sangeeta Goswami, MD, PhD; Shelley Herbrich, PhD; Yulong Chen, Ph.D.; Padmanee Sharma, MD, PhD Checkpoint Blockade Therapy Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
506 Oral Presentation FcγRIIB expressed on CD8 T cells limits responsiveness to PD-1 checkpoint inhibition in cancer Kelsey B. Bennion, BS; Marvi Tariq, MD; Megan M. Wyatt, MS; Kirsten M. Baecher, MD; Chrystal M. Paulos, PhD; Ragini R. Kudchadkar, MD; Michael Lowe, MD, MA; Mandy L. Ford, PhD Checkpoint Blockade Therapy Adoptive immunotherapy;Antibody;Biomarkers;Checkpoint blockade;Coinhibition;Costimulation;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine
507 Oral Presentation High endothelial venules control the journey of stem-like CD8+ T cells from lymph node to tumor during cancer immunotherapy with combined anti-PD-1 plus anti-CTLA-4 antibodies Lucas Blanchard; Estefania Vina; Dorian Tarroux; Emma Lefrançais; Nathalie Ortega; Jean-Philippe Girard Checkpoint Blockade Therapy Angiogenesis;Antibody;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
508 Poster Presentation Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition Dante Bortone; Anne Monette, PhD; Nicholas Tschernia; Alexandria Cogdill; Yana G. Najjar, MD; Randy F. Sweis, MD; Sara Valpione, MD, PhD; Erik Wennerberg; Praveen K. Bommareddy, Bpharm, MS, PhD; Cara Haymaker; Uqba Khan; Heather M. McGee; Wungki Park, MD; Houssein A. Sater; Christine N. Spencer, PhD; Maria Ascierto; Valentin Barsan; Vinita Popat, BA; Daniel Wells; Steven Vensko; Sarah Dexheimer; Vesteinn Thorsson; Roberta Zappasodi; Nils-Petter Rudqvist, PhD; Benjamin G. Vincent, MD Checkpoint Blockade Therapy Bioinformatics;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Gene expression;Systems biology;T cell
509 Poster Presentation Immune checkpoint blockade boosts anti-tumour B cell responses in lung adenocarcinoma    Jesse Boumelha, BA; Kevin Ng, BA; Katey Enfield, PhD; Charles Swanton, PhD; George Kassiotis, PhD; Julian Downward, PhD Checkpoint Blockade Therapy B cell;Checkpoint blockade
510 Poster Presentation A PD-L1 reporter cell line based on the immune checkpoint protein profiling of ATCC cell lines facilitates cancer immunotherapy drug screening Hyeyoun Chang, PhD; Brian Della Fera, BS; Haiyun Liu, PhD; Arunajyothi Bandla, MS; Kevin Tyo, PhD; John G. Foulke, MS; Luping Chen, BS; Zhizhan Gu, MD, PhD; Fang Tian, PhD Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Gene expression;Immune monitoring;Immune suppression;T cell;Targeted therapy;Tumor evasion
511 Oral Presentation T cell-instructed inflammation drives immune checkpoint inhibitor therapy resistance    Nam Woo Cho, MD PhD; Sophia Guldberg; Eun Ji Kim; Kamir Hiam-Galvez; Katherine Wai; Lauren Levine; Rachel DeBarge; Jacqueline Yee; Naa Ashitey; Matthew Spitzer, PhD Checkpoint Blockade Therapy Checkpoint blockade;Cytokine;Granulocyte;Immune suppression;Inflammation;MDSC;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs)
512 Poster Presentation Time-of-day of pembrolizumab infusion and clinical outcomes of patients with NSCLC: too soon to promote morning infusions    Alessio Cortellini, MD, PhD; Adriana Barrichello; Joao Victor M. Alessi, MD; Biagio Ricciuti, MD; Victor R. Vatz; Thomas Newsom-Davis; Joanne S. Evans; Giuseppe Lamberti, MD; Federica Pecci, MD; Patrizia Viola; Antonio D'Alessio; Claudia A.M. Fulgenzi; Mark Awad, MD, PhD; David J. Pinato, MD, MRes, PhD Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Clinical study;Immune monitoring
513 Poster Presentation Overcoming Hedgehog Mediated Anti-PD-1 Resistance in Melanoma through Prostaglandin Inhibition Nicholas C. DeVito, MD, Y-Van Nguyen, Nagendra Yarla, PhD, Michael P. Plebanek, PhD, Balamayooran BT. Theivanthiran, PhD,  Michael Aksu,  Vaibhav Jain,  Brent Hanks, MD, PhD Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;NK/NKT cell;Solid tumors;Tumor microenvironment
514 Oral Presentation Tumor context dictates reliance on TCF1 for response to immunotherapy    Giulia Escobar, PhD; Katherine Tooley; Joan Pagès Oliveras; Cheng Hanning; Xue Chang; Davide Mangani; Hazel Natanael; Carola Rutigliani; Luca Biasco; Ana Carrizosa Anderson Checkpoint Blockade Therapy Checkpoint blockade;Immune contexture;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
515 Poster Presentation Assessing the effect of post-traumatic osteoarthritis on murine tumor growth and responsiveness to immune checkpoint blockade    Elise F. Gray-Gaillard, MS; Younghwan Choi, PhD; Jin Han, PhD; Helen Nguyen, BS; Katlin Stivers, PhD; Anna Ruta, BS; Andrew M. Pardoll, MD, PhD; Jennifer H. Elisseeff, PhD Checkpoint Blockade Therapy Angiogenesis;Checkpoint blockade;Solid tumors;Surgery;Tumor stroma
516 Poster Presentation Clinical Tier Grading of Cancer Stem Cells According to Clinical Characteristics for Immune Checkpoint Inhibitors Guided by mRNA stemness index    Priya Hays, MS, PhD Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Solid tumors;Stem cell/cancer-initiating cell
517 Poster Presentation Splenic Tumor-Reactive CD8+ T Cells are Endowed With a Unique Potential for Expansion and are the Dominant Source of Systemic Anti-Tumor Immunity After ICB Therapy Brendan L. Horton, PhD; Duncan M. Morgan, Ph.D.; J. C. Love; Stefani Spranger, PhD Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Coinhibition;Gene expression;Solid tumors;T cell;T cell lineages
519 Poster Presentation Meta-analysis on immunotherapy-related hyperprogressive disease (HPD) incidence across tumor types and HPD definitions Min Jeong Kim; Min Jeong Kim, MD; Seung Pyo Hong, MD; Yeonggyeong Park, MD; Allison Belette, MD; Chiwoo Song, MD; Youjin Oh, MD; Sukjoo Cho, MD; Ilene Hong; Young Kwang Chae, MD, MPH, MBA Checkpoint Blockade Therapy Checkpoint blockade;Tumor microenvironment
520 Poster Presentation PD-1 Inhibits Bystander T Cell Activation and Protects from Activation Induced Cell Death Michael Sheng; Catherine T. Le; Cordelia M. Dunai, MS; Lam T. Khuat; Logan Vick; Kevin Stoffel; Arta M. Monjazeb, MD, PhD; Craig Collins; Robert J. Canter, MD; William J. Murphy Checkpoint Blockade Therapy Checkpoint blockade;Cytokine;Immune monitoring;T cell;T cell lineages
521 Poster Presentation AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; Chunshan Jin; Xinrong He; Yu Xia; Baiyong Li, Ph.D; Jing Min, Ph.D Checkpoint Blockade Therapy Antibody;Bispecifics;Checkpoint blockade;Tumor microenvironment
522 Poster Presentation Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer Danish Memon; Matthew D. Hellmann, MD; Martin L. Miller, PhD Checkpoint Blockade Therapy Bioinformatics;Checkpoint blockade;Clinical study;Gene expression;Immune suppression;Systems biology;Tumor evasion;Tumor microenvironment
523 Poster Presentation Small cell lung cancer molecular subtypes and vulnerability to immune checkpoint blockade Barzin Y. Nabet, PhD; Habib Hamidi, PhD; Romain Banchereau, PhD; Stefanie Morris, PhD; Leah Adler; Minu K. Srivastava, PhD; Namrata S. Patil, Ph.D.; Carl M. Gay, MD, PhD; John Minna, M.D.; John V. Heymach, MD, PhD; Joseph M. Chan, MD, PhD; Charles M. Rudin; Lauren A. Byers, MD; Stephen V. Liu, MD; Martin Reck; David S. Shames, PhD Checkpoint Blockade Therapy Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;Immune contexture;Immune suppression;Monocyte/Macrophage;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
524 Poster Presentation Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer receiving immune check-point inhibitors - applicability and potential caveats    Line Nederby, MSc, PhD; Sinne S. Brun, MD; Torben S. Hansen, MD; Christa H. Nyhus, MD; Lisbeth Bertelsen, MD; Rikke F. Andersen, MSc, PhD; Anders Jakobsen, MD, DMSc, Professor; Torben F. Hansen, MD, DMSc, Associate Professor Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Solid tumors
526 Poster Presentation miR-15a and miR-15b modulate natural killer and CD8+T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma    Kishore B. Challagundla, PhD; Anup Pathania, PhD; Philip Prathipati, PhD; Omalla A. Olwenyi, PhD; Srinivas Chava, PhD; Oghenetejiri V. Smith, MS; Subash C. Gupta, PhD; Nagendra K. Chaturvedi, PhD; Siddappa N. Byrareddy, PhD; Don W. Coulter, MD Checkpoint Blockade Therapy Immune suppression;Pediatric tumors;Tumor evasion;Tumor microenvironment
527 Poster Presentation Spatial proteomic and transcriptomic biomarkers of response to immune checkpoint inhibitors in operable lung cancer    Jonathan Stauber, PHD; Corinne C.R. Ramos, PhD; Adele Ponzoni; Amandine Gerstenberg Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Immune contexture;Solid tumors;Tumor microenvironment
528 Oral Presentation Acquired resistance to PD-(L)1 blockade in patients with non-small cell lung cancer (NSCLC) Biagio Ricciuti, MD; Giuseppe Lamberti, MD; Joao Victor M. Alessi, MD; Federica Pecci, MD; Alessandro Di Federico; Xinan Wang; Adriana Barrichello; Victor R. Vaz; Andy Pangilinan; Danielle Haradon; Lee Elinton; Mizuki Nishino; Scott J. Rodig, MD, PhD; Lynette M. Sholl, MD; Mark Awad, MD, PhD Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade
529 Poster Presentation Reduced dendritic cell infiltration in anti-PD-1 resistant head and neck squamous cell carcinoma    Shin Saito, MD; Hirofumi Shibata; Liye Zhou, Ph.D.; Katie Campbell, PhD; Ann Marie Egloff; Ravindra Uppaluri, MD PhD Checkpoint Blockade Therapy Checkpoint blockade;Dendritic cell;Neoantigens;Tumor infiltrating lymphocytes (TILs)
530 Poster Presentation B7-H3 is a Checkpoint Immunotherapy Target in Advanced Prostate Cancer Harboring PTEN and TP53 Defects    Di Zhao, PhD; Wei Shi; Yin Wang Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Immune suppression;Solid tumors
531 Poster Presentation Identifying genetic factors for resistance and response to immune checkpoint inhibitors (icis) in advanced non-small cell lung cancer (nsclc) patients using real-world data    Neeraj K. Singh, BTECH; Smita Agrawal, PhD; Babu Narayanan Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;Epigenetics;Solid tumors
532 Poster Presentation Anti-VISTA antibody HMBD-002 reprograms tumour associated macrophages and promotes cytotoxic T cell response      Bhushan Dharmadhikari, PhD; Dipti Thakkar, PhD; Olga Zharkova, PhD; Debleena Ray, PhD; Jason Lai, PhD; Konrad Paszkiewicz, PhD; Piers J. Ingram, PhD; Jerome Boyd-Kirkup, PhD Checkpoint Blockade Therapy Antibody;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;T cell;Tumor antigens;Tumor microenvironment
533 Poster Presentation A Tumor-Lung NLRP3-TLR4 Distant Signaling Axis Drives Immunotherapy Resistance via G-CSF-dependent Expansion of Circulating PD1+ PMN-MDSCs Balamayooran B.T. Theivanthiran, PhD; Nagendra Yarla, PHD; Tarek Haykal, MD; Michael P. Plebanek, PhD; Y-Van Nguyen; Nicholas C. DeVito, MD; Brent Hanks, MD, PhD Checkpoint Blockade Therapy Granulocyte;Immune suppression;TLR;Tumor evasion
534 Poster Presentation Sex-Linked Differences in Obesity Markedly Impact the Anti-Tumor Efficacy of PD-1 Blockade    Logan V. Vick, BA; Logan Vick; Ziming Wang; Craig Collins; Lam T. Khuat; Cordelia M. Dunai, MS; Kevin Stoffel; Sai Yendamuri; Sarbajit Mukherjee; Spencer R. Rosario; Robert J. Canter, MD; Arta M. Monjazeb, MD, PhD; William J. Murphy Checkpoint Blockade Therapy Biomarkers;Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
535 Poster Presentation Hydroxychloroquine synergizes with anti-PD-1 immune checkpoint blockade in squamous carcinoma of the head and neck Avani Vyas, Ph.D.; Silvia Cruz-Rangel; Nayel Khan, MD; Mikayla Bisignani; Lidia M. Arantes; Nicole Schmitt; Kirill Kiselyov; Robert L. Ferris, MD, PhD; Umamaheswar Duvvuri Checkpoint Blockade Therapy Checkpoint blockade;Coinhibition;Solid tumors;T cell;Tumor evasion
536 Poster Presentation Decoupling cytotoxic T lymphocyte and exhausted T lymphocyte transcriptomic signatures enhances immune checkpoint inhibitors response prediction in melanoma  Binbin Wang, Ph.D.; Kun Wang; Eytan Ruppin; Peng Jiang Checkpoint Blockade Therapy Bioinformatics;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
537 Poster Presentation Local immunotherapy with INTASYL™ self-delivering RNAi targeting CTLA-4 provides robust tumor control in vivo Benjamin Cuiffo, PhD; Melissa Maxwell; Dingxue Yan; Brianna Rivest; Andrew Boone; Shenghua Zhou, MD, PhD; James Cardia, PhD; Simon P. Fricker, PhD Checkpoint Blockade Therapy Checkpoint blockade;RNA;Solid tumors;T cell;Targeted therapy
538 Poster Presentation Comprehensive single cell transcriptomic profiling of untreated resectable lung cancers Sydney C. Connor, B.S.E; Jiajia Zhang, MD, MPH; Justina X. Caushi, PhD; Boyang Zhang; Zhen Zeng; Khaled Sanber; Gavin Pereira; Valsamo Anagnostou, MD PhD; Ada Tam; Nicholas Ionta; Franck Housseau; Patrick Forde, MBBCh; Hongkai Ji; Andrew M. Pardoll, MD, PhD; Kellie N. Smith Clinical Trials Completed Bioinformatics;Checkpoint blockade;Clinical study;Gene expression;Immune monitoring;Neoantigens;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
541 Oral Presentation mregDC/T helper niches enable local reactivation of CD8 T cells upon PD-1 blockade Assaf Magen, PhD; Pauline Hamon, PhD; Nathalie M. Fiaschi, PhD; Raquel Deering, PhD; Sacha Gnjatic, PhD; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Gavin Thurston, PhD; Alice O. Kamphorst, PhD; Miriam Merad, MD, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical study;Costimulation;Dendritic cell;Immune adjuvant;Immune monitoring;Systems biology;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
542 Poster Presentation B-Cell Receptor (BCR) Repertoire is a Dynamic Biomarker of Survival in Sarcoma Patients Treated with Neoadjuvant Immune Checkpoint Blockade (ICB)   Elise F. Nassif, MD, MS; Bin Liu, PhD; Wei-Lien Wang, MD; Alexander J. Lazar, MD, PhD; Davis Ingram; Khalida Wani, PhD; Sheila Duncan; Taylor J. Tate; Grace Mathew; Shadarra Crosby; Kenna Shaw; Monika A. Zelazowska, PhD; Barry W. Feig; Keila E. Torres, MD, PhD; Kelly K. Hunt, MD; B. Ashleigh Guadagnolo; Andrew J. Bishop; Phillip Andrew Futreal, PhD; Jennifer A. Wargo, MD, MMSc; Neeta Somaiah, MD; Kevin McBride, PhD; Christina L. Roland, MD, MS, FACS; Emily Z. Keung, MD, MA Clinical Trials Completed Antibody;B cell;Bioinformatics;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Surgery;Tumor microenvironment
543 Poster Presentation Response to checkpoint blockade in HCC is associated with IgG1 skewing   Robert E. Sweeney, II, MD; Edgar Gonzalez-Kozlova, Ph.D; Alexandra Tabachnikova; Christie Chang; Laura Walker; Assaf Magen, PhD; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Miriam Merad, MD, PhD; Sacha Gnjatic, PhD Clinical Trials Completed Antibody;B cell;Checkpoint blockade;Clinical study;RNA;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
544 Poster Presentation Companion diagnostic assays for pembrolizumab in patients with MSI-H/dMMR tumors Aurelien Marabelle, MD, PhD; Jeff Cesario; Lixin Lang; Deepti Aurora-Garg; Siddhartha Krishan Mathur; Diane Levitan; Deb Card; Fan Jin; David Adelberg; Thierry André; Amy Wehn Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical study;Solid tumors
545 Poster Presentation A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory effects of Intratumoral INT230-6 (Cisplatin, Vinblastine) in Early Stage Breast Cancer: the INVINCIBLE Trial    Angel Arnaout, MD; Susan Robertson, MD; Kianoosh Keyhanian, MD; Arif Awan, MD; Gregory Pond, phD; John Bartlett; Megan Hopkins; Linda Liao; Vida Talebian; Lazlo Radvyani; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Vanessa Lopez Ozuna; Melanie Spears Clinical Trials Completed Biomarkers;Chemotherapy;Clinical trial;Gene expression;Immune contexture;Immune monitoring;Surgery
546 Poster Presentation A Phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer Mary L. Disis, MD, FACP; Ying Liu; Sasha E. Stanton, MD, Ph.D.; William Gwin; Andrew Coveler; John B. Liao, MD, PhD; Jennifer Childs, MPH; Denise Cecil, PhD Clinical Trials Completed Clinical trial;Immune adjuvant;Immune monitoring;MDSC;Regulatory T cell (Treg cell);Solid tumors;Stem cell/cancer-initiating cell;T cell;Tumor antigens;Vaccine
547 Poster Presentation Safety and efficacy of de-escalated neoadjuvant chemoimmunotherapy of triple negative breast cancer (TNBC) using chemokine-modulating regimen (rintatolimod, IFN-α2b, celecoxib)  Shipra Gandhi; Mateusz Opyrchal; Cayla Ford; Ronald Slomba; Marie Quinn; Tracey O'Connor; Ellis Levine; Pawel Kalinski Clinical Trials Completed Chemokine;Clinical trial;Immune adjuvant;TLR;Tumor microenvironment
548 Poster Presentation The oncolytic virus pelareorep in combination with immune checkpoint inhibitor activates T-cell functioning in early breast cancer patients - immunophenotype results from AWARE-1 study    Thomas C. Heineman, MD. PhD; Thomas C. Heineman, MD, PhD; Houra Loghmani, PhD; Richard Trauger; Fernando Salvador, PhD; Luis Manso, MD, PhD; Tomás Pascual, MD, PhD; Manel Juan, MD, PhD; Aleix Prat, MD PhD; Joaquín Gavilá, MD, PhD; Matt Coffey, PhD; E. Azucena González-Navarro, PhD Clinical Trials Completed Adoptive immunotherapy;Chemokine;Clinical trial;NK/NKT cell;Solid tumors;T cell;T cell lineages;Tumor microenvironment
549 Poster Presentation Booster vaccination of a HER2 helper T-cell vaccine increased HER2 immunity in metastatic HER2 positive breast cancer.    Sasha E. Stanton, MD, Ph.D.; Jennifer Childs, MPH; Doreen M. Higgins, RN, BSN, OCN; Angela Kask, PhD; Yi Yang, MS; Mary L. Disis, MD, FACP Clinical Trials Completed Clinical trial;Solid tumors;T cell;Vaccine
551 Poster Presentation Intratumoral Influenza Vaccine in Early Colorectal Cancer    Mikail Gögenur, MD; Mustafa Bulut, MD; Lukas Balsevicius, MSc; Anne-Marie Kanstrup Fiehn, MD, Senior Resident; Marianne Bøgevang Jensen, MD; Nesibe Özgur Colak, MD; Tobias Freyberg Justesen, MD; Paulo Cesar Martins Urbano, MSc, PhD; Lasse Bremholm Hansen, MD, PhD; Ismail Gögenur, MD, DMSc Clinical Trials Completed Clinical trial;Immune suppression;Inflammation;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
552 Poster Presentation Characteristics of the tumor microenvironment in IDH1-mutated cholangiocarcinoma patients from ClarIDHy trial H. Duygu Saatcioglu; Juan W. Valle; Teresa Macarulla; Milind Javle, MD; Do-Youn Oh, MD, PhD; Lipika Goyal; Jake Conway; Janani S. Iyer; Fedaa Najdawi; Chintan Shah; Camelia Gliser; Susan Pandya; Scott R. Daigle; Ghassan K. Abou-Alfa, MD; Robin K. Kelley, MD Clinical Trials Completed Biomarkers;Solid tumors;Tumor microenvironment
553 Poster Presentation DKN-01 and tislelizumab as a second-line (2L) investigational therapy in advanced DKK1 high gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial    Samuel J. Klempner, MD; Jaffer A. Ajani, MD; Joseph Chao, MD; Hope Uronis; Cynthia A. Sirard, MD; Michael Kagey; Jason Baum; Lilin Zhang; In-Ho Kim; Do-Youn Oh, MD, PhD; Byoung Yong Shim, MD, PhD; Sun Jin Sym; Mohamad Sonbol; Mohamedtaki A. Tejani; Zev A. Wainberg; Devalingam Mahalingam, MBBChBAO; Keun-Wook Lee, MD Clinical Trials Completed Antibody;Clinical trial;Targeted therapy
554 Poster Presentation Artificial intelligence (AI)-powered immune phenotyping of advanced or metastatic urothelial carcinoma (aUC) clinical trial samples from hematoxylin and eosin (H&E)-stained whole slide images (WSI) Jake Conway; Limin Yu; Yash Belhe; Suyog Jain; Hans J. Grote; Mary Lin; Benjamin Trotter; Darpan Sanghavi; Aslihan Gerhold-Ay; XiaoZhe Wang; Sergine Brutus; Thomas Mrowiec Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;Immune contexture;Solid tumors;Targeted therapy;Tumor microenvironment;Tumor stroma
555 Poster Presentation Clinical and Pharmacodynamic Biomarker Results from PORTER, a multi-cohort Phase 1 Platform Trial of Combination Immunotherapy for Metastatic Castration-Resistant Prostate Cancer Patients Matthew D. Galsky, MD; Karen Autio, MS, MD; Kristopher Wentzel, MD; Julie N. Graff, MD; Terence Friedlander, MD; Julie Densmore; Christopher Cabanski; Kristin M. Shotts, PhD; Tim Howes, PhD; Jia Yu, PhD; Elaine Eisenbeisz; Marko Spasic, MD; Stephen Maddock, MD; Diane DaSilva, PhD; Dinesh Kumar, PHD; Jonni Moore, PhD; Richard Schretzenmair; Jennifer Lata, PhD; Arron Xu; Emma Reuschel; Snehal G. Wani; Matthew P. Morrow, PhD; Jeffrey Skolnik, MD; Sandra Santulli-Marotto, PhD; Lacey Padrón, PhD; Lisa H. Butterfield, PhD; Theresa M. LaVallee, PhD; Samantha Bucktrout, PhD; Michael Yellin, MD; Tibor Keler, PhD; Lisa M. Salvador; Jill O'Donnell-Tormey, PhD; Vanessa M. Lucey, PhD, MBA; Justin A. Fairchild, MPH; Ute Dugan, MD, PhD; Nina Bhardwaj, MD, PhD; Sumit K. Subudhi, MD, PhD; Lawrence Fong, MD Clinical Trials Completed Clinical trial;Dendritic cell;Immune adjuvant;Monocyte/Macrophage;Radiotherapy;Tumor microenvironment;Vaccine
556 Poster Presentation Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): Analysis from CheckMate 214    Saurabh Gupta, PhD; Celine Han, PhD; Bhakti Dwivedi, PhD; Jun Li, PhD; Morten Karsdal, PhD; Robert J. Motzer, MD; Nicholas N.W. Willumsen, PhD; David McDermott, MD; Toni K. Choueiri, MD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors
557 Poster Presentation The epitope-enhanced TARP peptide can induce specific T cells that can recognize wild-type TARP tetramer by either peptide or peptide-pulsed DC vaccination in patients with prostate cancer.    Purevdorj B. Olkhanud, M.D., Ph.D.; Refika B. Turnier; Kimberly Dunham; Masaki Terabe, PhD; Seth Steinberg, PhD; Brenda Roberson; Lauren V. Wood, MD; David F. Stroncek, MD; Ira H. Pastan; Jay A. Berzofsky, MD, PhD; Hoyoung M. Maeng, MD Clinical Trials Completed Clinical trial;Dendritic cell;T cell;Tumor antigens;Vaccine
558 Oral Presentation CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the Phase 1 COBALT-RCC study Sumanta Pal, MD; Ben Tran, MD; John B.A. Haanen; Michael E. Hurwitz, MD, PhD; Adrian Sacher; Neeraj Agarwal, MD; Nizar Tannir; Elizabeth Budde, MD, PhD; Simon Harrison, MBBS, PhD, FRACP; Sebastian Klobuch; Sagar S. Patel, MD; Mary Lee Dequeant, PhD; Verena Karsten, PhD; Kaitlyn Cohen, MS; Ellen B. Gurary, PhD; Henia Dar, PhD; Anna Ma, MS; Anjali Sharma, MD; Samer A. Srour Clinical Trials Completed CAR T cells;Clinical study;Clinical trial;Solid tumors;T cell
559 Poster Presentation Biomarker Correlates of Clinical Response with FLT3L/Nivo Backbone Treatment in the Multi-Cohort Phase 1 PORTER Platform Trial in Metastatic Castration-Resistant Prostate Cancer Patients Kristin M. Shotts, PhD; Timothy Howes, PhD; Jia Yu, PhD; Julie Densmore; Diane Da Silva; Dinesh Kumar, PHD; Sandra Santulli-Marotto, PhD; Christopher Cabanski; Elaine Eisenbeisz; Geoffrey Ivison, PhD; Aaron Mayer, PhD; Jonni Moore, PhD; Derek Jones; Kimberly A. Kraynyak, PhD; Alex Dolgoter; Richard O. Chen, MD; Lisa H. Butterfield, PhD; Theresa M. LaVallee, PhD; Samantha Bucktrout, PhD; Lacey Padrón, PhD; Ute Dugan, MD, PhD; Michael Yellin, MD; Tibor Keler, PhD; Jill O'Donnell-Tormey, PhD; Justin A. Fairchild, MPH; Lisa M. Salvador; Kristopher Wentzel, MD; Lawrence Fong, MD; Sumit K. Subudhi, MD, PhD; Nina Bhardwaj, MD, PhD; Karen Autio, MS, MD; Matthew D. Galsky, MD; Tim Howes, PhD Clinical Trials Completed Bioinformatics;Biomarkers;Checkpoint blockade;Clinical trial;Dendritic cell;Monocyte/Macrophage;Proteomics;Radiotherapy;Solid tumors;Vaccine
560 Poster Presentation Molecular and immunogenomics features associated with complete response and survival after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer Wolfgang Beckabir, AB; Alec D. Wilkinson, PhD; Mark G. Woodcock, MD; Mi Zhou, PhD; Hsing-Hui Wang, PhD; Karen P. McKinnon, PhD; Jonathan S. Serody, MD; Tracy L. Rose, MD; Matthew I. Milowsky, MD; William Y. Kim, MD; Benjamin G. Vincent Clinical Trials Completed Biomarkers;Checkpoint blockade;Chemotherapy;Clinical trial;Gene expression;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens
561 Poster Presentation Immune Activation and Clinical Response From Enzalutamide (enza) Alone or with Radium223 (Ra223) In Metastatic Castration-Resistant Prostate Cancer (mCRPC)    Peter D,. Zang, MD; Tanya B. Dorff, MD; Zhang-Xu Liu; Denice D. Tsao-Wei; Susan Groshen, PhD; Cheryl Kefauver; Czarina Patricio; Anishka D'Souza; Sarah Chevalier; Sumanta Pal, MD; Diane DaSilva, PhD; Martin Kast; David I. Quinn Clinical Trials Completed Clinical study;Cytokine;Radiotherapy;Solid tumors
562 Poster Presentation Tumor collection and establishment of tumor-initiating cell cultures to serve as the antigen source for AV-OVA-1 dendritic cell vaccines for patients with newly diagnosed advanced ovarian cancer    Ramez N. Eskander, MD; Lisa A. Abaid, MD; Bradley R. Corr, MD; James R. Mason, MD; Fabio Cappuccini, MD; Richard L. Friedman, MD, PhD; Rockelle M. Robles, BS; Katrina Lopez, BA; Gabriel I. Nistor, MD; Robert O. Dillman, MD Clinical Trials Completed Clinical trial;Dendritic cell;Neoantigens;Stem cell/cancer-initiating cell;Vaccine
563 Poster Presentation A Phase I Clinical Trial of Radiation Therapy, Durvalumab and Tremelimumab in Recurrent Gynecologic Cancer Larissa Lee, MD; Panagiotis A. Konstantinopoulos; Ursula A. Matulonis, MD; Joyce F. Liu; Neil Horowitz, MD; Elizabeth Lee, MD; Martin King, MD-PhD; Kelly J. Fitzgerald, MD PhD Clinical Trials Completed Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors
564 Poster Presentation Safety and clinical activities of the acid pH-sensitive anti-CTLA-4 mAb ONC-392 in ovarian cancer patients John Hays, MD; Tianhong Li, MD, PhD; Hui A. Chen, MD; George Zahrah, MD; Richard Frank, MD; John Hamm, MD; Merry-Jennifer Markham, MD; Thomas George, MD; Eric D. Whitman, MD, FACS; Mark G. Goldstein, MD; Kai He, MD, PhD; Rohit Joshi, MD; Dan Chen, MD, PhD; Yang Liu, PhD; Pan Zheng, MD, PhD; David O'Malley, MD Clinical Trials Completed Checkpoint blockade;Clinical study;Clinical trial
565 Poster Presentation Leukapheresis to obtain monocytes to produce dendritic cells for manufacturing AV-OVA-1 personal vaccines in a randomized phase II trial in patients with newly diagnosed advanced ovarian cancer    James R. Mason, MD; Lisa A. Abaid, MD; Bradley R. Corr, MD; Ramez N. Eskander, MD; Fabio Cappuccini, MD; Richard L. Friedman, MD, PhD; Rockelle M. Robles, BS; Katrina Lopez, BA; Gabriel I. Nistor, MD; Robert O. Dillman, MD Clinical Trials Completed Clinical trial;Dendritic cell;Myeloid cells;Neoantigens;Stem cell/cancer-initiating cell;Vaccine
566 Poster Presentation ENTPD1 as predictive marker of treatment response to Gemogenovatucel-T (Vigil) in newly diagnosed ovarian cancer    Rodney Rocconi, MD; Laura Stanbery; Min Tang; Adam Walter; Bradley J. Monk, MD FACOG FACS; Thomas Herzog, MD; Robert L. Coleman, MD; Luisa Manning, MD; Gladice Wallraven; Staci Horvath; Ernest Bognar; Neil Senzer, MD; Scott Brun; John J. Nemunaitis, MD Clinical Trials Completed Biomarkers;Clinical trial;Tumor antigens;Vaccine
568 Poster Presentation Phase 2 trial of induction and concomitant CTLA4 (ipilimumab) and PD-1 (nivolumab) immune checkpoint blockade and intensity modulated radiation therapy (IMRT) in HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC)    Maura L. Gillison, MD, PhD; Michelle Williams, MD; Jason M. Johnson, MD; Cheuk H. Leung, MS; Jay Reddy, MD, PhD; Adam S. Garden, MD; Renata Ferrarotto, MD; Frank Mott, MD; Xiuning Le, MD, PhD; Gary B. Gunn, MD; Anna Lee, MD, MPH; Clifton Fuller, MD, PhD; Charles Lu, MD; Amy Moreno, MD; Katherine A. Hutcheson, PhD; Neil Gross, MD; Miriam Lango, MD; Ryan P. Goepfert, MD; Jeffrey N. Myers, MD; Ehab Y. Hanna, MD; Weihong Xiao, MD; Bo Jiang; Nils-Petter Rudqvist, PhD; Jack J. Lee, PhD DDS; Jack Phan, MD, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors;T cell
569 Poster Presentation A CIVO intratumor microdose Phase 0 Trial of subasumstat (TAK-981) in combination with cetuximab or avelumab reveals Type 1 Interferon induction and immune activation in head and neck cancer patients Jeffrey Houlton, MD; Daniel R. Clayburgh; Ryan Li; Nathan Schauer, PhD; Marc Grenley; Connor Burns; Angela Merrell; Jason Frazier; Jonathan Derry; Emily Beirne; Wendy Jenkins; Allison J. Berger, PhD; Richard Klinghoffer, PhD Clinical Trials Completed Antigen presenting cells;Biomarkers;Checkpoint blockade;Clinical trial;Gene expression;Immune contexture;Post-translational modifications;Solid tumors;Tumor microenvironment;Tumor stroma
570 Oral Presentation Cabozantinib plus atezolizumab in advanced head and neck cancer previously treated with platinum-containing chemotherapy: Results from Cohort 17 of the COSMIC-021 Study     Sylvie Rottey, MD, PhD; Armando Santoro, MD, PhD; Suzanne Arnold; Saad A. Khan, MD; Allen L. Cohn; Bruno Fang, MD; Svetlana Andrianova; Ramu Sudhagoni; Leleesha Samaraweera; Maria Gonzalez-Cao, MD, PhD Clinical Trials Completed Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy
571 Poster Presentation Penpulimab for relapsed/refractory (R/R) classical Hodgkin's lymphoma (cHL): Extended follow-up of the multicenter, single-arm, phase 2 study. Yuqin Y. Song, MD; Keshu Zhou; Chuan Jin; Zhengzi Qian; Ming Hou; Lei Fan; Fei Li; Kaiyang Ding; Hui Zhou; Xiaoling Li; Bing Chen; Xiuhua Sun; Xianmin Song; Ming Jiang; Qingyuan Zhang; Lihong Liu; Guohua Yu; Yu Hu; Zheng Zhao; Ligen Liu; Hongwei Xue; Jun Luo; Bai He; Zhifang Yao; Fenghua Xu; Min Zhao; Baiyong Li, Ph.D; Yu Xia; Jun Zhu Clinical Trials Completed Antibody;Checkpoint blockade;Clinical trial
572 Poster Presentation Gut microbiota tuning promotes tumor-associated antigen cross-presentation and enhances CAR T antitumor effects Andrea Facciabene, PhD; Mireia Uribe-Herranz, PhD; Silvia Beghi, PhD; Marco Ruella, MD; Kalpana Parvathaneni, PhD; Guido Ghilrardi, MD; Yung Gu Lee, MD; Noelle Frey; John Scholler; Khatuna Gabunia, Research Specialist; Gary Wu; Elise Chong, MD; David L. Porter, MD; Carl June; Stephen J. Schuster, MD; Vijay Bhoj, MD Clinical Trials Completed Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Microbiome;Tumor antigens
574 Poster Presentation Blood-based extracellular matrix biomarkers are correlated with prognostic and fibrotic-related clinical characteristics and liver function markers in patients with advanced hepatocellular carcinoma Jaclyn Neely, PhD; Jin Yao, PhD; Christina Jensen; Morten Karsdal, PhD; Nicholas N.W. Willumsen, PhD Clinical Trials Completed Antibody;Biomarkers;Checkpoint blockade;Clinical study;Immune suppression;Proteomics;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
575 Poster Presentation Safety and feasibility of intratumoral injection of the RPx family of oncolytic immunotherapies in patients with liver metastasis Scott Baum; Andrew Price; Tze Chan; Joseph J. Sacco; Jeannie Hou; Johannes Wolff; Robert S. Coffin, PhD; Tom Hash; Ari M. VanderWalde, MD, MPH, MBioeth; Jiaxin Niu Clinical Trials Completed Adoptive immunotherapy;B cell;Checkpoint blockade;Clinical trial;Immune monitoring;Inflammation;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
576 Poster Presentation Comprehensive single cell sequencing analysis of paired tissue and blood samples from HCC patients treated with neoadjuvant anti-PD-1 therapy reveals treatment-induced clonal T cell dynamics    Wei Wang; Peter Hawkins; Lianjie Li, MD PhD; Nathalie M. Fiaschi, PhD; Assaf Magen, PhD; Se Jeong; Lauren Boucher; Christina Adler; Min Ni; Nicola C. James; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Elizabeth Miller; Israel Lowy, MD, PhD; Yi Wei; Alice O. Kamphorst, PhD; Miriam Merad, MD, PhD; Gurinder S. Atwal; Gavin Thurston, PhD; Namita T. Gupta, PhD; Raquel Deering, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs)
577 Poster Presentation The variation of T-Cell receptors (TCR) diversity and genomic Human Leukocyte Antigen (HLA-I) among non-small cell lung cancer (NSCLC) patients expressing high PDL-1 (>=50%) versus those with low or no PDL1 (<50%).    Afaf Abed, MBBS, FRACP; Aaron Beasley; Anna Reid; Leslie Calapre; Michael Millward, MD; Elin S. Gray Clinical Trials Completed Biomarkers
578 Poster Presentation Feasibility of eftilagimod alpha (soluble LAG-3 protein) combined with standard-of-care-therapy in advanced non-small-cell lung cancer (NSCLC) adenocarcinomas. Initial results from INSIGHT‑003 Akin Atmaca, MD; Daniel W. Mueller, PhD; Timursah Habibzade, Dr. (Uni Marmara); Marina Schaaf; Jorge Klagges; Regina Eickhoff, PhD; Elke Jaeger, Prof. Dr. med.; Salah-Eddin Al-Batran, Prof. Dr. med.; Thorsten O. Goetze, Prof. Dr. med. Clinical Trials Completed Adoptive immunotherapy;Antibody;Antigen presenting cells;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial;Solid tumors
579 Poster Presentation Novel digital image approach of multiplex immunofluorescence based PD-L1 expression enables the stratification of advanced NSCLC patients treated with durvalumab Nicolas Brieu, PhD; Felix Segerer; Harald Hessel; Ashok Gupta; Ikbel Achour, PhD; Guenter Schmidt, PhD Clinical Trials Completed Bioinformatics;Biomarkers;Checkpoint blockade
580 Poster Presentation Host Immune Profiling in First-line Immunotherapy Treated Advanced Stage Non-Small Cell Lung Cancer: Results From the INSIGHT Registry Study Hefez Halawani, MD; Eric S. Schaefer, MD; Ray Page, DO, Ph.D; Bassam Ghabach, MD; Wallace L. Akerley, MD Clinical Trials Completed Biomarkers;Checkpoint blockade;Immune monitoring;Inflammation;Proteomics;Solid tumors
581 Poster Presentation Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC Sukhvinder Johal, PhD; Miguel Miranda; Tina Sarbajna; Xiaojin Shi; Alastair Greystoke; Melissa L. Johnson, MD Clinical Trials Completed Checkpoint blockade;Clinical trial;Solid tumors
582 Poster Presentation Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern Cooperative Oncology Group (ECOG) performance status subgroups in EMPOWER-Lung 1 Saadettin Kilickap; Ahmet Sezer, MD; Mahmut Gümüs; Igor Bondarenko; Mustafa Ozguroglu; Miranda Gogishvili; Xuanyao He; Giuseppe Gullo; Petra Rietschel; Ruben G.W. Quek Clinical Trials Completed Antibody;Checkpoint blockade;Chemotherapy
583 Poster Presentation Quantitative computational assessment of PD-L1 enables robust patient selection for biomarker-informed anti-PD-L1 treatment of NSCLC patients Jan M. Lesniak, PhD; Markus Schick, PhD; Thomas Kunzke, PhD; Pallavi Sontakke, PhD; Thomas Padel, PhD; Anatoliy Shumilov, PhD; Farzad Sekhavati, PhD; Christian C. Sachs, PhD; Federico Pollastri, PhD; Ansh Kapil, Masters of Informatics; Nicolas Brieu, PhD; Carl Barrett; Hadassah Sade, PhD; Guenter Schmidt, PhD; Ross Stewart, PhD Clinical Trials Completed Bioinformatics;Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors
584 Poster Presentation Evaluation of a Composite Immunotherapy Signature in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab Khaled Tolba, MD; David R. Gandara, MD; Meagan Montesion, Ph.D.; Barzin Y. Nabet, PhD; Minu K. Srivastava, PhD; Lee Albacker, Ph.D; Mary Redman, Ph.D; David Kozono, MD, PhD; Craig Cummings, PhD; Roy Herbst, MD, PhD; David S. Shames, PhD; David Fabrizio Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;Immune contexture;Immunoscore
585 Poster Presentation Phase 1 dose escalation trial of the selective A2B adenosine receptor antagonist PBF-1129 in patients with metastatic non-small cell lung cancer (mNSCLC).    Dwight H. Owen, MD, MSc; Lai Wei, PhD; Mikhail M. Dikov, PhD; Shankar Suman; Ruohan Wu; Joseph Amann, PhD; Catherine Schweitzer; Sarah Ferguson; Michael B. Smith; Julio Castro; Erin Bertino, MD; Peter Shields, MD; Kai He, MD, PhD; Carolyn Presley, MD; Gregory Otterson, MD; David P. Carbone, MD, PhD Clinical Trials Completed Clinical trial;Solid tumors
586 Poster Presentation Durvalumab (D) +- tremelimumab (T) + platinum-etoposide (EP) in extensive-stage small-cell lung cancer (ES‑SCLC): RNA sequencing analysis to explore canonical markers of IO activity in CASPIAN Mingchao Xie, PhD; Priti Chugh; Cathy O'Brien; Zhongwu Lai; Ross Stewart, PhD; Luis Paz-Ares; Jonathan W. Goldman; Marina C. Garassino; Charles M. Rudin; J. Carl Barrett, PhD; Yashaswi Shrestha, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;T cell;Targeted therapy
587 Poster Presentation AMADEUS Trial: Tumor agnostic pre- and on-treatment biomarkers of response to nivolumab plus ipilimumab correlate with on-treatment tumoral T cell infiltration     Farah A. Alayli, PhD; Kwame Okrah; Apostolia M. Tsimberidou, MD; Alexandra Drakaki; Danny N. Khalil; Saad Khan; Stephen Hodi; David Oh; Meelad Amouzgar; Shikha Guatam; Robin Kageyama; Shannon Pfeiffer; Stefanie Meier; Christopher Cabanski; Diane Da Silva; Dinesh Kumar; Sandra Santulli-Marotto; Michael Tetzlaff; Wai Chin Foo; Travis Hollman, PhD, MD; Yanyun Li, PhD MD; Mathew Adamow; Philip Wong; Marko Spasic, MD; Richard O. Chen, MD; Samantha Bucktrout; Justin Fairchild; Lisa H. Butterfield; Theresa LaVallee; Lacey J. Padrón, PhD; Lisa M. Salvador; Jill O’Donnell-Tormey; Ute Dugan; Padmanee Sharma, MD, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Immunoscore;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
588 Poster Presentation Phase Ib study of the p38 inhibitor ARRY-614 with nivolumab, ipilimumab or nivolumab+ipilimumab in advanced solid tumors Ryan C. Augustin, MD; Andrew Poklepovic, MD; Xin Gao; William E. Gooding, MS; Sarah Brodeur; Julie Urban; Amy Rose, RN; Amy Goodman; Darcy L. Ploucha, MPAS; Roby A. Thomas; Dan P. Zandberg, MD; John M. Kirkwood, MD; Yana G. Najjar, MD; Diwakar Davar, MD; Liza C. Villaruz, MD; Jan H. Beumer, PharmD, PhD; Riyue Bao, PhD; Jason J. Luke, MD Clinical Trials Completed Antigen presenting cells;Checkpoint blockade;Clinical trial;Immune suppression;T cell;Targeted therapy;Tumor microenvironment
589 Poster Presentation Xevinapant plus nivolumab in patients with advanced solid tumors who progressed on prior anti-PD-1/PD-L1 treatment: results of a dose-optimization, exploratory phase 1b/2 trial Emiliano Calvo Aller; Glenn J. Hanna, MD; Maria Vieito Villar; Caroline Even; Victor Moreno, MD, PhD; Chul Kim, MD; Shuchi Gulati, MD, FACP; Daniel Morgensztern; Ana Acuna-Villaorduna; Philippe Cassier; Dennie Jones; Florilene Bouisset; Daniela A. Sahlender; Elisabeth Rouits; Dany Spaggiari; Lars Damstrup; Carlos-Alberto Gomez-Roca Clinical Trials Completed Antibody;Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy
590 Oral Presentation Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers    Manoj Chelvanambi, PhD; Nathaniel Deboever, MD; Elise F. Nassif, MD, MS; Ashish V. Damania, MS; Lili Chen, PhD; Cheuk H. Leung, MS; Emily Z. Keung, MD, MA; Chia-Chin Wu, PhD; Russell G. Witt, MD; Michael G. White, MD; Sarah B. Johnson, MS; Matthew C. Wong, BS; Aditya K. Mishra, PhD; Matthew J. Lastrapes; Neeta Somaiah, MD; Humam Kadara, PhD; Sreyashi Basu; James P. Allison, PhD; Padmanee Sharma, MD, PhD; Kevin McBride, PhD; Wolf H. Fridman, MD, PhD; John V. Heymach, MD, PhD; Boris Sepesi, MD, FACS; Nadim J. Ajami, PhD; Christina L. Roland, MD, MS, FACS; Jennifer A. Wargo, MD, MMSc; Tina Cascone, MD, PhD Clinical Trials Completed B cell;Checkpoint blockade;Microbiome;Solid tumors
591 Poster Presentation Immunogenicity of durvalumab: analysis of pooled pan-tumor data    Anthony B. El-Khoueiry, MD; Diansong Zhou; Mustafa Ozguroglu; Melissa L. Johnson, MD; Ghassan K. Abou-Alfa, MD; Mallory Makowsky; Lee M. Krug; Ashok Gupta; Cecil Chen Clinical Trials Completed Checkpoint blockade;Clinical trial;Solid tumors
592 Poster Presentation Phase 1/2a study of the novel nonfucosylated anti-CTLA-4 monoclonal antibody BMS-986218 +- nivolumab in advanced solid tumors: part 1 results Claire F. Friedman, MD; Richard D. Carvajal, MD; Diwakar Davar, MD; Eduardo Castanon, MD; Paolo A. Ascierto, MD; Emiliano Calvo; Mark H. O'Hara, MD; Steven F. Powell, MD; Ronnie Shapira-Frommer, MD; Elena Garralda, MD, MSc; Daniel John Renouf, MD; Ruth Perets, MD, PhD; Mona R. Yunan, BA; Palanikumar Ravindran, PhD; Amy Hammell, PhD; Shaun M. O’Brien, PhD; Ke Xu, PhD; Nicholas S. Wilson, PhD; Amy Jhatakia, MS; Anandaroop Mukhopadhyay, PhD; Martin Gutierrez, MD Clinical Trials Completed Antibody;Checkpoint blockade;Clinical study;Clinical trial;Post-translational modifications;Solid tumors
594 Poster Presentation Dose Escalation of Next Generation Anti-CTLA-4 antibody ONC-392 in Combination with Fixed Dose of Pembrolizumab in Patients with Advanced Solid Tumors    Siwen Hu-Lieskovan, MD, PhD; Kai He, MD, PhD; Mei Tang, MD, PhD; Dan Chen, MD, PhD; Yang Liu, PhD; Pan Zheng, MD, PhD; Tianhong Li, MD, PhD Clinical Trials Completed Checkpoint blockade;Clinical trial;Solid tumors
595 Oral Presentation Flt3L-primed In Situ vaccination and pembrolizumab induce systemic tumor regressions of bulky tumors in patients with lymphomas and ER/PR+ breast cancer  Thomas U. Marron, MD, PhD; Julie Fasano, MD; Deborah Doroshow; Dana Ostrowski, BA; Joan Sorich, BA; Martine Van-Voorthuysen; Jennifer Coffey; Erin Moshier; Andres M. Salazar, MD; Michael Yellin, MD; Marshall R. Posner, MD; Joseph Sparano, MD; Jonah Shulman, MD; Paula Klein, MD; Hanna Irie, MD; Seunghee Kim-Schulze, PhD; Sacha Gnjatic, PhD; Miriam Merad, MD, PhD; Joshua Brody, MD; Haley Labo Clinical Trials Completed Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;Radiotherapy;Solid tumors;TLR;Vaccine
596 Poster Presentation Results from a Phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab Rachel E. Sanborn, MD; Nashat Y. Gabrail, MD; Benedito Carneiro; Mark H. O'Hara, MD; Rodolfo E. Bordoni, MD; Michael S. Gordon, MD; Danny N. Khalil, MD, PhD; Ralph J. Hauke, MD; Cherie Taglienti, PhD; Mark Rogalski; Rachel Styles; Diego Alvarado, Ph.D.; Deena Maurer; Linda Crew; Tibor Keler, PhD; Michael Yellin, MD Clinical Trials Completed Antibody;Checkpoint blockade;Clinical trial;Solid tumors
597 Poster Presentation Preliminary safety, efficacy and pharmacokinetic results of the EP4 antagonist INV-1120 from a first-in-human study in subjects with advanced solid tumors John Sarantopoulos, MD; Amita Patnaik; Yi Zhu; Zhaopie Zeng; Johannes Nippgen; Yongkui Sun Clinical Trials Completed Clinical trial;Solid tumors;Tumor microenvironment
598 Poster Presentation First in human study of S-488210/S-488211, a cancer peptide vaccine, in patients with advanced solid tumours    Mark D. Linch, FRCP PhD; Paramivir Sawhney, MRCP; Jasmin Waterhouse, MRCP; Kayani Mahaz, MRCP; Anuradha Jayaram, MRCP PhD; Dionysis Papadatos-Pastos; Takahiro Hasegawa; Ide Nobuyuki; Takayuki Kanazawa; Tomohiko Harada Clinical Trials Completed Clinical trial;Cytokine;Immune toxicity;Solid tumors;Tumor antigens;Vaccine
599 Poster Presentation Mechanism of Action for OT-101 TGF-&szlig; immunotherapy      Vuong N. Trieu, PhD; Osmond D'Cruz, PhD Clinical Trials Completed Checkpoint blockade;Chemotherapy;Clinical trial;Immune suppression;Immune tolerance;Tumor microenvironment
600 Poster Presentation Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression Erika Klohe, BS, MBA; Sunil Suchindran, PhD; Gurpreet S. Kapoor, PhD; Jimson D'Souza, MD; Ellie Corigleano, PhD; Dejka M. Araujo, MD; Sandra P. D'Angelo, MD; Sandra P. D’Angelo, MD Clinical Trials Completed Biomarkers;Clinical trial;Solid tumors;T cell lineages;Targeted therapy
601 Poster Presentation Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)  Gurpreet S. Kapoor, PhD; Stefan Zajic, PhD; Sunil Suchindran, PhD; Jaegil Kim, PhD; Uma Saxena, BS; Aishwarya Bhaskar, MS; Heather Kaczynski, BS; Michael J. Nathenson, MD; Jimson D'Souza, MD; Benjamin Rich, BS; Sandra P. D'Angelo, MD; Mihaela Druta, MD; Brian A. Van Tine, MD, PhD; Neeta Somaiah, MD; David A. Liebner, MD; Scott Schuetze, MD, PhD; Ioanna S. Eleftheriadou, PhD Clinical Trials Completed Adoptive immunotherapy;Biomarkers;Clinical trial;Gene expression;Solid tumors;T cell
602 Poster Presentation Mass spectrometry-based protein biomarker analysis in chemoimmunotherapy combinations identifies unique immune signatures in pancreatic cancer Marco Tognetti, PhD; Nigel Beaton, PhD; Kamil Sklodowski, PhD; Roland Bruderer, PhD; Lukas Reiter Clinical Trials Completed Biomarkers;Post-translational modifications;Proteomics
603 Poster Presentation A randomized, placebo-controlled, first in human phase I single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy male volunteers of the immunostimulant 7HP349  Lionel D. Lewis, MA., MB.BCh., MD; William Schary, PhD; Siddhartha De, PhD; Peter Vanderslice, PhD; Ronald J. Biediger, PhD; Yared Hailemichael, PhD; Darren Woodside, PhD; William W. Overwijk, PhD; Frank Lee, MD; Upendra Marathi, PhD Clinical Trials Completed Clinical trial;Immune adjuvant
604 Poster Presentation First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial    Sandra P. D'Angelo, MD; Celeste Lebbé; Laurent Mortier; Andrew S. Brohl, MD; Nicola Fazio; Jean-Jaques Grob, MD; Natalie Prinzi, MD; Glenn J. Hanna, MD; Jessica C. Hassel; Felix Kiecker; Anja von Heydebreck; Gülseren Güzel; Paul T. Nghiem, MD, PhD Clinical Trials Completed Antibody;Checkpoint blockade;Clinical trial;Immune suppression;Solid tumors;Targeted therapy;Tumor evasion
605 Poster Presentation Neoadjuvant Vidutolimod (Vidu) and Nivolumab (Nivo) Results in MPR and Immune Activation in High-Risk Resectable Melanoma (MEL): Final Phase II Clinical Trial Results.  Diwakar Davar, MD; Arivarasan Karunamurthy, MD; Joe-Marc J.M. Chauvin, PhD; Robert Morrison, PhD; Yulong Bai, PhD; Jie Sun, PhD; Hong Wang, PhD; Douglas J. Hartman; Julie E. Stein, MD; Christopher Deitrick, PhD; Riyue Bao, PhD; Jagjit Singh; Quanquan Ding; Wentao Gao, PhD; Drew Hurd, BSc; Ornella Pagliano; Amy Rose, RN; Yana G. Najjar, MD; Jason J. Luke, MD; David Mauro, MD, PhD; Arthur M. Krieg, MD; James E. Wooldridge, MD; Dmitri Bobilev, MD, PhD; John M. Kirkwood, MD; Janis M. Taube, MD; Hyun Jung Park; Hassane Zarour, MD Clinical Trials Completed Clinical trial;TLR
606 Poster Presentation Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology Sonia Dolfi, PhD; Tracy Tang, PhD; Georgina V. Long  AO, BSc PhD MBBS FRACP FAHMS; Paolo A. Ascierto, MD; F. Stephen Hodi, Jr., MD; Evan J. Lipson, MD; Dirk Schadendorf, MD; John B. Wojcik, MD, PhD; Jennifer R. Postelnek, B.A.; Yu Wang, MB, PhD, MSc; Anne Marie Sobiesk, PhD; Kaushal Mishra, PhD; Sarah Keidel, BM BCh; Karen Miller-Moslin, PhD; Hussein Tawbi; Charlie Garnett-Benson, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
607 Oral Presentation MCGRAW Trial: Evaluation of the safety and efficacy of an oral microbiome intervention (SER-401) in combination with nivolumab in first line metastatic melanoma patients     Isabella Glitza Oliva; Omid Hamid, MD; Patrick A. Ott; Genevieve M. Boland, MD, PhD; Ryan J. Sullivan, MD; Kenneth Grossmann; Christopher Desjardins; Nathan Hicks; Brian Weiner; Farah A. Alayli, PhD; Christine N. Spencer, PhD; Shikha Guatam; Christopher Loo; Benjamin Kamphaus; Julie Densmore; Christopher Cabanski; Diane Da Silva; Jennifer A. Wargo, MD, MMSc; Justin Fairchild; Marko Spasic; John Aunins; Kelly Brady; Elizabeth M. Burton, MBA; Jennifer Wortman; Theresa LaVallee; Mathew Henn; Hussein Tawbi Clinical Trials Completed Antibody;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Metabolism;Microbiome;Solid tumors;Tumor microenvironment
608 Poster Presentation Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) Georgina V. Long  AO, BSc PhD MBBS FRACP FAHMS; Tracy Tang, PhD; Abraham Apfel, PhD; David J. Paulucci, MS; Scott D. Chasalow, PhD; Daniel J. Tenney, PhD; Gina Fusaro, PhD; Dirk Schadendorf, MD; Hussein Tawbi; F. Stephen Hodi, Jr., MD; Pratik K. Thakkar, MPharm; James Larkin, MD; Jedd D. Wolchok, MD PhD; Megan Wind-Rotolo, PhD; Shu-Pang Huang, Ph.D.; Peter Mohr, Dr.; Caroline Robert, MD, PhD; Christoph Hoeller, MD; Jean-Jacque Grob; Helen Gogas, MD, PhD; Jeffrey S. Weber, MD, PhD; Han Chang, PhD; Rebecca A. Moss, MD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Gene expression;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
609 Poster Presentation Nitric oxide dependent improved relapse free survival to ipilimumab therapy in melanoma patients Joseph Markowitz, MD, PhD; Saurabh K. Garg, PhD; James Sun, MD; Youngchul Kim, PhD; Junmin Whiting, PhD; Jose Conejo-Garcia, MD, PhD; Mitch A. Phelps, PhD; Jeffrey S. Weber, MD, PhD; James J. Mule, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Clinical study;Immune monitoring;Post-translational modifications
610 Poster Presentation Immune biomarker analysis of RP1 in combination with nivolumab in patients with advanced solid tumors Kevin Harrington; Pablo Nenclares; Isla Leslie; Ari M. VanderWalde, MD, MPH, MBioeth; Tawnya L. Bowles; Joseph J. Sacco; Anna C. Olsson-Brown, MD; Jiaxin Niu; Katy K. Tsai; Jason A. Chesney, MD, PhD; Bartosz Chmielowski, MD, PhD; Adel Samson, PhD; Terence Rhodes, MD, PhD; Gino K. In, MD, MPH; Anna C. Pavlick, MD, MBA; Trisha M. Wise-Draper, MD, PhD; Miguel F. Sanmamed, MD, PhD; Laxminarasimha R. Donthireddy; Yawei Zhang; Jeannie Hou; Praveen K. Bommareddy, Bpharm, MS, PhD; Robert S. Coffin, PhD; Mark R. Middleton, MD, PhD; Mohammed M. Milhem, MBBS Clinical Trials Completed B cell;Immune monitoring;Immune suppression;Inflammation;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
611 Poster Presentation Biodistribution and shedding analysis following treatment with RP1 oncolytic immunotherapy in the skin cancer patients from the IGNYTE clinical trial Mohammed M. Milhem, MBBS; Ari M. VanderWalde, MD, MPH, MBioeth; Tawnya L. Bowles; Joseph J. Sacco; Anna C. Olsson-Brown, MD; Jiaxin Niu; Katy K. Tsai; Jason A. Chesney, MD, PhD; Bartosz Chmielowski, MD, PhD; Adel Samson, PhD; Terence Rhodes, MD, PhD; Gino K. In, MD, MPH; Anna C. Pavlick, MD, MBA; Trisha M. Wise-Draper, MD, PhD; Miguel F. Sanmamed, MD, PhD; Alireza Kalbasi; Colin Love; Aaron Clack; Jeannie Hou; Praveen K. Bommareddy, Bpharm, MS, PhD; Robert S. Coffin, PhD; Mark R. Middleton, MD, PhD; Kevin Harrington Clinical Trials Completed Biomarkers;Checkpoint blockade;Immune monitoring;Inflammation;Systems biology;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
612 Poster Presentation Peripheral immune signature of responsiveness to adoptive cell therapy with ex vivo expanded TILs using high dimensional single cell analysis    Cecilie Oelvang Madsen, BSc; Marta Velasco Santiago, MSc; Troels Holz Borch, MD, PhD; Inge Marie Svane, MD; Morten Hansen, PhD Clinical Trials Completed Adoptive immunotherapy;Biomarkers;Clinical trial;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
613 Oral Presentation Neoadjuvant SEMA4D blockade with nivolumab alters suppressive myeloid cells while elevating B cell and CD26hi T cell infiltration in the tumors of patients with resectable stage III melanoma Brian M. Olson, PhD; Crystal Mallow, BS; Christine Reilly, BS; Jacklyn N. Hammons, BS; Jayden Kim; Brian G. Burns; Agnes Harutyunyan; Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Maurice Zauderer, PhD; Keith Delman, MD; Melinda Yushak, MD, MPH; Ali Mokhtari, MD; Douglas C. Parker, MD; Chrystal M. Paulos, PhD; Gregory B. Lesinski, Ph.D.; Michael Lowe, MD, MA Clinical Trials Completed B cell;Biomarkers;Checkpoint blockade;Clinical trial;Immune monitoring;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
614 Oral Presentation Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients Bertrand Routy; John G. Lenehan; Brendan Daisley; Meriem Messaoudene; Kait Al; Corentin Richard; Wilson Miller, Jr.; Rahima Jamal; Scott Ernst; Diane Logan; Karl Belanger; Luara Martinez-Gili; Benjamin H. Mullish; Panteleimon Takis; Cecilia Hermosilla Samayoa; Marina Ninkov; Seema Nair Parvathy; Caroline Lambert; Arielle Elkrief; Rejean Lapointe, PhD; Mansour Haeryfar; Jeremy Burton; Michael Silverman; Saman Maleki, PhD Clinical Trials Completed Biomarkers;Checkpoint blockade;Microbiome;T cell
615 Oral Presentation Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (r/r) melanoma Alexander N. Shoushtari, MD; Lone H. Ottesen, MD, PhD; Victor Levitsky, MD, PhD; Thomas Birkballe Hansen; Thomas J. Hornyak, MD; Anthony Olszanski, MD, RhP; Martha Nyakas, MD; Jedd D. Wolchok, MD PhD Clinical Trials Completed Checkpoint blockade;Clinical study;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
616 Poster Presentation Understanding molecular consequences of immunotherapy on the germinal center axis Sabrina Solis, BS; Tomoaki Muramatsu, PhD; Sophie Gray-Gaillard, BA; Ramin Herati, MD Clinical Trials Completed Antibody;Autoimmunity;B cell;Biomarkers;Checkpoint blockade;Clinical trial;Immune toxicity;RNA;T cell;Targeted therapy
617 Poster Presentation Neoadjuvant intratumoral TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab; preliminary clinical and biomarker data in patients with operable locoregionally advanced melanoma Ahmad A. Tarhini, MD, PhD, MS; Zeynep Eroglu, MD; Amod A. Sarnaik, MD, FACS; Jonathan S. Zager, MD; Ricardo J. Gonzalez, MD; Deanryan B. De Aquino, BS; Edith Abraham, APRN; Justin A. Martin, MS; Allison Richards, MS; Yian Ann Chen, PhD; Denise Kalos, MS; Jessica Lloyd; Jonathan Hanna; Erica Browning, BS; David A. Canton, PhD; Kenneth Y. Tsai, MD, PhD; Jane L. Messina, MD; Pei-Ling Chen, MD; Vernon K. Sondak, MD Clinical Trials Completed Checkpoint blockade;Clinical trial;Immune monitoring
618 Poster Presentation Dietary fiber intake is associated with increased tertiary lymphoid structures in dedifferentiated liposarcoma following immune checkpoint blockade Raymond S. Traweek, MD; Russell G. Witt, MD; Elise F. Nassif, MD, MS; Nadim J. Ajami, PhD; Aditya K. Mishra, PhD; Ashish V. Damania, MS; Manoj Chelvanambi, PhD; Wei-Lien Wang, MD; Alexander J. Lazar, MD, PhD; Emily Z. Keung, MD, MA; Keila E. Torres, MD, PhD; Christopher P. Scally, MD; Xiaotao Zhang, MD, PhD; Carrie R. Daniel-MacDougall, MPH, PhD; Jennifer A. Wargo, MD, MMSc; Neeta Somaiah, MD; Christina L. Roland, MD, MS, FACS Clinical Trials Completed B cell;Checkpoint blockade;Microbiome;Solid tumors;Surgery;T cell;Tumor microenvironment
619 Poster Presentation Tebentafusp induced T and B cell epitope spread in patients with advanced melanoma Alexander Greenshields Watson, PhD; Camille Britton-Rivet, MSc; Sarah Stanhope, PhD; Laura Collins, MSc; Koustubh Ranade, PhD; Adel Benlahrech, BSc PhD Clinical Trials Completed Antibody;B cell;Bispecifics;T cell;Tumor antigens
620 Poster Presentation Molecular features in tumors at time of progression on tebentafusp associated with overall survival (OS)  Emma Leach, PhD; Laura Collins, MSc; Alexander Greenshields Watson, PhD; Shaad E. Abedin, MD, FACP; Sarah Stanhope, PhD; Koustubh Ranade, PhD Clinical Trials Completed Bispecifics;Clinical trial;Solid tumors;T cell;Tumor evasion;Tumor microenvironment
621 Poster Presentation Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria:Trial in progress    Maen Abdelrahim, MD, PhD, Pharm B; Abdullah Esmail; Ashish Saharia, MD; Gonzalo Sapisochin, MD; Grainne O. Kane, MD; Sudha Kodali, MD; David Victor, MD; Kirk Heyne, MD; Rafik M. Ghobrial, MD Clinical Trials In Progress Clinical study;Clinical trial;Immune monitoring;Immune suppression;Immune toxicity;Targeted therapy;Tumor microenvironment
622 Poster Presentation A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors   David J. Pinato, MD, MRes, PhD; Ruth Plummer; Martin Gutierrez, MD; Jeffrey Yachnin, MD, PhD; Aglaia Schiza; Martin Hojgaard; Knut B. Smeland; William Edenfield; Hans Prenen; Lars Ny, MD, PhD; Alan Anthoney; Nuria Kotecki, MD; Stefan N. Symeonides, MD PhD; Louis Viviers; Jeannie Daniel; Jennifer Pulini; Udai Banerji Clinical Trials In Progress Checkpoint blockade;Clinical trial;Solid tumors;T cell lineages;Targeted therapy
623 Poster Presentation Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies     Tom Haber, PhD; Jessica L. Symons; Bhushan Dharmadhikari, PhD; Thomas Müller, PhD; Dipti Thakkar, PhD; Jordi Ahnert Rodon, MD; Joshua J. Gruber, M.D., PhD; Melinda Telli, MD; Monica Mita, MD; Alain Mita, MD; Meera Patel, MD; Daniel Y. Wang, MD; Joseph W. Kim, MD; Shalini S. Yadav, PhD; Padmanee Sharma, MD, PhD; Leah DiMascio, PhD; Eric K. Rowinsky, MD; Piers J. Ingram, PhD; Jerome Boyd-Kirkup, PhD Clinical Trials In Progress Antibody;Biomarkers;Checkpoint blockade;Clinical study;Immune suppression;MDSC;Tumor microenvironment
624 Poster Presentation A phase I/II study evaluating the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy Omar H. Butt, MD, PhD; Yu Tao, MD; Jiayi Huang, MD; Jingquin Luo, PhD; Alice Y. Zhou, MD, PhD; Christopher Abraham; Ruth G. Katumba; Se Hwan Yang; Byung H. Lee; Michael P. Rettig, PhD; George Ansstas, MD; Tanner M. Johanns, MD, PhD; Milan G. Chheda, MD; Jian L. Campian, MD, PhD Clinical Trials In Progress Clinical study;Cytokine;T cell
625 Poster Presentation A phase 1 single ascending dose study evaluating the safety, tolerability, and pharmacodynamic effects of MDK-703, an IL-7 mimetic with extended half-life Richard Friend; Bryan Baxter; Inkyung Angie Park, Ph.D.; Steven Cwirla; Ronald Barrett Clinical Trials In Progress Clinical trial;Cytokine;T cell;T cell lineages
626 Poster Presentation Trial in progress: An intravenously administered second-generation STING agonist, BI 1703880 with a novel lead-in design in combination with ezabenlimab    Kevin Harrington; Elizabeth Dowling; Robert Latek; Michael Schmohl; Patricia Lorusso, MD Clinical Trials In Progress Checkpoint blockade;Clinical study;Clinical trial;Solid tumors
627 Poster Presentation Oral administration of MRx0518 in treatment-na&iuml;ve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy Mark Lythgoe, MBBS, MRPharmS; Benjamin H. Mullish; Adam E. Frampton; Paola Dama; Emily Pickford; Laura Tookman; Paula Cunnea; Christina Fotopoulou; Ian B. Jeffery; Gayle Fyvie; Alexander Stevenson, PhD; Jonathan Krell, PhD Clinical Trials In Progress Clinical trial;Microbiome;Solid tumors
628 Poster Presentation Trial in progress: Phase I dose-escalation study of VSV-GP (BI 1831169) monotherapy and with ezabenlimab (BI 754091) in patients with locally advanced or metastatic solid tumors    Mercedes M. Porosnicu, MD; Anne-Marie Quinson; Abi MacKay; Stephan Luecke; Ulrich M. Lauer Clinical Trials In Progress Checkpoint blockade;Clinical study;Clinical trial;Solid tumors
629 Poster Presentation Neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma    Nicholas J. Venturini, BA; Thomas U. Marron, MD, PhD; Maria Casanova-Acebes, Ph.D; John Mandeli, PhD; Deborah Doroshow; Natalie Lucas; Kathy Wu; Olivia Hapanowicz; Paula King; Pauline Hamon, PhD; Jessica Le Berichel; Diane Del Valle; Clotilde Hennequin; Seunghee Kim-Schulze, PhD; Sacha Gnjatic, PhD; Miriam Merad, MD, PhD; Zhen Zhao; Stephen Ward; Maria Isabel Fiel, MD; Mary B. Beasley; Edward Kim; Kirema Garcia-Reyes; Udit Chaddha; Timothy Harkin; David Yankelevitz; Ganesh Gunasekaran; Parissa Tabrizian; Myron E. Schwartz, MD; Andrew Kaufman; Daniel Nicastri; Andrew Wolf; Raja Flores Clinical Trials In Progress Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Granulocyte;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors
631 Poster Presentation Phase I dose escalation study in patients with advanced solid tumors with ANV419, a novel fusion protein selective for IL-2Rβ/γ Christoph Bucher, MD; Guzman Alonso, Dr; Juanita Lopez; Emiliano Calvo; Markus Joerger, MD; Vicky Sanchez Perez, MD; Elena Corral, MD; Daniela Di Blasi, PhD; Kirsten Richter, PhD; Christoph Huber, PhD; Julie Mouton; Silvio Costanzo; Sangeeta Jethwa, MD; Elena Gerralda, MD; Heinz Läubli, MD PhD Clinical Trials In Progress Antibody;Clinical study;Cytokine;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell
632 Poster Presentation Clinical update from a Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients with Metastatic Solid Tumours and Haematologic Malignancies Rohit Joshi; Jeffrey Goh; Sharron E. Gargosky, PhD; Warren Joubert, MD; Vineet Kwarta, MD; Meena Okera, MD; Sarwan Bishnoi; Jim Lederer, PhD; Frank Borriello, MD, PhD Clinical Trials In Progress Adoptive immunotherapy;Clinical study;Clinical trial;NK/NKT cell;Solid tumors;T cell
633 Poster Presentation A Phase 1, First in Human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.      Kim A. Reiss; Naoto Ueno, M.D.; Yuan Yuan, MD, PhD; Melissa L. Johnson, MD; E. Claire Dees, M.D.; Joseph Chao, MD; Mathew Angelos; Ramona F. Swaby, M.D.; Daniel Cushing, PhD; Amy Ronczka; Thomas Condamine, PhD; Debora Barton, MD; Michael Klichinsky, PharmD, PhD; Yara Abdou, MD Clinical Trials In Progress CAR T cells;Clinical study;Clinical trial;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment;Tumor stroma
634 Poster Presentation A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors.    Kim A. Reiss; Yuan Yuan, MD, PhD; Naoto Ueno, M.D.; Melissa L. Johnson, MD; E. Claire Dees, M.D.; Mathew Angelos; Joseph Chao, M.D.; Saar I. Gill, MD, PhD; Olga Shestova; Jonathan S. Serody, MD; Saul J. Priceman, PhD; Amy Ronczka; Rehman Qureshi; Poonam Sonawane, Ph.D.; Daniel Cushing, PhD; Debora Barton, MD; Michael Klichinsky, PharmD, PhD; Thomas Condamine, PhD; Ramona F. Swaby, M.D.; Yara Abdou, MD Clinical Trials In Progress CAR T cells;Clinical study;Clinical trial;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment;Tumor stroma
635 Oral Presentation KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer Roy Herbst, MD, PhD; Wei-Sen Lam; Matthew D. Hellmann; Matthew A. Gubens; Charu Aggarwal, MD MPH; Daniel Shao Weng Tan; Enriqueta Felip; Joanne W.Y. Chiu; Jong-Seok Lee; James Chih-Hsin Yang; Edward B. Garon; Giovanna Finocchiaro; Myung-Ju Ahn; Alexander Luft; Gregory A. Landers; Andrea Basso; Hua Ma; Julie Kobie; John Palcza; Razvan Cristescu; Lawrence Fong; Alexandra Snyder; Jianda Yuan; Martin Gutierrez, MD Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors
636 Poster Presentation A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers Steven P. Margossian, MD, PhD; John D. Powderly, II, MD; Nashat Y. Gabrail, MD; Yvonne M. Saenger, MD; J. Eva Selfridge; Nataliya Uboha; Jun Gong; Brian A. Van Tine, MD, PhD; Olatunji B. Alese, MD; Dae Won Kim, MD; Wen W. Ma; Tanios S. Bekaii-Saab, MD; Jeremy C. Jones; Angela T. Alistar, MD; Laura Agensky; Apollina Goel, PhD; Reena Lynam; Raymond J. Moniz, PhD; Steve N. Quayle, PhD; Cynthia Rajan; Kenneth J. Pienta, MD; Matteo Levisetti Clinical Trials In Progress Clinical study;Clinical trial;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
637 Poster Presentation Phase IIa combining NEO-201 with Pembrolizumab in adults with chemo-resistant solid tumors    Princess Mark-Adjeli; Christina M. Annunziata, MD, PhD; Christopher B. Cole; Maria Pia Morelli; Ann McCoy; Massimo Fantini, PhD; Sharon A. Mavroukakis; Anjum Zaki; Kwong Y. Tsang, PhD; Philip M. Arlen Clinical Trials In Progress Antibody;Checkpoint blockade;Clinical trial;Immune suppression;Neoantigens;Post-translational modifications;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor microenvironment
638 Poster Presentation COMMANDER-001: A Phase 1/2, First-in-Human, Multicenter, Open Label Study of SQZ-eAPC-HPV as Monotherapy and with Pembrolizumab in Patients with HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors (Trial in Progress) Meredith S. Pelster, MD, MSCI; Michael S. Gordon, MD; Justin C. Moser, MD; Trisha M. Wise-Draper, MD, PhD; Jong Chul Park, MD; Wade T. Iams, MD; Ricardo F. Zwirtes, MD; Julia J. Jennings; Nathan Miselis, PhD; Rui Ru Ji, PhD; Scott M. Loughhead, PhD; Howard Bernstein, MD, PhD; Armon Sharei, PhD; Antonio Jimeno, MD, PhD Clinical Trials In Progress Antigen presenting cells;Checkpoint blockade;Clinical trial;RNA;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine
639 Poster Presentation BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated TmodTM; CAR T-cell therapy Diane M. Simeone, MD; Maria Pia Morelli; J. Randolph Hecht, MD; Sandip P. Patel, MD; Marwan G. Fakih, MD; Kedar Kirtane; Theodore H. Welling; Sally Lau; Yi Lin, MD PhD; Mitesh J. Borad, MD; Edward B. Garon; Sarah Larson, MD; Shumei Kato; Peter Vu; Frederick L. Locke, MD; Dae Won Kim, MD; John B. Sunwoo, MD; David B. Miklos, MD; Matthew J. Frigault; Marcela V. Maus, MD, PhD; Sarah Nikiforow; Caron A. Jacobson, MD, MMSc; Kirstin B. Liechty; Armen Mardiros; Ariane Lozac'hmeur; Karl Beutner; John S. Welch; Eric W. Ng, MD; William Y. Go; David G. Maloney, MD, PhD; Scott Kopetz, PhD; Julian R. Molina, MD, PhD Clinical Trials In Progress Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Gene expression;Solid tumors;T cell;Tumor antigens;Tumor evasion
640 Poster Presentation Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against treatment-refractory glioblastoma    Thomas Look; Emanuele Puca, PhD; Riccardo Stucchi, PhD; Roberto De Luca, phD; Dario Neri; Michael Weller; Teresa Hemmerle, PhD; Tobias Weiss Clinical Trials In Progress Antibody;Chemotherapy;Clinical trial;Cytokine;Targeted therapy;Tumor stroma
641 Poster Presentation Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab: interim report of the EOGBM1-18/ROSALIE study    Ana Maia; Hélène Toussaint; Joao Gamelas Magalhaes; David Reardon, MD; Ahmed Idbaih; Maria Vieito; Ghazaleh Tabatabai; Agostina Stradella; François Ghiringhelli; Michael C. Burger; Iris Mildenberger; Ulrich Herrlinger; Macarena González; Alice Hervieu; Marta GilMartin; Mirjam Renovanz; Mehdi Touat; Patrick Y. Wen; Antje Wick; Laurent Chene; Cécile Gouttefangeas; Christophe Bonny; Jan Fagerberg; Wolfgang Wick Clinical Trials In Progress Immune monitoring;T cell;Tumor antigens;Vaccine
642 Oral Presentation EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study    David Reardon, MD; Ahmed Idbaih; Maria Vieito; Ghazaleh Tabatabai; Agostina Stradella; François Ghiringhelli; Michael Burger; Iris Mildenberger; Ulrich Herrlinger; Macarena González; Marta GilMartin; Mirjam Renovanz; Mehdi Touat; Patrick Y. Wen; Antje Wick; Cecile Gouttefangeas, PhD; Ana Maia; Chistophe Bonny; Jan Fagerberg, MD; Wolfgang Wick Clinical Trials In Progress Clinical trial;Immune monitoring;T cell;Vaccine
643 Poster Presentation Spatial-transcriptomic Analysis of Neoadjuvant Checkpoint Immunotherapy in Recurrent Glioblastoma Michael J. Schachter, PhD; Lu Sun; Wesley Kwong; Samantha I. Liang, PhD; Sandra Santulli-Marotto, PhD; Lacey J. Kitch, PhD; Willy Hugo; Robert M. Prins, PhD, MS; Dinesh Kumar, PHD Clinical Trials In Progress Angiogenesis;Bioinformatics;Checkpoint blockade;Clinical trial;Gene expression;Inflammation;Myeloid cells;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
644 Oral Presentation Major pathologic response after a single radiotherapy fraction + a single pembrolizumab dose given preoperatively in patients with cT1N0 triple negative breast cancer (TNBC) - preliminary results of a phase 1b/2 study (NCT04454528) Julia Tchou, MD PhD; Amy S. Clark; Neil Taunk; Gary Freedman; Nucleus H. Xu; Andy J. Minn, MD, PhD; Angela Bradbury; Angela Demichele Gross; Susan Domchek, MD; Hayley Knollman; Rachel Jankowitz; Payal D. Shah, MD; Oluwadamilola Fayanju; Anupma Nayak; Joseph Fraietta, PhD; Alexander Huang, MD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors;Surgery
645 Poster Presentation Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC)    Hyo S. Han, MD; Elizabeth E. Evans, PhD; Terrence L. Fisher, Jr., PhD; Hatem Soliman; Hung Khong; Aixa Soyano; Ricardo Costa; Loretta Loftus; Kimberley T. Lee; Avan Armaghani; Hien Liu; Frederick L. Locke, MD; Alexandria Shrewsbury, MS; Jessica Malka; Lavakumar Karyampudi; Maurice Zauderer, PhD; Brian Czerniecki, MD, PhD Clinical Trials In Progress Adoptive immunotherapy;Clinical trial;Dendritic cell;Vaccine
646 Poster Presentation Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole  decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC)    Sasha E. Stanton, MD, Ph.D.; Sasha Stanton; Lisa D. MacDonald, MSc; Stephan Fiset, MSc, MBA; Heather Hirsch; Kabir Mody, MD; Jeremy R. Graff, PhD; Aurelio S. Lobo, MSc; Danielle Lanroue; Heather Torrey, PhD; Nicole Moxon, RN, BSN, OCN; Staci Mellinger, RN; Tracy L. Kelly; David B. Page, MD; Kristina H. Young, MD, PhD Clinical Trials In Progress Solid tumors;Vaccine
647 Poster Presentation Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma  Don Stevens; Clifton Mo; Benjamin Garmezy; John Hamm, MD; Benedito Carneiro; Breelyn A. Wilky, MD; Rachel E. Sanborn, MD; Anthony El- Khoueiry; Alexa Buffa; Sonia De Munari; Burcu Yigit; Marco Purbhoo; Mark Exley; David J. Einstein, MD Clinical Trials In Progress Clinical study;Clinical trial;NK/NKT cell;Solid tumors;T cell
648 Poster Presentation Autologous macrophage-based immunotherapy Induces a pro-inflammatory state in GBM tumor microenvironment - (TEM-GBM)    Gaetano Finocchiaro; Bernhard Gentner; Marica Eoli; Francesca Farina; Alessia Capotondo; Elena Anghileri; Matteo Barcella; Valentina Brambilla; Maria Grazia G. Bruzzone; Matteo G. Carrabba; Valeria Cuccarini; Giorgio G. D'Alessandris; Francesco Di Meco; Valeria Ferla; Alberto Franzin; Paolo Ferroli; Filippo Gagliardi; Federico Legnani; Stefania Mazzoleni, Ph.D.; Pietro Mortini; Matteo Maria Naldini; Alessandro Olivi; Roberto Pallini; Monica Patanè; Rosina Paterra; Bianca Pollo; Marco Saini; Silvia Snider; Andrew Zambanini; Naldini Luigi; Carlo Russo; Fabio Ciceri Clinical Trials In Progress Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment
649 Poster Presentation Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19) Marco Purbhoo; Burcu Yigit; Xavier Michelet, PhD; Rachel Smith; Darrian Moskowitz; Maurice Kirby; Alexa Buffa; Sonia De Munari; Waldo Ortuzar Feliu; Koen Van Besien; Don Stevens; Mark Exley; Terese C. Hammond, MD Clinical Trials In Progress Adoptive immunotherapy;Clinical study;Clinical trial;COVID and Immunotherapy;Cytokine;Inflammation;NK/NKT cell;T cell
650 Poster Presentation Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients - Interim results from the GOBLET study    Dirk Arnold, MD, PhD; Maike Collienne, MD; Alexander Stein, MD, PhD; Guy Ungerechts, MD, PhD; Eray Goekkurt, MD; Jack Chater; Houra Loghmani, PhD; Matt Coffey, PhD; Richard Trauger; Uwe M. Martens, MD, PhD; Thomas C. Heineman, MD, PhD Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
651 Poster Presentation Phase 2 trial of AGEN1423, an Anti-CD73-TGFβ-Trap Bifunctional Antibody, in Combination with Balstilimab, with or without Chemotherapy in Subjects with Advanced Pancreatic Cancer Bruno Bockorny, MD; Joseph E. Grossman, MD; Jaymin M. Patel, MD; Bonnie L. Bullock, PhD; Benjamin Morin, PhD; Lilian Gaynor; Manuel Hidalgo Clinical Trials In Progress Checkpoint blockade;Chemotherapy;Clinical study;Coinhibition;Solid tumors
652 Poster Presentation A Phase 1 Dose Escalation Study of GCC19CART a Novel CoupledCAR Therapy for Subjects With Metastatic Colorectal Cancer Naifei Chen; Chengfei Pu; Lingling Zhao; Ning Li; Chang Wang; Yusheng Huang; Suxia Luo; Xun Li; Zhenzhou Yang; Jun Bie; Ruihong Zhu; Xi Huang; Haiyang Tang; Tingting Liang; Yizhuo Wang; Beibei Jia, Master; Dongqi Chen; Eugene Kennedy; Zhao Wu; Yongping Song; Lei Xiao; Jiuwei Cui; Victor Lu Clinical Trials In Progress Adoptive immunotherapy;CAR T cells;Clinical study;Clinical trial;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens
653 Poster Presentation APN401, a novel EPiC-based anti-cancer cell therapy, case report: Cbl-b silenced, autologous PBMCs induced stable disease in an appendix carcinoma patient    Romana Gugenberger, PhD; Alexander Dohnal; Andreas Tanzmann; Beate Pribitzer; Felix Batrina; Stefan Bunka; Sophia Spagl; Manuela Branka; Sarah Bischof; Kathrin Thell; Mario Kuttke; Maria Urban; Hannes Muehleisen; Bernhard Peball; Markus Raderer; Gerald Prager; Nina Worel Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical study;Clinical trial
654 Poster Presentation Personalised tumour-trained lymphocytes derived from regional lymph nodes for treatment of colorectal cancer    Anne-Laure Joly, PhD; Sofia Berglund, MD PhD; Erwan Le Maitre, PhD; Ana Lukic, PhD; Luigi Notari, PhD; Ola Nilsson, PhD; Guro Gafvelin, PhD, Associate Professor; Hans Grönlund, PhD, Associate Professor Clinical Trials In Progress Adoptive immunotherapy;Clinical trial;Solid tumors;T cell
655 Poster Presentation Pivotal screening and proposed treatment algorithm for immune checkpoint inhibitor‑induced cardio/myotoxicities in neoadjuvant-treated rectal cancer patients: experience from the CHINOREC trial Johannes Laengle, MD, PhD; Jutta Bergler-Klein, MD; Simon Hametner, MD; Ellen Gelpi, MD; Irene Kuehrer, MD; Branka Petricevic, MD; Askin Kulu; Clemens Bittermann, MD; Anton Stift, MD; Friedrich Laengle, MD; Klaus Machold, MD; Stephan Blueml, MD; Michael Bergmann, MD Clinical Trials In Progress Clinical trial;Immune toxicity;Radiotherapy
656 Poster Presentation Exploratory Platform Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION) Jaclyn P. Lyman, MSc; Eileen M. O'Reilly, MD; Zev A. Wainberg; George A. Fisher, MD, PhD; Robert A. Wolff, MD; Andrew H. Ko, MD; Mark H. O'Hara, MD; Harshabad Singh, MBBS; Ravi K. Amaravadi, MD; Alec C. Kimmelman, MD, PhD; Eric A. Collison, MD; Danny N. Khalil, MD, PhD; Rosemarie Schmidberger, MS; Christopher Cabanski; Stephen Maddock, MD; Marko Spasic, MD; Deena M. Maurer, PhD; Diane Da Silva; Christopher Perry, BS; Jia Xin Yu, PhD; Lacey J. Padrón, PhD; Samantha L. Bucktrout, PhD; Lisa H. Butterfield, PhD; Ramy Ibrahim, MD; Justin Fairchild; Theresa LaVallee; Thomas Lillie, MD, PhD; William A. Hoos, MBA, MS; Silvia Boffo, PhD; Ute Dugan; Jill O'Donnell-Tormey, PhD; Robert H. Vonderheide, MD, DPhil Clinical Trials In Progress Antigen presenting cells;Biomarkers;Checkpoint blockade;Chemotherapy;Clinical trial;Immune monitoring;Microbiome;Solid tumors;Tumor antigens;Tumor microenvironment
657 Oral Presentation NT-I7, a long-acting IL-7, plus pembrolizumab favors CD8 T-cell infiltration in liver metastases of heavily pre-treated, immunologically cold, MSS-colorectal and pancreatic cancer     Aung Naing, MD; Sara Ferrando-Martinez, PhD; Michael B. Ware, PhD; Cara Haymaker; Allison Bierly, PhD; Jack B. Goon; Marya F. Chaney, PhD; Swati Dhar; Chan-Young Ock, MD, PhD; Siyoung Lee; Kyunghyun Paeng; Taeseob Lee; Tolani Adebanjo; Se Hwan Yang, PhD; Byung Ha Lee, PhD; Richard D. Kim, MD Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical trial;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
658 Poster Presentation A Phase 2 study to assess the safety, efficacy of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer Paul D. Rhee, Ph.D.; Do-Youn Oh, MD, PhD; Min Hee Ryu, MD, PhD; Jun-Eul Hwang, MD, PhD; Jaeyong Cho, MD, PhD; Dae Young Zang, MD, PhD; Sang Cheul Oh, MD, PhD; Jeeyun Lee, MD, PhD; Keun-Wook Lee, MD, PhD; Sun Young Rha, MD, PhD; Byoung Yong Shim, MD, PhD; William Y. Ho, MD, PhD; Taewan Kim; Eunhye Baek; SeungJae Baek, MD, PhD; Michael Chisamore Clinical Trials In Progress Chemokine;Clinical study;Clinical trial;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment
659 Oral Presentation COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases Drew Rasco; Ecaterina E. Dumbrava, MD; Manish R. Sharma, MD; Dale Shepard, MD PhD; Daniel Vaena; Gini Fleming, MD; Bartosz Chmielowski, MD, PhD; Erika P. Hamilton, MD; Ryan J. Sullivan, MD; Kyriakos P. Papadopoulos, MD; Amita Patnaik; Eran Ophir, PhD; Gady Cojocaro, BS, PhD; Chet Bohac, MD, PharmD, MS; Adeboye H. Adewoye, MD; Manish R. Patel, MD; Michael J. Overman, MD Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical trial;Immune monitoring;NK/NKT cell;Proteomics;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
660 Poster Presentation Clinicopathologic Characteristics of Patients with Metastatic Colorectal Cancer with Molecular Responses Following Treatment with an Individualized Neoantigen Vaccine Regimen Chih-Yi Liao, MD; Benny Johnson; Alexander I. Spira, MD, PhD, FACP; David P. Carbone, MD, PhD; Brian S. Henick; Michael J. Overman, MD; Blase N. Polite; Sameek Roychowdhury; Amit Mahipal; Daniel Ahn; Melissa L. Johnson, MD; Desiree Schenk; Kyounghwa Bae; Matthew Davis; Karin Jooss, PhD; Andrew R. Ferguson, PhD; Benjamin Solomon Clinical Trials In Progress Clinical trial;Gene expression;Neoantigens;RNA;T cell;Tumor antigens;Vaccine
661 Poster Presentation Initial results from a Phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma    David H. Aggen, MD, PhD; Meredith McKean, MD; Nehal J. Lakhani, MD; Babar Bashir, MD, MS; Jean Hoffman-Censits; Omar Alhalabi, MD; Elizabeth A. Guancial; Isaac A. Bowman; Alan Tan, MD; Trupti Lingaraj, B.S.; Marissa Timothy, MS; Nerymar Ortiz-Otero; Wilmin Bartolini; Katherine Kacena; Karim Malek; Sergio L. Santillana, MD, MSc, MBA; Jason J. Luke, MD Clinical Trials In Progress Biomarkers;Clinical study;Clinical trial;Solid tumors;Targeted therapy;Tumor microenvironment
663 Poster Presentation Phase 2 multi-cohort clinical study evaluating Disitamab Vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (RC48G001, trial in progress) Matthew D. Galsky, MD; Peter H. O'Donnell; Earle Burgess; Michiel Van der Heijden; Laurence Krieger; Andrea Necchi; Evan Y. Yu; Nobuaki Matsubara; Matthew T. Campbell; Saikrishna Gadde; Jeanny B. Aragon-Ching; Vadim S. Koshkin; Wei Zhang; Kevin Sokolowski; Thomas Powles Clinical Trials In Progress Antibody;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Targeted therapy
664 Poster Presentation A phase I trial of Tremelimumab, Durvalumab (MEDI4736) and Belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE)    Sumati Gupta, MD; Benjamin L. Maughan, MD, PharmD; Manish Kohli; Bradley Cairns; Umang Swami; Neeraj Agarwal, MD Clinical Trials In Progress Angiogenesis;Checkpoint blockade;Clinical trial;Epigenetics;Solid tumors;Targeted therapy
665 Poster Presentation JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma    Jean Hoffman-Censits; Petros Grivas; Thomas T. Powles, MBBS, MD, MRCP; Danko Martincic; Jessica Hawley; Karin Tyroller; Sonja Seeberger; Silke Guenther; Natalia Jacob; Keyvan Tadjalli Mehr; Noah M. Hahn, MD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Targeted therapy
666 Oral Presentation Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)  Roger Li, MD; Gary Steinberg; Edward Uchio; Donald Lamm; Shah Paras; Ashish Kamat; Trinity Bivalacqua Bivalacqua; Vignesh Packiam Packiam; Michael Chisamore; John McAdory; Paola Grandi; Nataliya Hnat; James Burke Clinical Trials In Progress Checkpoint blockade;Clinical trial;Gene expression;Solid tumors;Targeted therapy
667 Poster Presentation A Phase 1, multiple-dose study to evaluate the safety and tolerability of XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (RCC) Sumanta Pal, MD; Sreeni Yalamanchili; Huajiang Li; Jitendra Kanodia; Raphael Clynes, MD, PhD; Zequn Tang, MD, PhD; Benjamin Garmezy Clinical Trials In Progress Antibody;Bispecifics;Clinical study;Clinical trial;Immune monitoring;Immune toxicity;Solid tumors;T cell;Targeted therapy
668 Poster Presentation A Phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer Mark N. Stein, MD; Oscar B. Goodman, Jr., MD; Tanya B. Dorff, MD; Vivek Narayan, MD, MSCE; Jose Avitia, MD; Rana R. McKay, MD; Luke T. Nordquist, MD, FACP; Matthew Rettig, MD; Michael T. Schweizer, MD; Roby A. Thomas, MD; Michael H. Silverman, MD; Li Yao, PhD; Raphael Clynes, MD, PhD; Jolene S. Shorr Clinical Trials In Progress Antibody;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors
669 Poster Presentation Use of HPV16 circulating tumor DNA detected in liquid biopsies to predict response in patients with advanced HPV16-positive cervical cancer Paula A. Bousquet, PhD; Milena Blaga; Berit Nicolaisen; Karsten Bruins Slot, MD, PhD; Agnete B. Fredriksen, PhD; Karoline Schjetne, PhD Clinical Trials In Progress Biomarkers;Clinical trial;Vaccine
670 Poster Presentation Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts Lucy Gilbert, MD, MSc, FRCOG; Kathleen N. Moore; Vanessa Samouëlian; Cara Mathews, MD; Maria-Pilar Barretina-Ginesta; Janet S. Rader; Anna V. Tinker; Adriano Gravina; Joanna Pikiel, Dr n. med.; Grace Antony; Eleftherios Zografos; Jennifer Veneris; Ana Oaknin, MD Clinical Trials In Progress Checkpoint blockade;Clinical study;Solid tumors
671 Poster Presentation A Phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies Eugenia Girda, MD; Emese Zsiros, MD, PhD; John Nakayama, MD; Sarah Whelan, PhD; Srinand Nandakumar; Seema Rogers; Beverly Benson; Michael T. Lotze, MD; Robert J. Brown; Robert M. Wenham Clinical Trials In Progress Clinical trial;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
672 Poster Presentation Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer (OVCA) Robert M. Wenham, MD, MS, FACS, FACOG; Marco L. Davila, M.D., Ph.D.; Daniel Abate-Daga, PhD; Melissa McGettigan, MD; Xuefeng Wang, PhD; Theresa Boyle, PhD, MD; Pamela D. Garzone, PhD; Amit Kumar, PhD; Jose Conejo-Garcia, MD, PhD Clinical Trials In Progress Adoptive immunotherapy;CAR T cells;Clinical trial;Solid tumors;T cell;Targeted therapy
673 Poster Presentation Efficacy and Safety of Zimberelimab (GLS-010) Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer: A Multicenter, Open-Label, Single-Arm, Phase II Study Xiaohua Wu; Lingfang Xia; Jing Wang; Chunyan Wang; Qingming Zhang; Jianqing Zhu; Qunxian Rao; Huijun Cheng; Zheng Liu; Yongmei Yin; Xiaohong Ai; Kurban Gulina; Hong Zheng; Xiaoyong Luo; Baoping Chang; Li Li; Haiyan Liu; Yunxia Li; Ge Lou; Qi Zhou; Yanling Zhu; Zemin Xiao; Jiandong Tong; Ke Wang; Jie Chen; Xia Wang; Lijie Song; Zhixia Wei; Yijing Ye; Jiman Zhu Clinical Trials In Progress Checkpoint blockade
674 Poster Presentation IMMUNOCERV, an ongoing Phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers    Kyoko Yoshida-Court, PhD; Olsi Gjyshi, MD, PhD; Madison O’Hara, BS; Lilie L. Lin, MD; Anuja Jhingran, MD; Melissa M. Joyner, MD, MBA; Tatiana Cisneros Napravnik; Erica J. Lynn; Lauren E. Colbert, MD, MSCR; Jagannadha K Sastry, PhD; Ann H. Klopp, MD, PhD Clinical Trials In Progress Adoptive immunotherapy;Clinical study;Clinical trial;T cell
675 Poster Presentation TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma    Irene Brana, MD; Valerii Cheshuk; Claus Andrup Kristensen; Maria Eugenia Ortega; Brieuc Sautois; Antonio López-Pousa; Judith Christian; Willem Lybaert; Julio Peguero, MD; John Park, BSc(Med), MBBS, MPH, FRACP; Robert Metcalf; Lisle Nabell; Bernard Doger de Spéville; Jordi Rubió Casadevall; Ainara Soria Rivas; Martin Forster; Frederic Triebel, MD, PhD Clinical Trials In Progress Antibody;Antigen presenting cells;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;Immune monitoring;Solid tumors;T cell
676 Poster Presentation A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04 Ezra Cohen, MD; Kevin Harrington; Jean-Pascal Machiels, MD, PhD; Sjoukje Oosting; Bhumsuk Keam, MD, PhD; Beatriz B. Cirauqui, MD; Annette M. Lim; Keun-Wook Lee, MD; Tim Welliver, MD, PhD; Christine Ju; Feng Jin; Alison J. Forgie, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Athanasios C. Tsiatis, MD Clinical Trials In Progress Antigen presenting cells;Checkpoint blockade;Chemotherapy;Clinical trial;Coinhibition;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
677 Poster Presentation A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti-PD-1) in recurrent or metastatic head and neck squamous cell carcinoma Rom Leidner, MD; Robert Haddad, MD; Nawel Bourayou, MD; Sonia Ioannidis; Feng Zhou; Zhiwan Dong, PhD; Ezra Cohen, MD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy
678 Poster Presentation A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03  Kevin Harrington; Ezra Cohen, MD; Bhumsuk Keam, MD, PhD; Jean-Pascal Machiels, MD, PhD; Sjoukje Oosting; Brett G.M. Hughes, MD; Jong Chul Park, MD; Tim Welliver, MD, PhD; Christine Ju; Feng Jin; Alison J. Forgie, PhD; Jaume Pons, PhD; Sophia S. Randolph, MD, PhD; Athanasios C. Tsiatis, MD Clinical Trials In Progress Clinical trial;Costimulation;Dendritic cell;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
679 Poster Presentation NT-I7 for the treatment of locally recurrent squamous cell carcinoma of head and neck undergoing salvage surgery: A clinical trial in progress    Hyunseok Kang, MD, MPH; Matthew Spitzer, PhD; Mi-Ok Kim, PhD; Patrick Ha, MD; Daniel Johnson, PhD; Byung Ha Lee, PhD; Se Hwan Yang, PhD Clinical Trials In Progress Clinical trial;Cytokine;Tumor infiltrating lymphocytes (TILs)
680 Poster Presentation A Phase 1b open-label, single-arm dose expansion study of IK-175, an oral AHR inhibitor, in combination with nivolumab in patients with primary PD-1 inhibitor resistant advanced head and neck cancer    Trupti Lingaraj, B.S.; Marissa Timothy, MS; Nerymar Ortiz-Otero; Wilmin Bartolini; Katherine Kacena; Karim Malek; Sergio L. Santillana, MD, MSc, MBA Clinical Trials In Progress Biomarkers;Clinical study;Clinical trial;Solid tumors;Targeted therapy;Tumor microenvironment
681 Poster Presentation A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer Christine H. Chung, MD; Dimitrios Colevas, MD; Douglas R. Adkins; Jong Chul Park, MD; Cristina P. Rodriguez, MD; Michael K. Gibson, MD PhD; Ammar Sukari, MD; Barbara A. Burtness, MD; Faye M. Johnson, MD, PhD; Ricklie A. Julian, MD; Nabil F. Saba, MD; Lara A. Dunn, MD; Tanguy Y. Seiwert, MD; Francis P. Worden; Rami Y. Haddad, MD; Nashat Y. Gabrail, MD; Julie E. Bauman, MD, MPH; Laura Agensky; Apollina Goel, PhD; Reena Lynam; Steven P. Margossian, MD, PhD; Raymond J. Moniz, PhD; Steve N. Quayle, PhD; Cynthia Rajan; Kenneth J. Pienta, MD; Matteo Levisetti; Sara I. Pai, MD PhD Clinical Trials In Progress Checkpoint blockade;Clinical study;Clinical trial;Cytokine;T cell;Targeted therapy;Tumor microenvironment
682 Poster Presentation Changing the Radiation and Immune-Oncology Paradigm with the Radioenhancer NBTXR3: Overcoming resistance to anti-PD-1 blockade from the bench to the clinic Ari Rosenberg, MD; Jessica Frakes, MD; Jiaxin Niu; Jared Weiss, MD; Jimmy Caudell; Patricia Said; Pavel Tyan; Sebastien Paris; Tanguy Y. Seiwert, MD; Colette Shen; Sergio Szyldergemajn; Omar Vivar, PhD; Leonard A. Farber, MD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors;T cell
683 Poster Presentation CD8 T cell repertoire analysis of patients with resectable head and neck cancer enrolled in a phase II neoadjuvant study of α-PD1 administered alone or in combination with α-CTLA4 or α-LAG3     Patricia M. Santos, PhD; Aditi Kulkarni; Housaiyin Li; Jie Chen; Lazar Vujanovic, PhD; Seungwon Kim; Umamaheswar Duvvuri; Dan P. Zandberg, MD; Robert L. Ferris, MD, PhD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
684 Poster Presentation NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation Phase I trial (Study 1100) Colette Shen; Jessica Frakes, MD; Jiaxin Niu; Jared Weiss, MD; Jimmy Caudell; Tanguy Y. Seiwert, MD; Patricia Said; Mickael Guedj; Pavel Tyan; Omar Vivar, PhD; Sergio Szyldergemajn; Leonard A. Farber, MD; Ari Rosenberg, MD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Radiotherapy;Solid tumors
685 Poster Presentation Preliminary Results of MT-401 in Post-Transplant MRD+ AML Patients Mythili Koneru, MD, PhD; Juan Vera, M.D.; Shukaib Arslan; Hongtao Liu, MD, PhD; Margarida Magalhaes-Silverma, MD; Nelli Bejanyan; Antonio DiStasi; Betul Oran, MD, MS; Jingmei Hsu; Robin McCallum; Silvia Quintero; Gerald M. Garrett; Karrie Wang; Eric A. Smith, PhD; Tsvetelina Hoang, PhD; Tara Shahim; Jeannette Crisostomo; Anna Wilga-Savitski; Jennifer Pickering; Laura Angelo; Anastasiya Smith, PhD Clinical Trials In Progress Adoptive immunotherapy;Biomarkers;Clinical study;Clinical trial;Immune monitoring;Leukemia/Lymphoma;T cell;Tumor antigens
686 Poster Presentation Mechanism of action of LAVA-051, a bispecific V&gamma;9V&delta;2 T-cell engager (bsTCE), confirmed in the clinical setting Roeland Lameris; Jurjen M. Ruben; Rob Roovers; Arnon P. Kater; Thilo Riedl; Victoria Iglesias; Annemiek Broijl; Ilse Tuinhof; Sanjana Umarale; Anton E.P. Adang; Tanja D. de Gruijl, PhD; Paul Parren; Benjamin Winograd, MD, PhD; Hans J. Van der Vliet, MD, PhD Clinical Trials In Progress Bispecifics;Clinical trial;NK/NKT cell;T cell;Targeted therapy
687 Poster Presentation Proteomic profiling in blood identifies novel pretreatment and mechanistic markers related to inflammatory adverse events in relapsed/refractory large B-cell lymphoma after axicabtagene ciloleucel Kelly Speth, PhD; Gayatri Tiwari; Sabina Adhikary; Qinghua Song; Justin Chou; Frederick L. Locke, MD; Caron A. Jacobson, MD, MMSc; David B. Miklos, MD; Olalekan O. Oluwole, MBBS, MPH; Marie José Kersten; Max S. Topp, MD; Jenny J. Kim, MD, MS; Adrian Bot Clinical Trials In Progress Biomarkers;CAR T cells;Clinical study;Clinical trial;Immune toxicity;Inflammation;Leukemia/Lymphoma;Proteomics
688 Poster Presentation Prediction of HCC response to neoadjuvant immunotherapy using multiparametric magnetic resonance imaging: a preliminary study.    Octavia Bane, PhD; Enamul Bhuiyan, PhD; Paul Kennedy, PhD; Muhammed Shareef, MD; Pauline Hamon, PhD; Mark Buckup, PhD; Sacha Gnjatic, PhD; Stefanie Hectors, PhD; Hung Kam Cheung; Elizabeth Miller; Maria Isabel Fiel, MD; Stephen Ward; Myron E. Schwartz, MD; Thomas U. Marron, MD, PhD; Miriam Merad, MD, PhD; Bachir Taouli, MD, MSHA Clinical Trials In Progress Biomarkers;Checkpoint blockade;Immune adjuvant;Solid tumors;T cell
689 Poster Presentation PRELIMINARY RESULTS OF A PILOT STUDY OF INTRATUMORAL INJECTION OF AUTOLOGOUS DENDRITIC CELLS AFTER HIGH-DOSE CONFORMAL EXTERNAL BEAM RADIOTHERAPY IN UNRESECTABLE PRIMARY LIVER CANCERS    Lionel A. Kankeu Fonkoua, MD; Panwen Wang, Ph.D.; Christopher L. Hallemeier, M.D.; Thomas D. Atwell, MD; Nguyen H. Tran, M.D.; Amit Mahipal, MBBS; Elham Babadi, M.D.; Svetlana Bornschlegl, M.S.; Anatilde M. Gonzalez Guerrico, Ph.D.; Kodi Martinez; Gabrielle McCoy; Kevin M. Regan; Zuoyi Shao, Ph.D.; Henan Zhang; Junwen J. Wang, Ph.D.; Ying Li, PhD; Allan B. Dietz, Ph.D.; Haidong Dong, MD, PhD; Yi Lin, MD PhD; Sean S. Park, M.D.Ph.D; Lewis R. Roberts, M.B.,Ch.B., Ph.D. Clinical Trials In Progress Adoptive immunotherapy;Antigen presenting cells;Clinical trial;Dendritic cell;Radiotherapy;Solid tumors;Vaccine
690 Poster Presentation Correlates of poor response to neoadjuvant anti-PD-1 therapy in hepatocellular carcinoma (HCC) include WNT pathway activation and loss of HLA expression Kunal Kundu, PhD; Nathalie M. Fiaschi, PhD; Wei Wang; Baijun Kou, PhD; Assaf Magen, PhD; Pauline Hamon, PhD; Sacha Gnjatic, PhD; Myron E. Schwartz, MD; Alice O. Kamphorst, PhD; Thomas U. Marron, MD, PhD; Miriam Merad, MD, PhD; Chunguang Guo, PhD; Gavin Thurston, PhD; Namita T. Gupta, PhD; Kamil J. Cygan, PhD Clinical Trials In Progress Bioinformatics;Checkpoint blockade;Solid tumors;Tumor evasion;Tumor microenvironment
691 Poster Presentation Immune pressure in an advanced hepatocellular cancer patient following treatment with personalized neoantigen DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab) Mark Yarchoan, MD; Edward J. Gane, MD; Renzo Perales, PhD; Alfredo Perales-Puchalt, MD, PhD; Gabor Bartha, PhD; Sarah Rochestie; Neil Cooch; Joann Peters; Ildiko Csiki, MD, PhD; Jian Yan, PhD; Niranjan Y. Sardesai, PhD Clinical Trials In Progress Clinical study;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Vaccine
692 Poster Presentation Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab)    Renzo Perales, PhD; Alfredo Perales-Puchalt, MD, PhD; Gabor Bartha, PhD; Josette Northcott; Richard O. Chen, MD; John Lyle; Dan Norton; Neil Cooch; Edward J. Gane, MD; Mark Yarchoan, MD; Thomas U. Marron, MD, PhD; Sarah Rochestie; Joann Peters; Ildiko Csiki, MD, PhD; Jian Yan, PhD; Niranjan Y. Sardesai, PhD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine
693 Oral Presentation Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab as second-line (2L) treatment for advanced hepatocellular carcinoma (HCC)    Edward J. Gane, MD; Mark Yarchoan, MD; Thomas U. Marron, MD, PhD; Sarah Rochestie; Renzo Perales, PhD; Neil Cooch; Jian Yan, PhD; Joann Peters; David B. Weiner, PhD; Ildiko Csiki, MD, PhD; Alfredo Perales-Puchalt, MD, PhD; Niranjan Y. Sardesai, PhD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Vaccine
694 Poster Presentation An Open-Label Phase I Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of VG161 in Patients with Advanced Primary Liver Cancer Yinan Shen, MD; Guoming Shi; Xingmei Liang; Xinyan Jin; Youlei Wang; Guyue Wei; Yi Chen; Xiaoyong Huang; Jiacheng Lu; Huiqun Xia; Miao Xiao; Shah Rahimian; Ronghua Zhao; Yuwei Li, MD; Danni Lin; Tian Fang; Wei Chen; Tao Ma; Xueli Bai; Tingbo Liang Clinical Trials In Progress Clinical trial;Solid tumors
695 Poster Presentation Immune correlates associated with clinical benefit in patients with immune checkpoint refractory HPV-associated malignancies treated with triple combination immunotherapy     Meghali Goswami, PhD; Julius Strauss, MD; Yo-Ting Tsai, PhD; Caroline Jochems, MD, PhD; Jennifer L. Marte, MD, MPH; James L. Gulley, MD, PhD; Jeffrey Schlom, PhD; Renee N. Donahue, PhD Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical study;Immune monitoring;Solid tumors;T cell;Vaccine
696 Poster Presentation Abatacept For Immune Checkpoint Inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated,  Randomized, Double-Blind, Placebo-Controlled Trial    Kerry L. Reynolds, MD; Meghan J. Mooradian, MD; Daniel A. Zlotoff, MD, PhD; Paul Ridker, MD, MPH; Tomas Neilan, MD MPH On Behalf Of The ATRIUM Investigators Clinical Trials In Progress Clinical study;Immune toxicity
697 Poster Presentation A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed/refractory small cell lung cancer (SCLC) Lauren A. Byers, MD; John V. Heymach, MD, PhD; Don L. Gibbons, MD, PhD; Jianjun Zhang, MD, PhD; Alberto Chiappori, MD; Erik Rasmussen, MS; Benjamin E. Decato, PhD; Marie-Anne D. Smit, MD, MS; Nooshin Hashemi Sadraei, MD Clinical Trials In Progress Adoptive immunotherapy;Biomarkers;CAR T cells;Clinical trial;Solid tumors;T cell;Targeted therapy
698 Poster Presentation A phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial)    Ming Chen; Honglian Ma, MD; Xianghui Du; Yujin Xu; Yongling Ji; Zhengbo Song Clinical Trials In Progress Checkpoint blockade;Clinical trial;Radiotherapy
699 Poster Presentation Interim Results from a Phase IB, First-in-Human Study of a Novel Complement Factor H Inhibitor (GT103) in Patients with Refractory Non-Small Cell Lung Cancer (NSCLC) Jeffrey M. Clarke, MD; Thomas E. Stinchcombe, MD; Jeffrey Crawford, MD; Hirva M. Mamdani, MD; Lin Gu; Neal Ready, MD, PhD; Andrew Nixon, PhD; Stephen Baleviic; Michael Campa; Liz Gottlin; Ryan Bushey; James Herndon; Scott Antonia; Edward Patz; George Simon, MD; Jeffrey Clarke, MD Clinical Trials In Progress Antibody;Clinical trial;Solid tumors
700 Poster Presentation LuCa-MERIT-1: First-in-human open label dose confirmation trial evaluating safety, tolerability, and efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer Patrick Forde, MBBCh; Akin Atmaca, MD; Neru Munshi; Malgorzata Kaczorowska, M.D.; Patrick Brueck, MD, MBA; Thomas Schell; Oezlem Tuereci, MD; Ugur Sahin Clinical Trials In Progress Antigen presenting cells;Clinical study;Clinical trial;Dendritic cell;RNA;Solid tumors;T cell;Tumor antigens;Vaccine
701 Poster Presentation Brightplex TCE and Brightplex MDSC assays combination improves advanced NSCLC patients' stratification under anti-PD1/L1 immunotherapy in the PIONeeR project Lamia Ghezali, PhD; Marcellin Landri; Florence Monville, PhD; Vanina Leca, PhD; Théo Vasse; Chafik Hamdad; Margaux Mercadal; Laurent Vanhille, PhD; Alboukadel Kassambara, PhD; Thomas Sbarrato, PhD; Maryannick Le Ray, PharmD; Marie Roumieux, PhD; Richard Malkoun; Noémie Resseguier; Arnaud Boyer, MD; Clarisse Audigier-Valette, MD; Stephanie Martinez, MD; Hervé Pegliasco, MD; Patrice Ray, MD; Lionel Falchero, MD; Antoine Serre, MD; Nicolas Cloarec, MD; Louisiane Lebas, MD; Stéphane Hominal, MD; Patricia Barré, MD; Sarah Zahi, MD; Ahmed Frikha, MD; Pierre Bory, MD; Lilian Laborde; Julien Mazières, MD, PhD; Virginie Martin; Maurice Pérol, MD; Laurent Greillier, MD, PhD; Fabrice Barlesi, MD, PhD; Jacques Fieschi, PhD Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical study;Granulocyte;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs)
702 Poster Presentation Tertiary lymphoid structures (TLS) observed in non-small cell lung cancer (NSCLC) tumors treated with Pulsed Electric Fields Jeff S. Iding, MD; Paul VanderLaan, MD, PhD; Marcelo F. Jimenez, MD, PhD; José M. Fernández García-Hierro, MD; Javier Flandes Aldeyturriaga, MD, PhD; Erik H. F. M. van der Heijden, MD, PhD; Calvin S. H. Ng, MD, FRCSEd, FCSHK, FHKAM; Rainbow W. H. Lau, MBChB, FRCS(CTh), FHKAM, FCSHK; Maria D. Ludeña, MD; Rafael Carías, MD; Oderay M. Cedeño, MD; Alicia Moreno-Gonzalez, PhD; Beryl A. Hatton, PhD; William Krimsky, MD, FCCP, DAABIP Clinical Trials In Progress B cell;Clinical study;Clinical trial;Inflammation;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor microenvironment
703 Poster Presentation First-line Tumor Treating Fields (TTFields; 150 kHz) therapy plus pembrolizumab for advanced or metastatic intrathoracic non-small cell lung cancer: the phase 2 EF-36/KEYNOTE B36 pilot study Rupesh Kotecha, MD; Corey J. Langer; Vinicius Ernani; Anne Tsao, MD Clinical Trials In Progress Checkpoint blockade;Clinical study;Clinical trial;Solid tumors
704 Poster Presentation Phase I study of tislelizumab in combination with bevacizumab and pemetrexed in first-line treatment for advanced elderly non-squamous non-small cell lung cancer: trial in progress    Xiubao Ren, MD; Liang Liu, MD Clinical Trials In Progress Angiogenesis;Checkpoint blockade;Chemotherapy
705 Poster Presentation Phase 2 study of SEA-CD40 combination therapies in advanced malignancies (SGNS40-002, trial in progress) April Salama, MD; Meredith McKean, MD; Thaddeus Beck, MD; Omid Hamid, MD; Sandeep Mashru, MD; Sapna P. Patel, MD; Timothy Kuzel, MD, FACP; Michael Castine, MD; Vincent T. Ma, MD; Keenan Fenton; Jonathan Hayman, MD; Adil Daud, MD Clinical Trials In Progress Chemotherapy;Clinical trial;Solid tumors;Targeted therapy
706 Poster Presentation NOUS-PEV, a Novel Personalized Viral-based Prime/Boost Cancer Immunotherapy Targeting Patient-Specific Neoantigens: Interim Results from the First Subjects in the Phase 1b Study Oliver Bechter, MD; Juan Martin-Liberal; Anna M. D'Alise, PhD; Guido Leoni, PhD; Gabriella Cotugno, PhD; Loredana Siani, PhD; Rosa Vitale, PhD; Valentino Ruzza, PhD; Elisa Micarelli, PhD; Irene Garzia, PhD; Thea Faivre, PhD; Sven Gogov, PhD; Patricia Delaite, MD; Stefano Colloca, MD; Maria Ambrosio, PhD; Rossella Merone, PhD; Elisa Scarselli, MD; Stefan N. Symeonides, MD PhD Clinical Trials In Progress Checkpoint blockade;Clinical study;Neoantigens;T cell;Vaccine
707 Poster Presentation A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers Emanuela Romano, MD, PhD; Jacques Medioni, MD; Thibault De La Motte Rouge, MD; Nicolas Fischer, PhD; Clélia Bardonneau; Walter Ferlin, PhD; Dirk Hose, MD, PhD; Anja Seckinger, MD; Matteo Simonelli, MD; Giuseppe Curigliano, MD, PhD Clinical Trials In Progress Antibody;Bispecifics;Checkpoint blockade;Clinical study;Monocyte/Macrophage;Solid tumors;Targeted therapy;Tumor antigens
708 Poster Presentation MEDI1191 (IL-12 mRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (C/SC) lesions    Michael Abadier, PhD; Emily Jennings; Jim Eyles; Philip Martin, PhD, MS, DVM; Fernanda Pilataxi; Yuling Wu, PhD; Xiaoru Chen; Analia Azaro; Benjamin Ridgway; Marc Phillips; Benedito A. Carneiro, MD; Omid Hamid, MD; Thomas U. Marron, MD, PhD; Dmitriy Zamarin; Eduardo Castañón; Sandip P. Patel, MD; Elena Garralda, MD, MSc; Vivek Subbiah; Anthony B. El-Khoueiry, MD; Paula G. Fraenkel; Nicholas Durham, PhD Clinical Trials In Progress Biomarkers;Clinical trial;Immune monitoring;Solid tumors;T cell;Tumor microenvironment
709 Poster Presentation Phase II Study to Assess the Safety and Efficacy of the CLEVER-1 Antibody Bexmarilimab in Combination with PD-1 blockade in Patients with Advanced Solid Tumors - BEXCOMBO    Petri Bono, PhD; Juho M. Jalkanen; Inka Pawlitzky; Marie-Louise H. Fjaellskog; Cecilia Ahlin, MD Clinical Trials In Progress Antibody;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
710 Poster Presentation Safety and survival results from a phase 1/2 trial of intratumoral agent INT230-6 (cisplatin vinblastine) induces immunological cancer cell death alone or with pembrolizumab in patients with refractory, metastatic cancers Jacob S. Thomas, MD; Anthony B. El-Khoueiry, MD; Diana L. Hanna, MD; Anthony Olszanski, MD, RhP; Nilofer Azad, MD; Giles Whalen, MD; Matthew Ingham, MD; Luis H. Camacho, MD; Franco Abbate, Ph.D.; Lewis H. Bender, MS, MA, MBA; Ian B. Walters, MD, MBA; Lillian L. Siu Clinical Trials In Progress Checkpoint blockade;Clinical trial;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
711 Poster Presentation Interim Results of a Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR) Cancers Resistant to Prior PD-(L)1 Inhibition Katherine M. Bever, MD; Hao Wang, PhD; Jennifer Durham, PhD; Colleen Apostol; Nilofer Azad, MD; Ilene Browner, MD; Stephanie Gaillard, MD PhD; Daniel A. Laheru, MD; Valerie Lee, MD; William H. Sharfman, MD; Mark Yarchoan, MD; Qingfeng Zhu, PhD; Robert A. Anders, MD, PhD; Andrew M. Pardoll, MD, PhD; Suzanne L. Topalian, MD; Nicolas J. Llosa, MD; Elizabeth M. Jaffee, MD; Dung T. Le, MD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Solid tumors
712 Poster Presentation Retrospective Tumor Microenvironment Analysis from a Personalized neoTCR-T Cell Therapy Clinical Trial and Its Potential Applications for Off-the-Shelf HPV TCRs Eric Stawiski; Chad Smith; Tyler Borrman; Zheng Pan, PhD; Stefanie J. Mandl, PhD; Vinnu Bhardwaj Clinical Trials In Progress Adoptive immunotherapy;Bioinformatics;Clinical trial;Gene expression;Immune suppression;Neoantigens;Solid tumors;T cell;Tumor microenvironment
713 Poster Presentation The PRAME opportunity -  high peptide copy numbers, homogenous expression and high prevalence to address a broad patient population across different solid cancers with TCR-based therapeutics Cedrik M. Britten; Dejka M. Araujo, MD; Linus Backert; Carsten Bokemeyer; Richard D. Carvajal, MD; Manik Chatterjee; Asim Dash; Lena K. Freudenmann; Jens Fritsche, PhD; David Fuhrmann; Valentina Goldfinger; Tobias AW. Holderried; Franziska Hoffgaard; Jens Hukelmann; Amir A. Jazaeri, MD; Ahmed O. Kaseb, MD; Florian Köhler; Daniel Kowalewski; Jason J. Luke, MD; Van Morris; Shivani Mukhi; Martina Ott; Ran Reshef, MD, MSc; Michael Römer; Lida Rostock; Swapna Satam; Arun Satelli; Christoph Schräder; Merline Thambi; Apostolia M. Tsimberidou, MD; Maike Wagner; Martin Wermke, MD; Heiko Schuster; Oliver Schoor; Toni Weinschenk Clinical Trials In Progress Adoptive immunotherapy;Biomarkers;Bispecifics;Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy;Tumor antigens
714 Poster Presentation ATOR-1017, a 4-1BB antibody, demonstrates promising safety and proof of mechanism in a first-in-human study in patients with advanced solid malignancies. Ana Carneiro, MD PhD; Sumeet V. Ambarkhane, MBBS, MD; Karin Enel Smith, PhD; Gustav J. Ullenhag, PhD, MD; Lena Schulz; Tova Landstrom; Peter Ellmark, PhD; Malin Carlsson; Jeffrey Yachnin, MD, PhD Clinical Trials In Progress Antibody;Antigen presenting cells;Biomarkers;Clinical trial;Costimulation;Cytokine;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
715 Poster Presentation Emerging results from the use of an Oncolytic Adenovirus armed with TNFa and IL-2 (TILT-123) in different Phase I Solid Tumor Clinical trials Victor Cervera-Carrascon, PhD, PharmD; Inge M. Svane, MD, PhD; Katriina Peltola; Tuomo Alanko; Riitta Korpisaari; Susanna Juteau; Marjut Jaakkola; Jorma Sormunen; Juha Kononen; Eva Ellebaek Steensgaard, MD, PhD; Tine Monberg; Marco Donia, MD, PhD; Amir Khammari; Brigitte Dreno; Joao M. Santos, MS; Suvi Sorsa; Riikka Havunen; Akseli Hemminki, MD, PhD Clinical Trials In Progress Adoptive immunotherapy;Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
716 Poster Presentation AURELIO-04: A phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors Stephane Champiat, MD, PhD; Aurelien Marabelle, MD, PhD; Diwakar Davar, MD; Peter Grell, MD; Kaissa Ouali, MD; Anna Patrikidou, MD; Andreu Schoenenberger; Lenka Palova Jelinkova, PhD; Irena Adkins, PhD; Sascha Tillmanns, PhD; Joachim Kiemle-Kallee, MD; Richard Sachse, MD; Elena Garralda, MD, MSc Clinical Trials In Progress Checkpoint blockade;Clinical study;NK/NKT cell;Solid tumors;Tumor microenvironment
717 Poster Presentation Interim clinical update of the Phase 1b trial of ATRC-101 as monotherapy or in combination with pembrolizumab for select advanced solid tumors    Bartosz Chmielowski, MD, PhD; John Weroha, MD, PhD; Susanna Ulahannan, MD, MMED; John D. Powderly, II, MD; Frances Valdes-Albini; Tanios S. Bekaii-Saab, MD; Deborah Doroshow; Alejandro Recio-Boiles; Jordan Berlin, MD; Yan Xing, MD, PhD; Sudha Khurana, PhD; Jonathan Benjamin, MD, PhD; Steven Isakoff; Benjamin Weinberg, MD Clinical Trials In Progress Antibody;B cell;Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy
718 Poster Presentation Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and/or metastatic solid tumors     Byoung Chul Cho, MD, PhD; Sang J. Shin, MD; Jae Lyun Lee; Byoung Y. Shim; Hyo J. Lee, PhD, MD; Nari Yun, PhD; Mina Ham, MS; YunHee Jeong, MS; Wooyul Lee, MD, PhD; Hyunjin Kang, MS; Jisoo Kim, PhD; Myoung Ho Jang, PhD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Cytokine;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell
719 Poster Presentation Phase 1 study of the Porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor Nivolumab in patients with advanced solid tumours    Natalie Cook; Sarah P. Blagden; Juanita Lopez; Debashis Sarker; Alastair Greystoke; Saira Bashir; Aglaia Skolariki; Salma ElBadri; Cienne Morton; Ana OrtegoFranco; Shybi MohamedKhan; Catherine Eagle; Eimear Flanagan; Louise Goodwin; Caroline Phillips; Jane Robertson, MD; Craig Tilston; Helen Timmis, MBChB; Simon A. Woodcock; Ruth Plummer Clinical Trials In Progress Biomarkers;Clinical study;Cytokine;Immune monitoring;Immune toxicity;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;T cell
720 Poster Presentation Enhancing the anti-tumor immunity and therapeutic potential of ICT01, a butyrophilin3A-targeted, &gamma;9&delta;2 T cell-activating monoclonal antibody, with low dose IL-2 in patients with advanced solid tumors: The EVICTION-2 trial Johann De Bono; Stephane Champiat, MD; Francois-Xavier Danlos, MD; Martin Wermke, MD; Volker Kunzmann, MD, PhD; Aude de Gassart, PhD; Emmanuel Valentin, PhD; Marina Iche; Maelle Mairesse, PhD; Patrick Brune; Daniel Olive, MD, PhD; Paul A. Frohna, MD, PhD, PharmD Clinical Trials In Progress Clinical study;Cytokine;Immune monitoring;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
721 Poster Presentation Pixatimod (P) in Combination with Nivolumab (N) +/- low-dose Cyclophosphamide (Cy) in Advanced Cancers: A Phase IIA Basket Trial. Diwakar Davar, MD; Hong Wang, PhD; Sarah Behr, BSc; Aubrey Murano; Sarah Johnson; Amy Rose, RN; Darryn Bampton; Keith Dredge, PhD; Hassane Zarour, MD; John Rhee, MD; Liza C. Villaruz, MD; Yana G. Najjar, MD; Jason J. Luke, MD Clinical Trials In Progress Clinical study;Monocyte/Macrophage;Solid tumors;TLR
722 Poster Presentation Cbl-b silenced, autologous PBMCs as a novel anti-cancer therapy using the closed cell processing platform EPiC - a phase 1b trial with APN401 Romana Gugenberger, PhD; Alexander Dohnal; Kathrin Thell; Sarah Bischof; Mario Kuttke; Bernhard Peball; Hannes Muehleisen; Maria Urban; Andreas Tanzmann; Beate Pribitzer; Felix Batrina; Stefan Bunka; Sophia Spagl; Manuela Branka; Markus Raderer; Gerald Prager; Thorsten Fuereder; Nina Worel Clinical Trials In Progress Adoptive immunotherapy;Biomarkers;Checkpoint blockade;Clinical study
723 Poster Presentation A phase 1, first-in-human, open-label, multicenter study of INCA32459, a bispecific anti-PD1 and anti-LAG-3 antibody, in patients with select advanced malignancies Sarina A. Piha-Paul, MD; Nawel Bourayou, MD; Richard Schaub; Yan-ou Yang; Wendy Wei; Patrick Mayes, PhD; Tara C. Gangadhar, MD Clinical Trials In Progress Bispecifics;Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy
724 Poster Presentation    A phase I study of HCW9218, a bifunctional TGF-β Antagonist/IL-15 protein complex, in advanced solid tumors    Melissa A. Geller, MD, MS, FACOG; Manish R. Patel, DO; Hing C. Wong; Peter R. Rhode; Philip M. Arlen; Pallavi Chaturvedi; Jack O. Egan; Giles M. Leclerc; Martin Felices; Shannon Lunn; Bethany Hanke; Deepa Kolseri; Rose Wangen; Jeffrey S. Miller, MD Clinical Trials In Progress Chemokine;Clinical study;Cytokine;NK/NKT cell;Solid tumors
725 Poster Presentation Phase I safety and preliminary efficacy of PM8002 in subjects with advanced solid tumors, a bispecific antibody targeting PD-L1 and VEGF-A Ye Guo; Suxia Luo; Yanru Qin; Yongmei Yin; Guiling Li; Jingfen Wang; Yongsheng Li; Jun Guo; Feng Zhang; Yi Huang; Hong Luo; Dongqing Lv; Cheng Ying; Chunyan Wang; Chuan-Chu Chou, PhD; Chundan Gong; Ruixia Chang; Jing Liu; Guoqiang Hu Clinical Trials In Progress Angiogenesis;Antibody;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Tumor microenvironment
726 Poster Presentation Phase I results of FT516, an off-the-shelf, iPSC-derived NK cell therapy expressing a high-affinity, non-cleavable CD16 (hnCD16) combined with avelumab in patients with advanced solid tumors Martin Gutierrez, MD; Manish R. Patel, DO; Feng Liu, PhD; Peter Szabo, MD, PhD; Bob Valamehr, PhD; Yu-Waye Chu, MD; Brandon Beagle, PhD; Jeffrey Chou, MD, PhD; David S. Hong, MD Clinical Trials In Progress Adoptive immunotherapy;Antibody;Checkpoint blockade;Clinical trial;NK/NKT cell;Solid tumors
727 Poster Presentation Interim Phase I clinical data of FT538, an off-the-shelf, multiplexed-engineered, iPSC-derived NK cell therapy, combined with monoclonal antibodies in patients with advanced solid tumors Martin Gutierrez, MD; Melissa L. Johnson, MD; David Sommerhalder, MD; Wells A. Messersmith, MD, FACP, FASCO; Haeseong Park, MD, MPH; Muhammad Furqan, MD; Jason A. Chesney, MD, PhD; Ryan Bjordahl, PhD; Lingmin Zeng, PhD; Peter Szabo, MD, PhD; Yu-Waye Chu, MD; Brandon Beagle, PhD; Bob Valamehr, PhD; Jeffrey Chou, MD, PhD; David S. Hong, MD Clinical Trials In Progress Adoptive immunotherapy;Antibody;Checkpoint blockade;Clinical trial;NK/NKT cell;Solid tumors
728 Poster Presentation Phase 1 study of P-MUC1C-ALLO1 allogeneic CAR-T cells in patients with epithelial-derived cancers    Jason Henry, M.D.; David Oh; Jeff D. Eskew, PhD; Joaquina Baranda, MD; Ildefonso Ismael Rodriguez Rivera, MD; Ecaterina E. Dumbrava, MD; Ezra Cohen, MD; Rajesh Belani, MD; Joanne McCaigue; Devon J. Shedlock, PhD; Julia Coronella, Ph.D.; Christopher E. Martin, PhD; Hamid Namini, PhD; Ann Murphy; Eric M. Ostertag, Ph.D. M.D. Clinical Trials In Progress Adoptive immunotherapy;CAR T cells;Clinical trial;Solid tumors
729 Poster Presentation Targeting epidermal growth factor receptor (EGFR)-expressing solid tumors with AFM24, a novel CD16A bispecific innate cell engager: Comprehensive correlative science findings from a Phase 1 study Gabriele Hintzen, PhD; Susanne Wingert; Michael Emig; Pilar Nava-Parada; Kerstin Pietzko; Laura Kohlhas; Uwe Reusch, PhD; Melissa M. Berrien-Elliott; Todd A. Fehniger, MD, PhD; Mark Foster; Paolo Nuciforo; Ester Castillo Andreo; Sina Staeble; Paulien Ravenstijn; Bettina Rehbein; Erich Rajkovic; Arndt Schottelius; Joachim Koch, Prof. Clinical Trials In Progress Antibody;Bispecifics;Solid tumors;Targeted therapy
731 Poster Presentation A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: Interim results of a Phase 1 study (SGNB6A-001)  Antoine Hollebecque; Juanita Lopez; Sarina A. Piha-Paul, MD; Afshin Dowlati; Amita Patnaik; Vladimir Galvao; Bruno Buckorny; Kartik Sehgal; Edwin Kingsley; Rachel E. Sanborn, MD; Solange Peters; Yan Sun; Gabriela Patilea-Vrana; Natalya Nazarenko; Emiliano Calvo Clinical Trials In Progress Antibody;Biomarkers;Clinical study;Clinical trial;Solid tumors;Targeted therapy
732 Poster Presentation First-in-human trial to evaluate safety, PK/PD and initial clinical activity of NM21-1480, an affinity-balanced PD-L1x4-1BBxHSA trispecific antibody: Results of Phase 1 dose escalation    David S. Hong, MD; Jason J. Luke, MD; Melissa Johnson, MD; Shirish M. Gadgeel, MD; Alexander I. Spira, MD, PhD, FACP; James C.H. Yang, MD, PhD; Jennifer M. Johnson, MD; Taryn R. Losch-Beridon; Daniel Snell, PhD; Stefan Warmuth, PhD; Maureen Cleaver; Elmar vom Baur, PhD; David M. Urech, PhD; Peter Lichtlen, MD, PhD Clinical Trials In Progress Antibody;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;T cell;Tumor microenvironment
733 Poster Presentation A Phase 2 study of vudalimab (XmAb20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer    June Hou; Oscar Goodman, MD; David Berz, MD; Li Yao, PhD; Nital Soni, MS Clinical Trials In Progress Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;T cell
734 Poster Presentation A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors Hans Prenen; Thierry Lesimple; Marie Robert; Brant Delafontaine; Jean-Pascal Machiels, MD, PhD; Tarek Meniawy; Eric Van Cutsem, MD, PhD; Nuria Kotecki, MD; Sarina A. Piha-Paul, MD; Michael T. Schweizer, MD; Shirish M. Gadgeel, MD; Jeannie Daniel; Louis Viviers; Jason Howe; Antoine Italiano, MD, PhD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy
735 Poster Presentation A Phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors: Initial dose-escalation results Melissa L. Johnson, MD; Nehal J. Lakhani, MD; Eugenia Girda, MD; Anthony Olszanski, MD, RhP; Lawrence Fong, MD; Hyunsil Han, PhD; Kerry A. Casey, PhD; Siyu Li, PhD; Jennifer E. Visich, PhD; Dmitris Skokos, PhD; Frank Seebach, MD; Israel Lowy, MD, PhD; Matthew G. Fury, MD, PhD; Melissa Mathias, MD; Neil H. Segal, MD Clinical Trials In Progress Antibody;Bispecifics;Checkpoint blockade;T cell
736 Poster Presentation A clinical stage engineered toxin body (ETB) targeting PD-L1 (MT-6402) induces peripheral pharmacodynamic responses unique from PD-L1 monoclonal antibodies   Swati Khanna, Ph.D.; Rachael M. Orlandella, PhD; Elizabeth P. Saputra; Sydney Matthews; Lydia Navarrete-Galvan; Sara LeMar; Joseph D. Dekker, Ph.D.; Eric Poma, Ph.D.; Chris B. Moore, Ph.D. Clinical Trials In Progress Angiogenesis;Checkpoint blockade;Clinical trial;Cytokine;Immune suppression;MDSC;Solid tumors;Tumor microenvironment
737 Poster Presentation Interim results of a first-in-human Phase 1 dose-escalation trial of TAK-102, a glypican-3 targeted armored chimeric antigen receptor T-cell immunotherapy in patients with advanced solid tumors Takafumi TK. Koyama, MD, PhD; Toshio Shimizu; Toshihiko Doi; Noboru Yamamoto; Shunsuke Kondo; Abood Okal, PhD; Aman Singh; Janet Markman; Takenori Akaike; Hideaki Kagehara; Yasutoshi Kuboki Clinical Trials In Progress CAR T cells;Clinical trial;Cytokine;Solid tumors;T cell;Tumor microenvironment
738 Poster Presentation Interim dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in advanced malignancies (NEON-2) Nehal J. Lakhani, MD; Amita Patnaik; Meredith McKean, MD; Justin F. Gainor, MD; Cathy Vo Buu; Amanda Enstrom; Rupert Davies; Stacey R. Dillon; Hany Zayed; Michael Chisamore; James Michael Pluda; Allison L. Naumovski; Stanford L. Peng Clinical Trials In Progress Checkpoint blockade;Clinical trial;Coinhibition;Costimulation;Solid tumors;T cell
739 Poster Presentation A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory, or MSS/MSI-low ICI na&iuml;ve advanced or metastatic solid tumors Han Myint, MD, FRCPath, FRCP; Eric Christenson, MD; Siqing Fu, MD, PhD; Martin Gutierrez, MD; Ashley Martz; Stephanie Zeidan, M.S.; Megan M. Nelson, MS; Alina Barbu, Ph.D.; Aaron Morawski; Chelsea Zhou, PhD; Zachary Cusumano, Ph.D.; Rachel O’Neill, Ph.D.; Ron Copeland, Ph.D.; Dallas B. Flies, PhD; Solomon Langermann, PhD; Julia W. Cohen; Dung T. Le, MD Clinical Trials In Progress Antibody;Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Solid tumors;Tumor microenvironment;Tumor stroma
740 Poster Presentation A first-in-human trial of hSTC810 (anti-BTN1A1 Ab), a novel immune checkpoint with a mutually exclusive expression with PD-1/PD-L1, in patients with relapsed/refractory solid tumors Soohyeon Lee, MD PhD; Sangjoon Shin; Lynn Howie; Hyunjin Jung; Steven S. Yoo; David S. Hong, MD Clinical Trials In Progress Antibody;Checkpoint blockade;Clinical trial;Solid tumors
741 Poster Presentation First in humaun phase I trial of DT-9081, a selective EP4 receptor antagonist in patients with recurrent andor metastatic solids tumors Jean-Pierre Delord, MD; Christophe Le Tourneau, MD; Nuria Kotecki, MD; Patricia Zerr, PHD; Claire Jouffroy Zeller, Pharm D; Samira El Farouk, PhD; Asmaa AB. Boudribila, MD; Jean-Pascal Machiels, MD, PhD Clinical Trials In Progress Clinical study;Clinical trial;Solid tumors;Targeted therapy
742 Poster Presentation A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors    Bradley McGregor, MD; Toni K. Choueiri, MD; Neil J. Shah, MBBS; Aung Bajaj; Jad Chahoud; Bert O’Neil; Joel Michalski; Benjamin Garmezy; Lixian Jin, MD, MPH; Usman Aziz; Fiona Xu; Robert J. Motzer, MD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Solid tumors;Targeted therapy
743 Poster Presentation Pharmacokinetic and Pharmacodynamic Profile of a First-in-Human Study with MDNA11, an Engineered Long-Acting Beta-only IL-2 Agonist    Minh D. To, PhD; Nina Merchant; Melissa Coello; Carole Galligan; Kritika Mehta; Victoria G. Atkinson, MD; Martin Bexon, MD; Jim Coward; Jenny Lee; Charlotte R. Lemech, MBBS BSc(med) FRACP MD(res); Peter Lloyd; Jesus F. Antras; Arash Yavari; Fahar Merchant, PhD Clinical Trials In Progress Clinical trial;Cytokine;NK/NKT cell;T cell
744 Poster Presentation Interim single-agent safety and anti-tumor activity from dose escalation phase of ABILITY study on MDNA11, a long-acting beta-only IL-2 agonist.     Minh D. To, PhD; Fahar Merchant, PhD; Victoria G. Atkinson, MD; Martin Bexon, MD; Jim Coward; Jenny Lee; Charlotte R. Lemech, MBBS BSc(med) FRACP MD(res); Jesus F. Antras; Peter Lloyd; Arash Yavari; Melissa Coello; Nina Merchant Clinical Trials In Progress Clinical trial;Cytokine;Solid tumors
745 Poster Presentation IMP-MEL: A phase 1 first-in-human dose-finding study of a novel invariant natural killer T-cell agonist (iNKT) IMM60 in advanced melanoma and non-small-cell lung cancer (NSCLC) Nicholas Coupe, MD, PhD; Ian B. Walters, MD, MBA; Justin A. Fairchild, MPH; Matthew Parkes, PhD; David Thomspson; Robert A. Kramer, PhD; Uzi Gileadi, DPhil; Mark R. Middleton, MD, PhD Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;MDSC;Myeloid cells;NK/NKT cell;Solid tumors;Tumor microenvironment
746 Poster Presentation AFM24 and atezolizumab combination in patients with advanced epidermal growth factor receptor-expressing (EGFR+) solid tumors: Initial results from the Phase 1 dose-escalation study    Omar Saavedra Santa Gadea, MD, MSc; Daniela Morales-Espinosa; Juanita Lopez; Eric Christenson, MD; Anthony B. El-Khoueiry, MD; Andrés Cervantes; Christa Raab; Ulrike Gärtner; Kerstin Pietzko; Laura Kohlhas; Daniel Schütz; Gabriele Hintzen, PhD; Paulien Ravenstijn; Michael Emig; Pilar Nava-Parada Clinical Trials In Progress Antibody;Bispecifics;Checkpoint blockade;Clinical trial;NK/NKT cell;Solid tumors;Targeted therapy
747 Poster Presentation A Phase 1 Trial of IO-202, An Antagonist Antibody Targeting Myeloid Checkpoint LILRB4 (ILT3), as Monotherapy and in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors    Aung Naing, MD; John D. Powderly, II, MD; Meredith S. Pelster, MD, MSCI; Alexander I. Spira, MD, PhD, FACP; Reva E. Schneider, MD; Paul H. Woodard, MD; Luke E. Chung, MD; Elizabeth Wieland, MS; Sydney Ray, MS; Kyu Hong, MS; Tao Huang, PhD; X. Charlene Liao, PhD; Hong Xiang, PhD; Wen Hong WL. Lin, MD, MS; Heinz-Josef Lenz, MD, FACP Clinical Trials In Progress Clinical trial;Myeloid cells;Solid tumors
748 Poster Presentation A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors    Han Myint, MD, FRCPath, FRCP; Satish Shah, MD; Martin Gutierrez, MD; Emese Zsiros, MD, PhD; Megan M. Nelson, MS; Stephanie Zeidan, M.S.; Nadia Myrthil, MBA; Aaron Morawski; Alina Barbu, Ph.D.; Jahangheer S. Shaik, Ph.D.; Chelsea Zhou, PhD; Chrysi Kanellopoulou, Ph.D.; Ron Copeland, Ph.D.; Zachary Cusumano, Ph.D.; Dallas B. Flies, PhD; Solomon Langermann, PhD; Patricia Lorusso, MD; Kunle Odunsi, MD PhD Clinical Trials In Progress Antibody;Biomarkers;Clinical study;Clinical trial;Solid tumors
749 Poster Presentation Use of positron emission tomography for the diagnosis of immune checkpoint inhibitor myocarditis Nicolas L. Palaskas, MD; Yang Lu, MD; Rebecca Caldwell; Praise Oderinde; Gaspar Pina; Abdelrahman Ali; Khatera Shah; Cezar Iliescu; Syed Wamique Yusuf; Efstratios Koutroumpakis; Shaden Khalaf; Ihab Hamzeh; Bilal A. Siddiqui, MD; Sumit K. Subudhi, MD, PhD; Anita Deswal Clinical Trials In Progress Immune toxicity;Inflammation
750 Poster Presentation TWT-101: A First-In-Clinic, Phase 1/2 Study Of CFI-402411, a Hematopoietic Progenitor Kinase-1 (HPK1) Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies    Kyriakos P. Papadopoulos, MD; Siqing Fu, MD, PhD; Erika P. Hamilton, MD; Alexander I. Spira, MD, PhD, FACP; Scott Laurie, MD; Judy S. Wang, MD; Brigette Ma, MD; Anna Spreafico, MD PhD; Manish R. Sharma, MD; Quincy Chu, MD; Mark R. Bray; Glenn Michelson; Dih-Yih Chen; Linh Nguyen; Emily Roberts-Thomson, MMSc; Omid Hamid, MD Clinical Trials In Progress Clinical study;Clinical trial;Cytokine;Regulatory T cell (Treg cell);Targeted therapy
751 Poster Presentation PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME. Cheon Ho H. Park, PhD; Sang Soon Byun; Ki Dae Kim; Hye Rim Han; Weon Sup Lee Clinical Trials In Progress Adoptive immunotherapy;Antibody;Antigen presenting cells;Checkpoint blockade;Clinical study;MDSC;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
753 Poster Presentation A Phase 1b/2 Study of a Novel Anti-CTLA-4 NEObodyTM ADG116 Monotherapy and in Combination with Toripalimab (Tori; Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors    John Park, BSc(Med), MBBS, MPH, FRACP; Matthew NC. Hsien; Gary Richardson; Anthony W. Tolcher, MD; Hong Jae Chon; Sang Joon Shin; Ho Yeong Lim; Anis Hamid; Daneng Li, MD; Kristine Shi; Songmao Zheng; Guizhong Liu; Ai Li; Lvyu Zhu; Ruby Dai; Wei Peng; Dana D.H. Lowe, PhD; Peter Luo; Jiping Zha, MD, PhD Clinical Trials In Progress Antibody;Checkpoint blockade;Clinical study;Clinical trial
754 Poster Presentation A phase 1/2 study of ASP1570 in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapies Manish R. Patel, MD; David J. Park; Stefano Tarantolo; Afshin Dowlati; Daniel J. Olson, MD; Yuichiro Kaneko; Mei Tang; Serguei A. Soukharev; Masaomi Takizawa; Yohei Okada; Christine Fredericks; Derek Smith; Teresa Flegel; Tsubasa Watanabe; Sue Lee; Jason J. Luke, MD Clinical Trials In Progress Clinical study;Clinical trial;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
755 Poster Presentation Results of a Phase I trial of FT500, a first-in-class, off-the-shelf, iPSC‑derived NK cell therapy combined with PD-1/PD-L1 checkpoint blockade therapy and IL-2 in patients with advanced solid tumors Sandip P. Patel, MD; Manish R. Patel, DO; Martin Gutierrez, MD; Marlisa Anderson, MPH; Peter Szabo, MD, PhD; Bob Valamehr, PhD; Yu-Waye Chu, MD; Brandon Beagle, PhD; Jeffrey Chou, MD, PhD; David S. Hong, MD Clinical Trials In Progress Adoptive immunotherapy;Antibody;Checkpoint blockade;Clinical trial;Leukemia/Lymphoma;NK/NKT cell;Solid tumors
756 Poster Presentation INCLINE-101, A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in Patients with Select Advanced or Metastatic Solid Tumors Cesar A. Perez, MD; Jason Henry, M.D.; Timothy G. Humphries, MD; Sunnie Kim, MD; Adi Diab; Ons Harrabi, BA; Feng Jin, PhD; Hong I. Wan, PhD; Candy Bermingham, PhD; Anthony B. El-Khoueiry, MD Clinical Trials In Progress Antibody;B cell;Clinical study;Clinical trial;Solid tumors;TLR;Tumor infiltrating lymphocytes (TILs)
757 Poster Presentation A Phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with lorigerlimab in patients with advanced solid tumors (AST) John D. Powderly, II, MD; Patrick Kaminker, PhD; Enxu Zhao, MS; Denise Casey, MD; Eugene Shenderov, MD, PhD Clinical Trials In Progress Antibody;Checkpoint blockade;Clinical trial;Coinhibition;Solid tumors;Targeted therapy
758 Poster Presentation A Phase 1 Dose Escalation and Expansion Study of the anti-CD200R1 Antibody 23ME-00610 in Patients with Advanced Solid Malignancies Drew Rasco, MD; Albiruni R. Razak; Maike Schmidt, PhD; Sariah Kell; Dylan Glatt, PhD; Erin Belshaw; Sophia R. Majeed, PharmD, PhD; Shivaani Kummar, MBBS Clinical Trials In Progress Antibody;Checkpoint blockade;Clinical trial;Genetic polymorphism;Solid tumors;T cell
759 Poster Presentation Phase 1b study of LNS8801 in combination with pembrolizumab in patients with secondary resistance to immune checkpoint inhibitors Jordi Rodon; Marya F. Chaney, PhD; Justine V. Cohen, DO; Tina Garyantes; Jessica J. Lin, MD; Patricia Lorusso, MD; Alain Mita, MD; Monica Mita, MD; Carolyn Muller, MD; Christopher Natale, PhD; Marlana Orloff, MD; Kyriakos P. Papadopoulos, MD; Sapna P. Patel, MD Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical trial;Genetic polymorphism;Solid tumors;Targeted therapy
760 Poster Presentation A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors Benjamin L. Schlechter, MD; Daniel Olson, MD; Samuel Saibil, MD; Mridula George, MD; Riemke Bouvier; Jessica McKinley; Brooke Pieke, MS; Jill Geisburger; Nathan J. Ternus, BS; Kara Moss; Deyaa Adib, MD; Ecaterina E. Dumbrava, MD Clinical Trials In Progress CAR T cells;Clinical study;Cytokine;Solid tumors;T cell;Targeted therapy
761 Poster Presentation Pharmacokinetic and pharmacodynamic data from a Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumors    Randolph Noelle; Melissa L. Johnson, MD; Jordi Rodon; Marjorie Zauderer; Lionel Lewis; Mariano Severgnini; Jefferson Parker; Maureen Lane; Reinhard von Roemeling; Alex S. Martin; Michael Molloy; Robert E. Martell; Tong Dai Clinical Trials In Progress Antibody;Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Cytokine;Immune monitoring;Solid tumors
762 Poster Presentation First-in-human Phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR) George Simon, MD; Vivek Subbiah; Lee Rosen, MD; Heinz-Josef Lenz, MD; Haeseong Park, MD, MPH; Minesh Patel; David Miles; Stephanie Wallis; Vladimir Evilevitch; David Krige, PhD; Mark Powell; Tom Lillie Clinical Trials In Progress Clinical study;Cytokine;Solid tumors;T cell;Tumor microenvironment;Tumor stroma
763 Oral Presentation Phase 1/2 Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies: Initial Results From Dose Escalation  Diwakar Davar, MD; Morteza Aghmesheh, MD, GradDipSc, PhD, FRACP; Alain P. Algazi, MD; David Bajor, MD; Vinod Ganju, MBBS, FRACP; Douglas E. Laux, MD; Alexander I. Spira, MD, PhD, FACP; Elizabeth S. Ahern; Jaspreet S. Grewal, MD, PhD, MPH; Jamie Rand, MD; Randy F. Sweis, MD; Mette Kriegbaum, PhD; Jens-Jakob Karlsson, PhD; Yang Wu, PhD; Tuan-Anh Tran, PhD; Stina M. Singel, MD, PhD; Nashat Y. Gabrail, MD Clinical Trials In Progress Clinical study;Clinical trial;Solid tumors;TLR
764 Poster Presentation First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim Data Brian A. Van Tine, MD, PhD; Eugene Ahn, MD; John D. Powderly, II, MD; Herbert L. Duvivier, MD, JD; Drew Rasco; Rebecca A. Redman, MD; Steven F. Powell, MD; Agnes Rethy; Chris B. Moore, Ph.D.; Amy Yuet; Rachael M. Orlandella, PhD; Swati Khanna, Ph.D.; David R. Spigel, MD; Angela Georgy; Joseph D. Dekker, Ph.D. Clinical Trials In Progress Antibody;Checkpoint blockade;Clinical trial;Monocyte/Macrophage;T cell;Targeted therapy;Tumor microenvironment
766 Poster Presentation Phase I/II Evaluation of the Combination of Entinostat, M9241 and Bintrafusp Alfa in Patients with Advanced HPV Related Malignancies    Julius Strauss, MD; Charalampos Floudas, MD, DMSc, MS; Danielle Pastor, DO, Ph.D.; Jason M. Redman, MD; Deneise Francis, BSN, RN, OCN, CCRP; Elizabeth Lamping, RN; Lisa Cordes, PharmD, BCACP, BCOP; Jennifer L. Marte, MD, MPH; Renee N. Donahue, PhD; Caroline Jochems, MD, PhD; Sofia R. Gameiro, PharmD, PhD; Jeffrey Schlom, PhD; James L. Gulley, MD, PhD Clinical Trials In Progress Checkpoint blockade;Clinical study;Clinical trial;Solid tumors
767 Poster Presentation Safety and Preliminary Efficacy of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36&gamma; for Intratumoral (ITu) Injection, and durvalumab (IV) in TNBC, HNSCC, and Melanoma    Randy F. Sweis, MD; Daniel J. Olson, MD; Adil Daud, MD; Ronnie Shapira-Frommer, MD; Antonio Jimeno, MD, PhD; Patrick Reagan, MD; Shivaani Kummar, MBBS; Raghad Abdul-Karim, M.D.; Salomon Stemmer; Meredith McKean, MD; Ravit Geva, MD; Ruth Perets, MD, PhD; Manish R. Patel, MD; Thomas U. Marron, MD, PhD; Shilpa Gupta; Anupam Desai, M.D.; Jeffrey S. Weber, MD, PhD; Kim A. Margolin, MD, FACP, FASCO; Jong Chul Park, MD; Sima Zacharek, PhD; Andressa Sodre Laino, PhD; Joshua Frederick; Oleg Milberg; Lili Zhu; Kinjal Mody; Natalia Lopez; Praveen Aanur, MD; Robert S. Meehan, MD; Lisa Johansen; Sara Lavoie; Khanh T. Do, MD; Ryan J. Sullivan, MD Clinical Trials In Progress Biomarkers;Checkpoint blockade;Clinical trial;Costimulation;Cytokine;Inflammation;Solid tumors;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
768 Poster Presentation Peripheral pharmacodynamic (PD) effects of ociperlimab (OCI) in combination with tislelizumab (TIS) in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study Wei Tan; Yang Shi; Han Yan; Zhirong Shen; Nageshwar Budha; Ahsan Rizwan; Ruiqi Huang; Hao Zheng; Rang Gao; Sophia Frentzas; Steven Kao; Tarek Meniawy; Yun Zhang Clinical Trials In Progress Biomarkers;Checkpoint blockade;Chemokine;Clinical study;Cytokine;Regulatory T cell (Treg cell);Solid tumors;Tumor evasion
769 Poster Presentation Results from an ongoing open-label, multicenter, phase 1 trial of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors    Emil deGoma, MD; Gonzalo Tapia-Rico; Joanne Lundy, MBBS FRACP; Gary Richardson; Niky Zhao; Karen Ebsworth; Huibin Yue; Shichiang Miao; Rita Jain; Thomas Schall; Kathleen Sullivan; Penglie Zhang; Paul de Souza, MBBS, MPH, PHD, FRACP Clinical Trials In Progress Checkpoint blockade;Clinical study;Clinical trial;Cytokine;Solid tumors;T cell
770 Poster Presentation Safety, efficacy, and pharmacokinetic results from a phase I first-in-human study of ABBV-151 with or without anti-PD1 mAb (budigalimab) in patients with locally advanced or metastatic solid tumors Anthony W. Tolcher, MD; Desamparados Roda-Perez; Kai He, MD, PhD; Victor Moreno, MD, PhD; Carlos Gomez-Roca, MD; Jean-Pascal Machiels, MD, PhD; Albiruni R. Razak; Mohammad Sahtout; Xiaowen Guan; Stacy Jaryno-Daly; Rachel Leibman; Martha E. Blaney, PharmD; James P. O'Brien, MD; Patricia Lorusso, MD; John D. Powderly, II, MD; Talia Golan; Kathy Miller, MD; Jordi Bruix Clinical Trials In Progress Antibody;Clinical trial;Cytokine;Regulatory T cell (Treg cell);Solid tumors
771 Poster Presentation A phase 1, first in human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors    Lei Chen, MD; Anthony W. Tolcher, MD; Nashat Y. Gabrail, MD; Minal A. Barve, MD; Xiaohua Wu; Jian Zhang; Michael Shi, MD; Chuan Qi, MD; Steven Yu, PhD; Jenny Yao; Jianming Wang; Christopher T. Cavanaugh Clinical Trials In Progress Antibody;Bispecifics;Checkpoint blockade;Clinical trial;Immune suppression;Solid tumors
772 Poster Presentation  A Phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01) Manish R. Sharma, MD; Deanne Lathers, PhD; Melissa L. Johnson, MD; Jason J. Luke, MD; Igor Puzanov, MD, MSCI, FACP; Brendan D. Curti, MD; Christopher Chen; Anthony B. El-Khoueiry, MD; Brian S. Henick; Margaret K. Callahan, MD, PhD; Mario Sznol, MD; Sandip P. Patel, MD; Dawn Wilson; Melissa Ricker; Lizhi Cao; Pushpa Jayaraman; Jenny Che; Li Peng, PhD; David Feltquate; Anthony W. Tolcher, MD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Glycoproteomics;Immune suppression;Solid tumors;T cell
773 Poster Presentation A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of an Anti-CTLA-4 NEOBodyTM ADG116 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors: A Preliminary Update    Anthony W. Tolcher, MD; John D. Powderly, II, MD; Kristine Shi; Songmao Zheng; Guizhong Liu; Jin Shang; Xinwei Wang; Wenda Li; Dana D.H. Lowe, PhD; Michael Chisamore; Peter Luo; Jiping Zha, MD, PhD Clinical Trials In Progress Antibody;Checkpoint blockade;Clinical study;Clinical trial
774 Poster Presentation A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors Christophe Le Tourneau, MD; Sarina A. Piha-Paul, MD; Hans Prenen; Brant Delafontaine; David J. Pinato, MD, MRes, PhD; Armando Santoro, MD, PhD; Rebecca Kristeleit, MD PhD; Kristen R. Spencer, DO, MPH; Tara C. Gangadhar, MD; Howard Burris, III; Nuria Kotecki, MD; Bristi Basu; Donna M. Graham; Anna Maria Di Giacomo; Solmaz Sahebjam, MD; Massimo Di Nicola; Carlos Gomez-Roca, MD; Pascale Tomasini; Paolo A. Ascierto, MD; Giuseppe Curigliano, MD, PhD; Thomas Karasic; Ryan Geschwindt, BS; Jeannie Daniel; Eric Van Cutsem, MD, PhD Clinical Trials In Progress Checkpoint blockade;Clinical trial;Solid tumors;T cell;Targeted therapy
775 Poster Presentation Initial results from dose escalation of a phase 1/2 first-in-human, open label study of AU-007, a monoclonal antibody that binds to IL-2 and prevents its binding to CD25, in patients with solid tumors    James R. Vasselli, MD; Paul de Souza, MBBS, MPH, PHD, FRACP; Sophia Frentzas; Andrew Weickhardt, MD; Timothy L. Wyant, PhD; Jenny Tang, MS; Lori Richards; Aron Knickerbocker, B.Sc., M.B.A.; Inbar Amit; Yanay Ofran, Ph.D. Clinical Trials In Progress Adoptive immunotherapy;Antibody;Clinical study;Clinical trial;Costimulation;Cytokine;Immune contexture;Solid tumors;T cell;Targeted therapy
776 Poster Presentation ITIL-306-201: A multicenter, first-in-human phase 1a/1b study of ITIL-306, an engineered autologous tumor-infiltrating lymphocyte (TIL) cell therapy product, in adults with advanced solid tumor Jeffrey P. Ward, MD Ph.D.; Armin Ghobadi, MD; John B. Liao, MD, PhD; Adam Schoenfeld; Scott S. Tykodi; Yizhou Jiang, PhD; John Le Gall, MD, MBA; Ruben Alvarez-Rodriguez; Marika Sherman; Tiffany Singson; Jeffrey McLeroy Clinical Trials In Progress Clinical study;Clinical trial;Costimulation;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
777 Poster Presentation Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignancies Sarah Whelan, PhD; Christopher Karim; Jordan Ye; Timothy Ingallinera; Ganesh Cherala; Katherine Jameson; Anja Williams; Adam Sharp; Matthew G. Krebs, MD, PhD; Simon Pacey; Sarah P. Blagden; Ruth Plummer; Daniel Hochhauser; Jeff Evans; Johann De Bono; Janine Powers Clinical Trials In Progress Biomarkers;Chemokine;Clinical study;Clinical trial;Cytokine;Solid tumors;T cell
778 Oral Presentation Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in 'cold' and I-O refractory metastatic solid tumors   Breelyn A. Wilky, MD; Anthony B. El-Khoueiry, MD; Andrea J. Bullock, MD; Apostolia M. Tsimberidou, MD; Daruka Mahadevan, MD, PhD; Kim A. Margolin, MD, FACP, FASCO; Jonathan C. Trent, MD, PhD; Bruno Bockorny, MD; Justin C. Moser, MD; Peter J. Hosein, MD; Marwan G. Fakih, MD; Benjamin L. Schlecter, MD; Jacob S. Thomas, MD; Ani S. Balmanoukian, MD; Rachel E. Sanborn, MD; Ghassan K. Abou-Alfa, MD; Gary K. Schwartz, MD; Diana L. Hanna, MD; Waldo Ortuzar Feliu, MD; Joseph E. Grossman, MD; Katherine Rosenthal, RN, MSN, OCN, CCRP; James L. Godwin, MD; Jaymin M. Patel, MD; Bonnie L. Bullock, PhD; Justin Stebbing, MD, PhD, FRCP, FRCPath; Bhupendra Rawal, MS, MS; Hunter Cole, MPH; Chloe Delepine, MEng, MS; Jacky Chow, PhD, MS; Ross C. Walker, PhD, MS; Chris MacDermaid, PhD; Dhan Chand, PhD; Michael S. Gordon, MD; Heinz-Josef Lenz, MD, FACP; Steven J. O'Day, MD Clinical Trials In Progress Antibody;Antigen presenting cells;Checkpoint blockade;Clinical study;Clinical trial;Coinhibition;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;T cell
779 Poster Presentation A Phase I, Dose Escalation and Expansion Study of PT199, a Next Generation CD73 Monoclonal Antibody, Administered Alone and in Combination with a PD-1 Inhibitor in Adult Patients with Advanced Solid Tumors    Ramzi Melhem, MD; Harold M. Wright, PhD; Hui Zou, PhD; Claudia Ramos; Jack Li, PhD; Ming Wang, PhD Clinical Trials In Progress Antibody;Checkpoint blockade;Clinical trial;Coinhibition;Solid tumors;Tumor microenvironment
780 Poster Presentation SRK-181, a latent TGFβ1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors    Timothy A. Yap, MD; Justin F. Gainor, MD; Meredith McKean, MD; Melissa Johnson, MD; Bruno Bockorny, MD; Minal A. Barve, MD; Randy F. Sweis, MD; Ulka Vaishampayan, MD; Ahmad A. Tarhini, MD, PhD, MS; Deepak Kilari; Yawen Ju; Si-Tuen Lee-Hoeflich; Stephen DeWall; Lan Liu; Nisha Shah; Ann Marie Kennedy; Lu Gan, MD, PhD Clinical Trials In Progress Clinical study
781 Poster Presentation DELTA-2: A phase 1, open-label, multicenter study of ITIL-168, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, with pembrolizumab in patients with advanced solid tumors Oladapo Yeku, MD, PhD; Daniel Olson, MD; Jeffrey P. Ward, MD Ph.D.; Sandip P. Patel, MD; Jeff Aycock, BSc; Amber C. Donahue; Yizhou Jiang, PhD; John Le Gall, MD, MBA; Zachary J. Roberts, MD, PhD; Rubén Alvarez-Rodríguez; Judy Seng; Tong Shen; Nishi Kothari Clinical Trials In Progress Adoptive immunotherapy;Clinical study;Clinical trial;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
782 Oral Presentation Intratumoral sotigalimab with pembrolizumab activates antigen-presenting cells and induces local and distant anti-tumor responses in first-line metastatic melanoma: Results of a phase I/II study    Salah-Eddine Bentebibel, PhD; Daniel H. Johnson, MD; Barbara M. Pazdrak; Daniel J. McGrail, PhD; Srisuda Lecagoonporn, PhD DPharm; Cara Haymaker; Dzifa Y Duose; Khalida Wani, PhD; Heather Sonnemann; Houssein Safa, MD; Jared K Burks; Patrick Hwu; Cho Sungnam; Chantale Bernatchez, PhD; Suhendan Ekmekcioglu, PhD; Gregory Lizée; Adi Diab Clinical Trials In Progress Antibody;Antigen presenting cells;B cell;Biomarkers;Checkpoint blockade;Clinical trial;Dendritic cell;Immune monitoring;Solid tumors
783 Poster Presentation Trial in progress: A phase 1/2 open-label study (IOV-GM1-201) of TALEN-mediated PD-1-inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC Allison Betof, MD, PhD; Trisha M. Wise-Draper, MD, PhD; Kai He, MD, PhD; Amod A. Sarnaik, MD, FACS; Jonathan R. Thompson, MD; Friedrich G. Finckenstein, MD; Parameswaran Hari; Madan Jagasia; Anjali Desai; Akiko Suzuki; Xiao Wu; Jason A. Chesney, MD, PhD Clinical Trials In Progress Adoptive immunotherapy;Checkpoint blockade;Clinical trial;Neoantigens;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
784 Poster Presentation Immune profiling of patients with advanced Melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies - results of a Phase I trial expansion Paula L. Codó, Dr.Sc.Nat.; Marina Gonzalez; Peter Wengenmayer; Igor Samoylenko, MD. PhD; Sebastian Ochsenreither, P.D. Dr.; Erika Richtig, MD; Ioannis Thomas, MD; Michael Erdmann, MD; Celeste Lebbe, MD, PhD; Juan Martin-Liberal, MD PHD; Patrick Terheyden, P.D. Dr. med.; Artem Poltoratskiy, MD; Marina Sekacheva, MD; Yuliya Semiletova, MD; Thomas Eigentler, MD; Beate Schmitt-Bormann, Dr.; Dominik Vahrenhorst; Sarah-Katharina Kays, PhD; Tobias Seibel, II, PhD; Gianluca Quintini, PhD; Birgit Scheel, Dr.; Martin H. Falk, MD PhD; Ulrike Gnad-Vogt, Dr. med. Clinical Trials In Progress Biomarkers;Clinical study;Clinical trial;Gene expression;Immune monitoring;RNA;Solid tumors;TLR;Tumor microenvironment
785 Poster Presentation A phase I study of intralymphatic (IL) administration of ipilimumab (IPI) with intravenous nivolumab (NIVO) using the Sofusa DoseConnect&trade; device in patients with advanced melanoma.    Anastasios Dimou, MD; Vera Suman; Kristina Denic; Lisa Kottschade; Heather Montane; Heidi D. Finnes; Kristina Franta; Jill Schimke; Yiyi Yan; Robert McWilliams; Matthew Block; James Jakub; Joel Reid; Svetomir N. Markovic, MD, PhD Clinical Trials In Progress Clinical study;Immune toxicity
786 Poster Presentation Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from ongoing expansion part in study 008     Thomas Eigentler, MD; Igor Samoylenko, MD, PhD; Sebastian Ochsenreither, P.D. Dr.; Erika Richtig, MD; Ioannis Thomas, MD; Michael Erdmann, MD; Celeste Lebbe, MD, PhD; Juan José Soto-Castillo, MD; Patrick Terheyden, P.D. Dr. med.; Artem Poltoratskiy, MD; Marina Sekacheva, MD; Yuliya Semiletova, MD; Janina Henze, Dr.; Beate Schmitt-Bormann, Dr.; Paula L. Codó, Dr.Sc.Nat.; Martin H. Falk, MD PhD; Ulrike Gnad-Vogt, Dr. med. Clinical Trials In Progress Clinical study;Clinical trial;RNA;Solid tumors;TLR
787 Poster Presentation DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma Brian Gastman, MD; Amod A. Sarnaik, MD, FACS; Donald P. Lawrence, MD; Anthony Olszanski, MD, RhP; Bartosz Chmielowski, MD, PhD; Jose Lutzky, MD; Marcus O. Butler, MD; Omid Hamid, MD; Pippa Corrie, PhD, FRCP; Evidio Domingo-Musibay, MD; Sajeve S. Thomas, MD; Fiona Thistlethwaite, MD, PhD; Gregory A. Daniels, MD, PhD; Thomas R.J. Evans, MD, MBBS, FRCP; Andrew J.S. Furness, MD PhD; Geoffrey Gibney, MD; Mark Harries, MA, FRCP, PhD; Theresa M. Medina, MD; Daniel Olson, MD; Lalit Pallan, MBchB, PhD; Eric D. Whitman, MD, FACS; Melissa Wilson, MD, PhD; Jeff Aycock, BSc; Robert E. Hawkins, MBBS, PhD, FRCP; Yizhou Jiang, PhD; Audrey Kennedy, BSc; Paul B. Robbins, PhD; Zachary J. Roberts, MD, PhD; John Le Gall, MD, MBA Clinical Trials In Progress Adoptive immunotherapy;Clinical study;Clinical trial;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
788 Poster Presentation A Phase 1b study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of neoadjuvant use of PH-762 administered intratumorally in subjects with advanced melanoma    Simon P. Fricker, PhD; Caroline Robert, MD, PhD; François-Xavier Danloss, MD; Emilie Routier, MD; Benjamin Cuiffo, PhD; James Cardia, PhD Clinical Trials In Progress Checkpoint blockade;Clinical trial;RNA;Solid tumors;Surgery;Tumor microenvironment
789 Oral Presentation Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study) Amod A. Sarnaik, MD, FACS; Karl D. Lewis, MD; Harriet Kluger, MD; Omid Hamid, MD; Eric D. Whitman, MD, FACS; Sajeve S. Thomas, MD; Martin Wermke, MD; Mike Cusnir, MD; Evidio Domingo-Musibay, MD; Giao Q. Phan, MD; John M. Kirkwood, MD; Jessica C. Hassel; Marlana Orloff, MD; James Larkin, MD; Jeffrey S. Weber, MD, PhD; Andrew J.S. Furness, MD PhD; Nikhil I. Khushalani, MD; Theresa M. Medina, MD; Friedrich G. Finckenstein, MD; Madan Jagasia; Parameswaran Hari; Giri Sulur; Wen Shi, MD, PhD; Xiao Wu; Jason A. Chesney, MD, PhD Clinical Trials In Progress Adoptive immunotherapy;Clinical study;Clinical trial;Neoantigens;Solid tumors;Tumor infiltrating lymphocytes (TILs)
790 Oral Presentation Phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and AS01B in combination with intravenously administered nivolumab Jens Tijtgat, MD; Julia Katharina Schwarze, MD, MSc; An-Sofie Vander Mijnsbrugge, MD; Steven Raeymaeckers, MD, PhD; Ivan Van Riet, PhD; Xenia Geeraerts, PhD; Latoya Stevens, PhD; Sandra Tuyaerts, PhD; Bart Neyns, MD, PhD Clinical Trials In Progress Antigen presenting cells;Checkpoint blockade;Clinical study;Clinical trial;Dendritic cell;Immune adjuvant;Solid tumors;Vaccine
791 Poster Presentation Immune checkpoint blockade enhances Cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model Mariam M. George, PhD; Allison Betof, MD, PhD; Taha Merghoub, PhD; Linda Hamadene, MD; Daniel Hirschhorn; Alan N. Houghton, MD; Jedd D. Wolchok, MD PhD Combination Immunotherapies Checkpoint blockade;Chemotherapy
792 Poster Presentation Natural killer T cell immunotherapy combined with fusogenic oncolytic virus and PD-1 blockade enhances survival in a mouse model of spontaneous lung adenocarcinoma    Jordan D. Lukacs, BSc Combination Immunotherapies Adoptive immunotherapy;Carcinogenesis;Checkpoint blockade;NK/NKT cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
793 Poster Presentation Treatment of anti-SIRPα in combination with anti-TAA exerts superior anti-tumor activity Xiaofeng Niu, PhD; Chunnian Wang, PhD; Jinfeng Zhao; Haiying Wang; Li Zhang; Jiahui Hu; Jingfeng Yu; Yefeng Lu; Xiaoli Guo; Haixia Jiang; Rui Gao, PhD; Zhihao Wu, PhD; Yangsheng Qiu, PhD; Quan Qiu, PhD; Zheng Song, PhD; Dawei Sun, PhD; Hongtao Lu, PhD Combination Immunotherapies Antibody;Antigen presenting cells;Checkpoint blockade;Dendritic cell;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors
794 Poster Presentation TKM-011, Anti-CD20 Antibody Confers Multi-Properties Against Burkitt's Lymphoma in Comparable Efficacy to Rituximab and Obinutuzumab    Jutatip Panaampon, PhD; Seiji Okada, MD, PhD Combination Immunotherapies Antibody;Monocyte/Macrophage;NK/NKT cell
795 Poster Presentation STAT3 signaling as a checkpoint for TLR9-driven epigenetic reprogramming of acute myeloid leukemia into antigen-presenting cells     Dongfang Wang, PhD; Priyanka Duttagupta, PhD; Yu-Lin Su, PhD; Haiqing Li; Mingye Feng; Bin Zhang; Ya-Huei Kuo; Guido Marcucci, MD; Marcin Kortylewski, PhD Combination Immunotherapies Leukemia/Lymphoma;Myeloid cells;TLR;Tumor evasion
796 Poster Presentation Repurposing NSAIDs for cancer immunotherapy: mechanisms beyond COX inhibition Gang Zhou, PhD; Nada S. Aboelella; Md Ye. Gazi; Gary A. Piazza Combination Immunotherapies Adoptive immunotherapy;CAR T cells;Checkpoint blockade;Chemotherapy;Inflammation;Myeloid cells;T cell;Tumor microenvironment
797 Poster Presentation Real-world treatment duration of atezolizumab+carboplatin+etoposide among older patients with extensive-stage small cell lung cancer (ES-SCLC) and the impact of performance status and brain metastases Husam Albarmawi, PhD; Scott Robinson, MPH, MA; Kevin Dietz; Kris Norris; Nindhana Paranthaman, MD; Sarika Ogale, PhD; Taylor T. Schwartz, MPH Combination Immunotherapies Solid tumors
798 Poster Presentation Real-World Overall Survival among Patients Receiving First-Line (1L) Pembrolizumab in the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the United States Christopher M. Black, PhD; Liya Wang; Karthik Ramakrishnan; Gleicy Hair; Daisuke Goto Combination Immunotherapies Checkpoint blockade;Chemotherapy;Solid tumors
799 Poster Presentation Real-World Use of Pembrolizumab Combination Regimens in First-Line Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma  Christopher M. Black, PhD; Liya Wang; Karthik Ramakrishnan; Daisuke Goto Combination Immunotherapies Checkpoint blockade;Chemotherapy;Solid tumors
800 Poster Presentation Clinicopathological and molecular predictive factors of survival in non-small cell lung cancer patients treated with first-line immunotherapy with or without chemotherapy: a systematic review and meta-analysis    Alessandro Di Federico, MD; Francesco Gelsomino; Andrea De Giglio, MD; Francesca Sperandi; Barbara Melotti; Andrea Ardizzoni Combination Immunotherapies Biomarkers;Checkpoint blockade;Chemotherapy;Clinical study;Clinical trial
801 Poster Presentation The anti-tumor efficacy of immunogenic chemotherapy is enhanced by the dual A2aR/A2bR antagonist etrumadenant, relieving the necessity for an extended chemotherapy regimen Daniel DiRenzo; Dana Piovesan, MSc; Ferdie Soriano, BS; Livia Yamashiro; Janine Kline; Dillon H. Miles, PhD; Ehesan Sharif; Manmohan R. Leleti; Matthew Walters Combination Immunotherapies Chemotherapy;Immune suppression;Tumor microenvironment
802 Poster Presentation Eliciting calreticulin-mediated 'eat me' phagocytic signal is additive/synergistic with CD47 blockade in enhancing tumor associated macrophage phagocytosis of tumor cells and deceasing xenograft tumor growth in Ewing sarcoma    Wen Luo, PhD; Mitchell S. Cairo; Janet Ayello, MS, MT(ASCP); Timothy P. Cripe; Kevin A. Cassady; Hai Hoang Combination Immunotherapies Antibody;Chemotherapy;Monocyte/Macrophage;Pediatric tumors;Solid tumors;Tumor microenvironment
803 Poster Presentation Enhhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-tocopheryloxacetic acid-lysine Emmanuel T. Akporiaye, Ph.D.; William L. Redmond, Ph.D.; Melissa Kasiewicz, B.S. Combination Immunotherapies Chemotherapy;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
804 Poster Presentation Novel AI-derived approach to identify Lomitapide as an anticancer agent inducing autophagic cell death in colorectal cancer Seung Ju Park; Seulgi Lee; Boah Lee Combination Immunotherapies Bioinformatics;Checkpoint blockade;Chemotherapy;Coinhibition;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
805 Poster Presentation Multiple combinational strategies of immunotherapy for urothelial carcinoma in one institution    Jo-Pai Chen, MD; Sung-Hsin Kuo, MD PhD; Wei-Chen Lu Combination Immunotherapies Checkpoint blockade
807 Poster Presentation Selective depletion of tumor-specific regulatory T cells in combination with low dose chemotherapy with or without PD-1 blockade improves anti-tumor T cell responses in solid tumors    Dorothèe Saddier Axe; Michelle R. Kuhne, PhD; Renu Jain, PhD; Brian M. Weist, PhD Combination Immunotherapies Antibody;Checkpoint blockade;Chemokine;Chemotherapy;Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
808 Poster Presentation Blocking 'don't-eat-me' signal of CD47-SIRPα by anti-SIRP&alpha; antibody enhances anti-tumor efficacy of trastuzumab deruxtecan Mayumi Sue, PhD; Takuya Tsubaki, PhD; Yoko Ishimoto; Shinko Hayashi; Saori Ishida; Yoshitaka Isumi, PhD; Jun Ishiguro, PhD; Reimi Kawaida; Toshiaki Ohtsuka; Teiji Wada, PhD; Toshinori Agatsuma, PhD; Norihito Kawasaki, PhD Combination Immunotherapies Antibody;Antigen presenting cells;Checkpoint blockade;Chemotherapy;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy
809 Poster Presentation Anti-CLDN18.2 antibody ZL-1211 enhances anti-tumor activities in combination with chemotherapy in gastric cancer models    Anthony Cao, PhD; Qiuping Ye, PhD; Karl Hsu, MD; Hua Gong; Jiaqing Yi, PhD; Haiying Zhou, PhD; Xinyan Tang, PhD Combination Immunotherapies Antibody;Chemotherapy;NK/NKT cell;Solid tumors;Tumor antigens
810 Poster Presentation Novel Renal Cell Carcinoma Immunotherapy Combining TLR9-Targeted STAT3 Antisense Oligonucleotide with PD-1 blockade     Marice Alcantara, PhD; Alexander Chehrazi-Raffle, MD; Nazli Dizman, MD; Wilson Tang, BS; Luis Meza, MD; Zeynep Zengin, MD; Dongfang Wang, PhD; Dayson Moreira, PhD; Alan Horsager, PhD; JoAnn Hsu, BS; Sumanta Pal, MD; Marcin Kortylewski, PhD Combination Immunotherapies Checkpoint blockade;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
811 Poster Presentation PD1 and LAG3 synergize on CD8+ T cells to hinder IFN&gamma;-dependent anti-tumor immunity Lawrence P. Andrews, PhD; Carly Cardello; Jian Cui, PhD; Creg Workman, PhD; Dario A. Vignali, PhD Combination Immunotherapies Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs)
812 Poster Presentation Development of BCMA-targeted immunotherapy using vaccine-induced antigen-specific memory CD8+ T cells for treating patients with multiple myeloma    Jooeun Bae; Derin Keskin, Ph.D.; Yueyi Huang, M.S.; Sean Rowell, BS; Sarah Nikiforow; Gerry MacDonald; Jerome Ritz; Nikhil Munshi; Kenneth Anderson Combination Immunotherapies T cell
813 Poster Presentation Cancer vaccine triple synergistic combination immunotherapy enhances anti-cancer efficacy Jay A. Berzofsky, MD, PhD; William Becker, Ph.D.; Purevdorj B. Olkhanud, M.D., Ph.D. Combination Immunotherapies Checkpoint blockade;Coinhibition;Costimulation;Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine
814 Poster Presentation DT-9081, a selective EP4 receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models    Anne-Laure Blayo, PhD; Claire Jouffroy-Zeller; Nathalie Lenne; Imane Nafia; Patricia Zerr; Stéphan Schann, PhD; Xavier Leroy, PhD Combination Immunotherapies Checkpoint blockade;Coinhibition;Immune suppression;Solid tumors;T cell;Tumor microenvironment
815 Poster Presentation CRB-601, a selective integrin avβ8 blocking antibody, exhibits potent anti-tumor activity in anti-PD-1 resistant models  Daqing Wang, Ph.D; Vaishali Shinde; Maneesh Singh, Ph.D; Rachael Brake, Ph.D; Andrew Kolodziej, Ph.D Combination Immunotherapies Antibody;Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
816 Poster Presentation Blockade of SIRPα on macrophages to enhance CAR T activity against glioblastoma Rebecca M. Brock, PhD; Alesandra S. Echeandia-Marrero; Matthew Dysthe, B.S.; Robin Parihar, MD, PhD; Nabil Ahmed, MD, MPH; Meenakshi Hegde, MD Combination Immunotherapies Antibody;CAR T cells;Checkpoint blockade;Monocyte/Macrophage;Tumor microenvironment
817 Poster Presentation Engineered toxin body targeting CTLA-4 (MT-8421) depletes Tregs in the tumor microenvironment and synergizes with αPD-1 to enhance T cell immunity  Lauren R. Byrne; Swati Khanna, Ph.D.; Rebecca Martin, Ph.D.; Caleigh Howard; Lilia A. Rabia, Ph.D.; Michaela M. Sousares; Jay Zhao, Ph.D.; John Majercak, Ph.D.; Eric Poma, Ph.D.; Chris B. Moore, Ph.D. Combination Immunotherapies Antibody;Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
818 Poster Presentation Combination therapy with anti-PD1 and anti-LAG3 leads to unique peripheral and intratumoral CD8+ T cells signatures in patients with metastatic melanoma    Anthony R. Cillo, PhD; Carly Cardello; Lilit Karapetyan; Feng Shan, MS; Cindy Sander, BS; Elizabeth Rush, BS; Aofei Li; Arivarasan Karunamurthy, MD; Sheryl R. Kunning; John M. Kirkwood, MD; Tullia Bruno, PhD; Dario A. Vignali, PhD Combination Immunotherapies Bioinformatics;Biomarkers;Checkpoint blockade;Gene expression;Systems biology;T cell;Tumor microenvironment
819 Poster Presentation Intratumoral administration of High-Concentration Nitric Oxide and Anti PD-1 treatment leads to higher tumor regression rates and prolonged survival in CT26 tumor-bearing mice Hila Confino; David Greenberg, Prof.,MD; Selena Chaisson; Jedidiah Mercer Monson, MD; Steve Lisi; Amir Avniel; Ido Wolf, MD. PhD; Yana Epshtein Combination Immunotherapies Adoptive immunotherapy;B cell;Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
820 Poster Presentation Linear DNA amplicons as a novel antiviral and cancer vaccine strategy Luigi Aurisicchio, PhD; Antonella Conforti; Mirco Compagnone; Erika Salvatori; Lucia Lione; Eleonora Pinto; Clay Shorrock; James Hayward; Brian Viscount; Fabio Palombo; Yuhua Sun; Ben Minghwa Liang Combination Immunotherapies Neoantigens;Tumor antigens;Vaccine
821 Poster Presentation The potential clinical usage of Fc-optimized anti-CCR8 therapeutic antibodies as a monotherapy or combined with other promising immune-modulating agents beyond PD-1/L1    Shuang Dai; Weifeng Huang; Longjun Yan; Shaogang Peng; Shihui Zhou; Zhijun Yuan; Chao Wang; Chuan-Chu Chou, PhD; Andy Tsun; Tianhang Zhai Combination Immunotherapies Antibody;Bispecifics;Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
822 Poster Presentation Overcoming the suppressive tumor microenvironment with a live bacterial immunotherapy    Andrew C. Scott, PhD; Matthieu Besneux, PhD; Oluwatobiloba Oke; Mary Chol; Claudia Prevosto, PhD; Nicholas Glanville, PhD; Livija Deban, PhD Combination Immunotherapies Checkpoint blockade;Dendritic cell;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;TLR;Tumor microenvironment
823 Poster Presentation IMM20059, a novel anti-EPN1 antibody, in combination with Atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy John P. Dowling; John P. Dowling, PhD; Pavel A. Nikitin; Cezary R. Swider; Chris Nicolescu; Halley Shukla; Jamie L. Bingaman-Steele; Nirja B. Patel; Eden L. Sikorski; Benjamin C. Harman; Jillian M. DiMuzio; Karen Lundgren; Yumi Ohtani; Michael J. Morin; Matthew K. Robinson; Fang Shen Combination Immunotherapies Antibody;B cell;Checkpoint blockade;Chemokine;Solid tumors;Tumor microenvironment
824 Poster Presentation NX-1607, a small molecule inhibitor of the CBL-B E3 ubiquitin ligase, promotes T and NK cell activation and enhances NK-mediated ADCC in a mouse lymphoma tumor model    Marilena Gallotta, PhD; Jennifa Gosling; Austin Tenn-McClellan; Serena Ranucci; Jose Gomez Romo; Frederick Cohen; Gwenn M. Hansen, PhD; Arthur T. Sands, MD PhD; Cristiana Guiducci; Ryan Rountree, PhD Combination Immunotherapies Leukemia/Lymphoma;NK/NKT cell;Regulatory T cell (Treg cell);T cell
826 Poster Presentation IL7R TME expression correlates with immunotherapy response and is associated with T-cell stemness with decreased apoptosis Nicolas Poirier; Isabelle Girault, MD; Aurore Morello, PhD; Justine Durand; Margaux Seite Combination Immunotherapies Bioinformatics;Cytokine;Immune monitoring;T cell
827 Poster Presentation The Role of Combination Immune Checkpoint Inhibitors as Salvage Therapy for PD-1/PD-L1-resistant Merkel Cell Carcinoma     Tarek Haykal, MD; Georgia Beasley, MD, MHSc; April Salama, MD; Brent Hanks, MD, PhD Combination Immunotherapies Checkpoint blockade;Clinical study;Immune adjuvant;Solid tumors
828 Poster Presentation Combination of Flt3L and STING agonism sensitizes non-T cell-inflamed tumors to checkpoint blockade therapy Emily F. Higgs, PhD; Thomas F. Gajewski, MD, PhD Combination Immunotherapies Antigen presenting cells;Dendritic cell;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs)
829 Poster Presentation In situ vaccination utilizing intratumoral electroporation of plasmids expressing IL-12 and CD40 ligand (CD154) has efficacy against murine tumors. Gregory W. Ho, BA; Steven Fiering, BS, MS, PhD Combination Immunotherapies Cytokine;Solid tumors;Targeted therapy;Tumor microenvironment
830 Poster Presentation Targeting B cell Suppression to Improve the Efficacy of Immunotherapies in Brain Cancer David Hou, BA; Brandyn Castro, MD; Andrew Zolp; Mark Dapash, MD; Victor A. Arrieta, MD, PhD; Jana Biermann, PhD; Johannes C. Melms, PhD; Maciej S. Lesniak, MD; Benjamin Izar, MD, PhD; Jason M. Miska, PhD; Junfei Zhao, PhD; Catalina Lee-Chang, PhD Combination Immunotherapies B cell;Checkpoint blockade;Immune suppression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
831 Poster Presentation Targeting tumor oxidative metabolism to overcome hypoxia-induced immunotherapy resistance in prostate cancer Priyamvada Jayaprakash, PhD; Michael A. Curran, PhD; Brittany A. Morrow, BS; Joseph R. Marszalek; Krithikaa Rajkumar Bhanu; Meghan Rice; Jason P. Gay; Christopher P. Vellano; Benjamin Cowen; Dean J. Welsch, PhD Combination Immunotherapies Checkpoint blockade;Immune suppression;MDSC;Metabolism;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
832 Poster Presentation Antigen spread mediated by oncolytic adenovirus Delta-24-RGDOX during intratumoral adoptive T cell therapy in immunocompetent mice with disseminated tumors    Hong Jiang, PhD Combination Immunotherapies Adoptive immunotherapy;CAR T cells;Immune suppression;Inflammation;Solid tumors;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
833 Poster Presentation Blockade of human LILRB4/ILT3 inhibits the formation of lung metastasis in melanoma model.    Darya Khantakova, BS; Martina Molgora, PhD; Julie M. Roda, PhD; Geoffrey Stone, PhD; Susan Gilfillan, PhD; Tihana Trsan, PhD; Marina Cella, MD; Alan Kutach, PhD; Daniel Kaplan, PhD; Jer-Yuan Hsu, PhD; Marco Colonna, MD Combination Immunotherapies Antibody;Immune suppression;Myeloid cells
834 Poster Presentation Integrin αvβ8 inhibitor improves immune checkpoint therapy in advanced ovarian cancer model and its activity can be monitored in blood    Megan Krumpoch; Huidong Chen; Lia Luus; Michaela Mentzer; Aleksey Molodtsov; Adrian S. Ray; Vinod Yadav; Matthew Clark; Ian Gerken; Justin Snider; Blaise Lippa; Bruce N. Rogers; Gerard Bain; Natalia J. Reszka-Blanco; Combination Immunotherapies Biomarkers;Checkpoint blockade;Immune suppression;Immune tolerance
835 Poster Presentation AZD4820 Oncolytic Vaccinia Virus Encoding IL-12 Mediates Anti-tumor Activity Through Oncolysis and Tumor-specific Immunity     Cheyne Kurokawa; Sonia Agrawal; Abhisek Mitra; Elena Galvani; Shannon Burke; Ankita Varshine; Raymond Rothstein; Johann Foloppe; Nathalie Silvestre; Eric Quemeneur; Puja Sapra; Carl Barrett; Scott Hammond; Jason Laliberte; Nicholas Durham, PhD; Michael Oberst; Maria Broggi Combination Immunotherapies Targeted therapy;Tumor antigens
836 Poster Presentation Activating the Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas    Sara Labiano, PhD; Reyes Hernández-Osuna; Virginia Laspidea; Marc Garcia-Moure, PhD; Javier Marco-Sanz; Iker Ausejo; Montserrat Puigdelloses, PhD; Oren J. Becher, MD; Ana Patiño-Garcia, PhD; Candelaria Gomez-Manzano, MD, PhD; Juan Fueyo, MD, PhD; Marta M. Alonso, PhD Combination Immunotherapies Antibody;Antigen presenting cells;Costimulation;Dendritic cell;Immune contexture;Immune monitoring;Pediatric tumors;Solid tumors;Tumor microenvironment;Tumor stroma
837 Poster Presentation Redirecting IL-7-induced bystander tumor-infiltrating lymphocytes by bispecific T-cell engager augments antitumor response    Kun-Joo Lee; Nara Tae; Yeon-Woo Kang; Dain Moon; Youngsik Oh; Ji-Hae Kim, BS; Minji Lee; Ha Won Song; Sun Shim Choi; Donghoon Choi; Dae Hee Kim; Seung-Woo Lee Combination Immunotherapies Adoptive immunotherapy;Bispecifics;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
838 Poster Presentation Combination MRx0518 and anti-PD-1 overcomes checkpoint inhibitor resistance via myeloid modulation    June Li; Karen Millerchip; Carlos Ramos, BS; Edwin Parra, MD, PhD; Luisa Solis; Alex Stevenson; Aurelie Couturier; Gayle Fyvie; Michael Chisamore; Rahul Parikh; Eric Bernicker; Diwakar Davar, MD; Arvind Chaudhry; Nizar Tannir; Shubham Pant; Cara Haymaker Combination Immunotherapies Biomarkers;Checkpoint blockade;Dendritic cell;Immune monitoring;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell
839 Poster Presentation Selective Targeting of GARP-LTGF&szlig; Axis in the Tumor Microenvironment Augments PD-1 Blockade via Enhancing CD8+ T Cell Anti-Tumor Immunity Anqi Li, MD; Yuzhou Chang; No-Joon Song, PhD; Xingjun Wu; Dongjun Chung; Brian P. Riesenberg, PhD; Maria Velegraki, MD, PhD; Hyunwoo Kwon; Karthik Chakravarthy, BS; Chelsea M. Bolyard; Yi Wang; Qin Ma; Zihai Li, MD, PhD Combination Immunotherapies Antibody;Regulatory T cell (Treg cell);T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
840 Poster Presentation Triple-drug oral immunotherapy targeting myeloid cells for treatment of metastatic osteosarcoma evaluated in spontaneous canine model Cheryl London, DVM, PhD; Dan Regan, DVM, PhD; Lyndah Chow, PhD; Kristen Weishaar, DVM; Heather Gardner, DVM, PhD; Doug Thamm, VMD; Steven Dow, DVM, PhD Combination Immunotherapies Granulocyte;Inflammation;Monocyte/Macrophage;Myeloid cells;Tumor microenvironment
841 Poster Presentation XTX202, a tumor-selective protein-engineered IL-2, exhibited enhanced anti-tumor activity in combination with checkpoint inhibition in mice Wilson D. Guzman, A.B; Uli Carl Bialucha; Hanumantha Rao Madala; Haley Duprey; Manoussa Fanny; Stephanie Hsiao; Parker Johnson; Jake Taylor; Rebekah O’Donnell; Magali Pederzoli-Ribeil; Benjamin Nicholson; Jennifer O’Neil; Caitlin O’Toole Combination Immunotherapies Checkpoint blockade;Cytokine;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
842 Poster Presentation Development of a multiplex test for predicting response to combined immunotherapies in patients with metastatic melanoma Gabriele Madonna, MS; Pedro Machado Almeida, PhD; Mariaelena Capone, MD; Vito Vanella, MD; Lucia Festino, MD; Antonio Sorrentino, PhD; Marco Cassano, PhD; Benjamin Pelz, PhD; Diego G. Dupouy, PhD; Paolo A. Ascierto, MD Combination Immunotherapies Biomarkers;Checkpoint blockade;Immune contexture;Proteomics;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
843 Poster Presentation Lag3 blockade in combination with GITR improves anti-tumor immune responses in a preclinical melanoma model Rachana Maniyar, PhD; Roberta Zappasodi, PhD; Yuval Elhanati; Samantha St.Jean; Sebastian Carrasco; Benjamin D. Greenbaum, PhD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD Combination Immunotherapies Antibody;B cell;Biomarkers;Checkpoint blockade;T cell;Tumor microenvironment
844 Poster Presentation Combined immunotherapy efficacy on a multifocal hepatocellular carcinoma model based on hydrodynamic oncogene transfer    Maria C. Ochoa; Sandra Sanchez-Gregorio; Alvaro Teijeira, PhD; Saray Garasa, BS; Carlos E. De Andrea, MD; Maria Villalba; Iñaki Etxeberria; Ignacio I.M. Melero, MD, PhD Combination Immunotherapies Checkpoint blockade;Immune monitoring;Solid tumors
845 Poster Presentation Identifying patient subsets for CTLA4 and GITR depletion strategies in poorly T cell infiltrated tumors Arjun Mittal, BS; Jason J. Luke, MD; Riyue Bao, PhD Combination Immunotherapies Bioinformatics;Biomarkers;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
846 Poster Presentation Trastuzumab, an anti-HER2 antibody Modulates Cytotoxicity Against Cholangiocarcinoma (CCA) via Multiple Mechanisms. Seiji Okada, MD, PhD; Jutatip Panaampon, PhD Combination Immunotherapies Antibody;Solid tumors;Targeted therapy
847 Poster Presentation CF33-CD19t Oncolytic Virus (onCARlytics) in Combination with Off-the-shelf Allogeneic CyCART-19 T Cells Targeting de novo CD19+ Solid Tumors    Anthony K. Park, PhD; Isabel Monroy; Colin Cook; Shuyang He; Kathy Karasiewicz; Monil Shah; Nimali Withana; Leslie M.O. Chong; Robert Hariri, MD PhD; Yuman Fong, BS, MD; Saul J. Priceman, PhD Combination Immunotherapies CAR T cells;Solid tumors;T cell;Targeted therapy
848 Poster Presentation Impact of immunotherapy time-of-day infusion on overall survival in patients with metastatic renal cell carcinoma Jimmy S. Patel; Amber S. Draper; Yena Woo; Layla Dhabaan; Pretesh Patel, MD; Ashesh Jani; Bradley C. Carthon, MD, PhD; Viraj A. Master, MD, PhD; Haydn Kissick, PhD; Mehmet A. Bilen, MD; Zachary Buchwald, MD PhD; David C. Qian, MD, PhD Combination Immunotherapies Clinical study;Immune tolerance
849 Poster Presentation NT-I7, a novel long-acting interleukin-7, improves engraftment of patient immune cells and efficacy of anti-PD-1 therapy in a preclinical humanized melanoma model    Yee Peng Phoon, PhD; Kang Kai, PhD; Alexandra A. Wolfarth, PhD; Sara Ferrando-Martinez, PhD; Byung Ha Lee, PhD; Brian Gastman, MD Combination Immunotherapies Adoptive immunotherapy;Checkpoint blockade;Immune adjuvant;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
850 Poster Presentation Interim results for Phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies    Ruth Plummer; Mikael H. Sodergren, MD, PhD; Brid Ryan; Ilian Tachkov; Vikash Reebye; Tim Meyer; David J. Pinato, MD, MRes, PhD; Debashis Sarker; Bristi Basu; Sarah P. Blagden; Natalie Cook; Jeff Evans; Jeffrey Yachnin; Cheng-Ean Chee; Daneng Li, MD; Anthony B. El-Khoueiry, MD; Maria Diab; Kai-Wen Huang; Antonio D'Alessio; Claudia A.M. Fulgenzi; Marcus Noel; Bridget P. Keenan, MD, PhD; Devalingam Mahalingam, MBBChBAO; Nina Raulf; Rose Hogson; Choon Ping Tan; Joanna Nicholls; Alison Adderkin; Julia Vassiliadou; Robert Habib; John Rossi; Nagy Habib Combination Immunotherapies Checkpoint blockade;Clinical study;Immunoscore;MDSC;Monocyte/Macrophage;T cell;Tumor microenvironment
851 Poster Presentation Voyager V1 (VV1) oncolytic virus combined with immune checkpoint therapy boosts CTL responses to multiple tumor antigens and correspondingly deepens tumor responses in murine models of melanoma, lung and colon cancer. Priyanka Ram; Navpreet Tung, PhD; Himani Sharma; Ben Fulton, PhD; Kah-Whye Peng, PhD; Stephen J. Russell, MD, PhD; Markus Mohrs, PhD; Gavin Thurston, PhD; Christos Kyratsous, PhD; Alina Baum, PhD; Jessica R. Kirshner, PhD; John Lin, MD, PhD; Saida Dadi-Mehmetaj, PhD Combination Immunotherapies Checkpoint blockade;Neoantigens;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine
852 Poster Presentation Investigating The Functional Role of GPNMB in Glioblastoma And The Tumor Immune Microenvironment And Its Targeted Elimination Using CAR-Ts    Neil Savage, BSc; Franz J. Zemp; Nick Mikolajewicz, PhD; Hong Han, PhD; Chitra Venugopal, PhD; Chirayu Chokshi, PhD; Nazanin Tatari, PhD; Thomas Kislinger, PhD; Jason Moffat, PhD; Doug Mahoney, PhD; Sheila K. Singh, PhD, MD Combination Immunotherapies Adoptive immunotherapy;CAR T cells;Glycoproteomics;Monocyte/Macrophage;Proteomics;Solid tumors;Stem cell/cancer-initiating cell;Targeted therapy;Tumor antigens;Tumor microenvironment
853 Poster Presentation Novel CEAxCD47 (NILK-2401) and CEAxCD3 (NILK-2301) kl bispecific antibodies for multimodal immunotherapy of CEA-expressing solid cancer Anja Seckinger, MD; Vanessa Buatois, PhD; Valéry Moine; Lise Nouveau; Bruno Daubeuf; Sara Majocchi, PhD; Ulla Ravn; Nicolas Bosson; Krzysztof Masternak, PhD; Yves Poitevin; Giovanni Magistrelli; Pauline Malinge; Limin Shang, PhD; Nicolas Fischer, PhD; Klaus Strein, MD, PhD; Walter Ferlin, PhD; Dirk Hose, MD, PhD Combination Immunotherapies Antibody;Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Solid tumors;T cell;Targeted therapy;Tumor antigens
854 Poster Presentation HPK1 inhibition relieves suppression downstream of TCR activation to drive enhanced cytokine production and antigen-specific killing, an effect that is further enhanced by immune checkpoint blockade Rajesh K. Singh, PhD; Bindi Patel; Rameshwari Rayaji; Sachie Marubayashi; Sean Cho; Stefan Garrido-Shaqfeh; Joseph Kulusich; Cesar Meleza; Nidhi Tibrewal; Joice Thomas; Pradeep Nareddy; Ehesan Sharif; Sharon Zhao; Dave Green; Manmohan R. Leleti; Jay P. Powers; Matt J. Walters; Daniel DiRenzo Combination Immunotherapies Checkpoint blockade;Coinhibition;Cytokine;T cell
855 Poster Presentation Diacylglycerol kinase alpha and zeta dual inhibitors enhance T cell responses and promote robust and durable anti-tumor T cell immunity    Marcos W. Steinberg, PhD; Darina Spasova; Danelle Eto; AnneMarie Pferdekamper; Phuong Nguyen; Brian Le; Zachary Naiman; Susan Murphy; Maricel Gozo; James Skipper; Taylor Ismaili; Xikui Liu; Sunil Sahdeo; Xiao Hu; Isharat Yusuf; Kristen Taylor Meadows; Laura Carter Combination Immunotherapies Costimulation;Immune suppression;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
856 Poster Presentation SNS-101, a highly pH-selective VISTA:PSGL-1 inhibitory antibody, potentiates anti-PD-1 sensitivity, expands memory T-cells and enhances tumor infiltration of CD8 T-cells    Thomas Thisted, PhD; Tim Eitas, PhD; Kanam Malhotra, MS; Yuliya Kleschenko, PhD; Faith Finley, BS; Zhi-Gang Jiang, PhD; Arnab Mukherjee, PhD; Zuzana Biesova, PhD; Anokhi Cifuentes, MS; Robert H. Pierce, Jr., MD; Edward H. van der Horst, PhD Combination Immunotherapies Antibody;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
857 Poster Presentation Identifying novel immunotherapy targets under the pressure of Inhibitory cytokine TGF-β1. Liangzhe Wu; Nicholas Gascoigne; Ling Wu, Ph.D.; Vivian Tan, BSc.; Manoj N. Krishnan; Unnikrishnan Unniyampurath; Benson Chua; Liangzhe Wu, B.Sc Combination Immunotherapies Adoptive immunotherapy;Cytokine;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor microenvironment
858 Poster Presentation HBM7008 (B7H4x4-1BB HBICE) Synergizes HBM7004 (B7H4xCD3 HBICE) for Solid Tumor Therapy Xiaodong Wu, PhD; Yongqiang Wang; Gezi Jia; Bing Huang, Ms., Ph.D.; Yunxing Yang; Yun He; Yiping Rong Combination Immunotherapies Antibody;Bispecifics;Solid tumors;T cell
859 Poster Presentation Combination of HER2 ADC and lemzoparlimab elicits enhanced efficacy in both HER2 high-and low-expressing breast and gastric cancers Yanni Zhang, Ph.D; Yu Pang; Ao Li; Ke Xu; Ming Yang; Zhengyi Wang, PhD; Andrew Zhu Combination Immunotherapies Antibody;Biomarkers;Monocyte/Macrophage;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs)
860 Poster Presentation In vivo effectiveness of Tumor Treating Fields (TTFields) concomitant with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) Yiftah Barsheshet; Tali Voloshin; Boris Brant; Gadi Cohen; Lilach Avigdor; Roni Blatt; Shay Cahal; Tharwat Haj Khalil; Efrat Zemer-Tov; Rom Paz; Anat Klein-Goldberg; Catherine Tempel-Brami; Sara Jacobovitch; Alexandra Volodin; Tal Kan; Bella Koltun; Cfir David; Adi Haber, PhD, MBA; Moshe Giladi, PhD; Uri Weinberg, MD PhD; Yoram Palti Combination Immunotherapies Checkpoint blockade;Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
861 Poster Presentation Combined irreversible electroporation and local CD40 agonism stimulate neoantigen specific systemic immune responses that inhibit liver metastasis in an orthotopic pancreatic cancer model.    Jayanth Shankara Narayanan, PhD; Rebekah White, M.D.; Tomoko Hayashi, MD PhD; Dennis A. Carson, MD; Stephen P. Schoenberger, PhD Combination Immunotherapies Antigen presenting cells;Dendritic cell;Neoantigens;Solid tumors;Surgery;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
862 Poster Presentation Administration of intratumoral hu14.18-IL2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma Mark R. Albertini, MD; Cindy L. Zuleger, PhD; Erik A. Ranheim, MD, PhD; Oyewale Shiyanbola, MD; Andrew Kosharek, B.A.; Paul M. Sondel, MD, PhD; Zachary S. Morris, MD, PhD; Jens Eickhoff, PhD; Michael A. Newton, PhD; Irene M. Ong, PhD; Rene Welch Schwartz, PhD; Rubi Hayim, BS; Sarah Adrianowycz, DVM; Rachel Uyehara, DVM; Ilene D. Kurzman, PhD; Michelle Turek, DVM; David M. Vail, DVM Combination Immunotherapies Checkpoint blockade;Immune monitoring;Radiotherapy;Solid tumors;T cell;Vaccine
866 Poster Presentation Potentiating radiotherapy-induced abscopal immunity by ATR abrogation and CTLA-4 blockade in colorectal cancer Rodney Cheng-En Hsieh, MD, PhD; Ricardo Alexandre De Azevedo; Pham Hong Anh Cao; Arthur J. Liu, BS; Akash R. Boda, MS; Michelle Winkler, BS; Broderick Turner; Michael A. Curran, PhD Combination Immunotherapies Antigen presenting cells;Checkpoint blockade;Solid tumors;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
867 Poster Presentation Deciphering of radiotherapy-induced immunomodulation effect synergized with immunotherapy in hepatocellular carcinoma by spatial multi-omics profiling Mai Chan Lau; Lisda Suteja; Lawrence Cheung; Jeffrey C. Lim; Chun Jye Lim; Xinru Lim; Neslihan A. Kaya; Jiang Feng Ye; Felicia Wee; Han Chong Toh; Su Pin Choo; Suat Ying Lee; Joycelyn Jie Xin Lee; Jin Liu; Tony Kiat Hon Lim; Weiwei Zhai; David Tai; Joe Poh Sheng P. Yeong, MD, PhD Combination Immunotherapies Bioinformatics;Biomarkers;Immune contexture;Radiotherapy;T cell;Tumor microenvironment
868 Oral Presentation CD122-directed IL-2/anti-IL-2 complexes massively expand stem-like tumor-specific T cells and enhance abscopal responses to radiation and anti-PD-1 Kateryna Onyshchenko; Ren Luo, PhD; Liqun Wang, MD; Gabriele Niedermann Combination Immunotherapies Checkpoint blockade;Cytokine;Radiotherapy;T cell
869 Poster Presentation NBTXR3-enhanced proton beam immunoradiotherapy reshapes tumor immune microenvironment and improves abscopal effect in an anti-PD1-resistant lung cancer      Yun Hu, PhD; Sebastien Paris; Narayan Sahoo; Genevieve Bertolet; Qi Wang; Qianxia Wang; Hampartsoum Barsoumian; Jordan Da Silva; Ailing Huang; Claudia S. Kettlun Leyton; Tiffany A. Voss; Ethan Y. Hsu; Fatemeh Masrorpour; Carola Leuschner; Nahum Puebla Osorio; Quynh N. Nguyen; Saumil Gandhi; Jing Wang; Maria A. Cortez; James Welsh, MD Combination Immunotherapies Antibody;Checkpoint blockade;Immunoscore;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
870 Poster Presentation High-dose radiation is required for effective combination with tumor-specific vaccination in a prostate cancer model    Hemanth K. Potluri, BA; Carolina A. Ferreira, PhD; Joseph Grudzinski, PhD; Christopher Massey; Reinier Hernandez, PhD; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD Combination Immunotherapies Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
871 Poster Presentation Irradiation potentiates NK cells for surveillance against parental and cancer stem cells of hepatocellular carcinoma through LFA-1/ICAM-1 axis.    Tung Uong Nguyen Thanh, MSc; Huy Nguyen Phuoc Quang, MSc; Mee Sun Yoon, MD PhD Combination Immunotherapies Adoptive immunotherapy;Cytokine;NK/NKT cell;Radiotherapy;Stem cell/cancer-initiating cell
872 Poster Presentation Liposomal doxorubicin enhances the radiation-induced abscopal effect by promoting the release of tumor cell mitochondrial DNA    Liqun Wang, MD; Ren Luo, PhD; Kateryna Onyshchenko; Gabriele Niedermann Combination Immunotherapies Chemotherapy;Dendritic cell;Radiotherapy;T cell
873 Poster Presentation Radiation-induced dynamic alterations in PD-1/PD-L1 activity and relevant immune cell profiles depending on treatment response status in mouse tumor models Yi Na Yoon, Ph.D.; Yu Jin Lim; Jae-Sung Kim Combination Immunotherapies Immune monitoring;Immune suppression;MDSC;Monocyte/Macrophage;Radiotherapy;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
874 Poster Presentation Optimizing a combination radio-immunotherapy regimen in a preclinical model of treatment-resistant, high-risk neuroblastoma Lauren K. Zebertavage, PhD; Amy K. Erbe, PhD; Taylor Aiken, MD; Allison Schopf; Megan Nielsen; Sydney Katz; Zachary S. Morris, MD, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD Combination Immunotherapies Chemotherapy;Pediatric tumors;Radiotherapy
875 Poster Presentation Targeting CCR8-expressing tumor infiltrating Tregs in combination with radiotherapy enhances anti-tumor immunity    Yurun Zhang, PhD; Vikash Bhagwandin, PhD; Sandra V. Hatcher; Ziyun Ding, PhD; Liang Tang; Ricky A. Sharma, MD, PhD; Sophia X. Pfister, PhD Combination Immunotherapies Radiotherapy;Regulatory T cell (Treg cell);Tumor microenvironment
876 Poster Presentation Volumetric muscle loss injury impacts murine tumor growth and response to immune checkpoint blockade therapy Anna Ruta, BS; Jordan Garcia, MD; Locke Davenport Huyer, PhD; Joscelyn Mejias, PhD; Kavita Krishnan, BS; Helen Nguyen, BS; Elise F. Gray-Gaillard, MS; Jin Han, PhD; Andrew M. Pardoll, MD, PhD; Jennifer H. Elisseeff, PhD Combination Immunotherapies Checkpoint blockade;Surgery
877 Oral Presentation Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression Sofia Bruni, MS; Mara De Martino, PhD; Florencia L. Mauro, MS; Maria F. Mercogliano; Cecilia J. Proietti; Rosalia Cordo-Russo; Patricia V. Elizalde, PhD; Roxana Schillaci, PhD Combination Immunotherapies Antibody;Biomarkers;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
878 Poster Presentation BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade via DNA damage-induced STING/NF-κB/type I IFN signaling Kiranj Chaudagar, PhD; Marguerite Li; Christina J. Hong; Srikrishnan Rameshbabu; Raymond Chen; Alison J. Thomas; Brian M. Olson, PhD; Akash Patnaik, MD, PhD, MMSc Combination Immunotherapies Checkpoint blockade;Immune suppression;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
879 Poster Presentation Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer    Akash Patnaik, MD, PhD, MMSc; Kiranj Chaudagar, PhD; Hanna Hieromnimon; Taghreed Hirz; Shenglin Mei, PhD; David Sykes, MD, PhD Combination Immunotherapies Biomarkers;Checkpoint blockade;Coinhibition;Immune suppression;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment
880 Poster Presentation Activation of STAT3 signaling is associated with resistance to immune checkpoint inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) Alexander Chehrazi-Raffle, MD; Marice Alcantara, PhD; Nazli Dizman, MD; Wilson Tang, BS; Luis Meza, MD; Zeynep Zengin, MD; Dongfang Wang, PhD; Dayson F. Moreira, PhD; Daniela Castro; Ameish Govindarajan, MD; Alan Horsager; JoAnn Hsu, BS; Sumanta Pal, MD; Marcin Kortylewski, PhD Combination Immunotherapies Biomarkers;Coinhibition;Cytokine;Myeloid cells;Targeted therapy;Tumor evasion
881 Poster Presentation Significant Therapeutic Effects of Anti-ROR1 CAR NK Against Neuroblastoma by Oncolytic virus Armored with IL-21 in-vitro and in-vivo   Yaya Chu, PhD; Meijuan Tian, PhD; Uksha Saini, PhD; Dean A. Lee, MD, PhD; Timothy P. Cripe, MD PhD; Elaine R. Mardis, PhD; Gregory Behbehani, MD PhD; Stanley Riddell, MD; Kevin A. Cassady, MD; Mitchell S. Cairo Combination Immunotherapies Adoptive immunotherapy;Cytokine;NK/NKT cell;Pediatric tumors;Solid tumors;Targeted therapy
882 Poster Presentation Using Oncogenic Pathway Agonism to Sensitize RAS Mutant Cancers to Immunotherapy Alvaro De Mingo Pulido, PhD; Charles H. Adelmann, PhD; Kim T. Nguyen; Cynthia Dixey; Francisca Beato; Karol Prieto, PhD; Marco Napoli, PhD; Elsa Flores, PhD; Karen Mann, PhD; Jason Fleming, MD; Kenneth Y. Tsai, MD PhD Combination Immunotherapies Checkpoint blockade;Chemokine;Cytokine;Inflammation;T cell;Targeted therapy;Tumor microenvironment
883 Poster Presentation MCLA-145, an anti CD137&times;PD-L1 Bispecific antibody, induces T cell activation and proliferation in ex vivo models of hepatocellular carcinoma    Jyaysi Desai, PhD; Lissane Noordam; Patrick Boor, PhD; Rachid Bouzid; Diana Mittag; Paul Tacken; Jeroen Lammerts van Bueren; Cecile Guijen; Jaap Kwekkeboom; Dave Sprengers; Sonja Buschow Combination Immunotherapies Adoptive immunotherapy;Checkpoint blockade;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
884 Poster Presentation PERK inhibitor HC-5404 demonstrates immune-activation and anti-tumor efficacy in combination with anti-PD1 immune checkpoint inhibitor antibody Anissa S.H. Chan, PhD; Jeremy Drees, PhD; Yunfang Li; Takashi O. Kangas; Weiyu Zhang, PhD; Maria Fumagalli; Iman Dewji; Xiaohong Qiu; Nick Collette; Ben Harrison; Ashley LaCayo; Veronica Calvo Vidal, PhD; Crissy Dudgeon, PhD; Michael Stokes, PhD; Eric Lightcap, PhD; David Surguladze, PhD; Nandita Bose, PhD Combination Immunotherapies Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
885 Poster Presentation Enhancing immune checkpoint inhibitor efficacy with anti-angiogenics in ovarian cancer Sarah B. Gitto, PhD; Sergey Medvedev; Veethika Pandey, PhD; Dalia K. Omran; Matthew J. Anderson; Lauren E. Schwartz, MD; Fiona Simpkins, MD; Daniel J. Powell, Jr., PhD Combination Immunotherapies Angiogenesis;Antibody;Checkpoint blockade;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
886 Poster Presentation Combined allogeneic NK cell and Herzuma is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity    Yong W. Moon, MD, PhD; Mithun Gosh; Hee-Jung An; Tae Hoen Kim; Sa Deok Hong; Nar Bahadur Katuwal; Minsil Kang Combination Immunotherapies Adoptive immunotherapy;NK/NKT cell
887 Poster Presentation Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1-specific immune checkpoint blockade     Marcin Kortylewski, PhD; Chia-Yang Hung, PhD Combination Immunotherapies Myeloid cells;T cell;TLR;Tumor microenvironment
888 Poster Presentation Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models    Kana Ichikawa; Ammar Adam; Hsin-Jung Wu; David L. Lahr; Lan Xu; Brandon Antonakos; Liv Johannessen; Steven F. Bellon; Ryan Kruger; Richard C. Centore; Martin Hentemann Combination Immunotherapies Checkpoint blockade;Epigenetics
889 Poster Presentation IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that directly targets solid tumours and breaks immune tolerance    Giusy Di Conza, PhD; Lars Van der Veen; Chiara Tarantelli; Francesco Bertoni; Amy Fraser; Pritom Shah; Simon Tiede; Laura Tesmer; Gerhard Hummer; Oscar Vadas; Michael Lahn; Nomanbhoy Tyzoonn; Zoe Johnson, PhD Combination Immunotherapies Checkpoint blockade;Immune suppression;Immune toxicity;Leukemia/Lymphoma;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor microenvironment
890 Poster Presentation Using intratumor microdevices to identify highly synergistic combinations between targeted agents and immunotherapies in breast cancer    Oliver Jonas Combination Immunotherapies Biomarkers;Solid tumors;Tumor microenvironment
891 Poster Presentation Immune related vulnerabilities of non-neuroendocrine small cell lung cancer    Ryan Kowash; Mingrui Zhu, B.S.; Benjamin Drapkin, M.D., Ph.D.; John Minna, M.D.; Luc Girard, PhD; Esra Akbay, PhD Combination Immunotherapies Antibody;Checkpoint blockade;Immune monitoring;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor antigens;Tumor evasion
892 Poster Presentation The novel telomerase-directed telomere-targeted anticancer agent 6-thio-dG (THIO) demonstrates potent activity and induces antitumor immunity in hepatocellular carcinoma (HCC) models    Ilgen Mender, Ph.D.; Silvia Siteni, Ph.D.; Mihail Obrocea; Vlad Vitoc; Sergei Gryaznov, PhD; Jerry Shay, Ph.D. Combination Immunotherapies Checkpoint blockade;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
893 Poster Presentation Myeloid derived suppressive cells attenuate the anti-tumor efficacy of androgen deprivation therapy and targeted radionuclide therapy in a murine prostate cancer model.   Anusha Muralidhar, MS; Carolina de Aguiar Ferreria, PhD; Reinier Hernandez, PhD; Jamey Weichert, PhD; Douglas G. McNeel, MD, PhD Combination Immunotherapies Immune contexture;Immune suppression;MDSC;Myeloid cells;Radiotherapy;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
894 Poster Presentation A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models.      Ravikumar Muthuswamy, PhD; Steve Thorne, PhD; Carly Carter, PhD; Ming Zhang, PhD; Dan Byrd, PhD Combination Immunotherapies Biomarkers;Immune adjuvant;Immune contexture;Immune suppression;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma;Vaccine
895 Poster Presentation Enhanced anti-tumor efficacy by combination of checkpoint immunotherapy and antibody-drug conjugates utilizing the topoisomerase I inhibitor linker-payload AZ'0133 Bilal Omar, PhD; Steve Arbitman; Kalyani Daita; Ana Paucarmayta; Huiyanangel Chow; Judith Anderton; Raymond Rothstein; Allison Gerber; Kathy A. Mulgrew; Leslie Wetzel; Edward Rosfjord; Nadia Luheshi, PhD; Krista Kinneer; Scott A. Hammond, PhD Combination Immunotherapies Antigen presenting cells;Bispecifics;Checkpoint blockade;T cell;Targeted therapy;Tumor antigens
896 Poster Presentation ONCOLYTIC HERPES SIMPLEX VIRUS IMMUNO-VIROTHERAPY IN COMBINATION WITH TIGIT IMMUNE CHECKPOINT BLOCKADE TO TREAT GLIOBLASTOMA    Eleni Panagioti, PhD; Hunter J. Kelley, MSC; William F. Goins, PhD; Keith L. Ligon, MD, PhD; Karen O. Dixon, PhD; Ana C. Anderson, PhD; Vijay Kuchroo; Antonio E. Chiocca, MD, PhD Combination Immunotherapies Checkpoint blockade;Coinhibition;Immune suppression;Solid tumors;T cell lineages;Tumor evasion;Tumor microenvironment;Vaccine
897 Poster Presentation Partners for Bispecifics: combinatorial approaches to augment T-cell function and mitigate exhaustion Nora Philipp; Marion Subklewe, Prof. Dr. med.; Amelie Muth; Michael Von Bergwelt-Baildon, MD, PhD; Veit Bücklein Combination Immunotherapies Bispecifics;Checkpoint blockade;Leukemia/Lymphoma;T cell
898 Poster Presentation Triple therapy (binimetinib, bevacizumab, pembrolizumab) modulates the tumor immune microenvironment in microsatellite stable colorectal cancer PDXs in a humanized mice model    Julie Lang, PhD; Adrian Dominquez; Matthew Lewis, MS; Sarah J. Hartmann, MS; Jordi M. Lanis, PhD; Hannah Strassburger; Wells A. Messersmith, MD, FACP, FASCO; S. Lindsey Davis, MD; Alexis D. Leal, MD; Sunnie Kim, MD; Kimberly R. Jordan, PhD; Tyler Friedrich, MD; Christopher Lieu, MD; Todd Pitts, PhD Combination Immunotherapies Checkpoint blockade;Immune contexture;Immune monitoring;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
899 Poster Presentation BET inhibitors synergize with anti-PD1 by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells    Kyle Romine, PhD; Kevin MacPherson; Hyun-jun Cho; Yoko Kosaka, PhD; Patrick Flynn; Kaelan H. Byrd; Jesse L. Coy; Matthew T. Newman; Jamie Scott; Andrew C. Adey; Evan F. Lind, PhD Combination Immunotherapies Checkpoint blockade;Immune suppression;Leukemia/Lymphoma;T cell
900 Poster Presentation Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation.  Sheila Dakhel Plaza, PhD; Giulia Rotta; Samuele Cazzamalli, PhD; Ettore Gilardoni, PhD; Riccardo Stucchi, PhD; Christian Pellegrino, PhD; Jacqueline Mock, PhD; Roberto De Luca, phD; Emanuele Puca, PhD; Dario Neri, Professor Combination Immunotherapies Antibody;Cytokine;Immune toxicity;Solid tumors;Targeted therapy;Tumor microenvironment
901 Poster Presentation Inhibition of GAS6/MerTK signaling by novel MerTK antibody, 20A77, exerts significant anti-tumor efficacy with little retinal degeneration in mice Atsushi Sawada; Masayoshi Toyoura; Aki Takaiwa; Toshikazu Inoue; Koji Nakamura Combination Immunotherapies Antibody;Monocyte/Macrophage;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
902 Poster Presentation NKX019, an Off-the-Shelf CD19 CAR-NK Cell, mediates improved anti-tumor activity and persistence in combination with CD20-directed therapeutic mAbs Mira Tohmé, PhD; Tina Davis, MS; Max Zhang; Hadia Lemar; Bao Duong, PhD; Joanne Tan, PhD; James B. Trager, PhD Combination Immunotherapies CAR T cells;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy
903 Poster Presentation APR-246 induces an increase in tumor immunogenicity in a p53 independent manner         Divya Venkatesh, Ph.D.; Judith Michels, MD PhD; Cailin Lu, MD; Sadna Budhu, PhD; Mariam M. George, PhD; Ouathek Ouerfelli, PhD; Lars Abrahmsen, PhD; Roberta Zappasodi, PhD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD Combination Immunotherapies Antigen presenting cells;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor antigens
904 Poster Presentation LDH inhibition improves response to CTLA-4 blockade by enhancing effector T cell activity and impairing regulatory T cell suppression Svena Verma, BS; Inna Serganova, PhD; Sadna Budhu, PhD; Lauren Dong, BS; Levi M. Mangarin, BS; Myat K. Ko; Ronald Blasberg; Roberta Zappasodi, PhD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD Combination Immunotherapies Checkpoint blockade;Metabolism;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
905 Poster Presentation Broad anti-tumor activity of a potent and selective small molecule antagonist of PD-L1 ABSK043 in combination with other agents in preclinical models    Haiyan Ying, PhD; Yongxian Zhang; Fei Yang; Wenqun Xin; Jie Wang; Jie Zhang; Zhui Chen Combination Immunotherapies Checkpoint blockade;Chemotherapy;Immune suppression
906 Poster Presentation Telomere dysfunction mediates anti-tumor immunity in small cell lung cancer    Mingrui Zhu, B.S.; Buse Eglenen-Polat, M.D.; Matthew Bender, B.S.; Ilgen Mender, Ph.D.; Silvia Siteni, Ph.D.; Benjamin Drapkin, M.D., Ph.D.; Jerry Shay, Ph.D.; Esra Akbay, PhD Combination Immunotherapies Checkpoint blockade;Coinhibition;T cell;Targeted therapy
907 Poster Presentation Blockade of VEGF, Angiopoietin-2, and PD1 reprograms dysfunctional endothelial cells in glioblastoma to quasi-antigen-presenting cells Zohreh Amoozgar, PharmD, PhD; Jun Ren; Nancy Wang; Patrik Andersson; Gino Ferraro; Shanmugarajan Krishnan; Pin-Ji Lei; Sonu Subudhi; Kosuke Kawaguchi; Rong En Tay; Igor L. Gomes-Santos; Peigen Huang; Hye-Jung Kim; Dai Fukumura; Rakesh K. Jain, PhD Combination Immunotherapies Angiogenesis;Antigen presenting cells;Solid tumors;T cell;Tumor antigens
908 Poster Presentation Tumor-intrinsic p38 signaling as a therapeutic target to overcome non-T cell-inflamed tumors and immunotherapy resistance    Rebekah Dadey, PhD; Shannon Winski, PhD; Patrice A. Lee, PhD; Sarah Brodeur; Tullia Bruno, PhD; Heath Skinner, PhD; Robert L. Ferris, MD, PhD; Jason J. Luke, MD; Riyue Bao, PhD Combination Immunotherapies Bioinformatics;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
909 Poster Presentation Overcoming resistance to NK-mediated lysis in enzalutamide-resistant prostate cancer cells      Madeline Dahut, BS; Kristen N. Fousek, PhD; Lucas A. Horn, PhD; Haiyan Qin; Jeffrey Schlom, PhD; Claudia M. Palena, PhD Combination Immunotherapies NK/NKT cell;Solid tumors;Tumor evasion;Tumor microenvironment
910 Poster Presentation STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer     Liya Ding; Qiwei Wang; Antons Martincuks; Michael J. Kearns; Tao Jiang; Ziying Lin; Xin Cheng; Changli Qian; Hye-Jung Kim; Inga-Maria Launonen; Anniina Färkkilä; Thomas M. Roberts; Joyce F. Liu; Panagiotis A. Konstantinopoulos; Ursula A. Matulonis, MD; Hua E. Yu, PhD; Jean Zhao, PhD Combination Immunotherapies Antigen presenting cells;Checkpoint blockade;Chemokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor microenvironment
911 Poster Presentation Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice    Xinyue Dong; Jun Ren; Zohreh Amoozgar, PharmD, PhD; Meenal Datta; Somin Lee; Sylvie Roberge; Mark Duquette; Dai Fukumura; Rakesh K. Jain, PhD Combination Immunotherapies Adoptive immunotherapy;Angiogenesis;CAR T cells;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
912 Poster Presentation Epigenetic remodeling enhances therapeutic responses to STING agonism in vivo Rana Falahat, PhD; Anders Berglund, PhD; Patricio Perez-Villarroel; Shari Pilon-Thomas, PhD; Glen N. Barber, PhD; James J. Mule, PhD Combination Immunotherapies Epigenetics;Immune adjuvant;Immune suppression;T cell;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
913 Poster Presentation Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab.     Heather Torrey, PhD; Walead Ebrahimizadeh, PhD; Valarmathy Kaliaperumal, MSc; Aurelio S. Lobo, MSc; Barry Kennedy, PhD; Tran Ngo, BSc; Lisa D. MacDonald, MSc; Stephan Fiset, MSc, MBA; Jeremy R. Graff, PhD; Heather A. Hirsch Combination Immunotherapies B cell;Gene expression;Immune suppression;NK/NKT cell;Regulatory T cell (Treg cell);T cell;Targeted therapy;Tumor microenvironment;Vaccine
914 Poster Presentation Regulating negative immune regulators to enhance immune checkpoint blockade antitumor potential  Yared Hailemichael, PhD; Glenn Winn; Michael A. Davies, MD, PhD Combination Immunotherapies Checkpoint blockade;Chemokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;T cell lineages;Tumor microenvironment;Tumor stroma
915 Oral Presentation Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 blockade therapy in small cell lung cancer Evelyn M. Nguyen, BA; Andrew Chow, MD, PhD; Charles M. Rudin, MD, PhD; Triparna Sen, PhD; Hirokazu Taniguchi, MD, PhD Combination Immunotherapies Checkpoint blockade;Epigenetics;Targeted therapy
916 Poster Presentation Acquired resistance to immune checkpoint blockade by phenotypic plasticity of melanoma Emily J. Robitschek, BS; Arnav Mehta, M.D., Ph.D.; Jia-Ren Lin, Ph.D.; Dennie Frederick; Alvin Shi, PhD; Ana B. Larque, MD, PhD; Benchun Miao, Ph.D; Rumya Raghavan; Tatyana Sharova; John Shin, M.D.; Manolis Kellis, Ph.D; Nir Hacohen, PhD; Keith Flaherty, MD; Genevieve M. Boland, MD, PhD; Ivan Chebib, MD; David Liu, MD, MPH, MS; Ryan J. Sullivan, MD Combination Immunotherapies Bioinformatics;Checkpoint blockade;Epigenetics;Gene expression;Immune contexture;Tumor evasion;Tumor microenvironment
917 Poster Presentation Reversing the immune-excluded ('cold') tumor immune microenvironment in oral squamous cell carcinoma     Yewen Shi, MD PhD; Alanis E. Rodriguez-Rosario; Tongxin Xie; Frederico O. Gleber-Netto; Curtis R. Pickering; Abdullah A. Osman; Andrew Sikora, MD, PhD; Jeffrey N. Myers, MD; Roberto Rangel, PhD Combination Immunotherapies Checkpoint blockade;Chemokine;Cytokine;Gene expression;Immune suppression;Inflammation;Monocyte/Macrophage;Solid tumors;Tumor evasion;Tumor microenvironment
918 Poster Presentation Treatment-related adverse event (TRAE)-related discontinuation rate of immunotherapy alone (IO-only) compared to immunotherapy combined with chemotherapy (chemo-IO): a meta-analysis Seunghwan Shin, MD; Sumin Lee; Huijeong Kim; Chiyoon Oum; SooIck Cho; Yoojoo Lim; Ken Nesmith; Chan-Young Ock, MD, PhD Combination Immunotherapies Checkpoint blockade;Immune toxicity
919 Poster Presentation Acute Respiratory Failure and the Risk Immunotherapy Related Pneumonitis during the Covid Pandemic Scott Amrhein, MD; Andrew Faucheux, MD; Lara Khoury, MD; John Kalada, MD; Greg Russell, MS; Thomas W. Lycan, Jr., DO COVID and Immunotherapy COVID and Immunotherapy;Immune toxicity
920 Poster Presentation Alteration of T cell responses against SARS-CoV-2 omicron variant after vaccination with mRNA booster in lung cancer patients Karthik Chakravarthy, BS; No-Joon Song, PhD; Chelsea M. Bolyard; Kelsi Reynolds; Kevin P. Weller; Sarah Reisinger; Yi Wang; Anqi Li, MD; Mark P. Rubinstein, PhD; Peter Shields, MD; Zihai Li, MD, PhD COVID and Immunotherapy Checkpoint blockade;COVID and Immunotherapy;Solid tumors;T cell;T cell lineages
922 Poster Presentation Effect of COVID-19 vaccination status on adverse events and outcomes in advanced non-small cell lung Cancer (aNSCLC) patients Treated with Immunotherapies Rohini George, PhD; Babu Narayanan, PhD; Smita Agrawal, PhD COVID and Immunotherapy COVID and Immunotherapy;Vaccine
923 Poster Presentation Deep single-cell, proteogenomic insights from SARS-CoV-2 infected lung tissues    Arutha Kulasinghe; Chin Wee Tan; Ning Liu; James Monkman; Emily Killingbeck; Youngmi Kim, PhD; Liuliu Pan, PhD; Tony Blick; Dharmesh Bhuva; Kristen Feher; Michael Leon; Mark Gregory; Kirsty Short, PhD; Fernando Guimaraes; Michael Rhodes, PhD; Gabrielle Belz; Melissa Davis COVID and Immunotherapy Biomarkers;COVID and Immunotherapy;Gene expression;Immune monitoring;Proteomics
924 Poster Presentation Barcode Enabled Antigen Mapping (BEAM) and Single-Cell sequencing enables next-generation systems immunology analysis of the post-COVID-19 immune landscape Peter Finnegan, BS; Bruce Adams, PhD; Daniel Reyes, MS; Sean Marrache, PhD; Payam Shahi, PhD; FuNien Tsai, PhD; Thomas Vollbrecht, PhD; Micheal Stubbington, PhD COVID and Immunotherapy B cell;COVID and Immunotherapy;Gene expression;T cell;Targeted therapy
925 Poster Presentation PhenoComb, a tool for evaluating complex phenotypes in high-dimension cytometry datasets.    Ann M. Strange; David M. Woods, PhD; Brian Thompson; Carol M. Amato, MS; Paulo E. Burke Data Sharing, Handling and Access Bioinformatics
926 Poster Presentation Evaluating diverse deconvolution methods for tumor spatial transcriptomic datasets Guangyuan(Frank) Li, BS; Amir Bayegan; Joon Sang Lee, PhD; Donald G. Jackson, PhD; Jack Pollard, PhD Data Sharing, Handling and Access Bioinformatics;Gene expression;Systems biology;Tumor microenvironment
927 Poster Presentation Streamlining cancer immunotherapy research with the CRI iAtlas data resource and web portal Vésteinn Thorsson; Carolina Heimann; Andrew E. Lamb; David L. Gibbs; Dante Bortone; Sarah Dexheimer; Steven Vensko; Yooree Chae; Ilya Shmulevich; Benjamin G. Vincent; James A. Eddy Data Sharing, Handling and Access Bioinformatics;Checkpoint blockade;Gene expression;Immune contexture;Systems biology;Tumor microenvironment
928 Poster Presentation Standardizing the analysis of spatial imaging features in tumor samples Jason L. Weirather, PhD; Ian Dryg, PhD; Madison Turner; Ann-Elizabeth Le, MS; Anne E. Carlisle, PhD; Kathleen L. Pfaff, PhD; F. Stephen Hodi, Jr., MD; Scott J. Rodig, MD, PhD Data Sharing, Handling and Access Bioinformatics;Tumor microenvironment;Tumor stroma
929 Poster Presentation The Data Management and Resource Sharing  Center for the Cancer Moonshot Immuno-Oncology Translational Network    Alan D. Hutson, PhD; Himangi Marathe, PhD; Martin Morgan; Kunle Odunsi, MD PhD; Song Liu, PhD Data Sharing, Handling and Access Adoptive immunotherapy;Bioinformatics;Biomarkers;CAR T cells;Gene expression;Systems biology;Tumor microenvironment
930 Poster Presentation Provider insights on managing patients on immunotherapy, barriers to clinical trials, and biomarker testing preferences Tariqa Ackbarali, MS, PhD; Joel Neal, MD, PhD; Yelena Janjigian, MD; Michael J. Overman, MD Education and Treatment Management Biomarkers;Checkpoint blockade;Clinical trial;Immune toxicity;Solid tumors
931 Poster Presentation Targeting the lymphocyte-activation gene-3 (LAG-3) immune checkpoint in patients with cancer: awareness and confidence among oncology healthcare professionals (HCP)    Marie N. Becker, PhD; Timothy A. Quill, PhD; Tian Zhang, MD; Evan J. Lipson, MD Education and Treatment Management Checkpoint blockade;Solid tumors
932 Poster Presentation Immunotherapy efficacy and tolerability in advanced hepatocellular carcinoma (HCC) in a diverse and underserved population in the United States - Importance of baseline liver function and screening Fernand Bteich, MD; Kush Desai; Chenxin Zhang; Charlotte McGuckin; John Yan, MD; Sharmin Sultana; Lawrence Leung, PhD; Andreas Kaubisch, MD; Milan Kinkhabwala, MD; Sarah Bellemare, MD; Adebola Adedimeji, Ph.D., M.B.A., M.P.H., M.S.; Clara Tow; Yvonne M. Saenger, MD Education and Treatment Management Checkpoint blockade;Clinical study;Immune toxicity;Solid tumors
933 Poster Presentation Real-world treatment patterns and clinical outcomes in patients with metastatic NSCLC after receiving first-line pembrolizumab with pemetrexed/platinum chemotherapy in The US Oncology Network Jerome H. Goldschmidt, MD; Srinivas Annavarapu, MBBS, PhD; Divea Venkatasetty, MPH; Melissa L. Santorelli, PhD, MPH; Thomas Burke, PharmD, PhD; Nathan A. Pennell, MD, PhD Education and Treatment Management Checkpoint blockade
934 Poster Presentation Immunotherapy-Based Strategies for Advanced Non-Small Cell Lung Cancer: Identifying and Reducing Clinician Knowledge Gaps with Online Education Elizabeth J. Heller, PhD; Keira P. Smith; Eden ED. Maack, PhD; Lyn Brook; Sarah A. Williams, MAT; Beth Sandy, MSN, CRNP Education and Treatment Management Checkpoint blockade;Immune toxicity;Solid tumors
935 Poster Presentation A Case Report of Pediatric Adenoviral Reactivation after CAR T-cell Therapy Jimmy Maiarana, MD; Saara Kaviany, DO; Jim Connelly, MD; Carrie Kitko, MD; Richard H. Ho, MD Education and Treatment Management CAR T cells;Clinical study;Immune monitoring;Immune suppression;Immune toxicity;Leukemia/Lymphoma;Pediatric tumors
936 Poster Presentation Assessing educational needs for immune-related adverse events curriculum in clinical practice Gong He, MD; Austin Wesevich, MD, MPH; Pankti Reid, MD, MPH Education and Treatment Management Immune toxicity;Solid tumors
937 Poster Presentation Post-immunotherapy survivorship in advanced melanoma (aMEL):  routine versus symptom-based imaging surveillance, a retrospective review in a large integrated healthcare network, Kaiser Permanente Northern California (KPNC)   Juraj Kavecansky, Md; Richie H. Xu; Lue-Yen Tucker; Jahan Tavakoli; Alexander Menter; Thach-Giao Truong Education and Treatment Management Checkpoint blockade;Epidemiology;Immune adjuvant;Solid tumors
939 Oral Presentation Augmentation of CD8 T cell memory via CDK4/6 inhibition can be sequentially combined with PD-1 blockade to avoid toxicities Lestat Ali, MD; Ana Garrido-Castro, MD; Sara Tolaney; Stephanie Dougan, PhD Immune Cell Types and Biology Adoptive immunotherapy;Bioinformatics;Checkpoint blockade;Clinical trial;Immune toxicity;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
940 Poster Presentation siRNA screen of upregulated genes identifies targets for a multiantigen polyepitope vaccine to prevent HNSCC Fnu Alka, Ph.D.; James Annis; Brady M. Bernard, PhD; Sasha E. Stanton, MD, Ph.D. Immune Cell Types and Biology Carcinogenesis;Immune monitoring;RNA;T cell;Tumor antigens;Vaccine
941 Poster Presentation Botensilimab modulates innate and adaptive gene expression programs resulting in superior immune stimulation relative to a first-generation anti-CTLA-4 antibody Shanmugarajan Krishnan, PhD; Jacky Chow, PhD, MS; Kah Teong Soh, PhD; Kayla Ostergard; Christopher MacDermaid; Marc Van Dijk; Dennis Underwood; Dhan Chand, PhD; Cailin Joyce, PhD Immune Cell Types and Biology Antigen presenting cells;Bioinformatics;Biomarkers;Checkpoint blockade;Dendritic cell;Gene expression;Myeloid cells;Systems biology
942 Poster Presentation Flow cytometry immunophenotyping of neck lymph nodes sampled by fine needle aspiration (FNA) in patients suffering from advanced cutaneous squamous cell carcinoma: a pilot study  Vilma Lagebro; Krzysztof Piersiala; Gregori Margolin, MD PhD; Susanna Kumlien Georén, PhD; Lars-Olaf Cardell, Professor, Senior Physician Immune Cell Types and Biology Checkpoint blockade;Immune monitoring;Immune suppression;T cell;T cell lineages
943 Poster Presentation Harnessing Anti-Tumor Metabolic Sensing Switch GPR84 on Macrophages for Cancer Immunotherapy Gang Xin; Ruohan Zhang; Bao Zhao; Cankun Wang; Wantong Li; Nuo Sun; Qin Ma; Jianying Li, MS; Haitao Wen; William Carson, III; Zihai Li, MD, PhD; Anjun Ma Immune Cell Types and Biology Bioinformatics;Monocyte/Macrophage;Myeloid cells;Targeted therapy
944 Oral Presentation Targeting of Notch ligand Jagged2 in lung cancer cells drives anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages J. Mandula; Rosa Sierra-Mondragon; Darwin C. Chang; Rachel Jimenez; Eslam Mohamed; Jimena Trillo; Alyssa Obermayer; Carlos Moran-Segura; Das Satyajit; Julio Vazquez-Martinez; Timothy Shaw; Jose Conejo-Garcia, MD, PhD; Paulo Rodriguez Immune Cell Types and Biology Adoptive immunotherapy;Antigen presenting cells;Bioinformatics;Gene expression;Monocyte/Macrophage;RNA;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
945 Poster Presentation Overlapping and Distinct Patterns of LILRB Receptors Support Complementary Targeting Approach in Cancer    Jeffrey Smith; Amy Mueller; Vikki Spaulding; Michelle Priess; Krithi Bala, PhD; Andrew Dunn; Sarah Jaffe; Morgan Thompson; Jean-Christophe Pignon; Alexa Diiorio; Andre Cunha, PhD; Heather Condurso; Kristin O'Malley, BSc; Olivia Petrillo, MS; Prashanna Balaji Venkatasubramanian; Geneva Young; Christina Meyer, PhD; Michael Meehl, PhD; Katalin Kis-Toth; Monica Gostissa, PhD; Dmitri Wiederschain, PhD; Ben Umiker, PhD; Yasmin L. Hashambhoy-Ramsay, PhD Immune Cell Types and Biology Bioinformatics;Gene expression;Immune contexture;Monocyte/Macrophage;Myeloid cells;Proteomics;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
946 Poster Presentation Dissecting myeloid cell-mediated mechanisms of resistance to immune checkpoint blockade in bladder cancer    Michelle Tran, MD PhD Candidate; Adam M. Farkas, PhD; Kristin G. Beaumont, PhD; Amir Horowitz, PhD; John Sfakianos; Matthew D. Galsky, MD; Nina Bhardwaj, MD, PhD Immune Cell Types and Biology Checkpoint blockade;Immune suppression;Inflammation;Monocyte/Macrophage;Myeloid cells;Tumor microenvironment
947 Poster Presentation Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche     Judith Agudo, PhD; Pilar Baldominos Immune Cell Types and Biology Adoptive immunotherapy;Dendritic cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
948 Poster Presentation Developing engineered animal models to investigate tumor-specific T cell responses and immune-related adverse events after immunotherapy Martina Damo; Noah Hornick; Nikhil Joshi, PhD Immune Cell Types and Biology B cell;T cell;T cell lineages;Tumor microenvironment
949 Poster Presentation INOVATIVE IN VIVO (IN OVO) CAM MODEL TO PREDICT EFFICACY AND MODE OF ACTION OF A NEW ANTITUMOR VACCINE STC-1010 ON HUMAN COLORECTAL ADENOCARCINOMA    Yan Wang; Corinne Tortorelli, Pharm.D, Ph.D; Arnaud Peyronnier; Benoit Pinteur; Lionel Chalus; Paul Bravetti; Jean Viallet; François Ghiringhelli Immune Cell Types and Biology Biomarkers;Cytokine;Dendritic cell;Immune monitoring;Neoantigens;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
950 Poster Presentation TNFR2 HuGEMMTM murine model for evaluation of hTNFα-hTNFR2 signaling effect on induced regulatory T cell differentiation    Demi Liu; Xuefei Yan Immune Cell Types and Biology Adoptive immunotherapy;Antibody;Immune suppression;T cell
951 Oral Presentation Spatial Atlases of Immunological Development within the Lymph Node Tyler D. Hether, PhD; Stephanie Zimmerman, PhD; Zachary Lewis, PhD; Shanshan He, MD, PhD; Liang Zhang, PhD; Kathy Ton; Liuliu Pan, PhD; Wei Yang, PhD; Stefan Phelan, MS; Charles Glaser; Andy Nam; Emily Brown; Michael Patrick; Gary Geiss, PhD; Sarah E. Church, PhD; Michael Rhodes, PhD; Yan Liang, MD PhD; Jason W. Reeves, PhD; Joseph M. Beechem, PhD Immune Cell Types and Biology Adoptive immunotherapy;Antigen presenting cells;B cell;Costimulation;Gene expression;Monocyte/Macrophage;RNA;T cell
952 Poster Presentation The temporal contribution of interferon-&gamma; in driving T-cell exhaustion and response to immune checkpoint blockade.    Vaishali Aggarwal, PhD; Chang Liu, PhD; Lawrence P. Andrews, PhD; Madhu Malinee; Carly Cardello; Creg Workman, PhD; Dario A. Vignali, PhD Immune Cell Types and Biology Checkpoint blockade;Cytokine;T cell;T cell lineages;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
953 Poster Presentation Treatment with SQ3370, a doxorubicin-based therapeutic, corresponds with immunomodulation of the tumor microenvironment Masa Aleckovic, PhD; Sangeetha Srinivasan, PhD; Jesse M. McFarland, PhD; Leslie Priddy, B.S; Matthew Tso, MS; Jose M. Mejia Oneto, MD, PhD Immune Cell Types and Biology Chemotherapy;Clinical trial;Dendritic cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
954 Poster Presentation SQ2270, a Novel MMAE-based Therapeutic, Promotes Tumor Growth Inhibition and Extensive Immune Cell Infiltration in the RENCA Cancer Model  Masa Aleckovic, PhD; Sangeetha Srinivasan, PhD; Jesse M. McFarland, PhD; Leslie Priddy, B.S; Matthew Tso, MS; George Coricor, PhD; Jose M. Mejia Oneto, MD, PhD Immune Cell Types and Biology T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
955 Poster Presentation Gingivo-buccal oral cancer: Inferring prognosis from immune contextures of tumor and surrounding margin.  Ankita Chatterjee, PhD; Partha P. Majumder; Nidhan K. Biswas; Arindam Maitra; Arnab Ghosh Immune Cell Types and Biology Gene expression;Immune contexture;Immune suppression;Solid tumors;Tumor microenvironment
956 Oral Presentation Spatial clustering reveals immune hub interaction with reservoir of stem-like CD8 T cells and predicts immunotherapy response in lung cancer patients. Jonathan H. Chen; Linda T. Nieman; Maxwell Spurrell; Mari Mino-Kenudson, MD; Justin F. Gainor, MD; Nir Hacohen, PhD Immune Cell Types and Biology Immune contexture;Solid tumors;Systems biology;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
957 Poster Presentation Assessment of the spatial distribution and cell-to-cell interactions into the tumor micro-environment, within and between serial slides stained with Brightplex, a sequential chromogenic multiplex assay    Aurelie Collignon; Alboukadel Kassambara; Alex Trinh; Maité Chamourin; Georgia Culley; Marion Olive; Clemence Jaume; Assil Benchaaben; Jerome Galon; Jacques Fieschi, PhD Immune Cell Types and Biology Biomarkers;Immune contexture;Immune monitoring;Immune suppression;Immunoscore;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
959 Poster Presentation PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors Rebekka Duhen, PhD; Olivier Fesneau, PhD; Kimberly Samson; Alexandra Frye; Michael F. Beymer; Venkatesh Rajamanickam; David Ross; Eric Tran, PhD; Brady M. Bernard, PhD; Andrew D. Weinberg, PhD; Thomas Duhen, PhD Immune Cell Types and Biology Adoptive immunotherapy;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor microenvironment
960 Poster Presentation TT-816, a novel small molecule immune checkpoint inhibitor targeting cannabinoid CB2 receptor, stimulates innate and adaptive immunity for cancer therapy    Peidong Fan, PhD; Elfatih Elzein, PhD; Lina Yao, MD, PhD Immune Cell Types and Biology Checkpoint blockade;Dendritic cell;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment
961 Poster Presentation Tumor-infiltrating mucosal-associated invariant T cells (MAIT) from patients with pancreatic cancer recognize shared tumor antigens in an MR1-restricted fashion    Jéssica O. Kamiki, MSc; Patrícia A. António; Rodrigo Eduardo; Sara Cascais; Bernardo Marinheiro; Andreia Maia; Eric De Sousa; Joana R. Lerias, DVM, PhD; Carolina M. Gorgulho; Mireia Castillo-Martin; Markus Buechler; Antonio Beltran; Carlos Carvalho, MD; Ridong Chen; Sam Jeong; Markus J. Maeurer, MD, PhD, FRCP(London) Immune Cell Types and Biology Adoptive immunotherapy;Gene expression;Immune monitoring;Inflammation;Microbiome;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
962 Poster Presentation IFI16 promotes immune responses through IFN-&gamma; pathway activation in metastatic cutaneous melanomas Yuta Kobayashi, MD, PhD; Matias A. Bustos, PhD; Qiang Yu, PhD; Dave Hoon, MSc, PhD Immune Cell Types and Biology Chemokine;Cytokine;Gene expression;Immune suppression;Monocyte/Macrophage;RNA;Tumor microenvironment
963 Poster Presentation Significantly different immune microenvironment between triple-negative breast cancer with and without neoadjuvant chemotherapy through multiplex immunohistochemistry    Miseon Lee, MD.PhD, MD,PhD; Hyun Lee, MD; Gyungyub Gong; Hee Jin Lee Immune Cell Types and Biology Tumor microenvironment
964 Poster Presentation Dynamic immune landscapes during melanoma progression reveal a role for endogenous opioids in driving T cell dysfunction    Davide Mangani; Linglin Huang; Meromit Singer; Ruitong Li; Rocky Barilla; Giulia Escobar, PhD; Katherine Tooley; Hanning Cheng; Conor Delaney; Kathleen Newcomer; Jackson Nyman; Nemanja Marjanovic; James Nevin; Orit Rozenblatt-Rosen; Vijay Kuchroo; Aviv Regev; Ana C. Anderson, PhD Immune Cell Types and Biology Checkpoint blockade;Immune suppression;Immune tolerance;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
965 Oral Presentation Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway to generate TCF1+ progenitor CD8 T cells to improve efficacy of PD-1 checkpoint blockade.    Geoffrey J. Markowitz, PhD; Yi Ban, Ph.D.; Diamile Tavarez; Michael Crowley, Ph.D.; Liron Yoffe, Ph.D.; Mitchell Martin; Tito Sandoval, Ph.D.; Dingcheng Gao, Ph.D.; Juan Cubillos-Ruiz, Ph.D.; Timothy E. McGraw, Ph.D.; Nasser K. Altorki, M.D.; Vivek Mittal, Ph.D. Immune Cell Types and Biology Adoptive immunotherapy;Checkpoint blockade;Gene expression;Metabolism;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
966 Poster Presentation Multispectral Immunohistochemistry reveals an immunosuppressive tumour microenvironment in Esophageal Adenocarcinoma Charles J. Rayner, MB BS MRCS; Tyler F. Wooldridge, BSc (Hons); Sunny Sunshine; Izhar Bagwan, MBBS, MD, FRCPath; Shaun R. Preston, MD FRCS; Hardev S. Pandha, PhD, FRCP, FRACP, FR; Nima Abbassi-Ghadi, PhD FRCS; Nicola E. Annels, BSc, PhD Immune Cell Types and Biology Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors;Surgery;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
967 Poster Presentation Unfavorable neoantigen architectures blunt anti-tumor T cell responses in a mouse model of lung adenocarcinoma    Malte Roerden, MD, PhD; Kim B. Nguyen, B.A.; Nory G. Klop-Packel; Christopher J. Copeland; Nishant Singh; Michael Birnbaum, PhD; Stefani Spranger, PhD Immune Cell Types and Biology Antigen presenting cells;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor evasion
968 Poster Presentation Improved antitumoral activity of antigen-specific CD8+T cells in comparison to unspecific activated CD8+T cells in a 2D T cell killing assay targeting HER2+ breast cancer    Ina Rohleff; Matthias Bleisch; Kanstantsin Lashuk; Julia Schueler, DVM PhD Immune Cell Types and Biology Checkpoint blockade;Solid tumors;T cell;Tumor antigens
969 Poster Presentation Next-generation immunotherapy using patient-derived APC Zhen Bian, Ph.D; Lei Shi, PhD; Harry Stylli; Yuan Liu; Jane Zen Immune Cell Types and Biology Antigen presenting cells;Myeloid cells
970 Poster Presentation Exhausted T cells are characterized by inappropriate lipid accumulation Kellie Spahr, BS; Nicole E. Scharping, PhD; Greg M. Delgoffe, PhD Immune Cell Types and Biology Immune suppression;Metabolism;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
971 Poster Presentation VISTA regulates the differentiation and function of myeloid-derived suppressor cells Keman Zhang, PhD; Amin Zekeri, PhD; Juan Dong, PhD; Sarah Stone; Li Wang, PhD Immune Cell Types and Biology Gene expression;MDSC;Monocyte/Macrophage;Myeloid cells
972 Poster Presentation Enrichment of atypical memory double negative (CD27- IgD-) tumour infiltrating B cells following neoadjuvant chemotherapy for early-stage breast cancer Esme Carpenter, MRes; Thanussuyah Alaguthurai; Farhana Hossain; Rosalind Graham; Helen Kakkassery, MRes; Sean Keane; Sheeba Irshad, MD PhD Immune Cell Types and Biology B cell;Chemotherapy;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
973 Poster Presentation Extrafollicular Expansion and Differentiation of B Cells Drives Anti-Tumor Responses in Metastatic Cancer Noor E. Nader, BS; Dongyan Liu; Hye Mi Kim, BS; Ayana Ruffin, PhD; Sheryl R. Kunning; Xiaron Zhang, MD, MS; Daniel Dunlap, MD; Roy Semaan, MD; Rajeev Dhupar, MD, MBA, FACS; Adam C. Soloff, PhD; Tullia Bruno, PhD Immune Cell Types and Biology Antibody;Antigen presenting cells;B cell;Solid tumors;Tumor antigens;Tumor microenvironment
974 Poster Presentation Regulatory B cells producing IL-10 are increased in human tumour draining lymph nodes. Krzysztof Piersiala, MD; Krzysztof Piersiala; Pedro Farrajota Neves da Silva; Vilma Lagebro; Gregori Margolin; Susanna Kumlien Georén, PhD; Lars Olaf Cardell Immune Cell Types and Biology B cell;Immune monitoring;Immune suppression;Solid tumors
975 Poster Presentation Characterization of signaling and metabolic differences between γδ and αβ CAR T cells Xiomar E. Bustos, MS; Daniel Abate-Daga, PhD; Leticia Tordesillas, PhD Immune Cell Types and Biology Adoptive immunotherapy;CAR T cells;Metabolism;Proteomics;T cell;T cell lineages
976 Poster Presentation T-cell metabolic activity is impacted by the nutrient composition within the tumor microenvironment Jesse Bucksot, PhD; Dorys A. Lopez-Ramos, PhD; Tushar Pandey; Anuja K. Antony, MD; Joseph R. Peterson, PhD; Daniel J. Cook Immune Cell Types and Biology Metabolism;Systems biology;T cell;Tumor microenvironment
977 Poster Presentation Highly cytotoxic resilient CD8+ T cells avoid exhaustion by lowering ROS through ME1 upregulation    Joanina K. Gicobi, BS; Haidong Dong, MD, PhD; Cindy Liu Immune Cell Types and Biology Checkpoint blockade;Metabolism;T cell
978 Poster Presentation Dendritic cell-intrinsic PTPN22 negatively regulates anti-tumor immunity    Santiago Acero-Bedoya, MS; Thomas F. Gajewski, MD, PhD; Emily F. Higgs, PhD Immune Cell Types and Biology Dendritic cell;Genetic polymorphism;Myeloid cells;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
979 Poster Presentation Compound screen identifies inhibitor of apoptosis proteins (IAP) antagonist as an inducer of T cell proliferation after cross-presentation by dendritic cells     Esmee Hoefsmit, MSc; Paula T. van Royen; Disha Rao; Johanna A. Stunnenberg; Petros Dimitriadis; Cor Lieftink; Ben Morris; Elisa A. Rozeman; Irene L.M. Reijers; Ruben Lacroix; Huma Shehwana; Maarten A. Ligtenberg; Roderick L. Beijersbergen; Daniel S. Peeper; Christian U. Blank Immune Cell Types and Biology Antigen presenting cells;Checkpoint blockade;Dendritic cell;T cell
980 Poster Presentation In-depth characterization of cDC1 ex vivo and in vitro models: development and comparison of conventional dendritic cell culture systems for industry Anna Licht; Tamera Ashworth; Laura L. Goodfield; Hannah Gardner; Johanna Lahdenranta, PhD; Philip E. Brandish, PhD; Kevin McDonnell, PhD; Nicholas Keen, PhD Immune Cell Types and Biology Dendritic cell
981 Poster Presentation Peritumoral stromal remodeling licenses cDC1 through CD40 to elicit T-cell inflammation    Athanasios Papadas, MD; Alexander P. Cicala; Alejandro Rizo; Chelsea Hope; Katerina Politi, PhD; Christian Capitini, MD; Kristina Matkowskyj; Scott I. Abrams, PhD; Fotis Asimakopoulos, MD PhD Immune Cell Types and Biology Antigen presenting cells;Dendritic cell;Glycoproteomics;Immune contexture;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
982 Poster Presentation cDC1 cells are required to sustain CD8 T cell stemness in cancer and for the success at the onset of various immunotherapies. Alvaro Teijeira, PhD; Carlos Luri; Saray Garasa, BS; Assunta Cirella; Ignacio I.M. Melero, MD, PhD Immune Cell Types and Biology Antigen presenting cells;Checkpoint blockade;T cell
983 Poster Presentation BCL-2 inhibition mediates Treg to TH17 plasticity through inhibition of FOXO1    Rosy Liao, BS; Anika T. Thomas-Toth; Joshua McKeever; Andrew Koh, PhD; James L. LaBelle, MD, PhD Immune Cell Types and Biology Cytokine;Gene expression;Regulatory T cell (Treg cell);T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
984 Poster Presentation MEK1 within extracellular vesicles inhibits tumor growth by promoting anti-tumor immunity Jack D. Bui, MD, PhD; Stephen Searles, PhD; Jarrod Yee, MS; Preston Lee, MS; Christine Caron, MS; Calvin Lee, MS; Irina Matei, PhD; David C. Lyden, MD, PhD Immune Cell Types and Biology Extracellular vesicles/exosomes;Monocyte/Macrophage;Tumor microenvironment
985 Poster Presentation Inhibition of fibroblast growth factor receptor 4 (FGFR4) signaling activates tumor interferon (IFN) signaling in hepatocellular carcinoma (HCC) Nannan Zhang, PhD; Zhui Chen; Bin Shen; Zhixuan Zhu; Jueping Shi; Jiacheng Zhang; Pan Liang; Jie Wang Immune Cell Types and Biology Solid tumors;T cell;Targeted therapy;Tumor microenvironment
986 Poster Presentation Local and lymphoid immune surveillance mechanisms in 'exceptional survivors' of stage IV breast cancers following standard of care chemo- and targeted therapies Helen Kakkassery, MRes; Thanussuyah Alaguthurai; Rosalind Graham; Esme Carpenter, MRes; Farhana Hossain; Sean Keane; Sheeba Irshad, MD PhD Immune Cell Types and Biology Immune monitoring;NK/NKT cell;Solid tumors;T cell;T cell lineages
987 Poster Presentation Comprehensive immunophenotyping and genomics from single blood tube for T-cell dynamics in clinical trials    Manling Ma-Edmonds, MS; Gregg Masters; Omar J. Jabado, PhD; Lisa Grimm, MS; Mahesh B. Bachu, PhD; Matthew Loya, BS; Gabrielle Suppa, MS; Jordan M. Blum, PhD; David Soong, PhD; Han Si, PhD; Brandon Higgs; Nicole Bottrel, MS; Erin Henitz, MS; Christopher Chiu, PhD; Kate Sasser; Mark Fereshteh Immune Cell Types and Biology Bioinformatics;Biomarkers;Clinical trial;Gene expression;Immune monitoring;RNA;Surfaceome;Systems biology;T cell;T cell lineages
988 Poster Presentation B-Cell Receptor (BCR) Repertoire and Antibody Recognition Analysis of Melanoma Patients Treated with Neoadjuvant Immune Checkpoint Blockade (ICB) Monika A. Zelazowska, PhD; Somnath Paul, PhD; Joshua B. Plummer; Manoj Chelvanambi, PhD; Beth A. Helmink, MD PhD; Russell G. Witt, MD; Michael G. White, MD; Shalaka R. Lotlikar, PhD; Melissa Simper, PhD; Sarah B. Johnson, MS; Alexandra L. Hebertson; Bin Liu, PhD; Jennifer A. Wargo, MD, MMSc; Kevin McBride, PhD Immune Cell Types and Biology Antibody;B cell;Bioinformatics;Checkpoint blockade;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
989 Poster Presentation A luciferase-based method to assess antigen-specific T cell responses and antigen presentation to evaluate immunomodulatory checkpoints and therapeutics    Jimena Alvarez Freile, MSc; Yuzhu Qi; Lisa Jacob; Maria Franceskin Lobo; Harm Jan Lourens; Gerwin Huls; Edwin Bremer Immune Cell Types and Biology Antibody;Antigen presenting cells;Checkpoint blockade;Immune monitoring;Immune suppression;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor microenvironment
990 Poster Presentation Heterogeneity in glioblastoma tumor microenvironment: strategies for cancer-associated fibroblast targeting    Jonathan Stauber, PHD; Corinne C.R. Ramos, PhD; Sandra Delebecq; Adele Ponzoni; Lisa Guzzi Immune Cell Types and Biology Biomarkers;Solid tumors;Tumor microenvironment;Tumor stroma
991 Poster Presentation AB598, a therapeutic anti-human CD39 antibody, binds and inhibits CD39 enzymatic activity in vivo to promote anti-tumor immunity Kaustubh Parashar; Julie Clor; Amy E. Anderson, PhD; Urvi Vani; Jaskirat Singh; Enzo Stagnaro; Ferdie Soriano, BS; Angelo Kaplan; Janine Kline; Lisa Seitz, MS; Stephen W. Young; Nigel P. Walker, PhD; Matthew Walters; Ester Fernandez-Salas; Christine Bowman, PhD Immune Cell Types and Biology Antibody;Antigen presenting cells;Chemotherapy;Cytokine;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment
992 Poster Presentation Intratumoral S100A8-to-CD8 ratio in inflamed Merkel cell carcinoma tumors correlates with response to PD-1 pathway blockade Shira Tabachnick-Cherny, PhD; Thomas Pulliam; Haroldo J. Rodriguez Chevez, BS; Kimberly S. Smythe, BS; Rima Kulikauskas; Kristina Lachance; Daniel Hippe; Paul T. Nghiem, MD, PhD Immune Cell Types and Biology Biomarkers;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor microenvironment
993 Poster Presentation InteractPrint predicts clinically meaningful interactions between cancer epithelial cells and immune cells: Lessons from a single-cell breast cancer atlas Lily Xu, B.A.; Kaitlyn Saunders, B.A.; Hildur Knutsdottir, PhD; Kenian Chen, PhD; Julia Maués; Christine Hodgdon; Evanthia Roussos Torres; Sangeetha M. Reddy; Lin Xu, PhD; Isaac Chan, MD, PhD Immune Cell Types and Biology Bioinformatics;Tumor microenvironment
994 Poster Presentation Investigating the ability of tumor cell-derived type I interferon to potentiate anti-ovarian cancer immune responses    Fiona Chatterjee, BA; Ellen Duong, PhD; Arjun Bhutkar, PhD; Stefani Spranger, PhD Immune Cell Types and Biology Cytokine;Dendritic cell;Solid tumors;T cell
995 Poster Presentation V domain immunoglobulin suppressor of T cell activation (VISTA) re-programs macrophage biology and promotes phagocytosis and M2c-differentiation Yusheng Lin, PhD candidate; Ghizlane Choukrani; Lena Dubbel; Lena Rockstein; Jimena A. Freile; Yuzhu Qi; Harm Jan Lourens; Nienke Visser; Valerie Wiersma; Hao Zhang; Emanuele Ammatuna; Tom V. Meerten; Gerwin Huls; Edwin Bremer Immune Cell Types and Biology Cytokine;Immune suppression;Leukemia/Lymphoma;Monocyte/Macrophage;Myeloid cells
996 Poster Presentation Functional and transcriptomic profiling of myeloid cells in pediatric solid tumors to inform next generation immunotherapy Cristina F. Contreras; Sabina Kaczanowska, PhD; Francesca Buffa; Rosandra N. Kaplan, MD Immune Cell Types and Biology Gene expression;Immune monitoring;Monocyte/Macrophage;Myeloid cells;Pediatric tumors;Solid tumors
997 Poster Presentation T cell immunotherapies trigger neutrophils to eliminates heterogenous tumors Daniel Hirschhorn; Sadna Budhu, PhD; David Redmond; Jacob Ricca; Billel Gasmi; Mathieu Gigoux, PhD; Cailian Liu, MD; Yanyun Li, PhD MD; Czrina Cortez, BS; David Schroder, MD; Arshi Arora; Travis Hollman, PhD, MD; Lukas kraehenbuehl; Hyejin Choi, PhD; Sara Schad; Isabell Schulze; Rebekka Duhen, PhD; Andrew D. Weinberg, PhD; Andrew Chow, MD, PhD; Mikala Egeblad, PhD; Katherine S. Panageas, PhD; Gabrielle A. Rizzuto; Olivier de Henau; Aliya Holland; Jean Albrengues, PhD; Linda Hamadane; David Ng; Xue-Yan He; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD Immune Cell Types and Biology Checkpoint blockade;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
998 Poster Presentation Neutrophil subsets in head and neck cancer    Sandra SE. Ekstedt, PhD; Krzysztof Piersiala; Magnus Starkhammar, MD; Gregori Margolin, MD, PhD; Susanna Kumlien Georén, PhD; Lars Olaf Cardell, MD, PhD Immune Cell Types and Biology Granulocyte;Solid tumors;Tumor microenvironment
999 Poster Presentation Investigating the immunomodulatory role of innate lymphoid cells in epithelial ovarian carcinoma Douglas C. Chung, Bsc; Kathrin Warner, PhD; Jehan Vakharia, BSc; SeongJun Han, PhD; Maryam Ghaedi, PhD; Carlos Garcia-Batres, MSc; Nicolas Jacquelot, PhD; Azin Sayad, MSc; Sarah Ferguson, MD, FRCSC; Pamela S. Ohashi, PhD Immune Cell Types and Biology Bioinformatics;Cytokine;Gene expression;Immune contexture;Immune suppression;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1000 Poster Presentation Melanoma Lymph Node Metastases are Associated with Hypoxia and Immunologic Dysfunction Dustin McCurry, MD; Chistopher Deitrick; Yan Zang; Arivarasan Karunamurthy, MD; Theresa L. Whiteside, PhD; Diwakar Davar, MD; Hassane Zarour, MD; Jason J. Luke, MD; John M. Kirkwood, MD; Riyue Bao, PhD; Yana G. Najjar, MD Immune Cell Types and Biology Bioinformatics;Checkpoint blockade;Immune suppression;Metabolism;Monocyte/Macrophage;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
1001 Poster Presentation Immunophenotyping of brain tumors identifies interferon enriched phagocytes in human gliomas Pravesh Gupta, PhD; Minghao Dang, Ph.D.; Dapeng Hao, PhD; Krishna Bojja, BS; Tuan M. Tran, PhD; Huma Shehwana, PhD; Carlos Kamiya-Matsuoka, MD; Jianzhuo Li, PhD; Alessandra Audia, PhD; Cynthia Kassab, PhD; Martina Ott, PhD; Joy Gumin, PhD; Sanaalarab Alenazy, PhD; Alicia Goldman, MD; Sameer A. Seth, MD; Atul Maheshwari, MD; Veerakumar Balasubramaniyan, PhD; Brian Vaillant, MD; John F. de Groot, MD; Antonio Iavarone, MD; Frederick F. Lang, MD; Nicholas E. Navin, PhD; Amy B. Heimberger, M.D.; Linghua Wang, PhD; Krishna Bhat, PhD Immune Cell Types and Biology Antigen presenting cells;Immune contexture;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment
1002 Poster Presentation Circulating myeloid states induced with anti-PD-1 and GM-CSF combination therapy are associated with treatment resistance in human biliary cancer Bridget P. Keenan, MD, PhD; Elizabeth McCarthy; Arielle Ilano; Diamond Luong; Hai Yang; Li Zhang, PhD; Kathryn Allaire; Zenghua Fan, PhD; Tony Li; David S. Lee; Yang Sun, PhD; Alexander Cheung; Hewitt Chang; Brandon Chen; Brenna Sheldon; Robin K. Kelley, MD; Chun Jimmie Ye, PhD; Lawrence Fong, MD Immune Cell Types and Biology Checkpoint blockade;Monocyte/Macrophage;Solid tumors;T cell
1003 Poster Presentation Macrophage adhesion to tumor cells positively impacts tumor growth      Jovan Nikolic, PhD; Joseph Ackerman, PhD; Sarah Taheraly; Thierry Rose, PhD; Ouardia Aït-Mohamed, PhD; Martine Ben Amar, PhD; Jean-François Joanny, PhD; Philippe Benaroch, PhD Immune Cell Types and Biology Monocyte/Macrophage;Myeloid cells;Tumor microenvironment
1004 Poster Presentation Signaling pathways inducing tumoricidal phagocytosis in pancreatic cancer Li Qiang, Ph.D.; Stephanie Dougan, PhD; Samantha Liu; Gabrielle Ro; Michael Dougan, MD, PhD; Lestat Ali, MD; Patrick Lenehan; Felix Hambitzer Immune Cell Types and Biology Monocyte/Macrophage;Tumor microenvironment
1005 Poster Presentation PD-L1 knockout Natural Killer cells as a cellular product for therapeutic use in combination with humanized ADCC-competent anti-PD-L1 Tayler J. Croom-Perez, PhD; Jeremiah L. Oyer; Md Faqrul Hasan, Masters; Thomas A. Dieffenthaller; Liza D. Robles-Carrillo; Alicja J. Copik, PhD Immune Cell Types and Biology Adoptive immunotherapy;Checkpoint blockade;NK/NKT cell
1006 Poster Presentation Single-cell functional genomics of natural killer cell evasion in blood cancers Olli Dufva; Sara Gandolfi; Jani Huuhtanen; Olga Dashevsky; Khalid Saeed; Jay Klievink; Petra Nygren; Jonas Bouhlal; Jenni Lahtela; Anna Näätänen; Bishwa Ghimire; Tiina Hannunen; Pekka Ellonen; Hanna Duàn; Jason Theodoropoulos; Essi Laajala; Jouni Härkönen; Petri Pölönen; Merja Heinäniemi; Shizuka Yamano; Ryosuke Shirasaki; David Barbie; Jennifer Roth; Rizwan Romee; Michal Sheffer; Harri Lähdesmäki; Dean A. Lee; Ricardo De Matos Simoes; Matti Kankainen; Constantine S. Mitsiades; Satu Mustjoki Immune Cell Types and Biology Adoptive immunotherapy;Biomarkers;Gene expression;Leukemia/Lymphoma;NK/NKT cell;Systems biology;Tumor evasion
1007 Poster Presentation Microglia recruit and activate natural killer cells to control tumor progression in breast cancer brain metastasis Timothy P. McMullen, BA; Aaron Longworth; Dennis Ma; Devon A. Lawson, PhD; Katrina Evans Immune Cell Types and Biology Bioinformatics;Immune suppression;Myeloid cells;NK/NKT cell;Tumor evasion
1008 Poster Presentation Cross-Species Characterization of Splenic Natural Killer (NK) Cells Reveals Organ-Specific Heterogeneity with Implications for Cancer Immunotherapy Lauren E. Farley, BS; Khurshid Iranpur, BS; Aryana M. Razmara, MS; Sylvia M. Cruz; Marshall Lammers, BS; Cyrus J. Sholevar, MD; Robert M. Rebhun, DVM PhD; Michael S. Kent, DVM; William Culp, VMD; Richard J. Bold, MD; Sean J. Judge, MD; William J. Murphy; Robert J. Canter, MD Immune Cell Types and Biology NK/NKT cell
1009 Poster Presentation Knockout of the inhibitory receptor TIGIT enhances anti-tumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-competent TIGIT antibodies Md Faqrul Hasan, Masters; Tayler J. Croom-Perez, PhD; Jeremiah L. Oyer; Thomas A. Dieffenthaller; Liza D. Robles-Carrillo; Alicja J. Copik, PhD Immune Cell Types and Biology Adoptive immunotherapy;Checkpoint blockade;NK/NKT cell
1010 Poster Presentation A Single-Cell Transcriptomic Atlas of Human NK Cells to Guide Cancer Immunotherapy Ryan J. King, PhD; Azim Amirabad, PhD; Amir Bayegan; Joachim Theilhaber; Nicole Acuff; Shannon McGrath; Ziangming Li; Franck Rapaport, PhD; Jack Pollard, PhD; Donald G. Jackson, PhD Immune Cell Types and Biology Bioinformatics;NK/NKT cell;RNA;Tumor microenvironment
1011 Poster Presentation Antibody targeting NKG2D ligands MICA/B to unleash anti-tumor immunity of NK and ILC1 cells Sizhe Liu, BS; Tyler A. Smith, PhD; Lisha Zhu, PhD; Payal Dhar, PhD; Jennifer D. Wu, PhD Immune Cell Types and Biology Antibody;Immune contexture;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs)
1012 Poster Presentation Fibroblast activation protein regulates human natural killer cell migration.    Rachael E. Maynard, MD, PhD Candidate; Allison Fitzgerald; Apsra Nasir; Eric Glasgow, PhD; Sandra Jablonski, PhD; Pieter Van Der Veken; Gray Pearson, PhD; Emily Mace, PhD; Louis M. Weiner, MD Immune Cell Types and Biology NK/NKT cell;Solid tumors
1013 Poster Presentation Prognostic value of Natural Killer cell activity and derived neutrophils-to-lymphocytes ratio in non-small cell lung cancer patients receiving immune checkpoint inhibitors    Line Nederby, MSc, PhD; Sara W.C. Wen, MD; Torben S. Hansen, MD; Christa H. Nyhus, MD; Lisbeth Bertelsen, MD; Rikke F. Andersen, MSc, PhD; Anders Jakobsen, MD, DMSc, Professor; Torben F. Hansen, MD, DMSc, Associate Professor Immune Cell Types and Biology Biomarkers;Checkpoint blockade;Immune suppression;NK/NKT cell;Solid tumors
1014 Poster Presentation Complement C3 deficiency increases the anti-tumor immunity of NK cells and controls tumor growth Girdhari Lal, PhD; PRADIPTA PAL, M.Sc (Integrated Biotechnology); Sourav Paul; Heikrujam Thoihen Meitei; Praneet Wahi; Arvind Sahu, PhD Immune Cell Types and Biology Cytokine;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1015 Poster Presentation Natural Killer cells in immunotherapy-induced MHC-I tumor escape Eric Miao; Jennifer Poursine-Laurent; Kathleen CF. Sheehan; Robert D. Schreiber, PhD; Wayne M. Yokoyama; Sytse J. Piersma, PhD Immune Cell Types and Biology Checkpoint blockade;Immune suppression;Neoantigens;NK/NKT cell;Solid tumors;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1016 Poster Presentation IL-2 expanded tumor infiltrated Natural Killer (TINK) cells from canine sarcomas possess potent anti-tumor cytotoxicity     Weiqing Jing, PhD; Himaly Shinglot; Juliana Chi Kei Ng; Ali Zhang; Bernard Seguin; Jeffrey Bryan; Timothy Fan; Jennifer D. Wu, PhD; Seth M. Pollack Immune Cell Types and Biology NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs)
1017 Poster Presentation A tumor model in the humanized immuno-reconstituted hIL15 transgenic mice revealed the impact of other immune components on the development and function of NK cells against malignancies Li Yang; Chunlei Dai; Hongmei Xu; Hui Qi; Xuzhen Tang; Qingyang Gu; Qunsheng Ji, PhD Immune Cell Types and Biology Immune suppression;NK/NKT cell;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1018 Poster Presentation Multifunctional Natural Killer Cell Engager Releasing CXCL10 Augments Natural Killer Cell Recruitment and Anti-tumor Efficacy against Glioblastoma Xue Yao, Master; Sandro Matosevic, PhD Immune Cell Types and Biology Antibody;Bispecifics;Chemokine;Cytokine;NK/NKT cell;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1019 Oral Presentation CSF1R+PD-L1+ Tumor-associated Macrophages Trigger MAIT Cell Dysfunction at the HCC Invasive Margin Benjamin Ruf, M.D.; Matthias Bruhns, M.Sc.; Sepideh Babaei, Ph.D.; Noemi Kedei, MD; Chi Ma, MD, PhD; Lichun Ma, Ph.D.; Mahler Revsine; Bernd Heinrich, MD; Varun Subramanyam, B.Sc; Jonathan Qi, B.Sc.; Simon Wabitsch, M.D.; Benjamin Green, M.D.; Kylynda C. Bauer, Ph.D.; Yuta Myojin, MD, PhD; Mohamed-Reda Benmebarek, Ph.D.; Layla Greten; Justin McCallen, M.D.; Patrick Huang, D.V.M.; Marie Pouzolles, Ph.D; David Kleiner, M.D. Ph.D.; William Telford, Ph.D.; Kimia Dadkhah, Ph.D.; Allison Ruchinskas; Merrill Stoffroff; Jiman Kang, M.D.; Kesha S. Oza, M.D.; Mathuros Ruchirawat, Ph.D.; Alexander Kroemer, M.D.; Xin W. Wang, PhD; Manfred Claassen, Ph.D.; Firouzeh Korangy, Ph.D.; Tim F. Greten, MD Immune Cell Types and Biology Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Proteomics;Solid tumors;Systems biology;T cell;T cell lineages;Tumor microenvironment
1020 Poster Presentation Targetting TIM-3 on T regulatory cells make Nonresponsive cold Melanoma, more responsive to immune mediated tumor control. Hridesh Banerjee, PhD; Hector N. Rosado; Benjamin M. Murter, BS; Lawrence P. Kane, PhD Immune Cell Types and Biology Antigen presenting cells;CAR T cells;Cytokine;Immune monitoring;Immune toxicity;Inflammation;Metabolism;T cell;Tumor evasion;Tumor microenvironment
1021 Poster Presentation A pan-cancer signature identifies tumor-reacting CD8+ TILs and reveals their functional heterogeneity    Christopher A. Chamberlain, MSc; Arianna Draghi, MD; Shawez Khan; Katja Harbst, PhD; Mario Presti, MD; Aimilia Schina; Agnete Witness Præst Jensen, MSC; Anne-Christine Kiel Rasmussen, MSc; Torben Lorentzen, MD; Jakob Vasehus Schou, MD; Göran B. Jönsson, Professor, PhD; Inge M. Svane, MD, PhD; Marco Donia, MD, PhD Immune Cell Types and Biology Bioinformatics;Chemokine;Cytokine;Gene expression;Immune monitoring;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
1022 Poster Presentation Tumor-infiltrating CXCR6-expressing tissue-resident memory HPV-specific CD8+ T cells are terminally exhausted in HPV-associated head and neck squamous cell carcinoma Yang Cheng, PhD; Kathleen Atkinson; Talia Saal; Jean S. Campbell, PhD; Sara I. Pai, MD PhD Immune Cell Types and Biology Immune monitoring;Solid tumors;Systems biology;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1023 Poster Presentation The signal strength of signal 2 and 3 during T cell priming affect the functional fate of an anti-tumor T cell response. Duncan M. Morgan, Ph.D.; Vidit Bhandarkar, BS; Emi Lutz; K. D. Wittrup; Stefani Spranger, PhD; Teresa Dinter, BS Immune Cell Types and Biology Checkpoint blockade;Costimulation;Cytokine;T cell;T cell lineages
1024 Poster Presentation Illuminating stem memory T cell (Tscm) heterogeneity in human cancer: Characterization of a unique CD45RO+ Tscm population in human ovarian cancer    Erica G. Brown, BS; Monika Eiva; Veethika Pandey; Alexander Benton, BA; Stacy K. Thomas; Wenzhao Meng; Aaron M. Rosenfeld; Eline T. Luning Prak; Daniel J. Powell, Jr., PhD Immune Cell Types and Biology Stem cell/cancer-initiating cell;T cell;Tumor infiltrating lymphocytes (TILs)
1025 Poster Presentation Single Cell Evaluation of Costimulatory and Coinhibitory Receptors and Their Ligands Across Solid Tumor Indications Shawn P. Fahl, PhD; Kerri Colwell; Cavin Ott; Casey Smith; Kayla Williams; Alex Moore Immune Cell Types and Biology Coinhibition;Costimulation;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
1027 Poster Presentation Chronic antigen in solid tumors drives a distinct program of T cell residence Noah V. Gavil, BA; Milcah Scott, BS; Eyob Weyu; Olivia Smith; Stephen D. O'Flanagan; Sathi Wijeyesinghe, MD, PhD; Sahar Lotfi-Emran, MD, PhD; Stephen L. Shiao, MD, PhD; Vaiva Vezys, PhD; David Masopust, PhD Immune Cell Types and Biology Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1028 Poster Presentation IL-12 and IL-27 upregulate CD39 expression on CD8+ T-cells and differentially affect CD39+CD8+ T-cell effector function Lara Gerhardt, BSc; Rene Figueredo, MSc; Saman Maleki, PhD Immune Cell Types and Biology Cytokine;T cell;Tumor infiltrating lymphocytes (TILs)
1029 Poster Presentation Engineering of T cells with CCR10 for enhanced trafficking of adoptive cell therapy Jong Moo Hong; Hee Jin Lee; Gyung Yub Gong; Kwang Hee Kim, PhD Immune Cell Types and Biology Adoptive immunotherapy;Chemokine;T cell
1030 Poster Presentation PSGL-1-deficiency suppresses tumor growth of orthotopic pancreatic ductal adenocarcinoma tumors and enhances immune cell infiltration and CD8+ T cell responses Jennifer L. Hope, PhD; Yijuan Zhang, PhD; Ashley B. Palete; Hannah A. Faso; Sreeja Roy, PhD; Dennis C. Otero, PhD; Swetha Maganti; Cosimo Commisso, PhD; Linda M. Bradley, PhD Immune Cell Types and Biology Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
1031 Poster Presentation Acetyl CoA Carboxylase Inhibition Rewires T cell Fate and Tumor Immunotherapy Outcome    Katie Hurst; Brian P. Riesenberg, PhD; Elizabeth Hunt, BS; Alex M. Andrews, PhD; Megan Tennant, MS; Evelyn Gandy; Peng Gao; Lauren Ball, PhD; Emily Wallace; David Corcoran; Jessica E. Thaxton, PhD, MS Immune Cell Types and Biology Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1032 Poster Presentation Uncoupling CD39 and T cell antigen specificity in brain tumors   Jordan F. Isaacs; Sierra A. Kleist; Shawn C. Musial; Hanna N. Degefu; Pamela C. Rosato, PhD Immune Cell Types and Biology Immune suppression;Inflammation;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
1033 Poster Presentation Stem-like CD8 T-cells residing in antigen presenting immune niches are prognostic for local control in brain metastases and are sustained following radiation therapy Caroline S. Jansen, PhD; Prasanthi Chappa; Nataliya Prokhnevska, BS; Maria Cardenas; Roshan Prabhu; Jim Zhong; Kimberly B. Hoang; Subir Goyal, MBBS, PhD, MSc; Suzanna Logan; Jeffrey Olson; Edjah K. Nduom, MD; Luke del Balzo; Kirtesh R. Patel, MD; Stuart Burri; Anthony Asher; Scott Wilkinson, PhD; Ross Lake; Kristin Higgins; Pretesh Patel; Vishal Dhere; Mylin Torres; Adam G. Sowalsky, PhD; Mohammad K. Khan; Haydn Kissick, PhD; Zachary Buchwald, MD PhD Immune Cell Types and Biology Antigen presenting cells;Biomarkers;Dendritic cell;Immune contexture;Immunoscore;Radiotherapy;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1034 Poster Presentation Analysis of factors associated less differentiated T cells in breast cancer for improvement of adoptive T cell therapy Sung Wook Jung; Jeong-Han Seo, PhD candidate; Hyeonjin Lee; Gyungyub Gong; Hee Jin Lee Immune Cell Types and Biology Adoptive immunotherapy;Gene expression;T cell
1035 Poster Presentation High-dimensional Immune Profiling of Peripheral Epstein-Barr Virus-specific T cells in Nasopharyngeal Carcinoma    Nandita Kumar, BS; Hugh R. MacMillan, PhD; Joe Poh Sheng P. Yeong, MD, PhD; Melvin L. Chua, MBBS, FRCR, PhD, FAMS; Amit Jain, MBBS, MRCP, MMed; Evan W. Newell, PhD Immune Cell Types and Biology Antigen presenting cells;Biomarkers;Immune monitoring;T cell;Tumor antigens
1036 Poster Presentation Ron kinase as potential immunotherapeutic target for augmenting T cell activity in breast cancer metastasis Alicia S. Lai, PhD; Alana Welm, PhD Immune Cell Types and Biology Immune suppression;T cell;T cell lineages;Tumor evasion;Tumor infiltrating lymphocytes (TILs)
1037 Poster Presentation Single cell evaluation of antigen specificity, clonal dynamics and transcriptional signatures of CD8+ T cells in Head and Neck Squamous Carcinoma Housaiyin Li; Patricia M. Santos, PhD; Aditi Kulkarni; Alok V. Joglekar, PhD; Lazar Vujanovic, PhD; Robert L. Ferris, MD, PhD Immune Cell Types and Biology Checkpoint blockade;Neoantigens;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1038 Poster Presentation Loss of PD-1 signals improves CD8+ TIL function in a cell intrinsic and cell extrinsic manner    Samuel C. Markson, PhD; Kristen E. Pauken; Vikram Juneja; Osmaan Shahid; Kelly P. Burke; Jared Rowe; Jacklyn Long; Megan Fung; Jacob M. Luber; Jennifer Judge; Alison Ringel; Marcia C. Haigis, PhD; Meromit Singer; Arlene H. Sharpe Immune Cell Types and Biology Bioinformatics;Checkpoint blockade;T cell
1039 Poster Presentation The Prognostic value of tumour-specific T cells in Asian TNBC: using CD39+CD8+ T cells as a surrogate marker Jia Meng, PhD; Tira Tan, BSc (Hons), MBBS (UK), MRCP (UK); Jiangfeng Ye, PhD; Denise Goh; Chun Jye Lim; Valerie Koh; Felicia Wee; Jeffrey Chun Tatt Lim; Craig Joseph; Timothy Tay; Jason Chan, MBBS; Cedric Ng; Jabed Iqbal, MD, PhD, FCAP; Mai Chan Lau, PhD; Bin Tean Teh, MBBS,Ph.D.; Rebecca Alexandra Dent, MSc, MD, FRCP; Puay Hoon Tan, MBBS, FRCPA, FAMS, MD, FRCPath; Joe Poh Sheng P. Yeong, MD, PhD Immune Cell Types and Biology Biomarkers;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1040 Oral Presentation A population of ectoenzyme expressing T-cells with an immunosuppressive phenotype are associated with checkpoint immunotherapy resistance in metastatic melanoma patients.    David M. Woods, PhD; Carol M. Amato, MS; Ann M. Strange; Brian Thompson; Jeffrey S. Weber, MD, PhD; Ankita Mitra Immune Cell Types and Biology Biomarkers;Checkpoint blockade;Immune suppression;Solid tumors;T cell;T cell lineages
1041 Poster Presentation PIK3IP1/TrIP Immune Regulation on CD8+ T Cells Restricts Anti-Tumor Immunity Benjamin M. Murter, BS; Hridesh Banerjee, PhD; Sean C. Robinson; Andrea L. Szymczak-workman, PhD; Lawrence P. Kane, PHD Immune Cell Types and Biology Checkpoint blockade;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1042 Poster Presentation The dual function of the adenosine pathway in the liposarcoma tumor microenvironment Jacqueline Oliva; Younghee Lee; Rebeca Rodriguez; Katarzyna Tomczak; Davis Ingram; Xiao Zhou; Vinod Ravi; Anthony Conley; John Livingston; Joseph Ludwig; Neeta Somaiah, MD; Cara Haymaker Immune Cell Types and Biology Cytokine;Immune suppression;Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1043 Poster Presentation High VISTA expression on tumor-infiltrating lymphocytes is prognostic of poor survival in patients with endometrial cancer Sachin Patnaik, BA; Cassandra K. Gilmour, BS; Stefanie Avril, MD; Andrelie Branicky; Ajay Zalavadia, PhD; Judith Drazba, PhD; Li Wang, PhD Immune Cell Types and Biology Biomarkers;Immune suppression;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1044 Poster Presentation Proteasome mediated protein catabolism fuels antitumor immunity    Brian P. Riesenberg, PhD; Elizabeth G. Hunt; Megan Tennant, MS; Katie E. Hurst, MPH; Alex M. Andrews, PhD; Lee Leddy, MD, MsCR; David M. Neskey, MD; Elizabeth G. Hill, PhD; Guillermo O. Rangel Rivera; Chrystal M. Paulos, PhD; Peng Gao; Jessica E. Thaxton, PhD, MS Immune Cell Types and Biology Metabolism;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1045 Poster Presentation High dimensional profiling of Merkel cell polyomavirus-specific T cells in response to anti-PD-1 immunotherapy    Heeju Ryu, Ph.D.; Timothy Bi; Korok Sarkar; Candice Church, Ph.D.; Nirasha Ramchurren, PhD; Thomas Pulliam; Steven P. Fling, PhD; Paul T. Nghiem, MD, PhD; Evan W. Newell, PhD Immune Cell Types and Biology Biomarkers;Checkpoint blockade;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
1046 Poster Presentation Targeting Novel Pathways in Chronically Activated T Cells Prevents Functional Exhaustion Justyna Rzepecka, PhD; Andrew Hall, PhD; Mark Barbour; Emma Mallon; Marija Bedaj; Lucia Janicova; Xabier Cortes-Lavaud; Frances Acklam; Joanne Hay; Hayley Gooding; Darryl Turner; Preeti Singh; Aaron Crawford Immune Cell Types and Biology Checkpoint blockade;Coinhibition;T cell;Tumor microenvironment
1047 Poster Presentation From exhaustion to memory: altering T cell fate improves immunotherapeutic responses to cancer Nicole E. Scharping, PhD; Allison Cafferata; Maximilian Heeg, MD; Quynhanh Nguyen; Ananda W. Goldrath, PhD Immune Cell Types and Biology Adoptive immunotherapy;Proteomics;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs)
1048 Poster Presentation Interplay of IL-12 and IFNg to induce Treg fragility within the tumor microenvironment Ellen N. Scott, B.S.; Angela M. Gocher, PhD, MS; Creg Workman, PhD; Dario A. Vignali, PhD Immune Cell Types and Biology Cytokine;Regulatory T cell (Treg cell);Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1049 Oral Presentation Reconstruction of gene regulatory networks dissects transcriptional control of intratumoral regulatory T cells   Feng Shan, MS; Anthony R. Cillo, PhD; Carly Cardello; Daniel Yuan; Sheryl R. Kunning; Jian Cui, PhD; Robert L. Ferris, PhD; Tullia Bruno, PhD; Creg Workman, PhD; Panayiotis V. Benos, PhD; Dario A. Vignali, PhD Immune Cell Types and Biology Bioinformatics;Biomarkers;Gene expression;Immune suppression;Regulatory T cell (Treg cell);Systems biology;T cell;Tumor infiltrating lymphocytes (TILs)
1050 Poster Presentation Single cell transcriptome and epigenome profiling reveals the diversity of T cell states in ex vivo grown tumor-infiltrating lymphocytes from malignant pleural mesothelioma    Katarzyna Tomczak; Carlos Ramos, BS; Nathaniel Deboever, MD; Nicolas Zhou, DO, MSc; Jacqueline Liszeth Oliva, PhD; Chang-Jiun Wu, PhD; Chad D. Strange, MD; Annikka Weissferdt, MD; David C. Rice, MB, BCh, BAO, FRCSI; Reza J. Mehran, CD, MDCM, MSc, FRCSC, FACS; Jianjun Zhang, MD, PhD; Mehmet Altan, MD; Anne Tsao, MD; Boris Sepesi, MD, FACS; Cara Haymaker Immune Cell Types and Biology Epigenetics;Gene expression;Immune tolerance;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
1051 Poster Presentation Radiation dose-related temporal changes in STING-associated immune genes in murine CD8 T cells Ana Torres, BA; Amanda G. Shea, BS; Wonjong Jin, PhD; Caroline Kerr; Kaleb Schroeder; Paul A. Clark, PhD; Zachary S. Morris, MD, PhD Immune Cell Types and Biology Gene expression;Radiotherapy;T cell;T cell lineages
1052 Oral Presentation Tissue-specific interferon-gamma drives regulatory T-cells to restrain DC1-mediated priming of cytotoxic T-cells against lung cancer Maria Zagorulya, B.S.; Leon Yim, B.S.; Duncan M. Morgan, Ph.D.; Austin Edwards; Elen Torres-Mejia; Noor Momin, Ph.D.; Chloe V. McCreery; Izabella L. Zamora; Brendan L. Horton, PhD; K. D. Wittrup; J. C. Love; Stefani Spranger, PhD Immune Cell Types and Biology Antigen presenting cells;Checkpoint blockade;Costimulation;Cytokine;Dendritic cell;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor evasion
1053 Poster Presentation Identification of distinct immune landscapes of infiltrating T cells in colon cancer using multiplex immunofluorescence staining Hehuan Zhu, MSc; Jessica Roelands, MSc; Eiman Ahmed; Imke Stouten; Rachel Hoorntje; Ronald Vlierberghe; Marieke Ijsselsteijn; Noel Miranda; Rob Tollenaar; Wouter RL. Hendrickx, PhD; Davide Bedognetti, MD, PhD; Peter Kuppen Immune Cell Types and Biology Immunoscore;T cell;Tumor infiltrating lymphocytes (TILs)
1054 Poster Presentation Myeloid and T cell subsets defined in bladder cancer using single-cell RNA sequencing and paired protein profiling Viktor Sincic, MSc; Ashfaq Ali, PhD; Alar Aab, PhD; Thoas Fioretos, PhD; Carl Borrebaeck, PhD; Fredrik Liedberg, PhD; Kristina Lundberg, PhD Immune Cell Types and Biology Antigen presenting cells;Dendritic cell;Gene expression;Immune suppression;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
1055 Poster Presentation Immune cell subtypes associated with the level of tumor-infiltrating lymphocytes in breast tumor microenvironment    Su Min Cha; Jeong-Han Seo, PhD candidate; Jung-Wook Park, PhD candidate; Hee Jae Lee, PhD; Hee Jin Lee Immune Cell Types and Biology Bioinformatics;Gene expression;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1056 Poster Presentation ZG033, a novel CD137 agonist, induces superior anti-tumor activity without hepatotoxicity rely on Fc-mediated crosslinking    Liansheng Cheng; Wenting Liu; Dayan Zhang; Xiaoli Zeng; Guodong Shen Immune-stimulants and immune modulators Antibody;Costimulation;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs)
1057 Poster Presentation HBM7008, a first-in-class bispecific antibody targeting both B7-H4 and 4-1BB, exhibits robust anti-tumor immunity and low toxicity through B7-H4-directed 4-1BB activation    Bing Huang, Ms., Ph.D.; Fangfang Du; Xiaocheng Lv; Jianxun Zhao; Fei Chen; Zailian Lu; Yang Zhang; Victor Chen; Xin Gan; Jiuqiao Zhao; Yun He; Xiaodong Wu, PhD; Yiping Rong Immune-stimulants and immune modulators Bispecifics;Checkpoint blockade;Costimulation;T cell;Tumor infiltrating lymphocytes (TILs)
1058 Poster Presentation YH32364 (ABL104), a novel EGFR/4-1BB bispecific antibody exhibits potent antitumor efficacy with an excellent safety profile    Eunjung Lee, PhD; Hyejin Chung; Yangsoon Lee; Young Bong Park; Eun-Jung Lee; Hyunmo Koo; Mikyeong Ju; Ju Young Park; Sujin Ahn; Junhwan Kim; Kyeongsu Park; Wonjun Son; Jaehyun Eom; Hanbyul Lee; Jaeho Jung; Jonghwa Won; Se-Woong Oh Immune-stimulants and immune modulators Bispecifics;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
1059 Poster Presentation ON203: A new antibody targeting the oxidized form of macrophage migration inhibitory factor (oxMIF) exerts antitumorigenic activity and modulates the tumor microenvironment.  Barbara Maurer, PhD; Irina Mirkina, PhD; Julia Mayer, MSc; Christine Landlinger, PhD; Alexander Schinagl, PhD; Michael Thiele, PhD; Randolf J. Kerschbaumer, PhD Immune-stimulants and immune modulators Antibody;Cytokine;Immune contexture;NK/NKT cell;Solid tumors;Targeted therapy;Tumor antigens;Tumor microenvironment
1060 Poster Presentation EVOLVETM: a novel costimulatory T cell engager platform engineered for the treatment of immune suppressive tumors   Jeremy Myers, Ph.D.; Mohosin Sarkar; Eric M. Tam; Abudukadier Abulizi; Guixian Jin; Xingyue An; Evelyn Teran; Shu Shien Chin; Danielle M. Klaskin; Nana Adjoa Pels; Maria Hackett; Oksana A. Sergeeva; Hayden Karp; Julio Rodriguez; Sonali Dhindwal; Changqing Yuan; Zengzu Lai; Jennifer Zeiger; Amber Fearnley; Louis Matis; Jay Fine Immune-stimulants and immune modulators Costimulation
1061 Poster Presentation CLN-617 is an intratumorally injected and locally retained fusion of IL-2 and IL-12 that drives systemic anti-tumor activity Mehta K. Naveen, PhD; Kavya Rakhra; Kristan Meetze; Irina Shapiro; Karl D. Wittrup; Patrick A. Baeuerle, PhD; Jennifer S. Michaelson Immune-stimulants and immune modulators Bispecifics;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
1062 Poster Presentation ES009, a LILRB2-specific blocking antibody, reprograms myeloid cells into pro-inflammation phenotype and potentiates T cell activation    Xiaofeng Niu, PhD; Chunnian Wang, PhD; Jinfeng Zhao; Jiahui Hu; Yanfen Hu; Jun Sun; Xiaoyan Zheng, PhD; Yuting Qiu, PhD; Zhihao Wu, PhD; Yangsheng Qiu, PhD; Quan Qiu, PhD; Hongtao Lu, PhD Immune-stimulants and immune modulators Antibody;Checkpoint blockade;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor microenvironment
1063 Poster Presentation Anti-4-1BB x PD-1, a bispecific anti-cancer therapeutics.    Byoung S. Kwon, PhD; Hanna Lee; Jin Sung Park; SeungHee Han; Sungmin Park; Sun Woo X. Im; HyunTae Son; Joseph H. Jeong Immune-stimulants and immune modulators Antibody;Bispecifics;Costimulation;T cell;Tumor antigens
1064 Poster Presentation Exercise induced hormone irisin inhibits Integrin αv-TGF-β axis in tumor microenvironment to improve CD8+ T cell mediated tumor control No-Joon Song, PhD; Yuzhou Chang; Anqi Li, MD; Yi Wang; Kelsi Reynolds; Kevin P. Weller; Chelsea M. Bolyard; Gang Xin; Qin Ma; Zihai Li, MD, PhD Immune-stimulants and immune modulators Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);T cell
1065 Poster Presentation ACTM-838, a microbial-based immunotherapy that enriches in solid tumors after IV dosing, reverses the immunosuppressive TME to promote durable anti-tumor immunity, alone and in combination with anti-PD1 in mice    Akshata R. Udyavar, MS, PhD; Hailey He; John Brandenburg; Julie Janes; Oanh Pham, PhD; Sara Tribble; Ryan Daroy; Keith Cheung, PhD; Haixing Kehoe, MS; Bret Peterson, PhD; Emily Miyashita-Lin, PhD; Omkar Joshi, PhD; Nick Eisele, PhD; Christopher D. Thanos, PhD; Chan C. Whiting, PhD Immune-stimulants and immune modulators Antigen presenting cells;Checkpoint blockade;Cytokine;Immune monitoring;Immune suppression;Monocyte/Macrophage;Myeloid cells;T cell;TLR;Tumor microenvironment
1066 Poster Presentation Pharmacologic inhibition of DGKα activates T cells and enhances anti-tumor immunity    Adele Y. Wang, Dr., PhD; Jean-Philippe Belzie; Lance Stapleton; Weimei Xing; Gladys Muiru; Dmytro Kornyeyev; Edward Hsieh; Albert Liclican; Pamela Toy; Mengshu Xu; Kei Kim; Jacob S. Lee; Michelle R. Kuhne, PhD; Latesh Lad Immune-stimulants and immune modulators Checkpoint blockade;Solid tumors;T cell
1067 Poster Presentation Synergistic combination of Natural Killer cell engagers (NKEs) with proinflammatory cytokines Tian Zhang, PhD; Matthew S. Faber, PhD; Erik Pong, BS; Ke Liu, PhD; Matthew J. Bernett, PhD; Christine Bonzon, PhD; Juan E. Diaz, PhD; Dong Hyun Nam; Kendra N. Avery, PhD; Jing Qi, PhD; Rumana Rashid, PhD; Rena Bahjat, PhD; John R. Desjarlais, PhD; Katrina Bykova, PhD Immune-stimulants and immune modulators Antibody;Bispecifics;NK/NKT cell;Solid tumors;T cell
1068 Poster Presentation A ROR1 specific CD3 bispecific T-cell Engager engineered for solid tumors with an expanded therapeutic window Brian Rabinovich, PhD; Xueyuan Zhou, PhD; Jeffrey Takimoto, PhD; Paul Y. Song; Evren Alici, MD, PhD; Nikhita Khanna, MS Immune-stimulants and immune modulators Antibody;Solid tumors;T cell;Targeted therapy
1069 Poster Presentation OX40/CD137 dual agonism potentiates anti-tumour immunity by driving functional reprogramming and instability of regulatory T (Treg) cells Charlotte Imianowski; Paula Kuo; Edmund Poon; Matthew A. Lakins, PhD; Michelle Morrow, PhD; Rahul Roychoudhuri, MBBS., PhD Immune-stimulants and immune modulators Antibody;Bispecifics;Checkpoint blockade;Costimulation;Cytokine;Immune tolerance;Regulatory T cell (Treg cell);T cell
1070 Poster Presentation HexaBody-CD27 enhances T-cell activation, proliferation, cytokine secretion and cytotoxic activity independently of Fc gamma receptor-mediated crosslinking Isil Altinas; Kristina B. Nürmberger; Andrea Imle; Aras Toker; Kristin Strumane; Sina Fellermeier-Kopf; Andreea Ioan-Facsinay; Alexander Muik; Mustafa Diken; Frank J. Beurskens; Rob N. De Jong; Sebastian Kreiter, MD; David P.E. Satijn, PhD; Friederike Gieseke; Janine Schuurman; Tahamtam Ahmadi; Oezlem Tuereci, MD; Kate Sasser; Esther C.W. Breij, PhD; Ugur Sahin Immune-stimulants and immune modulators Antibody;Costimulation;Cytokine;Dendritic cell;Immune adjuvant;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1071 Poster Presentation Autologous tumor cell immunotherapeutic platform induces stress-correlated immunogenic cell death leading to immune activation within the draining lymph nodes    Christopher Cultrara, PhD; Kenneth Kirby; Essam Elrazaq; Christopher Uhl, PhD; Amelia Zellander, PhD; Lorenzo Galluzzi, PhD; Mark A. Exley, PhD; Jenny Zilberberg, PhD Immune-stimulants and immune modulators Antigen presenting cells;Dendritic cell;T cell;Tumor antigens;Vaccine
1072 Poster Presentation Intravenous BCG administration in mice stimulates NK and T cell-mediated antitumor immunity in the lung and overcomes resistance to immunotherapy    Eduardo Moreo Lapieza, Degree in Biotechnology; Santiago Uranga; Carlos Martín, PhD, MD; Nacho Aguiló Immune-stimulants and immune modulators Antigen presenting cells;Checkpoint blockade;Dendritic cell;Inflammation;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
1073 Poster Presentation Costimulatory CD28 trispecific antibodies targeting PDL1 and PDL2 enhance T cell activation in solid tumors Veronica G. Zeng, PhD; Juan E. Diaz, PhD; Jing Qi, PhD; Thuy Truong, PhD; Matthew Dragovich, PhD; Rumana Rashid, PhD; Christine Bonzon, PhD; Panida Lertkiatmongkol, PhD; Ruschelle Love, MS; Michael Hackett, PhD; Kendra N. Avery, PhD; Norman J. Barlow, PhD, DVM, MBA; John R. Desjarlais, PhD; Michael Hedvat, PhD; Gregory L. Moore, PhD Immune-stimulants and immune modulators Checkpoint blockade;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
1074 Poster Presentation A novel fully human CD28 antibody that cross-reacts with CTLA-4 and mouse CD28 for potential applications in cancer immunotherapy    Abdullah Elsayed, MSc; Frederik Peissert; Louis Plüss; Franziska Ulrich; Emanuele Puca, PhD; Roberto De Luca, phD; Cornelia Halin; Dario Neri, Professor Immune-stimulants and immune modulators Antibody;Bispecifics;Checkpoint blockade;Costimulation;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
1075 Poster Presentation HBM1020 Is A Fully Human Novel Anti-B7H7 Antibody with Excellent Preclinical Efficacy and Safety Profile    Xiaodong Wu, PhD; Yongqiang Wang; Jonna Liu; Xiaocheng Lv; Fei Chen; Izzie Wang; Jiuqiao Zhao; Yiping Rong Immune-stimulants and immune modulators Antibody;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor antigens
1076 Poster Presentation Anchored immunotherapy with intratumorally administered aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response    Sailaja Battula, PhD; Gregory Papastoitsis; Howard L. Kaufman, MD; K. D. Wittrup; Michael M. Schmidt, PhD Immune-stimulants and immune modulators Costimulation;Cytokine;Immune toxicity;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment
1077 Poster Presentation Development of a molecular targeted cytokine that specifically expands Vgamma9Vdelta2 T cells and potentiates anti-tumor activity      Bryan R. Becklund, PhD; Kaitlyn Robinson; Kyle Jones; Angelica Sanabria; Elisebeth Torretti; Andrew Eckles; Abrahim Hussain; Sae Jeong Ahn; Rajay Pandit; Florian J. Sulzmaier, PhD; John C. Timmer, PhD; Brendan P. Eckelman, PhD Immune-stimulants and immune modulators Antibody;Costimulation;Cytokine;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
1078 Poster Presentation Conditionally Activatable Interferon-alpha 2b Improves Tolerability and Exhibits Preferential Activity in Tumors Alexey Berezhnoy, PhD, DVM; Hsin Wang; Nicole Lapuyade; Na Cai; Carol LePage; Michael Winter, PhD; Michael Krimm; Kenneth R. Wong, MA; Robert T. Dunn II, PhD; Sean McAlister, PhD; Leila Boustany, PhD; Madan Paidhungat, PhD; Marcia Belvin, PhD; Erwan Le Scolan, PhD; Dylan L. Daniel, PhD Immune-stimulants and immune modulators Cytokine;Immune adjuvant;Inflammation;Tumor microenvironment;Tumor stroma
1079 Poster Presentation LAG3-targeted IL15/IL15Rα-Fc (LAG3 x IL15) fusion proteins for preferential TIL expansion via cis delivery of IL15 to LAG3+ cells Matthew J. Bernett, PhD; Suzanne Schubbert, PhD; Michael Hackett, PhD; Lukasz Ochyl, PhD; Lizett E. Scott, MS; Christine Bonzon, PhD; Rumana Rashid, PhD; Kendra N. Avery, PhD; Nicole Rodriguez, PhD; Irene Leung, PhD; Norman J. Barlow, PhD, DVM, MBA; Rena Bahjat, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD Immune-stimulants and immune modulators Antibody;Bispecifics;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
1080 Poster Presentation Using site-specific chemical conjugation to generate superior half-life extended or PD-1-targeted formats of a potent IL-18 variant resistant to IL-18 binding protein Jean Ph. Carralot, PhD; Camille Delon, MSc; Rubén Alvarez Sanchez, PhD; Roy Meoded, PhD; Philipp Moosman, PhD; Kea Martin, PhD; Arnaud Goepfert, PhD; Andrew S. Chi, MD PhD; Vijaya R. Pattabiraman, PhD; Bertolt D. Kreft, PhD Immune-stimulants and immune modulators Antibody;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
1081 Poster Presentation Exenokine-2: a half-life extended no-α-IL-2 with improved preclinical pharmacological properties supports first-in-human clinical development Lili Cheng, Ph.D; Fan Ye, Ph.D; Sandra Chen; Jianing Huang; Jenny Jiang; Henry He; Shirley Shi; Mingxing Yang; Qiang Fu; Ark Xia; Yudan Hong; Wang Xin; Karen Yuan; Hongchuan Liu; Hui Feng; Eugene Liu; Ziyang Zhong Immune-stimulants and immune modulators Cytokine;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment
1082 Poster Presentation IL-27 expressed in the tumor microenvironment is correlated with PD-L1 levels and can induce PD-L1 expression on immune and tumor cells  Karin Golan, PhD; Ricard Masia, M.D., Ph.D.; Yu Yang, M.S.; Yue Ren, Ph.D.; Kerry F. White, B.A.; Benjamin H. Lee, M.D., Ph.D.; Vito J. Palombella, PhD; Jonathan A. Hill, PhD Immune-stimulants and immune modulators Checkpoint blockade;Clinical trial;Cytokine;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment
1083 Poster Presentation AB821 is a CD8+ T cell selective IL-21 with enhanced bioavailability that mediates potent anti-tumor activity, cytotoxicity, and expansion of memory CD8+ T cells    Renee Greer, Ph.D.; Henry Nguyen, Ph.D.; Paul Mesko; Ruth Lan, Ph.D.; Wei Wei Prior; Hussein M. Sultan, PhD; Meghana Sukthankar; Irene Ni; S. Michael Chin; Kelly D. Moynihan, Ph.D.; Ton N. Schumacher, PhD; Robert D. Schreiber, PhD; Andy Yeung, Ph.D.; Ivana Djuretic, Ph.D. Immune-stimulants and immune modulators Antibody;Antigen presenting cells;Bispecifics;Cytokine;Immune toxicity;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1084 Poster Presentation  NTX-0250, a multimodal mRNA-based immunotherapy, eradicates large established tumors in a stringent mouse model of HPV16-driven cancer    Ole W. Haabeth, PhD; Diane DaSilva, PhD; Colin J. McKinlay, PhD; Weiqun Liu, PhD; Edward E. Lemmens, PhD; Christopher S. Rae, PhD; Adrienne Sallets; Daniel O. Frimannsson, PhD; Sangeeta Nath, PhD; Nicole E. Peck, PhD; Ou Li, PhD; Nicole Fay, PhD; Ruben Prins, BsC.; Meredith L. Leong; W. Martin Kast, PhD; Samuel Deutsch, PhD Immune-stimulants and immune modulators Costimulation;Cytokine;RNA;Solid tumors;T cell
1085 Poster Presentation The NAD+ Dependent Deacetylase Sirt2 is a Negative Regulator of the JAK/STAT Pathway in Effector T cells.    Imene Hamaidi, PhD; Lin Zhang, MD. PhD; Pingyan Cheng, MD; Min-Hsuan Wang; Erika Johnson; Bin Fang, PhD; Sungjune Kim, MD PhD Immune-stimulants and immune modulators Cytokine;Post-translational modifications;T cell
1086 Poster Presentation NKTR-288, a polymer-conjugated interferon gamma mutein for the treatment of solid tumors    Damon Hamel; Marlene Hennessy; Sarah Ingersoll; Olga Zemska; Phi Quatch; Rhoneil Pena; Thomas Chang; David Doherty; Guifen Xu; Arkopal Choudhury; Danni Yu; Werner Rubas; Christie Fanton; Brian Vuillemenot; Saul Kivimae; Takahiro Miyazaki; Jonathan Zalevsky Immune-stimulants and immune modulators Antigen presenting cells;Checkpoint blockade;Cytokine;Myeloid cells;Neoantigens;Solid tumors;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1087 Poster Presentation Addition of IL-2 Overcomes Lung Tumor Resistance to IL-12 by Coordinating Cytotoxic and Regulatory T Cell Responses Brendan L. Horton, PhD; Maria Zagorulya, B.S.; Noor Momin, Ph.D.; Yash Agarwal, B.Sc.; K. D. Wittrup; Stefani Spranger, PhD Immune-stimulants and immune modulators Cytokine;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor microenvironment
1088 Poster Presentation A highly potent anti-LAG-3-IL-2c that selectively targets tumor-specific CD8+ T cells Zoey Huang; Jianing Huang; Fan Ye; Sandra Chen; Danny Huang; Michael Hua; Ella Li; Jenny Jiang; Hanna Lin; Shirley Shi; Bella Yue; Henry He; Mingxing Yang; Qiang Fu; Ziyang Zhong Immune-stimulants and immune modulators Antibody;Checkpoint blockade;Cytokine;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1089 Poster Presentation Immunopheresis: A novel immunotherapy platform for extracorporeal removal of soluble target molecules in oncology        Steven Josephs, PhD; Robert Segal, MD, FACP; Steve Prince; Mathew Ong; Amir Jafri; Lawrence Florin; Victoria Manax, MD; Michael Matho, PhD; Sameera Bilgrami, PhD; Annette Marleau, PhD Immune-stimulants and immune modulators Checkpoint blockade;Cytokine;Immune suppression;Inflammation
1090 Poster Presentation Overcoming systemic toxicity of IL-12-based immunotherapy by tumor-targeting and IL-12 attenuation    Jihoon Chang, Ph.D; Donggeon Kim, DVM,PhD; Dahea Lee; Dongsu Kim; Soomin Ryu; Byoung C. Lee Immune-stimulants and immune modulators Antibody;Cytokine;Immune toxicity;Tumor microenvironment
1091 Poster Presentation CGC-601, a novel βγ-only IL-2 variant, enhances moderate immune activation without Treg expansion, and exhibits a superior safety evidence in vivo Lei Zhao, Ph.D.; Rong Wang; Chuan Feng; Yongji Jiang; Patrick Liu; Yuan Liu, Ph. D Immune-stimulants and immune modulators Cytokine;Regulatory T cell (Treg cell);Solid tumors
1092 Poster Presentation The CD8+ T cell selectivity of AB248 is essential for optimal anti-tumor activity and safety in nonclinical models Kelly D. Moynihan, Ph.D.; Danielle C. Pappas; Hussein M. Sultan, PhD; Terrence Park; Manu Kumar, Ph.D.; Ruth Lan, Ph.D.; Irene Ni; Jessie Chen; Michael Chin; Ton N. Schumacher, PhD; Andy Yeung, Ph.D.; Robert D. Schreiber, PhD; Ivana Djuretic, Ph.D. Immune-stimulants and immune modulators Cytokine;T cell
1093 Poster Presentation A novel IL12-based immunocytokine targeting Fibroblast Activation Protein (FAP) for the treatment of cancer Lisa Nadal; Frederik Peissert; Abdullah Elsayed, MSc; Tobias Weiss; Thomas Look; Michael Weller; Geny Piro; Carmine Carbone; Giampaolo Tortora; Mattia Matasci; Nicholas Favalli; Riccardo Corbellari; Cesare Di Nitto; Eleonora Prodi; Chiara Libbra; Simone Galeazzi; Claudiopietro Carotenuto; Cornelia Halin; Emanuele Puca, PhD; Dario Neri, Professor; Roberto De Luca, phD Immune-stimulants and immune modulators Antibody;Cytokine;Targeted therapy;Tumor antigens;Tumor microenvironment;Tumor stroma
1094 Poster Presentation Favorable preclinical efficacy and safety profile of AVB-001 a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first in human clinical development Guillaume Carmona, PhD; Amanda Nash, BS; Ryan Newman; Jake Schladenhauffen; Maria Jarvis; Samira Aghlara-Fotovat; Sudip Mukherjee; Andrea Hernandez; Andrew Hecht; Peter Rios; Shirin Nouraein; Rahul A. Sheth, MD; Weiyi Peng, MD PhD; Jose Oberholzer; Amir A. Jazaeri, MD; Omid Veiseh, Ph.D Immune-stimulants and immune modulators Cytokine;T cell
1095 Poster Presentation IL-12-Based Cytokine Factories Modulate Tumor Microenvironment to Eradicate Pancreatic Tumors in Mice and are Well Tolerated in Non-human Primates Amanda Nash, BS; Samira Aghlara-Fotovat, BA; Andrea Hernandez; Sofia Ghani; Ira Joshi; Douglas Ira; Peter Rios; Omid Veiseh, Ph.D Immune-stimulants and immune modulators Cytokine;Immune monitoring;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1096 Poster Presentation mWTX-330, an IL-12 INDUKINE molecule, Selectively Activates Tumor Infiltrating Lymphocytes and Reprograms the Tumor Microenvironment in Murine Syngeneic Tumor Models    Christopher Nirschl, PhD; Heather R. Brodkin, PhD; Connor J. Dwyer, PhD; Daniel J. Hicklin, PhD; Nesreen Ismail; Celesztina Domonkos, PhD; Cynthia Seidel-Dugan, PhD; Philipp Steiner, PhD; Zoe Steuert; Jenna M. Sullivan, PhD; William M. Winston, PhD; Andres Salmeron, PhD Immune-stimulants and immune modulators Cytokine;Metabolism;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1097 Poster Presentation MDK1654: A Branched Synthetic Peptide that Activates Both the IL-7 Receptor and the βγc Form of the IL-2/15 Receptor    Inkyung Angie Park, Ph.D.; Steven E. Cwirla; Alice V. Bakker; Ronald Barrett; Michael C. Needels; Praechompoo Pongtornpipat; Blake M. Williams; Prarthana Joshi; William J. Dower Immune-stimulants and immune modulators Cytokine;NK/NKT cell;T cell
1098 Poster Presentation Targeting wildtype IL-2 to CD8 T cells induces potent anti-tumor immune responses and decreases IL-2 mediated toxicity      Selvi Ramasamy, PhD; Joanathan Nardozzi; Shannon Boi; Joanna Swain; Anthony Coyle, PhD; Stefano Gulla Immune-stimulants and immune modulators Antibody;Cytokine;Immune toxicity;Regulatory T cell (Treg cell);T cell;Targeted therapy
1099 Poster Presentation ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein showing increased efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity Christoph Huber, PhD; Kirsten Richter, PhD; Laetitia Petersen; Nicole Egli; Patrizia Murer, PhD Immune-stimulants and immune modulators Antibody;Checkpoint blockade;Cytokine;NK/NKT cell;T cell
1100 Poster Presentation IL-15 enhances cytotoxicity of sipuleucel-T from metastatic castration-resistant prostate cancer patients by activating CD8+ T and NK effector cells     Muhammad A. Saeed, PhD; Kevin Kim; Russell K. Pachynski, MD Immune-stimulants and immune modulators Adoptive immunotherapy;Cytokine;NK/NKT cell;Solid tumors;T cell;Tumor microenvironment;Vaccine
1101 Poster Presentation ASKG315 - An IL-15 Prodrug with Antibody-Like PK, Enhanced Safety and Expanded Therapeutic Window Chunxiao Yu, Ph.D.; Kurt Shanebeck; Jieye Sun, Ph.D.; Chao Wang; Shiguang Yu, Ph.D.; Jeannie Luiz; Ray Chuang, Ph.D.; Ming Li, Ph.D.; Yong Wen, Ph.D.; Jeff Lu, Ph.D.; Yuefeng Lu, Ph.D. Immune-stimulants and immune modulators Cytokine;NK/NKT cell;T cell;Tumor microenvironment
1102 Poster Presentation A Single Spark Can Start a Prairie Fire - Re-think the Combination Strategy and Clinical Setting of IL-12 with Anti-PD-1 Pei-Yi Tsou; Wan-Ying Lin; Meng-Na Lee, Ph.D Candidate; San-chi Chen, MD Immune-stimulants and immune modulators Checkpoint blockade;Cytokine;Tumor microenvironment
1103 Poster Presentation Half-life extended, conditionally active IFNa prodrug induces tumor-selective activation and potent antitumor response     Alice Yam, PhD; Kshama A. Doshi, PhD; Krishna Bajjuri; Millicent Embry; Frank Xiao; Grace Lee; Stephanie Armstrong; Daniel Calarese; Xiaofan Li; Gang Yin; Kristin Bedard, PhD; Trevor Hallam, PhD Immune-stimulants and immune modulators Cytokine;Immune toxicity;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1104 Poster Presentation A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples the efficacy and toxicity of IL-2 therapy    Fan Ye, Ph.D; Zoey Huang; Jianing Huang; Lili Cheng, Ph.D; Sandra Chen; Danny Huang; Michael Hua; Ella Li; Jenny Jiang; Hanna Lin; Xin Wang; Bella Yue; Shirley Shi; Henry He; Karen Yan; Binfeng Lu, PhD; Ziyang Zhong Immune-stimulants and immune modulators Antibody;Checkpoint blockade;Cytokine;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1105 Poster Presentation A novel triple action and pre-clinical safety profile of SLC-3010 predict its favorable translation in the phase I clinical study. Woong Hee Yoon, Ph.D.; Junhyeok Heo, M.S.; Daeun Kim, M.S.; Geona Kim, M.S.; Kyungmi Han, M.S.; Jun-Young Lee, Ph.D. Immune-stimulants and immune modulators Antibody;Cytokine;Immune adjuvant;T cell
1106 Poster Presentation HZ-S506, a selective and orally bioavailable HPK1 degrader, is efficacious as a single agent or in combination with PD-1 antibody Yizhe Wu, PhD; Xinglu Zhou; Tingting Jin; Xinxin Jin Immune-stimulants and immune modulators Solid tumors;T cell
1107 Poster Presentation Anti-HVEM mAB therapy improves antitumoral immunity both in vitro and in a novel mice model expressing human HVEM and BTLA molecules using HVEM expressing tumors     Demerle Clemence, Pharm.D; Laurent Gorvel, PhD; Marielle Mello; Sonia Pastor; Clara Degos; Ana Zarubica; Frederic Fiore; Geoffrey Guittard, Ph.D.; Bernard Malissen, Ph.D.; Herve Luche, Ph.D.; Jacques Fieschi-Meric, PhD; Laurent Greillier, MD, PhD; Fabrice Barslesi, MD, Ph.D.; Daniel Olive, MD PhD Immune-stimulants and immune modulators Costimulation;Solid tumors;T cell
1108 Poster Presentation Screening for immune response indicators after p53 gene transfer and cabazitaxel treatment in human prostate carcinoma in vitro Nadine Assis, B.S.; Bryan Strauss Immune-stimulants and immune modulators Chemotherapy;Gene expression;Solid tumors
1109 Poster Presentation Progesterone impacts the growth and immune cell infiltration of murine mammary gland tumors    Lauryn R. Werner, BBA; Eilidh I. Chowanec; Julio Tinoco; Harmony Saunders; Dominika E. Helm; Sean M. Holloran; Richard C. Hastings; Junping Wei; Gangjun Lei; Xiao-Yi Yang; Mary A. Markiewicz; Prabhakar Chalise; Justin M. Balko; Zachary C. Hartman; Christy R. Hagan Immune-stimulants and immune modulators Immune suppression;Regulatory T cell (Treg cell);Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1110 Poster Presentation Effect of sub-ablative hyperthermia on PD-1/PD-L1 axis modulation in the tumor microenvironment. Md Raihan Chowdhury, PhD; Mohamed Farghaly Ramadan; Vassiliki A. Boussiotis, MD, PhD; Muneeb Ahmed; Marwan Moussa, MD Immune-stimulants and immune modulators Checkpoint blockade;Immune adjuvant;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
1111 Poster Presentation Immune modulation of melanoma brain metastases by IRAK-4 inhibition Bently Doonan, MD; Christina Von Roemeling, PhD; Erica Matich; Tyler Elliot; Vincent Archibald; Duane Mitchell, MD, PhD; Kelena Klippel; Vrunda Trivedi; Lan Hoang-Minh Immune-stimulants and immune modulators Checkpoint blockade;Immune adjuvant;Targeted therapy;Tumor microenvironment
1112 Poster Presentation PARP inhibition increases in the suppressive capacity of tumor-associated Tregs in a BRCA1-deficient model of ovarian cancer. Daniel M. Falcon, PhD; Ichiko Kinjyo, MD PhD; Sarah F. Adams, MD Immune-stimulants and immune modulators Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1113 Poster Presentation Epigenetic modifications influence immune regulatory pathways in murine and human neuroblastoma and melanoma tumor models Arika S. Feils, BS; Lizzie Frankel; Ankita Shahi (De); Alina Hampton; Paul M. Sondel, MD, PhD; Amy K. Erbe, PhD Immune-stimulants and immune modulators Epigenetics;Gene expression;Immune monitoring;Immune tolerance;Pediatric tumors;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1115 Poster Presentation T-DXd increases immune cell infiltration and enhances activity of immune checkpoint blockade in murine tumor models Liam Jenkins; Matt Wilson, BSc; Jerome Mettetal; Theresa Proia, PhD Immune-stimulants and immune modulators Checkpoint blockade
1116 Poster Presentation OxPhos inhibition offsets the metabolic advantage of pancreatic cancer and promotes a pro-inflammatory tumor microenvironment.    Madeline Steiner; Arthur J. Liu, BS; Sayan Alekseev; Charlotte Dahlem, PhD; Michael A. Curran, PhD Immune-stimulants and immune modulators Metabolism;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1117 Poster Presentation A Patient-Derived Tumor Organoid Platform to Investigate Radiation-Induced Neoantigen Exposure Samantha J. Van Nest, PhD, MS; Jared Capuano; Tuo Zhang, PhD; Bhavneet Bhinder; Xi Zhou; Adriana Irizarry; Laura Martin; Silvia C. Formenti, MD; Olivier Elemento, PhD; Nils-Petter Rudqvist, PhD; Sandra Demaria, MD Immune-stimulants and immune modulators Gene expression;Neoantigens;Radiotherapy;RNA;Tumor antigens
1118 Poster Presentation Immunologically relevant effects of PT-112 on cancer cell mitochondria   Takahiro Yamazaki, PhD; Lorenzo Galluzzi, PhD; Christina Y. Yim; Tyler D. Ames Immune-stimulants and immune modulators Chemotherapy;Cytokine;Inflammation;Solid tumors;Tumor infiltrating lymphocytes (TILs)
1119 Poster Presentation Glutamine antagonist prodrug JHU083 reprograms immunosuppressive tumor-associated macrophages to drives tumor immunity in urologic cancers    Monali Praharaj, MS; Fan Shen; Thomas Nirschl; Alee J. Lee; Xiaoxu Wang; Liang Zhao; Alok K. Singh, PhD; Debebe Theodros; Laura Sena; Elizabeth D. Thompson, MD PhD; Ada Tam; Srinivasan Yegnasubramanian; Edward J. Pearce; Robert D. Leone; Jesse Alt; Rana Rais; Barbara S. Slusher; Andrew M. Pardoll, MD, PhD; Jonathan Powell, MD, PhD; Jelani Zarif Immune-stimulants and immune modulators Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors
1120 Poster Presentation Neoadjuvant in situ intratumoral vaccination with empty cowpea mosaic virus nanoparticles is effective against canine mammary cancer. Daniel Alonso-Miguel, DVM; Guillermo Valdivia, DVM; Barbara Zimmermann, DVM; Lucia Lucia Barreno; Angela Alonso-Diez, DVM; Maria Dolores Perez-Alenza, DVM; Veronique Beiss; María Suárez-Redondo; Nicole Steinmetz, BS, PhD; Steven Fiering, BS, MS, PhD; Johannes Vom Berg; Laura Laura Peña, DVM; Hugo Arias-Pulido, PhD Immune-stimulants and immune modulators Chemokine;Cytokine;Immune adjuvant;Immune monitoring;Tumor microenvironment;Vaccine
1121 Poster Presentation Tigilanol tiglate is a naturally occurring small molecule oncolytic that effectively ablates tumors via intratumoural injection and can enhance response to immune checkpoint blockade    Jason K. Cullen, DPhil; Pei-Yi Yap; Blake Ferguson; Zara C. Bruce; Motoko Koyama; Herlina Handoko; Jacinta L. Simmons; Jenny Johns; Marjorie D’Souza; Natasa Broit; Praphaporn Stewart; Daniel Shelley; Tracey McMahon; Steven M. Ogbourne, Associate Professor; Yi Chieh Lim, PhD; Giovanni Appendino; Victoria A. Gordon, PhD; Paul W. Reddell, PhD; Glen M. Boyle, Professor; Peter G. Parsons, Professor Immune-stimulants and immune modulators Checkpoint blockade;Immune adjuvant;Solid tumors;Tumor infiltrating lymphocytes (TILs)
1122 Poster Presentation Radiotherapy-activated NBTXR3 nanoparticles induce Interferon Beta secretion by cancer cells Jordan Da Silva, PhD; Sebastien Paris Immune-stimulants and immune modulators Cytokine;Radiotherapy;Tumor microenvironment
1123 Poster Presentation Preclinical Activity and Safety Profile or JANX008, a Novel EGFR-Targeting Tumor-Activated T Cell Engager for Treatment of Solid Tumors Shahram Salek-Ardakani; Thomas R. DiRaimondo; Natalija Budimir; Lina Ma; Simon Shenhav; Vanessa Cicchini; Hua Wu; Renee Jocic; Fabrece Roup; Calvin Cambell; Carolina Caffaro; Hans Aerni; Ugur Eskiocak; Wayne Godfrey; Charles Winter; Marc Nasoff; Neil Gibson; David Campbell Immune-stimulants and immune modulators Antibody;Bispecifics;Solid tumors;T cell
1124 Poster Presentation Intratumoral administration of VAX014 cooperates with checkpoint blockade to reprogram tumor immune microenvironments and clear injected and noninjected tumors Matthew Giacalone, PhD, MBA; Katherine Reil; Shingo Tsuji; Kinsey Nelson; Elsa Molina; Kathleen McGuire Immune-stimulants and immune modulators Checkpoint blockade;Dendritic cell;Immune adjuvant;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
1125 Poster Presentation Intratumoral administration of SARS-CoV-2 reduces tumor progression and alters the tumor immune microenvironment similar to that of the seasonal influenza vaccine Eileena F. Giurini, MS; Kajal H. Gupta, PhD Immune-stimulants and immune modulators Cytokine;Immune adjuvant;Immune monitoring;Solid tumors;T cell;Tumor microenvironment;Vaccine
1126 Poster Presentation Molecular mechanisms of DC activation by melanoma cells responding to LTX-315   Xiao-Qing Li; Takahiro Yamazaki, PhD; Tianzhen He; Md Masud Alam; Jia Liu; Anna L. Trivett; Baldur Sveinbjørnsson; Øystein Rekdal; Lorenzo Galluzzi, PhD; De Yang, PhD; Joost J. Oppenheim, M.D. Immune-stimulants and immune modulators Antigen presenting cells;Costimulation;Cytokine;Dendritic cell;Solid tumors;TLR;Tumor microenvironment
1127 Poster Presentation Calcium phosphate biomaterials enhance immunotherapeutic mRNA delivery in melanoma     Hannah L. Martin, BS; Joshua A. Choe, MS; Iris Baurceanu; William L. Murphy, PhD Immune-stimulants and immune modulators Cytokine;Gene expression;RNA;Solid tumors;T cell
1128 Poster Presentation New viral-delivery of glycan-modifying sialidase induces anti-tumor immunity    Natalia Rodrigues Mantuano, PhD; Michael Sandholzer, MSc.; Andreas Zingg, MSc.; Heinz Läubli, MD PhD Immune-stimulants and immune modulators Checkpoint blockade;Immune suppression;Myeloid cells;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1129 Poster Presentation A Novel CpG motif Introduced into a Bispecifc AM003 Compound for the Treatment of Solid Tumors        Neta Zilony- Hanin, PhD; Erez Lavi; Zohar Pode, PhD; Sapir Dahan; Vitaliy Buravenkov; Leeron Shefet Carasso, PhD; Ido Bachelet; Raanan Berger, MD; Irit Carmi Levy, PhD Immune-stimulants and immune modulators Antigen presenting cells;Bispecifics;Dendritic cell;Immune adjuvant;Solid tumors;Tumor infiltrating lymphocytes (TILs)
1130 Poster Presentation Investigating macrophage modulation in a murine model of soft tissue sarcoma Kurt N. Hildebrand, BScH; Karys M. Hildebrand, PhD Candidate; Franz J. Zemp; Carolina Salazar Arcila; Michael J. Monument Immune-stimulants and immune modulators Monocyte/Macrophage;Myeloid cells;Solid tumors
1131 Poster Presentation GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses. Peter I. Joyce, PhD; Andrew Leishman; Asolina Braun; Mitul Patel; Michael Pinggera; Jessica Sette; Kate Anderton; Edd James; Valeriya Shunina; Anthony W. Purcell; Nicola Ternette; Jason Shiers, PhD; Martin Quibell; Wayne Paes; Tom McCarthy Immune-stimulants and immune modulators Antigen presenting cells;Neoantigens;Solid tumors;Surfaceome;T cell;Tumor antigens
1132 Poster Presentation Impact of intralesional oncolytic viral therapy targeting in situ activation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients Andreas Saltos, MD; Hong Zheng, PhD; Christy Arrowood; Georgia Beasley, MD, MHSc; James Ronald, MD, PhD; Ghassan El-Haddad, MD; Uzma Khan; Luiziane Guerra-Guevara; Steven Wolf; Lin Gu; Xiaofei F. Wang, PhD; Mark Cantwell, PhD; Scott J. Antonia, MD, PhD; Amer Beg, PhD; Neal Ready, MD, PhD Immune-stimulants and immune modulators Clinical study;Dendritic cell;Solid tumors;T cell;Tumor microenvironment
1133 Oral Presentation Remodeling the immunosuppressive tumor microenvironment with oncolytic virus-mediated delivery of a potent TGF-b inhibitor Kristin DePeaux, BS; Dayana B. Rivadeneira, PhD; Kevin Quann, MD PhD; Konstantinos Lontos, MD, PhD; Andrew Hinck, PhD; Greg M. Delgoffe, PhD Immune-stimulants and immune modulators Immune suppression;Inflammation;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1134 Poster Presentation Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using Kaede photoconvertible transgenic mice David R. Withers; Anne R. Diers, PhD; Zhi Li; Suaad Idris; Claire Willis; Paul Peter Tak, MD, PhD, FMedSci; Francesca Barone, MD, PhD Immune-stimulants and immune modulators Biomarkers;Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1135 Poster Presentation Single Cell Resolution of Immune Responses to Oncolytic Herpes Simplex Virus C134 in Preclinical Medulloblastoma Models Jack Hedberg, B.S.; Adam Studebaker; Luke Smith; Chun-Yu Chen; Jesse J. Westfall; Maren Cam; Amy Gross; Ryan Roberts; Timothy P. Cripe; Elaine R. Mardis, PhD; Kevin A. Cassady; Jeffrey Leonard; Katherine E. Miller Immune-stimulants and immune modulators Antigen presenting cells;Gene expression;Pediatric tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1136 Poster Presentation Induction of tertiary lymphoid structures in non-small cell lung cancer improves B and T cell anti-tumor immunity    Hye Mi Kim, BS; Dongyan Liu; Ayana Ruffin, PhD; Alexandra McDonough, BA; Caleb Lampenfeld; Sheryl R. Kunning; Ashwin Somasundaram, MD; Laura Stabile, PhD; Tullia Bruno, PhD Immune-stimulants and immune modulators B cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1137 Poster Presentation SuperNova1 (SNV1), a novel oncolytic-cell based platform for cancer therapy Duong H. Nguyen; Mohamed Hammad; Rachael Mooney; Forrest Neuharth; Ashley Alamillo; Ivelina Minev; Israel Romero; Stephanie Songco; Emma Kedl; Yunyi Kang; Hoi W. Ngai; Marisa McDonald; Linda Flores; Dae H. Kim; Jacqueline Lara; Thomas Herrmann; Barbara Härtl; Laura Edith; Daniela Kleinholz; Boris Minev; Karen Aboody; Antonio F. Santidrian Immune-stimulants and immune modulators Antigen presenting cells;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine
1138 Poster Presentation Engineered oncolytic viruses expressing immunomodulatory genes enhanced anti-tumor immune responses in vitro Zhongbao Song; Limin Tian; Guangxu Ding; Ka Fung Noi; Jie Xu; Qingyang Gu Immune-stimulants and immune modulators Cytokine;Dendritic cell;NK/NKT cell;T cell;Tumor antigens
1139 Poster Presentation Virotherapy with CodaLytic&trade;, a codon-modified influenza virus, induces an anti-tumor immune microenvironment across preclinical models with different immune contextures     Marcin Stawowczyk, PhD; Yiwen Zhao, PhD; Katie Pfeffer; Juliana Tafrova, PhD; Nusrat Jahan, PhD; James Rodriguez; Chen Yang, PhD; Sybil Tasker, MD; Steffen Mueller, PhD; J. Robert Coleman, PhD, MBA; Johanna K. Kaufmann, PhD Immune-stimulants and immune modulators Antigen presenting cells;Checkpoint blockade;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1140 Oral Presentation Cancer stem cells and PD-L1-expresing exosomes suppress anti-tumor effector B cells    Ying Xin; You Qin; Max Wicha; Alfred E. Chang; Qiao Li, PhD Immune-stimulants and immune modulators Adoptive immunotherapy;Antibody;B cell;Checkpoint blockade;Immune monitoring;Immune suppression;Stem cell/cancer-initiating cell;T cell;Targeted therapy
1141 Poster Presentation DKN-01 demonstrates immune modulatory activity and robust efficacy in colorectal cancer models    Michael S. Haas, PhD; Michael Kagey; Walter Newman, PhD; James B. Rottman, DVM, PhD, DACVP; Milad Moloudizargari, PhD; Ajay Goel, PhD; Cynthia A. Sirard, MD; Jason Baum Immune-stimulants and immune modulators Antibody;Biomarkers;Checkpoint blockade;Chemotherapy;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1142 Poster Presentation Hypoxia reduction in combination with anti-angiogenic therapy remodels the PDAC microenvironment Arthur J. Liu, BS; Michael A. Curran, PhD Immune-stimulants and immune modulators Angiogenesis;Checkpoint blockade;Chemotherapy;Immune suppression;MDSC;Targeted therapy
1143 Poster Presentation 5T4-CD40 bispecific antibodies activate immune responses in a 5T4-dependent manner Fang Liu, PhD; Wenci Gong; Yuanyuan Yang, PhD; Zhijian Cai; Feifei Cui; Lei Fang; Wenqing Jiang Immune-stimulants and immune modulators Antibody;Antigen presenting cells;B cell;Bispecifics;Costimulation;Dendritic cell;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1144 Oral Presentation IL17-producing &gamma;&delta; T cells promote resistance to CDK4/6 inhibitors in HR+HER2- breast cancer   Giulia Petroni, PhD; Kenneth H. Gouin, III; Claudia Galassi; Aitziber Buqué; Norma Bloy, PhD; Takahiro Yamazaki, PhD; Ai Sato, MSc; Carlos Jiménez-Cortegana; Alexander Kirchmair; Chiara Massa; Carlos Eduardo De Andrea; Belén Navarro; Irantzu Serrano; Esther Navarro Manzano; Francesca Finotello; Xi Zhou; Elena García-Martínez; María E. Rodríguez-Ruiz; Barbara Seliger; Víctor Sánchez-Margalet; Luis de la Cruz-Merino; Heather McArthur; Silvia Formenti; Simon Knott; Lorenzo Galluzzi, PhD Immune-stimulants and immune modulators Chemokine;Immune suppression;Radiotherapy;Solid tumors;T cell lineages;Tumor evasion;Tumor microenvironment
1146 Poster Presentation NKG2D co-stimulation via anti-sMIC/MIC targeting antibody enhances CD8 T cell functional heterogeneity and memory development in mouse prostate tumors    Tyler A. Smith, PhD; Sizhe Liu, BS; Lisha Zhu, PhD; Jennifer D. Wu, PhD Immune-stimulants and immune modulators Antibody;Costimulation;Epigenetics;Gene expression;Metabolism;RNA;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1147 Poster Presentation Differences in co-expression of T cell co-inhibitory and co-stimulatory molecules with PD1 across different human cancers Ahmad A. Tarhini, MD, PhD, MS; Dale J. Hedges, PhD; Aik Choon Tan, PhD; Paulo Rodriguez; Vineeth K. Sukrithan, MD; Aakrosh Ratan; Martin McCarter, MD; John D. Carpten, PhD; Howard Colman, MD; Alexandra Ikeguchi, MD; Igor Puzanov, MD, MSCI, FACP; Susanne M. Arnold, MD; Michelle L. Churchman, PhD; Patrick Hwu; Jose Conejo-Garcia, MD, PhD; William (Bill) S. Dalton, PhD, MD; George J. Weiner, MD Immune-stimulants and immune modulators Biomarkers;Checkpoint blockade;Costimulation;Gene expression;Immune monitoring;Solid tumors;T cell;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1148 Poster Presentation Signal-regulatory protein alpha (SIRPα) confers tumor cell resistance to anti-tumor immunity Chien-Huan Weng, PhD; Linda Hamadene, MD; Shabnam Eghbali, BA; Divya Venkatesh, Ph.D.; Sébastien Monette; Levi M. Mangarin, BS; Fadi Samaan, BS; Cailian Liu, MD; Pamela M. Holland, PhD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD Immune-stimulants and immune modulators Immune suppression;Inflammation;Solid tumors;Tumor evasion;Tumor microenvironment
1149 Poster Presentation Targeting regulatory T cells with CTM033, a novel anti-CCR8 antibody, inhibited tumor growth Yuanyuan Yang, PhD; Yuehua Chen; Feifei Cui; Wenqing Jiang; Lei Fang Immune-stimulants and immune modulators Antibody;Regulatory T cell (Treg cell);Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1150 Poster Presentation ATG-101, a tetravalent PD-L1x4-1BB BsAb, demonstrates potent in vivo anti-tumor efficacy in ICI-resistant or refectory mouse tumor models    Hui Yuwen; Tengteng Li; Yijing Ren; Jay Mei; Bo Shan; Bing Hou, Ph.D Immune-stimulants and immune modulators Bispecifics;Immune tolerance;Regulatory T cell (Treg cell);Tumor microenvironment
1151 Poster Presentation Revealing Novel Therapeutic Indications through Profiling of Immune Modulatory Properties by Uliledlimab Yanni Zhang, Ph.D; Zhen Sheng, PhD; Xinyun Zhu; Yanling Niu, PhD; Yuan Meng, MD; Zhengyi Wang, PhD; Andrew Zhu Immune-stimulants and immune modulators Angiogenesis;Antibody;Checkpoint blockade;Gene expression;Immune suppression;Myeloid cells;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs)
1152 Poster Presentation In vitro anticancer and immunomodulatory activities of a novel molecular glue compound NBT-018    Sophia E. Zhang; Magdalena Dragan; Nicole Potter; Everett Henry; L. Harris Zhang, Ph.D.; Harris Zhang Immune-stimulants and immune modulators Cytokine;Inflammation;Leukemia/Lymphoma;T cell;Targeted therapy
1153 Poster Presentation Preclinical activity of C-C chemokine receptor 2 (CCR2)-targeted immune stimulating antibody conjugate (ISAC), motivating clinical testing of TAK-500 Vicky Appleman; Atsushi Matsuda; Michelle L. Ganno; Angel E. Maldonado Lopez; Emily Rosentrater; Camilla L. Christensen; Samantha A. Merrigan; Hong Myung Lee; Min Young Lee; Linlin Dong; Jian Huang; Natasha Iartchouk; Dong Mei Zhang; Jianing Wang; He Xu; Tomoki Yoneyama; Konstantin I. Piatkov; Carole E. Harbison; Adnan O. Abu-Yousif Immune-stimulants and immune modulators Antibody;Antigen presenting cells;Dendritic cell;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;T cell;Targeted therapy;Tumor evasion;Tumor microenvironment
1154 Poster Presentation High-potency synthetic STING agonists rewire myeloid subsets in the tumour microenvironment to dismantle immunosuppressive stroma in refractory pancreatic ductal adenocarcinoma    Akash R. Boda, MS; Casey R. Ager, PhD; Kimal Rajapakshe, PhD; Krithikaa Rajkumar Bhanu; Spencer T. Lea, BA; Michael A. Curran, PhD Immune-stimulants and immune modulators Checkpoint blockade;Immune suppression;MDSC;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1155 Poster Presentation ONM-501, a polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates    Zirong Chen, PhD; Jason B. Miller, PhD; Wei Li; Katy Torres; Qingtai Su, Ph.D.; Gang Huang; Yasser Saud O Albaroodi; Rachel Morsch; Teresa McElvaney; Fiona Stavros; Don Kruppa; Tian Zhao, PhD; Jinming Gao, PhD; Ruolan Han Immune-stimulants and immune modulators Costimulation;Solid tumors;Tumor infiltrating lymphocytes (TILs)
1156 Poster Presentation STING Activation in Sarcoma: Assessing Translational Therapeutic Strategies    Karys M. Hildebrand, PhD Candidate; Kurt N. Hildebrand; Kayla L. Marritt; Carolina Salazar Arcila; Michael J. Monument Immune-stimulants and immune modulators Checkpoint blockade;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
1157 Poster Presentation Discovery of a novel, potent small molecule inhibitors of ENPP1 enhances anti-tumor efficacy in combination with immune check inhbitors.    Juhyeon Kim, Ph.D; Pyoung Oh Yoon; A-Ram Lee; Eunji Son; Young Cheol Lee; Eunmi Jung; HyoungRae Kim; YeonHee Lee; SoEun Park; Dae-Yon Lee; Chul-Woong Chung Immune-stimulants and immune modulators Checkpoint blockade;Cytokine;NK/NKT cell;T cell;Tumor microenvironment
1158 Poster Presentation High potency STING agonists induce adaptive-immunity dependent curative responses in checkpoint-refractory Glioblastoma models Spencer T. Lea, BA; Michael A. Curran, PhD; Chao-Hsien Chen, MD, PhD Immune-stimulants and immune modulators Checkpoint blockade;Immune adjuvant;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1159 Poster Presentation Use of small molecule STING agonist immunotherapy for canine soft tissue sarcoma: a cross-species analysis Ye-Jean Park, MD in progress; Joseph Kendal, MD, MSc, FRCSC; Carolina Salazar Arcila; Karys M. Hildebrand, PhD Candidate; Max Labrecque; Michael J. Monument Immune-stimulants and immune modulators Cytokine;Gene expression;Solid tumors
1160 Poster Presentation STING signaling compensates for mutation burden-low tumors to stimulate the immune response.    Jiayi Tan, MBBS; Colt Egelston, PhD; Weihua Guo, PhD; Peter P. Lee, MD Immune-stimulants and immune modulators Antigen presenting cells;Immune contexture;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1161 Poster Presentation Synthetic CD206 Targeted Constructs Carrying Pacletaxel or Novel Bisphosphonate Payloads Alter Macrophages Towards Pro-inflammatory Phenotypes; The Paclitaxel Construct Improves the Efficacy of anti-CTLA4 in CT26 Tumors David A. Ralph, PhD; Jeffrey Arnold, PhD; Michael Rosol, PhD Immune-stimulants and immune modulators Antigen presenting cells;Dendritic cell;Monocyte/Macrophage;Targeted therapy;Tumor microenvironment
1162 Poster Presentation A Nectin-4 targeted TLR9 agonist antibody conjugate induces robust immune cell activation and anti-tumor responses Amy Chen, BS; Min Li; Maja Bonacorsi; Emma R. Sangalang; Danielle Fontaine; Ons Harrabi, BA; Mingrui An; Tiffany Chou; Laura Doyle; Janet Sim, PhD; Bora Han, PhD; Hong I. Wan, PhD; Tracy C. Kuo; Maria Jose Costa; Pavel Strop Immune-stimulants and immune modulators Antibody;Antigen presenting cells;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;TLR;Tumor antigens;Tumor microenvironment
1163 Poster Presentation A unique dendritic cell activation state utilizes inflammasomes to stimulate memory T cell responses in humans Jon Chow, PhD; Veronica Komoroski, BS; Emily Gosselin, PhD; Andrew Cornforth, PhD Immune-stimulants and immune modulators Antigen presenting cells;Cytokine;Immune adjuvant;T cell;T cell lineages;TLR
1164 Poster Presentation Systemic administration of AXA-042, a novel TLR2/6 agonist, reshapes the tumor microenvironment, as revealed by single cell sequencing analysis. Bedrich Eckhardt; Kellie Mouchemore; Yang Liao; Wei Shi; Francesca Mercuri; Phil Kearney; Robin Anderson; Anna V. Galkin, PhD Immune-stimulants and immune modulators Gene expression;Granulocyte;Monocyte/Macrophage;TLR;Tumor microenvironment
1165 Poster Presentation Impact of SD-101, a toll-like receptor 9 class C (TLR9C), agonist on myeloid derived suppressor cells Chandra C. Ghosh, PhD; Steven C. Katz, MD Immune-stimulants and immune modulators Immune suppression;MDSC;Monocyte/Macrophage;TLR;Tumor microenvironment
1166 Poster Presentation Profiling the effects of targeted TLR9 stimulation within spontaneously arising breast tumors Caitlyn L. Miller, PhD; Idit Sagiv-Barfi, PhD; Patrick Neuhoefer, PhD; Debra K. Czerwinski, BS; Carolyn R. Bertozzi, PhD; Jennifer R. Cochran, PhD; Ronald Levy, MD Immune-stimulants and immune modulators Immune adjuvant;Inflammation;Solid tumors;T cell;Targeted therapy;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1167 Poster Presentation APR003, an oral liver- and GI-targeted TLR7 agonist, elicits a robust type I interferon response in advanced colorectal cancer patients    Andrew T. Miller, PhD; Trinh Le; Jaymes Holland; Ron Weitzman; Tom YH. Wu Immune-stimulants and immune modulators Immune adjuvant;TLR
1168 Poster Presentation A novel immunostimulatory TLR7/8 agonist is curative as a monotherapy in Lewis Lung Carcinoma and synergizes with anti-PD-1 in B16F10 and MC38 tumor models    Shannon M. Miller, PhD; Caleb Beyer; Danielle Talbot; Konner Jackson; Margaret Whitacre; Janine Ward; Roman Schoener; Helene G. Bazin, PhD; David Burkhart, PhD Immune-stimulants and immune modulators Antigen presenting cells;B cell;Checkpoint blockade;Costimulation;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors;TLR;Tumor infiltrating lymphocytes (TILs)
1169 Poster Presentation Systemic administration of TLR7/8 agonist micelles triggers a potent anti-tumor response mediated by neutrophils as primary effector cells followed by establishment of an immune memory response    Simon S. Jensen, PhD; Esben Christensen, PhD; Morten Just Petersen; Anders Hansen, PhD; Martin Bak, PhD; Camilla Stavnsbjerg, PhD; Svetlana Panina, MD, PhD; Thomas Andersen, PhD Immune-stimulants and immune modulators Granulocyte;Solid tumors;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1170 Poster Presentation EGFR-Ta:RNA: Multimodal mechanism of action potentiates immune checkpoint inhibitor activity     Babette Schade, PhD; Derrick Broka; Caroline De Feyter; Shoshana Klein, PhD; Alexei Shir, PhD; Alexander Levitzki, Prof; Davor Bajic, PhD; Lucia D’Amico, PhD; David Colecchia, PhD; Eric Kitas, PhD; Anita Jarzebinska, PhD; Esteban Pombo-Villar, PhD; Maya Zigler, Dr Immune-stimulants and immune modulators RNA;Solid tumors;Targeted therapy;TLR;Tumor microenvironment
1171 Poster Presentation CAN1012: a Selective and Potent TLR7 Agonist with Strong Antitumoral Properties Mediated by Localized Innate Immune Activation Henry Yu, PhD; Hong-Ming Hu, PhD; Rongliang Lou, PhD; Wanping Geng, PhD; Sanlong Wang; William L. Redmond, Ph.D.; Yoshinobu Koguchi, MD, PhD; Baotian Qin; John Mao, PhD; Shaoshan Wang, PhD Immune-stimulants and immune modulators Antigen presenting cells;Chemokine;Clinical trial;Cytokine;Dendritic cell;Immune adjuvant;MDSC;T cell;TLR;Tumor microenvironment
1172 Poster Presentation A unique dendritic cell activation states utilizes inflammasomes to stimulate anti-tumor immunity in mice Dania Zhivaki; Kelsy Finn, PhD; Emily Gosselin, PhD; Holly Concepcion, BS; Andrew Cornforth, PhD; Caitlin Sullivan, BS Immune-stimulants and immune modulators Antigen presenting cells;Cytokine;Dendritic cell;Immune adjuvant;Inflammation;Neoantigens;Solid tumors;T cell lineages;TLR;Vaccine
1173 Poster Presentation ST101, a peptide antagonist of novel I/O target CEBPβ, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responses    Claudio Scuoppo; Gerald S. Falchook, MD, MS; Elisa Fontana; Anja Williams; Nehal J. Lakhani, MD; Jeff Evans; Fabio Iwamoto; Meredith McKean, MD; Stefan N. Symeonides, MD PhD; Alistair McLaren; Jason Henry, M.D.; Gina Capiaux, PhD; Robert E. Michel, PhD; Stephen Kaesshaefer; Alice Bexon; Jim Rotolo, PhD Immune-stimulants and immune modulators Clinical trial;MDSC;Monocyte/Macrophage;Tumor microenvironment
1174 Poster Presentation Multi-epitope DNA vaccine targeting cancer neoantigens enhances efficacy of anti-PD1 therapy     Pratik S. Bhojnagarwala, MS; Alfredo Perales-Puchalt, PhD; Ebony Gary; Niranjan Y. Sardesai, PhD; David B. Weiner, PhD Immune-stimulants and immune modulators Checkpoint blockade;Tumor antigens;Vaccine
1175 Poster Presentation Memory T cells elicited by microorganisms cross-react with tumor-associated antigens. Luigi Buonaguro, MD; Maria Tagliamonte; Beatrice Cavalluzzo Immune-stimulants and immune modulators Adoptive immunotherapy;Microbiome;T cell;Tumor antigens;Vaccine
1176 Poster Presentation Optimizing immunization schedules for therapeutic vaccination Yushe Dang, PhD; Denise Cecil, PhD; Lauren Corulli, MS; Erin Rodmaker, BS; Mary L. Disis, MD, FACP Immune-stimulants and immune modulators Adoptive immunotherapy;T cell;Tumor antigens;Vaccine
1177 Poster Presentation Identification of and vaccination with antigen specific Th1 selective epitopes in bladder cancer: a step towards a multi-antigen vaccine for bladder cancer prevention  Yushe Dang, PhD; Lauren Corulli, MS; Erin Rodmaker, BS; Denise Cecil, PhD; Yi Yang, MS; Carissa Walsh, BS; Will Gwin, MD; Jonathan L. Wright,, MD; Jennifer Childs, MPH; Shizuko Sei, MD; Mary L. Disis, MD, FACP Immune-stimulants and immune modulators Adoptive immunotherapy;T cell;Tumor antigens;Vaccine
1178 Poster Presentation Delivery of DNA Origami Cancer Vaccine Using Alginate Microparticles       Amani Djouadi; Niksa Roki, Ph.D.; Carlos Castro, Ph.D. Immune-stimulants and immune modulators Antigen presenting cells;Immune adjuvant;T cell;TLR;Tumor antigens;Vaccine
1179 Poster Presentation EFFICACY STUDY OF STC-1010 ANTITUMOR VACCINE ASSOCIATED WITH STANDARD CHEMOTHERAPIES ON MC 38 SYNGENEIC COLON CANCER TUMOR MODEL    Corinne Tortorelli, Pharm.D, Ph.D; Celine Gongora; Doriane Mathe; Benoit Pinteur; Lionel Chalus; Paul Bravetti; Nicolas Gadot; Sylvie Lantuejoul; Charles Dumontet; François Ghiringhelli Immune-stimulants and immune modulators Biomarkers;Dendritic cell;Immune monitoring;Monocyte/Macrophage;Neoantigens;Solid tumors;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine
1180 Poster Presentation Listeria-based immunotherapy sculpts CD8+ T cell response in the tumor microenvironment to control renal cell carcinoma   Mariam Oladejo, B.Pharm; Laurence M. Wood, PhD Immune-Stimulants and Immune modulators T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1181 Poster Presentation Therapeutic vaccines consisting of cancer germline antigen-based synthetic long peptides are immunogenic in human hepatocellular carcinoma patients    Yannick S. Rakké, MD, MSc; Marij J. Schoenmaekers-Welters, PhD; Lisanne Noordam, MD, MSc; Sanne Boekestijn; Luc Magre, BSc; Robbie J. Luijten, BSc; Rachelle S. van Gemerden, MSc; Monique T.A. de Beijer, MSc; Michael Doukas, MD, PhD; Jeroen A.A. Demmers, PhD; Anna-Sophia Wiekmeijer, PhD; Willem-Jan Krebber, MSc; Cornelis J. Melief, MD, PhD; Jan N. IJzermans, MD, PhD; Jaap Kwekkeboom; Sjoerd H. van der Burg, Prof.Dr.; Sonja Buschow; Dave Sprengers Immune-stimulants and immune modulators Antigen presenting cells;Proteomics;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine
1182 Poster Presentation Modulating the tumor microenvironment by a targeting TGFB1 with vaccine-induced immune responses Brian T. Weinert, PhD; Tine Hannibal, PhD; Preeyam Patel; Evelina Martinenaite, PhD; Marion Chapellier, PhD; Marco Carretta; Alireza Alavi, PhD MBA; Ayako W. Pedersen, PhD; Muhammad Al-Hajj Immune-stimulants and immune modulators Gene expression;Immune suppression;T cell;Tumor microenvironment;Vaccine
1183 Poster Presentation ASKG915 - An Anti-PD-1 Antibody-IL-15 Prodrug Fusion Molecule with Enhanced Therapeutic Potentials Kurt Shanebeck; Chunxiao Yu, Ph.D.; Shiguang Yu, Ph.D.; Jieye Sun, Ph.D.; Dongfang Wang; Jeanine Luiz; Ming Li, Ph.D.; Ray Chuang, Ph.D.; Jing Chen, Ph.D.; Samantha Luiz; Lynwel Cunanan; Stone Shi, Ph.D.; Matt Hsu, Ph.D.; Yong Wen, Ph.D.; Jeff Lu, Ph.D.; Yuefeng Lu, Ph.D. Immuno-conjugates and chimeric molecules Bispecifics;Checkpoint blockade;Costimulation;Cytokine;NK/NKT cell;T cell;Tumor microenvironment
1184 Poster Presentation SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression and drives tumor clearance in vitro and in vivo    Dori Thomas-Karyat, PhD; Robert Lutz; Douglas Burtrum Immuno-conjugates and chimeric molecules Antibody;Checkpoint blockade;Immune suppression;T cell;Targeted therapy;Tumor evasion
1185 Poster Presentation Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)    Graham Garnett, MSc; Katina Mak; Renee Duan; Truman Hirkala-Schaefer; Manuel Lasalle; Nichole Escalante; Joy Guedia; Kara Moyes; Sam Lawn; Raffaele Colombo; Jamie Rich; Stuart D. Barnscher Immuno-conjugates and chimeric molecules Antigen presenting cells;Cytokine;Immune adjuvant;Myeloid cells;TLR
1186 Poster Presentation SGN-B6A induces immunogenic cell death as a secondary mechanism of action Robert P. Lyon; Vivian Trang, PhD; John Gosink; Michelle Ulrich; Allana Ubben; Sean Allred; Li-Ya Huang; Kelly Hensley; Piper M. Treuting; Kerry Klussman; Shaylin Higgins; Patrick Younan; Roma Yumul; Natalya Nazarenko Immuno-conjugates and chimeric molecules Antibody;Solid tumors;Targeted therapy;Tumor antigens
1187 Poster Presentation Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors    Devra Olson; Patrick Younan; Bernard A. Liu; Gabriele Blahnik-Fagan; John Gosink; Katie Snead; Elena Tenn; Kelly M. Hensley; Disha Sahetya; Albina Nesterova; Margo Zaval; Anthony Cao; Christine O'Day; Ryan A. Heiser, PhD; Timothy S. Lewis; Shyra J. Gardai; Taisuke Nakazawa; Masashi Shimazaki; Christopher Carosino; Sharsti Sandall, PhD Immuno-conjugates and chimeric molecules Checkpoint blockade;Cytokine;Gene expression;Solid tumors;Tumor antigens;Tumor microenvironment
1188 Poster Presentation Antibody Substrate Oligonucleotide Conjugates (ASOCs): a new class of immunotherapeutic agents to inhibit metastasis of tumor cells and block checkpoint inhibition    Beverly Packard, Ph.D.; Akira Komoriya Immuno-conjugates and chimeric molecules Antibody;Biomarkers;Checkpoint blockade;Solid tumors;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
1189 Poster Presentation A GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies    Guillem Pascual-Pasto, PhD; Brendan McIntyre; Rawan Shraim; Samantha Buongervino; Amy K. Erbe, PhD; Dontcho Jelev; Anna M. Giudice; Daniel Martinez; Laura Garcia-Gerique; Dimiter S. Dimitrov, PhD; Paul M. Sondel, MD, PhD; Kristopher R. Bosse Immuno-conjugates and chimeric molecules Antibody;Monocyte/Macrophage;Pediatric tumors;Tumor microenvironment
1190 Poster Presentation SGN-B7H4V induces immunomodulatory changes to the tumor microenvironment and pairs well with an anti-PD1 agent in a preclinical model Michelle Ulrich; Angela D. Epp; Kelly M. Hensley; Julie Hahn; Sean Allred; John Gosink; Piper M. Treuting; John Hernandez Villanueva; Sarah Anderson; Alyson J. Smith, PhD; Jason Schrum; Natalya Nazarenko; Shyra J. Gardai; Elizabeth Gray, PhD Immuno-conjugates and chimeric molecules Checkpoint blockade;Solid tumors;Targeted therapy;Tumor antigens
1191 Poster Presentation STRO-003 is a novel ROR1-targeted ADC for breast and lung cancer    Alice Yam, PhD; Jeff Hanson; Krishna Bajjuri; Sihong Zhou; Dayson Moreira, PhD; Jennifer Smith; Cristina Abrahams; Xiaofan Li, PhD; Grace Lee; Stephanie Armstrong; Amandeep Gakhal; Daniel Calarese; Young Park; Miao Wen; Gang Yin; Simon Chivers; Faye Hsieh; Guifen Xu; Werner Rubas; Andreas Maderna; Kristin Bedard; Trevor Hallam Immuno-conjugates and chimeric molecules Antibody;Solid tumors;Stem cell/cancer-initiating cell;Targeted therapy;Tumor antigens
1192 Poster Presentation Identification of oncogene-induced surface protein IL1RAP as an immunotherapy target in multiple cancers Hai-Feng Zhang, PhD; Wei Li, PhD; Christopher S. Hughes, PhD; Rajesh Kumar, PhD; Alberto Delaidelli, PhD; Yue Zhou Huang; Michael Lizardo, PhD; Rimas J. Orentas, PhD; Dimiter S. Dimitrov, PhD; Poul H. Sorensen, PhD, MD Immuno-conjugates and chimeric molecules Adoptive immunotherapy;Antibody;CAR T cells;Pediatric tumors;Proteomics;Solid tumors;Surfaceome;Targeted therapy;Tumor antigens
1193 Poster Presentation Inducing immunogenic cell death and antitumor activity in response to radioimmunotherapy     Denis Beckford, PhD; Jason Li; Caroline Jennings; Megan McCloskey; Le-Cun Xu; Debbie Lewis; Patrik Brodin; Amanda Chin; Monideepa Roy; Mary Chen; Helen Kotanides Immuno-conjugates and chimeric molecules Targeted therapy;Tumor microenvironment
1194 Poster Presentation Discovery and pre-clinical development of a novel and differentiated EphA2-targeted antibody in multiple bispecific formats    Maryam M. Bhatti; Michael S. Weiss; Amanda R. Haltom; Jessica A. Finn; Annie Gai; Anne Ye; Danhui Zhang, MD PhD; Cathrin J. Czupalla; Andreea Stuparu; Yvonne Leung, Ph.D.; Erin Wechsler, PhD; Iraz T. Aydin; Daniel Emerling, PhD; Amy Manning-Bog, PhD; Nikhil Vad; Alexander Scholz, PhD; Philippe Marguet; Shaun M. Lippow, PhD Immuno-conjugates and chimeric molecules Antibody;B cell;Bispecifics;Costimulation
1195 Poster Presentation Generation of a highly potent, cis-signaling PD1-IL2 immunocytokine using a novel chemical synthesis and conjugation platform Jean Ph. Carralot, PhD; Matilde Arévalo Ruiz, PhD; Rubén Alvarez Sanchez, PhD; Robert Tam, PhD; Lilian Gremlich, MSc; Andrew S. Chi, MD PhD; Vijaya R. Pattabiraman, PhD; Bertolt D. Kreft, PhD Immuno-conjugates and chimeric molecules Antibody;Checkpoint blockade;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
1196 Poster Presentation Streamlining T cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine Lindsay DeVorkin, PhD; Juntao (Matt) Mai, PhD; Kate Caldwell, MSc; Tim M. Jacobs, PhD; Raffi Tonikian, PhD; Karine Herve, MSc; Yuri Hwang, BSc; Cristina Faralla, PhD; Wei Wei, PhD; Emma Lathouwers, PhD; Rhys S. Chappell, BSc; Stefan Hannie, PhD; Katherine J. Lam, BSc; Harveer Dhupar, PhD; Tran N.T. Tran, MSc; Melissa Cid, PhD; Lena M. Bolten, PhD; Tova Pinsky, MSc; Ping Xiang, PhD; Courtenay Lai, PhD; Ahn Lee, PhD; Patrick Chan, PhD; Jasmine Chin, BSc; Aaron Yamniuk, PhD; Kush Dalal, PhD; Bryan C. Barnhart, PhD Immuno-conjugates and chimeric molecules Antibody;Bispecifics;Cytokine;Immune toxicity;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor microenvironment
1197 Poster Presentation Optimizing a T cell-engaging bispecific antibody targeting the highly recurrent p53 R175H neoantigen via affinity maturation Sarah R. DiNapoli; Katharine Wright; Emily HC. Hsiue, MD, PhD; Brian J. Mog; Sandra B. Gabelli, PhD; Kenneth W. Kinzler, PhD; Bert Vogelstein; Shibin Zhou, MD, PhD Immuno-conjugates and chimeric molecules Antibody;Bispecifics;T cell;Targeted therapy;Tumor antigens
1198 Poster Presentation A dual targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and a manageable safety profile     Melissa Dullaers, PhD; Geert Deschamps; Helene Bonnevaux; Stephane Guerif; Veronique De Brabandere; Celine Amara; Ann Brige; Eline Dejonckheere; Angela Virone-Oddos; Marielle Chiron; Annelies Roobrouck Immuno-conjugates and chimeric molecules Bispecifics;Leukemia/Lymphoma;T cell;Targeted therapy;Tumor antigens
1199 Poster Presentation Comparison of four in vitro cytotoxicity assays for assessing the potency of CD3-bispecific antibodies redirecting T cells to kill tumor target cells Jun Guan; Charlie Kang; Alejandro Amador Arjona; Ricardo Macarron; Patrick Mayes, PhD; Yao-Bin Liu, MD Immuno-conjugates and chimeric molecules Bispecifics;Cytokine;T cell
1200 Poster Presentation A Clinically Validated pH-Sensitive Nanomedicine Platform for Encapsulating Therapeutic Bispecific T cell engagers for Tumor Specific Delivery and Activation Stephen Gutowski; Qingtai Su, Ph.D.; Austin Burcham; Irina Kalashnikova, Ph.D.; Ashley Campbell; Zirong Chen, PhD; Bhargavi Allu; Jason B. Miller, PhD; Tian Zhao, PhD Immuno-conjugates and chimeric molecules Bispecifics;Immune toxicity;Solid tumors;T cell;Tumor microenvironment
1201 Poster Presentation SGN-BB228 is a first-in-class CD228-targeted costimulatory Antibody Anticalin bispecific delivering potent and conditional 4-1BB costimulation to tumor-specific T cells    Ryan A. Heiser, PhD Immuno-conjugates and chimeric molecules Bispecifics;Costimulation;Solid tumors;T cell;Targeted therapy
1202 Poster Presentation Tri-specific killer engagers target natural killer cells towards mesothelioma Philippa (Pippa) R. Kennedy, PhD; Quinlan M. Kile; Blake A. Jacobson, PhD; Brianna Ettestad; Nicholas A. Zorko, MD, PhD; Caroline Hallstrom; Behiye Kodal; Deborah A. Todhunter; Daniel A. Vallera; Gregory I. Berk, MD; Jeffrey S. Miller, MD; Manish R. Patel, DO; Martin Felices Immuno-conjugates and chimeric molecules Bispecifics;Cytokine;Immune suppression;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment
1203 Poster Presentation Antigen targeted butyrophilin heterodimer-based bispecific engagers induce V&gamma;9&delta;2+ T cell-mediated anti-tumor activity Derek Franklin, Ph.D.; Anne Lai, Ph.D.; Faraha Brewer, BSc; Arpita Patel, BSc; Kinsley Evans, BSc; Mahmud Hussain, Ph.D.; Louis Gonzalez, Ph.D.; Keith Wilson, Ph.D.; George J. Fromm, Jr., Ph.D.; Taylor H. Schreiber, MD, PhD; Suresh De Silva, Ph.D. Immuno-conjugates and chimeric molecules Bispecifics;Costimulation;Cytokine;Leukemia/Lymphoma;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs)
1204 Poster Presentation Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA) Shee Kwan Phung, BS; Yvette Soignier, PhD; Nicholas A. Zorko, MD, PhD; Trygve Nelson; Joshua S. Walker; Philippa (Pippa) R. Kennedy, PhD; Jeffrey S. Miller, MD; Martin Felices Immuno-conjugates and chimeric molecules Bispecifics;Costimulation;Immune suppression;MDSC;Myeloid cells;NK/NKT cell;Targeted therapy;Tumor microenvironment
1205 Poster Presentation Selective blockade of CD47-SIRP alpha 'don't eat me' signaling with a Her2-CD47 bispecific antibody-derivative Yuzhu Qi; Harm J. Lourens; Gerwin Huls; Edwin Bremer Immuno-conjugates and chimeric molecules Bispecifics;Monocyte/Macrophage;Targeted therapy
1206 Poster Presentation Discovery and preclinical pharmacology of bispecific antibodies targeting an HLA-A2 restricted tumor-associated antigen     Alejandro Ramirez, PhD; Nora Guidotti, PhD; John Leonard, PhD; Olivier Dalmas, PhD; Jake Kleiner; Joshua Goldsmith; Greg Tuffy; Jason Romero; Bindu Hegde, Ph.D.; Tina Giese; Lisa Kirkemo, PhD; Rafaela Truffer; Oralea Buchi; Nadine Uebersax; Philipp Wild, PhD; Rohan Eapen, PhD; Joanna Dreux; Alaina Cagalingan; Lena Flood, PhD; Kyle Pelot, PhD; Nathan Katz; Marvin H. Gee, PhD; Venita De Alm